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SUMMARY  
The genome is a very dynamic store of genetic information and constantly 
threatened by endogenous and exogenous damaging agents. To maintain fidelity of 
the information stored, several robust and overlapping repair pathways, such as the 
Base Excision Repair (BER) pathway, have evolved. The main BER glycosylase 
responsible for repairing alkylation DNA damage is the alkyladenine DNA 
glycosylase (AAG). Repair initiated by AAG can lead to accumulation of cytotoxic 
intermediates. Here, we report the involvement of AAG in the elicitation of the 
unfolded protein response (UPR), a mechanism triggered to restore proteostasis in 
the cell whose dysfunction is implicated in diseases like diabetes, Alzheimer’s 
disease and cancer. Firstly, we determined that not only human ARPE-19 cells were 
capable of eliciting the UPR, but that an alkylating agent, methyl methanesulfonate 
(MMS), also triggers the response, and that in the absence of AAG the response is 
greatly diminished. Our luciferase reporter assay indicates that the response is 
activated on multiple branches (IRE1 and ATF6) on both AAG-proficient and 
deficient cells. Although no transcriptional induction of UPR markers was detected 
by RT-qPCR at 6 hours post MMS treatment, preliminary western-blot data at 6 and 
24h, show activation of key UPR markers (p-eIF2α, BiP and XBP-1) upon MMS 
treatment in wild-type cells and little or no activation on AAG -/-. To investigate the 
impact of AAG modulation on the cellular proteome we also conducted a proteomic 
analysis, identifying 5480 protein groups in wild-type ARPE-19, 5377 in the AAG -/- 
A2C2 and 5264 in AAG -/- B6C3. After a high-stringency analysis, we identified 13 
proteins present only in wild-type cells, indicating promising targets for further 
investigation into the role of AAG in the UPR. We also identified 44 overrepresented 
GO-slim terms across all cell lines and 23 overrepresented pathways, mostly related 
to cellular metabolism processes. Whereas more experiments are required to 
characterize the nature of AAG’s contribution to the UPR, we demonstrate the 
existence of crosstalk between the DNA repair response and the ER stress response 
pathways, that is potentially relevant in a clinical setting. 
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1 Introduction 
 DNA DAMAGE AND REPAIR  
Not very long ago, the very thought of DNA conjured ideas of static 
information tightly packed and stable (Errol C Friedberg, 2003) which could not be 
further from truth. Greatly flexible and surprisingly unstable, the DNA is the target 
of dynamic processes that can sometimes alter the information it contains. Though 
sometimes advantageous from an evolutionary standpoint, mutations are nearly 
always harmful to the individual and, as widely known, can induce tumorigenesis.  
There are many agents that can elicit DNA damage and, strictly for 
classification purposes, they can be divided into endogenous and environmental 
sources (Errol C. Friedberg, Walker, Siede, & Wood, 2005). Endogenous sources can 
comprise but are not limited to spontaneous deamination of bases, oxidative 
damage, replication errors (Dizdaroglu, 2012; Meira, Burgis, & Samson, 2005), while 
the exogenous or environmental DNA damage can result from ionizing (Suzuki & 
Yamashita, 2012)and non-ionizing radiation (e.g. UV radiation) and chemical 
compounds that can act upon the DNA structure, such as alkylating  and crosslinking 
agents (Fu, Calvo, & Samson, 2012) 
Intricate and often overlapping repair mechanisms have evolved to face 
these constant challenges. Depending upon the nature of the lesion and the cell 
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lineage, there are basically two broad categories of repair mechanism: direct 
damage reversal that does not require lesion excision or re-synthesis (e.g. reversal 
of O6-methylguanine by the O6-methylguanine DNA methyltransferase) or more 
complex pathways that involve these processes. Among the latter, there are five 
main repair pathways: the Nucleotide Excision Repair (NER), responsible for 
removing potentially replication-blocking bulky lesions; Mismatch Repair (MMR) 
that deals with nucleotide misincorporations generated during replication and 
insertion/deletion loops; and Base Excision Repair (BER), that handles discrete base-
altering damage and can, in certain situations, repair single strand breaks (SSBs). 
However, to deal with the potentially lethal problem of double strand breaks (DSBs) 
there are two options: Homologous Recombination (HR), that is usually employed 
whenever these breaks arise during cell replication (especially in G2 and S cell cycle 
phases), and Non-Homologous End Joining (NHEJ), that repairs double-strand 
breaks when there are no templates available (G1, for instance) and can be error 
prone.  
Among these repair options, BER is regarded as one of the most active 
pathways, dealing with the high levels of spontaneous DNA degeneration and 
exposure to both environmental and endogenous insults (De Bont & van Larebeke, 
2004). A highly conserved repair pathway, it is responsible for handling a wide 
variety of non-helix distorting lesions, some of which can be seen in Figure 1. 
Base excision repair is initiated by a glycosylase that cleaves the glycosidic 
bond between the base and the DNA backbone. It is the main repair pathway for a 
somewhat diverse set of lesions caused by deamination, oxidation and alkylation, 
detailed in the sections below. 
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1.1.1 LESIONS REPAIRED BY BER 
One of the most abundant endogenous sources of DNA damage, reactive 
oxygen or nitrogen species (RONS) can arise both from physiological and 
pathological metabolic reactions, (as by-product of mitochondrial oxidative 
phosphorylation or inflammation, for example) and/or external sources, as 
radiation and carcinogenic compounds (Halliwell & Gutteridge, 2005). Of special 
significance are the superoxide radical (O2. -), hydrogen peroxide (H2O2) and 
hydroxyl radicals (OH.). These reactive radicals can oxidize DNA bases (which can be 
mutagenic and cytotoxic) and attack the sugar-phosphate backbone, causing single 
and double-strand breaks but can, as well, oxidize proteins and lipids, induce 
mitochondrial dysfunction and lead to a chain-reaction production of more ROS 
(Fritz & Petersen, 2011) . 
 
Figure 1: Commonly occurring damaged bases repaired by BER. 
Adapted from: Krokan and Bjoras, 2013. 
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1.1.1.1 DEAMINATED BASES AND APURINIC/APYRIMIDINIC (AP) SITES 
Defined by the loss of an exocyclic or intracyclic amino group, base 
deamination can occur in homeostatic conditions via hydrolysis or by reaction with 
RONS. Upon the loss of the amino moiety, adenine can give rise to hypoxanthine, 
cytosine to uracil, guanine to xanthine and oxanine. 5-methylcytosine, a putative 
transcription regulator, can be converted to thymine (Walsh & Xu, 2006). The 6-
amino group of purines and the 4-amino group in the pyrimidines are usually 
hydrogen donors in Watson-Crick base pairing, whereas when deaminated, the 
amino group is replaced by a keto moiety, an hydrogen acceptor (Kow, 2002), 
fundamentally changing the base-pairing and giving these lesions their high 
mutagenic potential.  
Abasic sites, also called AP sites (for apurinic/apyrimidinic sites), arise due 
to hydrolytic cleavage of the N-glycosidic bond, leaving deoxyribose residues in the 
DNA strand. Any occurrence (chemical or otherwise) that leads to the development 
of a positive charge in the nucleic base can weaken the glycosidic bond making the 
site vulnerable to hydrolysis and consequent formation of the abasic site. This 
process can occur spontaneously at a fairly considerable rate (Nakamura & 
Swenberg, 1999) but it is greatly increased by ROS damage and by glycosylase 
processing in BER repair (Lhomme, Constant, & Demeunynck, 1999). AP sites can be 
cytotoxic through their potential to cause replication block (Errol C Friedberg, 2003),  
are mutagenic and can be converted into SSBs when processed by downstream 
enzymes during BER. These SSBs, in turn, can be further converted into highly toxic 
DSB during a stalled replication fork event (Boiteux & Guillet, 2004)AP sites can be 
repaired by BER, in a process started by the AP endonuclease (APE1) and explored 
in a little more detail further in this section. 
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1.1.1.2 ALKYLATION DAMAGE 
Alkylation is the ability of a broad range of chemical compounds to transfer 
an alkyl group (e.g. methyl or ethyl) to biologically relevant molecules, such as DNA, 
RNA and proteins, thereby potentially altering its original properties, aptly reviewed 
in Fu, Calvo et al. (2012) and Codreanu, Ullery et al. (2014). Some level of exposure 
is practically unavoidable since alkylating agents originate from quite widespread 
and diverse sources: pollution, dietary additives, metabolic by-products and 
oxidized lipids (Goldman & Shields, 2003; Nagy, Ádány, Szűcs, & Ádám, 2013; 
Sedgwick, Bates, Paik, Jacobs, & Lindahl, 2007; West, Marnett, James D. West, & 
Marnett, 2006). Precisely due to its toxic properties, several alkylating compounds 
are employed as chemotherapeutic drugs, such as temozolomide, 
cyclophosphamide, mitomycin C and methyl methanesulfonate, widely used in 
alkylation research (Ciccia & Elledge, 2010).  
As variable as their origins are the lesions these compounds can cause. The 
structure of the resulting DNA damage depends on a series of factors that include: 
the reactivity of the compound (SN1 compounds can react with both ring nitrogens 
and extra cyclic oxygen groups in DNA bases, while SN2 react only with nitrogens), 
the number of reactive sites the alkylating agent has (whether it is monofunctional 
or bifunctional) and whether the nucleic acid is single or double-stranded. Figure 2 
shows some known alkyl lesions, in both RNA and DNA, caused by SN1 and SN2 
agents (Fu et al., 2012).  
The proportion of each lesion generated is also dependent on the agent’s 
reactivity. Proportionally, N7-methylguanine, (7MeG, Figure 2) is predominantly 
generated, accounting roughly for 60-70% of the lesions induced by SN2 
compounds, followed by N3-methyladenine (3MeA). 7MeG is quite innocuous by 
itself, but can spontaneously deaminate and, when processed by a BER-initiating 
DNA glycosylase, gives rise to an AP site which, as previously mentioned, is both 
toxic and mutagenic. 3MeA, however, is highly cytotoxic by itself, due to its position 
in the DNA minor grove, affecting its interaction with the DNA polymerase and 
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interfering with DNA synthesis (Drablos et al., 2004). Also, worth of note is O6-
methylguanine, caused by SN1 agents. Despite happening at a fairly lower rate than 
the previous cited lesions, is highly mutagenic because it can pair with thymine 
during replication (Bignami, O’Driscoll, Aquilina, & Karran, 2000).  
 
Figure 2: Alkyl lesions, in both RNA and DNA, caused by SN1 and SN2 agents. From Shrivastav, Li et al. 
(2010) 
 
It is reasonable to think that such variety of lesions require an adequately 
varied group of repair enzymes to process them. In fact, there are six structural DNA 
glycosylase superfamilies involved in BER: T4 Endonuclease V (EndoV), uracil DNA 
glycosylase (UDG), Helix-hairpin-Helix (HhH), helix-two turn-helix (H2TH), 
alkyladenine glycosylase (AAG) and alkylpurine DNA glycosylases (ALK), comprising a 
total of 11 glycosylases in mammals (Jacobs & Schär, 2012). Although evolutionarily 
well conserved, there are striking examples where no prokaryote homologues are 
found to the mammalian enzyme, as is the case for alkyladenine DNA glycosylase 
(AAG), discussed below, that has its own superfamily (Krokan & Bjørås, 2013). 
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1.1.1.3 LESION RECOGNITION AND PROCESSING  
BER is regarded as one of the most active repair pathways due to the 
volume (see Table 1) and variety of lesions it acts upon (Figure 1). Despite the 
presence of some variations to fine-tune the repair according to the lesion, this 
multistep repair process begins with the recognition of the damaged base by a 
glycosylase.   
To cope with a plethora of lesions, many glycosylases with high or low 
substrate specificity have evolved. They fall into one of six structural superfamilies: 
EndoV, UDG, HhH, H2TH, AAG and ALK (Figure 4). In 
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Table 2 there is a summary of known mammalian glycosylases and their 
activities.  
  
 
Figure 3 Damaged nucleotides. A) Oxidized nucleobases: 8-OHG, 7,8-dihydro-8-hydroxyguanine; 8oxoG, 8-
oxo7,8-dihydroguanine; FapyG, 2,6-diamino-4-hydroxy-5-formamidopyrimidine; mFapyG, N7-methylFapyG; Tg, 
thymine glycol; Sp, spiroiminodihydantoin; Gh, guanidinohydantoin; Ia, iminoallantion; 5-OHU, 5-hydroxyuracil; 
DHU, dihydrouracil; 5-OHC, 5-hydroxycytosine; DHT, dihydrothymine. B) Alkylated nucleobases: εA, 
1,N6ethenoadenine; εC, 3,N4-ethenocytosine; 3mA, N3-methyladenine; 3mG, N3-methylguanine; 7mG, 
N7methylguanine; Hx, hypoxanthine. C) Nucleobases repaired by the UDG/TDG family of DNA glycosylases: U, 
uracil; T, thymine; 5mC, 5-methylcytosine; 5hmC, 5-hydroxymethylcytosine; 5fC, 5-formylcytosine; 5caC, 
5carboxylcytosine. Adapted from: Brooks et al. 2013. 
  
The reasons why glycosylases are able to distinguish diverse damaged 
substrates are still unclear. One of the proposed models for the recognition process 
is that the enzyme scans the DNA probing for the altered base. The mechanism 
used for this scanning process has yet to be elucidated (if translocates either by 
sliding, hopping or diffusion), but it is very likely that, due to the great variations in 
glycosylase structure, different enzymes employ different tactics (Jacobs & Schär, 
2012). The consensus for most of the superfamilies (except ALK) is that during the 
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scanning process the enzyme bends the DNA structure, flattening and widening the 
minor groove which causes the damaged base to “flip out” of the DNA chain (Figure 
5), allowing it to be positioned in the active site for surveying (Kim & Wilson, 2012). 
If the base is recognized as damaged, its N-glycosidic bond is cleaved, generating an 
AP site (Dodson & Lloyd, 2002). 
  
 
Figure 4: DNA glycosylase structural superfamilies. Representative crystal structures from each class shown 
are: EndoV, T4 pyrimidine dimer DNA glycosylase EndoV; UDG, human uracil-DNA glycosylase UDG; Helix–
hairpin–Helix (HhH), human 8-oxoguanine DNA glycosylase OGG1; Helix-two turn-helix (H2TH), Bacillus 
stearothermophilus 8-oxoguanine DNA glycosylase MutM; AAG, human alkyladenine DNA glycosylase 
AAG/MPG; ALK, Bacillus cereus alkylpurine DNA glycosylase AlkD. Proteins are coloured according to secondary 
structure with the HhH and H2TH domains magenta. DNA is shown as grey sticks. Adapted from: Brooks, et al. 
2013.  
Table 1: Estimation of damage levels generated daily by endogenous sources in the human genome. 
Lesion Mode of formation 
Nº of residues 
generated daily per 
human genome 
Genome steady 
state level in 
repair proficient 
cells 
Uracil Cytosine deamination 400 ~1 
Thymine  
(opposite guanine) 
5-Methylcytosine 
deamination 
30 10-20 
Hypoxanthine Adenine deamination 10 ~1 
8-oxo-7,8-
dihydroguanine 
Guanine oxidation ~1000 ~1 
Formamido-pyrimidine Guanine oxidation ~200 ~5 
Thymine glycol and 
similar oxidized 
pyrimidines 
Pyrimidine oxidation ~500 ~5 
Etheno C 
Lipid peroxidation of 
cytosine 
~200 ~5 
Etheno A 
Lipid peroxidation of 
adenine 
~200 ~5 
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Lesion Mode of formation 
Nº of residues 
generated daily per 
human genome 
Genome steady 
state level in 
repair proficient 
cells 
3-Methyladenine 
SAM methylation of 
adenine 
~600 3000 
7-Methylguanine 
SAM methylation of 
guanine 
4000  
O6-Methylguanine 
Genomic alkylation by 
endogenous nitrosamines 
~200 ~1 
Abasic site Hydrolytic depurination 9000 ~5 
*Adapted from Kim et al., 2013.  
Glycosylases can also be classified according to their specific activities. The 
monofunctional glycosylases act like a canonical glycosylase, promoting the 
hydrolysis of the aromatic carbon of the base, resulting in its release. The end-result 
of the monofunctional process is an AP site that is identical to a spontaneously 
generated one. The bifunctional enzymes, however, conduct a nucleophilic attack to 
excise the base and have also a lyase activity that can nick the sugar-phosphate 
backbone either by β or β, δ elimination. In these processes, the glycosylase breaks 
the phosphodiester bond 3’ of the AP site generating either a phosphor-α,β-
unsaturated aldehyde (PUA) or a phosphate (PO4), respectively, that need to be 
further processed so that the polymerase is able fill the gap (Kim & Wilson, 2012; 
Wallace, Murphy, & Sweasy, 2012). The glycosylase then tends to stay bound to the 
site, what might serve to enhance the stability of the damaged area (Jacobs & 
Schär, 2012) until the AP endonuclease is recruited, beginning the next step of the 
process. 
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Figure 5: Stereotactic view of the base-flipping interaction of T4 Endonuclease V and DNA. The protein is 
depicted in yellow, whereas the damaged nucleotide and its pair are depicted in red. Adapted from Vassylyev et 
al., 1995.   
 
The first step in solving the abasic site generated by glycosylase activity is 
the recruitment, as mentioned above, of the AP endonuclease. AP endonuclease 
cleaves the phosphodiester bond 5’ to the AP site, generating 3’hydroxyl-nucleotide 
and 5’ deoxyribose phosphate termini, creating an adequate substrate for the 
polymerase β to act upon (Errol C. Friedberg et al., 2005). Besides its AP 
endonuclease activity, the main mammalian AP endonuclease (Demple & Sung, 
2005), APE1, can also process the 3’ blocking termini left by the bifunctional 
glycosylases. Some termini, such as the generated by the β,δ eliminating 
glycosylases, need the activity of yet another enzyme, the polynucleotide 
kinase/phosphatase - PNPK (Wiederhold et al., 2004). 
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Table 2: Mammalian glycosylases, their activities and substrates. 
DAMAGED 
BASE TYPE 
ACRONYM FULL NAME 
SUBCELLULAR 
LOCALIZATION 
AP LYASE 
ACTIVITY 
SUBSTRATES MOUSE KNOCKOUT HUMAN DISEASE 
DEAMINATED 
BASE UNG2 
Uracil DNA glycosylase 
2 Nucleus No 
U, 5-FU in ss and 
dsDNA, U:A and U:G 
context (alloxan, 
5hydroxyuracil, 
isodialuric acid) 
Partial defect in CSR, 
skewed SHM, B-cell 
lymphomas 
Complete defect in 
class switch rec., 
Hyper IgM 
syndrome, 
infections, lymphoid 
hyperplasia 
DEAMINATED 
BASE 
UNG1 Uracil DNA glycosylase 
1 
Mitochondria No As UNG2 Unknown Unknown 
DEAMINATED 
BASE 
TDG 
Thymine DNA 
glycosylase 
Nucleus No U:G, Etheno C:G, T:G 
Embryonic lethal, 
epigenetic role in 
development 
Unknown 
DEAMINATED 
BASE 
SMUG1 
Single-strand-selective 
monofunctional uracil-
DNA glycosylase 1 
Nucleus No 
5-hmU, U:G . U:A . 
ssU, 5-FU, 1C in ss 
and dsDNA 
Viable and fertile, 
SMUG1/UNG/MSH triple 
KO. reduced longevity 
Unknown 
DEAMINATED 
BASE 
MBD4/MED1 
Methyl-CpG-binding 
domain 4 
Nucleus No 
U or T in U/TpG:5-
meCpG 
Viable and fertile, C to T 
transitions, intestinal 
neoplasia 
Mutated in 
carcinomas with 
microsatellite 
instability 
ALKYLATED 
BASE 
AAG/MPG 
Alkyl adenine DNA 
glycosylase/Methyl 
purine DNA glycosylase 
Nucleus 
Mitochondria 
No 
3-MeA, 7-MeA, 3-
MeG, 7-MeG, Etheno 
A, m6A 
Viable and fertile, triple 
knockouts in 
MPG/AlkBH2/AlkBH3 
hypersensitive to 
inflammatory bowel disease 
Unknown 
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DAMAGED 
BASE TYPE 
ACRONYM FULL NAME 
SUBCELLULAR 
LOCALIZATION 
AP LYASE 
ACTIVITY 
SUBSTRATES MOUSE KNOCKOUT HUMAN DISEASE 
OXIDIZED MUTYH MutY homolog Nucleus 
Yes 
(β)/No 
A:G, A:8-oxoG 
OGG1/MUTYH double 
knockouts cancer prone 
MUTYH variants 
associated with 
colon polyposis 
OXIDIZED OGG1 
8-oxo-guanine 
glycosylase 1 
Nucleus Yes (β) 8-oxoG:C, FapyG 
Viable and fertile, 
OGG1/MUTYH double 
knockouts cancer prone 
OGG1 activity 
associated with CAG 
repeat expansion in 
Huntington’s disease 
OXIDIZED NTH1 
Endonuclease three 
homolog 1 
Nucleus Yes (β) 
Tg, Cg, FapyG, DHU, 
5-ohU, 5ohC 
Viable and fertile, 
NTHL1/NEIL1 double 
knockouts cancer prone 
Unknown 
OXIDIZED NEIL1 
Nei endonuclease VIII 
like 1 
Nucleus Yes (β, δ) 
Tg, 5-ohU, 5-ohC, FapyG/G, 
Urea, 8-oxoG 
Viable and normal at 
birth, obese after 7 
months, NTHL1/NEIL1 
double knockouts cancer 
prone 
Unknown 
OXIDIZED NEIL2 
Nei endonuclease VIII 
like 2 
Nucleus Yes (β, δ) 
Overlap with NTH1 
and NEIL1 
Unknown Unknown 
OXIDIZED NEIL3 
Nei endonuclease VIII 
like 3 
Nucleus Yes (β, δ) 
Oxidized purines, 
FapyG, FapyG 
Viable and fertile, 
memory and learning 
deficit 
Unknown 
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1.1.1.4 REPAIR SYNTHESIS  
After glycosylases acted upon the substrate base damage, the repair 
process proceeds to the next stage, where it can be divided into two main 
subpathways (Figure 6): short (SP-BER) and long-patch BER (LP-BER). The first and 
simplest, short-patch BER is thought to be the predominant form of BER taking 
place. During SP-BER, pol β uses the 3’ phosphate as a substrate to incorporate the 
correct nucleotide in the gap left by APE1. The nicks are then sealed by the ligase I 
in the nuclear environment, while in the mitochondria the key ligase is ligase III 
(Gao et al., 2011; Simsek et al., 2011). 
The literature so far has determined that pol β is responsible for the 
incorporation of the first nucleotide (Podlutsky, Dianova, Podust, Bohr, & Dianov, 
2001). What apparently conducts the cell to one pathway or another is the difficulty 
the ligase has sealing the nicks after the first nucleotide incorporation. The 
prolonged permanence of the DNA-bound enzyme stimulates the initiation of LP-
BER, either with the help of X-ray Repair Cross-Complementing protein 1 (XRCC1) or 
undergoing a polymerase switch, that changes the current enzyme by a 
multiprotein complex formed by PCNA/pol δ/ε (E Petermann, Keil, & Oei, 2006). The 
choice between pathways and enzymes employed seems to be based also in factors 
like cell energetic status (Eva Petermann, Ziegler, & Oei, 2003), proliferative context 
(Krokan & Bjørås, 2013), enzyme availability 0(Kim & Wilson, 2012), the initiating 
glycosylase (Fortini, Parlanti, Sidorkina, Laval, & Dogliotti, 1999) and nature of the 
lesion (Zharkov, 2008). 
Regardless of the protein complexes involved, in LP-BER the nucleotide 
incorporation proceeds as 2 to 12 nucleotides incorporated, displacing the non-
template strand (Robertson, Klungland, Rognes, & Leiros, 2009), which creates a 
single-stranded DNA flap processed, in mammals, by Flap Endonuclease 1 
(Balakrishnan & Bambara, 2013) as can be seen in Figure 7. 
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Figure 6 Subpathways in base excision repair. BER process begins branching out at the DNA incision level: 
either que glycosylase that began the process in the base excision step is monofunctional and requires the 
further processing of a AP endonuclease or it is bifunctional and its able to nick the sugar-phosphate backbone, 
requiring different downstream enzymes to complete the process. Adapted from Krokan and Bjoras, 2013.  
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Figure 7: Flap endonuclease 1 action over substrate. a) Flap endonuclease 1 recognizes the displaced flap; b) 
binds to it and c) bends it to position it correctively in the active site, d) cleaving it thereafter. Adapted from: 
Balakrishinan et al., 2013.  
 
1.1.1.5 LIGATION  
The final processing required is the sealing of the DNA nicks. 
Mechanistically, the enzymes catalyse the formation of a phosphodiester bond, 
which happens in tree steps: (I) a phosphoamide bond is formed (P-N) between the 
α-amino group of an active site lysine and the 5’ phosphate of AMP, then (ii) the 5’ 
phosphate group of NMP is transferred from the active site lysine to a 
phosphorylated DNA 5’ end, (iii) forming a pyrophosphate linkage (Tomkinson, 
Vijayakumar et al. 2006).  
It is still a matter of debate when and where the mammalian ligases I (LIG 
1) and IIIα (LIG 3) act in the process. For some time, it was believed that the protein 
complex ligase IIIα/XRCC1 was responsible for the majority of the short-patch BER 
(Caldecott, Tucker, Stanker, & Thompson, 1995; Cappelli et al., 1997) due mostly to 
its required interaction with the scaffold protein XRCC1 and the observation that 
mammalian cells lacking ligase IIIα were more sensitive to alkylation(E C Friedberg 
et al., 2006). However, Sleeth and his collaborators (2004) have shown that there is 
a certain redundancy of ligases in the BER processes, allowing LIG 1 to successfully 
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substitute LIG 3 in SP-BER. In accordance to those findings, more recent studies 
have shown that in mice, the absence of ligase III causes loss of mtDNA and severe 
mitochondrial dysfunction, but does not affect nuclear repair, while the ablation of 
ligase I impairs nuclear BER  (Gao et al., 2011). Interestingly, an additional 
experiment was conducted by Simsek and colleagues (2011) indicating that LIG 3 
can be replaced by LIG 1 (with the addition of a mitochondrial targeting sequence) 
without major consequences for the cell, suggesting that the ligase activity, rather 
than the specific ligase itself is important(Simsek et al., 2011). What is reinforced by 
the fact that nuclear BER usually employs large multiprotein complexes whereas no 
such repair complexes were detected in the mitochondria (Akbari, Otterlei, Pena-
Diaz, & Krokan, 2007).  
The next section will address some of the main characteristics of a very 
particular glycosylase:  Alkyladenine glycosylase, responsible for excising a broad 
range of damaged bases and sometimes, contrary than what is expected for a DNA 
repair enzyme, resulting in cytotoxicity to the cell.  
 
1.1.2 ALKYLADENINE DNA GLYCOSYLASE/METHYLPURINE DNA 
GLYCOSYLASE (AAG/MPG)  
1.1.2.1 STRUCTURE 
AAG is the only human glycosylase known to recognize a variety of lesions 
(cationic and neutral) such as 3-Methyladenine (3MeA), 3-Methylguanine (3MeG), 
oxanine (a deaminated guanine at the N1 position), N7-methylguanine (7MeG), 
1,N2-ethenoguanine (εG), 1,N6-ethenoadenine (εA), and hypoxanthine (Hx), 1-
methylguanine (m1G) and, in the case of Hx and εA, in single and double stranded 
substrates (C. I. Lee et al., 2009; Saparbaev et al., 2002). Though able to deal 
successfully with all the substrates cited previously, Hx is believed to be the 
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preferred biological substrate, due to its fast processing rates (O’Brien & 
Ellenberger, 2003). 
AAG belongs to a family completely distinct from the Helix-hairpin-Helix 
family, consisting of highly homologous mammalian enzymes of different 
structures. What can be discerned so far, by co-crystallization of AAG and different 
substrates is that it is composed by a single domain of mixed α/β with seven α 
helices and eight β sheets, as seen in Figure 8 A (Hollis, Lau, & Ellenberger, 2000; 
Lau, Schärer, Samson, Verdine, & Ellenberger, 1998; Setser, Lingaraju, Davis, 
Samson, & Drennan, 2011). The core is composed of a curved antiparallel β sheet 
with a protruding β hairpin that inserts itself into the minor groove while a series of 
α helices and connecting loops compose the rest of the DNA-binding interface (Lau 
et al., 1998).  
 
Figure 8: Crystal structure of human alkyl adenine glycosylase A) Crystal structure of human alkyl adenine 
glycosylase, complexed with pyrrolidine, a potent glycosylase activity inhibitor. AAG binds in the minor groove 
of DNA and flips the pyrrolidine in to its active site. Then, is Tyr162 (purple) is inserted in the flipped base’s 
place; B) Schematic representation of the enzyme contacts with DNA. The dashed lines connecting the 
extrahelical pyr represent water-mediated interactions with residues in the active site. Adapted from: Lau et al., 
1998; Hollis et. al., 2000).  
 
Chapter 1: Introduction 
 
43 
 
1.1.2.2 LESION SEARCH AND PROCESSING  
The question of how AAG faces the herculean task of finding its substrate 
among an overabundance of undamaged DNA is an important one. Even if taken 
into account the relative high generation rate of lesions (Table 1), the enzyme 
would have to search among tens of thousands undamaged bases in a stochastic 
method, what would be a very inefficient process (Mark Hedglin, O’Brien, & 
O’Brien, 2008). What is currently known, is that AAG appears to employ a 
processive search method, adopting a low-affinity conformation that allows the 
enzyme to translocate by rotation-coupled sliding along the DNA axis, and even to 
“hop” to change strands or avoid tightly DNA-bound proteins (M Hedglin & O’Brien, 
2010; Mark Hedglin et al., 2008). What grants the protein this ability is its positive 
electrostatic surface (Figure 9 A) coupled with a disorganization of loops that confer 
important electrostatic interactions (Figure 9 B).  
  
 
Figure 9: Low-affinity c structure of a truncated AAG. A) Electrostatic representation, where represent positive 
charges, white neutral and red are negative-charged areas. The yellow star represents Tyr162. B) Stick 
representation of the same structure as A, highlighting the disorganized areas. Loop 1 includes Glu131-Arg141, 
crucial active site residues, while loops 2 (Gly263−Lys273) and 3 (C-terminal residues after Asp289) do not take 
part in the active site formation, but a nonetheless important in the overall electrostatic potential of the 
protein. Adapted from: Setser et al., 2011.  
When the substrate is found, the enzyme attempts to excise it. The first 
structural insight of how this process happens came from the work of Lau and 
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colleagues (1998), where a catalytic portion of the enzyme co-crystallized with a 
DNA containing pyrrolidine, a glycosylase inhibitor. The DNA is bent around 22◦ 
through the interactions with the enzyme. In this process, the damaged base is 
rotated out of the axis (“flipped”) and a protrusion containing Tyr162 is inserted in 
the vacated slot, presumably serving as a stabilizer, as seen in the scheme 
contained in Figure 8 (Lau et al., 1998). In another similar study, where the N-
terminal truncated AAG (Δ79AAG) was complexed with εA, the contacts with the 
active site were different, the flipped base being stacked between Tyr127 on one 
side and Tyr159 and His136 on the other, with Tyr162 acting in the same manner as 
the previous study (Hollis et al., 2000).  
The mechanism by which AAG cleaves the glycosidic bond is not yet fully 
understood but it is believed that it occurs with the help of a deprotonated water 
molecule acting as a nucleophile, probably activated by Glu125 and aligned to its 
target by the hydrogen-bond interactions with the side chains of Glu125, Arg182 
and Val262, as seen in Figure 10 (Lau et al., 1998).  
 
Figure 10:3D representation of AAG active site. A) Experimental electron density map of the AAG active site. 
B) The active site water, with the representation of the hydrogen bonds it forms with the active site residues. 
Adapted from: Lau et al., 1998.  
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1.1.2.3 SUBSTRATE RECOGNITION AND SPECIFICITY  
As many other AAG characteristics, it is not yet clear how the enzyme 
achieves specificity with such broad variety of substrates. It is thought that more 
than one specificity filter is applied, the first being the nucleotide flipping step. The 
more distortion the damaged nucleobase inflicts upon the structure of the DNA, the 
lower is the kinetic barrier to its flipping, since it tends to bind more weakly to its 
partners (Wolfe, O’Brien, & O’Brien, 2009). Then, after the base is flipped, the 
catalytic mechanism in itself consists of another barrier as general acid catalysis 
allows only damaged purines to be excised, probably due to the lack of stabilising 
interactions that would allow the smaller pyrimidines to be aligned for the 
protonation/nucleophilic attack (Biswas et al., 2002). The third selective filter is the 
active site composition that causes steric clashes between the lateral chains of 
undamaged A and G bases (Connor & Wyatt, 2002). Lastly, the alkylation of N3 and 
N7 leads to the weakening of the N-glycosidic bond, decreasing the activation 
energy demanded to the cleavage and increasing AAG activity (Mark Hedglin et al., 
2008).  
1.1.2.4 INSIGHTS INTO FUNCTION AND BER IMBALANCE 
Although there is relatively extensive knowledge about its structure and 
action, the counterintuitive phenotypic effects of AAG activity remain puzzling. In 
some instances, it is known that the absence of AAG can render the cell sensitive to 
alkylation, as it is normally expected of a DNA repair enzyme (Engelward et al., 
1996). There is also indication that AAG activity is important to protect against 
colon carcinogenesis induced by inflammatory-derived alkylation damage in an 
animal model (J. A. Calvo et al., 2013; Meira et al., 2008). However, a growing body 
of evidence indicates that in many settings AAG activity can be detrimental to 
cellular survival.  
High AAG expression levels and activity was found in both primary breast 
tumour and breast cancer cell lines (Cerda, Turk, Thor, & Weitzman, 1998). More 
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recently, several other tumour types have also been shown to have elevated AAG 
levels, as lung cancer (Leitner-Dagan et al., 2012), oesophageal adenocarcinoma 
(Zair et al., 2013) and malignant glioma (Liu et al., 2012). In the former two 
investigations, the authors even established a positive correlation between the 
glycosylase expression levels and tumour grade.  
The generation of Aag knockout animal models also produced somewhat 
conflicting data on the role of this glycosylase in the protection against DNA 
damage. In a tissue-dependent manner (or sometimes in a cell type-dependent 
manner) the absence of AAG seems to protect from alkylation toxicity. Essays 
performed ex vivo in myeloid progenitors from Aag null mice showed Aag null cells 
to be more resistant to MMS when compared to Aag wild-type myeloid progenitors 
(Roth and Samson 2002). Moreover, mice exposed to streptozotocin (an alkylating 
agent that induces selective β-cell death in the pancreas) also seemed to be 
protected by the lack of Aag (Burns & Gold, 2007). 
Notwithstanding, there is one very illustrative piece of research that 
demonstrates quite clearly some of the particularities of AAG activity. In this 
investigation conducted by Meira, Moroski-Erkul et al. (2009) a continuum of Aag 
genotypes in mice (Aag -/-, Aag +/-, Aag WT and Aag Tg overexpressor) was analysed, 
showing that alkylation-induced cell death increases proportionally with the Aag 
gene copy number (and expression) and that in the retina, the degeneration seems 
limited to cells found in a particular region in the retina, namely the outer nuclear 
layer, while adjacent cells are not affected (Meira et al., 2009). A similar pattern was 
also found in a recent investigation that showed increased degeneration in 
cerebellar granular cells in Aag Tg (Aag overexpressors) mice when compared to 
WT animals, while Purkinje cells, also in the cerebellum, remained unaffected (J. A. 
Calvo et al., 2013). 
This alkylation-induced AAG-related degeneration was recently shown to 
be mediated by another enzyme, namely Poly (ADP)-Ribose Polymerase 1 (PARP1) 
(J. A. Calvo et al., 2013). PARP1 is an abundant nuclear protein that performs several 
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distinct cellular roles, as transcription regulation, chromatin remodelling, 
replication, and is involved in both SSB and DSB repair signalling (Gibson & Kraus, 
2012). It is believed that PARP1 acts as a SSB sensor, catalysing, from nicotinamide 
adenine dinucleotide (NAD+), the formation of poly-ADP ribose polymers (PAR) onto 
itself and other proteins, resulting in the recruitment of repair effectors such as 
XRCC1 and DNA pol β to the DNA break (Gassman, Stefanick, Kedar, Horton, & 
Wilson, 2012). Excessive accumulation of DNA damage may lead to PARP1 
hyperactivation, dramatically increasing energy consumption and ultimately leading 
to bioenergetics failure and cell death through a caspase-independent mechanism 
called programmed necrosis (Vandenabeele, Galluzzi, Vanden Berghe, & Kroemer, 
2010).  
AAG-mediated toxicity has been widely as a prospective strategy to 
sensitize neoplastic cells to alkylating treatments. Through such strategies, the 
effective therapeutic dosage can be lowered to minimize residual mutagenesis (and 
eventually secondary oncogenesis) in healthy tissues, usually associated with these 
treatments (Paik, Duncan, Lindahl, & Sedgwick, 2005). Increased sensitivity has 
been achieved by overexpressing either AAG alone or in combination with other 
modulations in breast (M. L. Rinne, He, Pachkowski, Nakamura, & Kelley, 2005), 
ovary (Fishel, He, Smith, & Kelley, 2007) and glioblastoma cell lines (Goellner et al., 
2011; Tang et al., 2011).  
The prevailing rationale for the underlying sensitization mechanism 
resulting from AAG overexpression is that, at least in part, the downstream BER 
enzymes are unable to cope with the increase in the repair by-products (e.g. AP 
sites) that such overexpression causes, generating what is called a BER imbalance 
(Fu et al., 2012; Klapacz et al., 2010; Meira et al., 2009). Though reasonable, there is 
no unifying theory that explains all the different outcomes observed as a 
consequence of AAG modulation. In fact, the absence of the glycosylase can be also 
used to render cells more vulnerable to alkylation damage, as observed by two 
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independent studies in ovarian carcinoma (Paik et al., 2005) and glioblastoma cell 
lines (Iyer et al., 2012). 
The cellular context (proliferative status, tissue, BER capabilities), lesion 
nature and subcellular source of imbalance may explain some of the varied 
outcomes. Since 2013 is it known that AAG also localizes to the mitochondria and 
there plays a role in short-patch BER (van Loon & Samson, 2013). Even before that, 
however, some of the AAG overexpression studies (Fishel, Seo, Smith, & Kelley, 
2003; Harrison et al., 2007) made use of targeting sequences that aimed to 
overexpress AAG in this subcellular compartment, with conflicting results. Harrison 
and colleagues (2007) found that nuclear overexpression, rather than mitochondrial 
overexpression, sensitizes primary rat astrocytes to MNU toxicity. However, it is 
possible that this effect is attributable to experimental issues leading to a much 
higher overexpression in the nucleus than in the mitochondria, caused by different 
transduction efficiencies. 
In contrast, the investigation conducted by Fishel et al. in 2003, found that 
AAG mitochondrial overexpression was the main determinant of MMS sensitivity. 
This finding is consistent with a series of characteristics inherent to mitochondrial 
DNA. Mitochondrial DNA is gene-dense, has no introns and a neglectable amount of 
intergenic sequences (Kazak, Reyes, & Holt, 2012). It has close proximity with the 
main source of cellular ROS and is absent of histone protection, rendering it more 
apt than the nucleus to accumulate lesions as deaminations and lipid peroxidation 
sub products (Kazak et al., 2012). It is also known that it accumulates more damage 
(and more quickly) from oxidative and alkylating agents (Yakes & Van Houten, 
1997).  
All these specific mtDNA traits could explain the higher mutation rate 
found in mitochondrial DNA (Craigen, 2012). To repair the damage, mitochondria 
relies heavily on its own BER, remarkably similar to the nuclear pathway (Harrison 
et al., 2007), with AAG probably being the main or even the only enzyme that is 
responsible for the removal of alkylated bases in the mitochondria. 
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Curiously, though AAG seems important to mitigate the effect of alkylation 
and methylation in vitro (Engelward et al., 1996), to battle chronic inflammation (J. 
a Calvo et al., 2012; Meira et al., 2008), to counterbalance the effects of the 
alkylating agents urethane and vinyl carbamate in mice (Barbin, Wang, O’Connor, & 
Elder, 2003; Ham et al., 2004) or to repair psoralen induced interstrand crosslinks 
(Maor-Shoshani, Meira, Yang, & Samson, 2008). It also seems that under some 
conditions, AAG activity may have deleterious effects. Studies linked AAG activity 
with β-cell necrosis in toxic-induced diabetes in mice (Burns & Gold, 2007) retinal 
degeneration induced by methyl methanesulfonate (Meira et al., 2009), with effects 
that are even more exacerbated with the overexpression of the enzyme. However, 
the dramatic effect observed by the overexpression is possibly due (at least in part) 
to the inability of the downstream BER enzymes to deal with the increase of the 
repair by-products such as AP sites, generating what is called of BER imbalance 
(Meira et al., 2005). 
Even so, taking into account the imbalance effects, AAG sometimes seems 
to exert adverse effects on the repair of certain lesions. A quite well investigated 
example is the hijacking of the enzyme caused by the lipid peroxidation by-product 
3,N4-Ethenocytosine (εC). When the enzyme encounters such lesion it tends to 
attach itself to it with 2-fold more affinity than to the εA substrate (Lingaraju, Davis, 
Setser, Samson, & Drennan, 2011) although it is incapable of repairing it. This 
inability is believed to be linked with the additional hydrogen bond it establishes 
(Figure 11) with the active site and with the absence of a nitrogen in the position 7, 
the protonation target for the base removal (Gros, Maksimenko, Privezentzev, 
Laval, & Saparbaev, 2004; C.-Y. I. Y. I. Lee et al., 2009). Thus, the enzyme is 
incapable of detaching itself from the lesion and may shield it from repair by human 
AlkB homolog 2 (ALKBH2), ultimately eliciting mutagenesis (Fu & Samson, 2012). 
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Figure 11 Superimposition of binding of εA and εC to AAG. The εA is coloured salmon (DNA) and blue 
(protein), while εC (Brooks, Adhikary et al. 2013) is silver and gold. Hydrogen bonds are represented by dashed 
lines. The catalytic water (red sphere) is in position to protonate N7 of εA that would, in turn, donate a 
hydrogen bond to Ala134. In contrast, εC does not have an ionisable group at this position. 
A similar situation seems to happen with some base-pair loops that are 
normally substrates to MMR. AAG binds to them with considerable strength making 
them inaccessible to repair, inducing mutagenesis and microsatellite instability 
(Klapacz et al., 2010). 
It was precisely the search for a better understanding of how AAG 
modulates the response to alkylation that guided us to a rather distinct avenue of 
investigation. The comparison of the MMS-induced transcriptional profiles in wild 
type and Aag -/- liver showed that the DNA repair process itself, initiated by Aag, is 
linked to a robust response (Figure 12 A, 229 unique transcripts modulated in the 
wild type liver vs. 108 in the Aag null liver; FC>1.5, adj. p-value<0.05), with 
minimum overlap between genotypes (26 transcripts are modulated in both, Figure 
12 A). Alkylating agents target a variety of cellular macromolecules and the 
genome-wide response to alkylation was found to encompass a plethora of 
biological processes. Clustering and gene ontology enrichment analysis showed that 
the alkylation-induced transcriptional response is profoundly altered in the absence 
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of Aag, when methylated DNA base damage is expected to persist (Figure 12 B). 
Importantly, transcripts related to endoplasmic reticulum (ER) stress/unfolded 
protein response (UPR) and the acute phase response are up-regulated after MMS 
treatment, but ONLY in the wild type (Figure 12 B).   
 
Figure 12: Aag deficiency modifies the transcriptional response to alkylation. Total RNA was isolated 
from livers of AAG proficient and AAG-deficient mice and submitted to microarray analysis A) Venn 
diagram representing the number of unique or common transcripts significantly modulated in a 
genotype-specific manner. B) Hierarchical clustering of the alkylation-induced transcriptional response 
(N=3 animals per genotype/treatment). Green/yellow areas represent an increase in transcription 
compared to untreated controls while blue areas represent a decrease (numbers on scale represent 
fold-change related to untreated controls). Grey areas represent no differential expression. A grey 
area can be noted only on the Aag -/-  livers (absence of change) relating to transcripts involved in ER 
stress, UPR and Acute Phase Response. 
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Thus, as suggested by these results, we hypothesized that Aag may have a 
hitherto unknown participation in the ER stress. With that in mind we begun to 
investigate how AAG modulation could impact ER stress and what is the mechanism 
behind this novel function.  
 
 ER STRESS AND UNFOLDED PROTEIN RESPONSE 
The ER is an organelle that provides an isolated environment where a 
variety of critical cellular processes happen: lipid and fatty acid biogenesis, cellular 
membrane manufacturing, calcium homeostasis control (Schönthal, 2012) and it 
also participates in the biogenesis of the autophagosomes (Ao, Zou, & Wu, 2014). 
More importantly, it is where an average of 30% of the whole proteome of the 
eukaryotic cells is properly folded (Hetz, 2012). Therefore, giving considerable 
variability in the demand, both due to cell function and metabolic state, the ER 
needs to be highly dynamic and respond quickly to a wide range of stimuli that 
encompasses viral infection, inflammation, hypoxia, glucose deprivation and 
temperature fluctuations (M. Wang & Kaufman, 2016). In order to sense and react 
to those threats, a complex network whose objective is to re-establish protein 
homeostasis has evolved. Functionally, the ER stress response can be divided in 
three waves: the first, whose objective is to reduce incoming protein load in the ER 
(by attenuating translation, for example), the second, aimed to enhance protein 
folding (by increasing the levels of chaperones and size of the ER) and if all these 
pro-adaptive strategies fail, the cell shifts to a third (pro-apoptotic) wave (Ron & 
Walter, 2007).  
Collectively these responses are named the Unfolded Protein Response 
and can be triggered by three ER transmembrane proteins that are able to sense ER 
stress and relay a signal to downstream effectors, named Inositol-Requiring Enzyme 
1 (IRE1), Protein kinase RNA (PKR)-like ER Kinase (PERK) and Activating Transcription 
Factor 6 (ATF6), as can be seen in Error! Reference source not found..  
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Figure 13: Schematic representation of the UPR. Upon BiP dissociation IRE1 and PERK dimerize and 
auto phosphorylate. Activated IRE1 splices XBP1 in its active form and XPB1s activates several UPR 
genes. Activated PERK phosphorylates both Nerf2 and eIF2α. P-eIF2α represses translation from 
usual ORFs and ATF4 is translated from a uORF, translocates to the nucleus to activate UPR genes. 
When BiP dissociates form ATF6, it exposes a Golgi localization signal that activates its translocation 
to this organelle with the help of Coat Protein II. Once in the Golgi, ATF6 is cleaved into its active 
form by Site proteases 1 and 2 and the cytoplasmic fragment translocates to the nucleus to also 
activate a series of UPR genes. 
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1.2.1 IRE1 
IRE1 is the most conserved of the three pathways in the UPR (Sidrauski & 
Walter, 1997). It is a type I transmembrane protein with a ER luminal and a cytosolic 
domains connected by a transmembrane helix (Shamu & Walter, 1996). It has two 
highly conserved isoforms: IRE1α (expressed in most cells) and IRE1β (present only 
in epithelial cells of the gut) (Tirasophon, Welihinda, & Kaufman, 1998; X. Wang et 
al., 1998). A summary of IRE1 activation’s consequences are shown on Figure 14. 
The canonical activation of the IRE1 cascade starts in its ER luminal domain. 
In unstressed cells, this domain is associated with a ubiquitous chaperone protein 
named Binding Immunoglobulin Protein (BiP). When BiP detects proteostatic 
perturbations in the ER, it releases IRE1 and associates with the unfolded proteins 
(Ron & Walter, 2007). This exposes a region that allows oligomerization, activating 
its kinase activity, what causes it to trans phosphorylate the other IRE1 monomers 
(Bertolotti, Zhang, Hendershot, Harding, & Ron, 2000). For some time it was 
believed that the kinase activity of IRE1 had as a target only itself, however, there is 
evidence that it can associate with tumour-necrosis factor (TNF)-receptor-
associated factor 2 (TRAF2) that ultimately leads to activation of JUN N-terminal 
kinase (JNK) and promotes autophagy or apoptosis through activation of caspase-12 
or with NF-κB (Ogata et al., 2006; Urano, 2000; Yoneda et al., 2001). 
In mammalians, the back to back dimerization and autophosphorylation 
drives a conformational change that activates an unconventional endoribonuclease 
activity on the cytosolic domain, that catalyses the splicing of the X-Box binding 
Protein 1 (XBP1) mRNA (Joshi et al., 2015; M. Maurel, Chevet, Tavernier, & Gerlo, 
2014). The endonuclease domain also participates in the IRE1-dependent decay of 
mRNA (RIDD) aimed at decreasing the protein load (discussed in further detail 
ahead on text). 
IRE1 acts by splicing 26 nucleotides from XBP1u (from unspliced) and 
causes a frameshift that produces XBP1s (spliced) which includes a C-terminal 
transactivation domain absent from the unspliced form (H Yoshida et al., 2001). This 
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change also increases the stability of the spliced transcript allowing it to translocate 
to the nucleus and transcriptionally activate UPR related genes (He et al., 2010). 
Some studies indicate that the XBP1u can negatively regulate XBP1 nuclear 
translocation and act as negative feedback regulator for its own splicing (A.-H. Lee, 
Iwakoshi, Anderson, & Glimcher, 2003; Hiderou Yoshida, Oku, Suzuki, & Mori, 
2006). However, when Xbp-1 -/- MEFs are complemented with XBP1u mutants that 
present improved stability, the protein generated by XBP1u is capable of activating 
BiP and Chop (Tirosh, Iwakoshi, Glimcher, & Ploegh, 2006).The XBP1u polypeptide 
seems also to recruit additional XPB1 mRNAs to close proximity to the ER 
membrane, facilitating XBP1 splicing capabilities (Yanagitani et al., 2009). Both 
studies seem to challenge the notion that XBP1u downregulates its spliced form, or 
at least indicate that the regulation of XBP1 is more nuanced than it was first 
assumed. 
In the UPR context, XBP1 has several targets that include chaperones to 
increase folding capacity in the ER (such as BiP, GRP94, DNAJC1, DNAJC3) and 
triggers the ER-associated protein degradation (ERAD) by activating the ER 
Degradation-Enhancing Alpha-Mannosidase-Like Protein (EDEM) gene (A.-H. Lee, 
Iwakoshi, & Glimcher, 2003). XBP1 is a very versatile transcriptional factor and 
besides targeting genes involved in glycosylation, redox metabolism, autophagy, 
lipid biogenesis and vesicular targeting, also has many tissue-dependent functions 
as development of pancreatic exocrine acinar cells, B cell differentiation and 
adipogenesis (Acosta-Alvear et al., 2007; A.-H. H. Lee, Chu, Iwakoshi, & Glimcher, 
2005; A.-H. H. Lee, Scapa, Cohen, & Glimcher, 2008). 
The expression of Xbp1 is also essential for embryonic development in mice 
and Xbp1 -/- foetuses die at day 13.5 to 14.5 showing severe liver growth 
impairment, implicating the transcription factor in hepatocyte growth and survival 
(Reimold et al., 2000). Xbp1 -/- mice carrying a liver-targeted form of Xbp1 are viable 
until early postnatal period, when they die by the lack of secretion of digestive 
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enzymes, possibly caused by inability of the developmental UPR activation to adapt 
pancreatic cells to a secretory role (A.-H. H. Lee et al., 2005). 
Perturbations on XBP1 expression are associated with many pathological 
effects. High levels of XBP1s in a subset of primary human myeloma cells and 
overexpression of XBP1s in mice replicated the pathological findings in patients with 
multiple myeloma (Carrasco et al., 2007). High XBP1 expression was also found in 
breast cancer primary cells and hepatocellular carcinoma (Fujimoto, Onda, Nagai, 
Nagahata, & Ogawa, 2003; Shuda et al., 2017). Xbp1 haploinsufficiency in mice 
results in hyperactivation of ER stress, insulin resistance and type 2 diabetes 
suggesting also a link with this pathology (Özcan et al., 2004). 
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1.2.1.1 REGULATED IRE1 DEPENDENT DECAY - RIDD 
In 2006 it was found in Drosophila that IRE1 was capable of degrading a 
subset of mRNAs in a XBP1-independent manner through its endoribonuclease 
domain (Hollien & Weissman, 2006). This mechanism was termed RIDD (from 
Regulated Ire1 Dependent Decay) and has been considered a sophisticated fine-
tune switch in the UPR.  
Figure 14: IRE1 targets and biological effects. XBP1u is spliced into its active form and transcriptionally 
activates a series of UPR related genes. HDAC: histone deacetylase, BiP: Binding immunoglobulin 
Protein, GRP94: 94 KDa Glucose-Regulated Protein, DNAJC1: DnaJ Heat Shock Protein Family (Hsp40) 
Member C1, DNAJC3: DnaJ Heat Shock Protein Family (Hsp40) Member C3, EDEM: ER Degradation-
Enhancing Alpha-Mannosidase-Like Protein. 
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When ER stress is triggered, RIDD degrades ER associated mRNAs and the 
28S ribosomal RNA to alleviate the protein load in the ER during stress and (Iwawaki 
et al., 2001), if the stress is prolonged and remains unresolved, gradually increases 
and degrades several anti-apoptotic miRNAs (caspase 2 inhibitors, for instance) 
(Upton et al., 2012), pre-miRNAs and even the BiP mRNA, driving the cell to 
apoptosis (Han et al., 2009). 
The degradation needs to be tightly coordinated: RIDD not only shows a 
preference towards ER-located mRNA (M. Maurel et al., 2014)s, but also towards a 
XBP1-like consensus site, 5’-CUGCAG-3’, associated with a hairpin-like secondary 
structure (Oikawa, Tokuda, Hosoda, & Iwawaki, 2010). Interestingly IRE1 was also 
found to be associated with the nuclear envelope (K. Lee et al., 2002) and therefore 
is reasonable to assume that it may also have access to mRNAs exiting through the 
nuclear pore widening its range of possible substrates. 
Moreover, RIDD seems to be active in basal conditions in moderate levels, 
presumably maintaining ER homeostasis via mRNA or miRNA degradation serving 
diverse functions as stimulating innate immunity (Cho et al., 2013) and controlling 
lipid homeostasis (So et al., 2012). Thus, although RIDD is far from well understood, 
it seems to play a prominent role in homeostasis of a wide range of processes.  
1.2.2 PRKR-LIKE ENDOPLASMIC RETICULUM KINASE - PERK 
PRKR-Like Endoplasmic Reticulum Kinase or PERK is also a type I 
transmembrane protein that has a great resemblance to IRE1. Both proteins are 
phylogenetically related and their ER luminal domains are conserved to the point of 
being interchangeable (Bertolotti et al., 2000). As with IRE1, its activation happens 
when BiP dissociates from the luminal domain to attend to accumulated unfolded 
proteins in the ER, however, distinct from IRE1, the homodimerization domain is 
not occluded by BiP and extends beyond the IRE1 homology domain, thus BiP 
inhibition is probably due to allostericity (K. Ma, Vattem, & Wek, 2002). 
Oligomerization leads to autophosphorylation and here lies another important 
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difference to IRE1: the kinase domain of PERK, rather than having only itself as 
substrate, is also capable of acting upon other proteins.  
Activation of PERK leads to two direct outcomes: phosphorylation of the α 
subunit of eukaryotic transcription factor 2 (eIF2α) and phosphorylation of Nuclear 
Factor (Erythroid-Derived 2)-Like 2, Nrf2, represented on Figure 15 (Cullinan et al., 
2003; Harding, Zhang, & Ron, 1999).  
The main consequence of eIF2α phosphorylation is a cell-wide attenuation 
of translation that can eventually lead to a depletion of the labile cyclin D1, making 
the cell unable to initiate DNA replication (Brewer & Diehl, 2000; Harding et al., 
1999), giving the cell time to trigger its ER stress adaptation programme. The 
phosphorylation of eIF2α leads to a change in the efficiency of the usage of AUG 
start codon in the open reading frame (ORF), by inhibiting the exchange GDP for 
GTP in eIF2α, interfering with the binding methionyl-initiator tRNA (Met-tRNAMet) 
and decreasing the concentration of the 43 S translation preinitiation complex. This 
reduces eIF2α activity and causes the ribosome to “skip” inhibitory uORFs contained 
in the mRNA (Ron & Walter, 2007; Schröder & Kaufman, 2005; Vattem & Wek, 
2004). Thus, it leads to preferential reading of upstream ORFs (uORFS) and 
translation of Activating Transcription Factor 4 (ATF4). The main effects of eIF2α 
activation can be seen on Figure 15. 
ATF4 regulates genes for amino acid metabolism, oxidative stress, 
mitochondrial function (Harding et al., 2003) receptor activator of nuclear factor-
kappa B (RANK) ligand (RANKL)(Blais et al., 2004), VEGF (Nathaniel Roybal, 
Hunsaker, Barbash, Vander Jagt, & Abcouwer, 2005). If PERK activation is sustained, 
ATF4 accumulates and activates the proapoptotic C/EBP-homologous protein 
(CHOP) (Harding et al., 2000). CHOP, in turn promotes apoptosis by downregulation 
of pro-survival BCL-2 expression and upregulation of Bcl2-Interacting Mediator of 
cell death (BIM) and p53 Upregulated Mediator of Apoptosis (PUMA) (Scorrano, 
2003). CHOP is also reported to inhibit p21, a protein that can have pro-survival 
nuclear effects by arresting cells during G1/S to allow cell recovery from stress (e.g. 
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DNA damage) (Karimian, Ahmadi, & Yousefi, 2016; Mihailidou, Papazian, 
Papavassiliou, & Kiaris, 2010). 
Another important target of CHOP is the Growth Arrest and DNA Damage-
inducible 34 (GADD34), a subunit of the Protein Phosphatase type 1 (PP1). Its 
activation leads to the dephosphorylation of eIF2α, resuming translation (Hetz, 
2012). Although this can signal the recovery of the ER stress, it can also be a 
mechanism to precipitate cell death, as the influx of new proteins into the ER can 
terminally enhance ER stress by triggering generation of ROS (Schönthal, 2012) 
The second target of PERK phosphorylation is the transcription factor Nrf2 
(Figure 15). Upon PERK phosphorylation, Nrf2 dissociates from Keap1 (Kelch-like 
ECH-associated protein 1) and translocates to the nucleus to activate genes that 
possess antioxidant response elements (ARE) (Digaleh, Kiaei, & Khodagholi, 2013). 
To effect this activation, Nrf2 heterodimerizes with other transcription factors such 
as ATF4 and c-Jun, Jun-B, and Jun-D (Kensler, Wakabayashi, & Biswal, 2007). The 
ARE-containing genes are a set of genes that command phase II metabolism of 
xenobiotics and among them are the subunits A1 and A2 of glutathione S-
transferase, heme oxygenase and NQO1 [NAD(P)H: quinone oxidoreductase] 
(Nguyen, Sherratt, & Pickett, 2003). This connects the UPR to yet another seemingly 
unrelated process, the oxidative regulation of the cell. 
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1.2.2.1 INTEGRATED STRESS RESPONSE – ISR 
The integrated stress response is an alternative UPR pathway that is 
activated by a wide range of extrinsic factors that include amino acid and glucose 
deprivation and viral infection among others, but can also be triggered by intrinsic 
signals like ER stress (Pakos‐Zebrucka et al., 2016). The ISR converges to the PERK 
pathway through phosphorylation of eIF2α that can be induced by at least 14 
distinct stimuli (Taniuchi, Miyake, Tsugawa, Oyadomari, & Oyadomari, 2016).  
Besides PERK, eIF2α can be phosphorylated by three distinct kinases in 
vertebrates: Heme-Regulated Inhibitor (HRI), activated during heme deficiency 
Figure 15: Main targets of PERK activation and biological effects. ARE: antioxidant response elements, 
ER; ERAD: Endoplasmic Reticulum-Associated Degradation, ISR: Integrated Stress Response. 
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(Donnelly, Gorman, Gupta, & Samali, 2013), Protein Kinase R (PKR), activated during 
viral infection by the binding of double-stranded RNA (dsRNA) to its two conserved 
dsRNA binding domains (P. D. Lu, Harding, & Ron, 2004), General Control Non-
depressible 2 (GCN2) is activated under amino acid deprivation by the binding of 
uncharged tRNA to the regulatory domains (Novoa, Zeng, Harding, & Ron, 2001) 
and although each of these kinases are inducible by distinct stimuli, they share 
extensive homology with other (Taniuchi et al., 2016). 
Although phosphorylation of eIF2α by any of the cited kinases invariably 
results in transcription of ATF4, the signalling of the ISR can be modulated by a 
multitude of factors. Not only extent and duration of eIF2α phosphorylation 
changes how the signals are interpreted, but the formation of heterodimers 
between ATF4 and other bZIP or AP-1 members can greatly influence the activation 
outcomes (Pakos‐Zebrucka et al., 2016). When bound to DNA, ATF4 is a monomer, 
but it can form heterodimers with ATF3, to enhancing pro-survival gene 
transcription, while when interacting with CHOP it can precipitate cell death. 
(Hiwatashi et al., 2011; Ohoka, Yoshii, Hattori, Onozaki, & Hayashi, 2005; Q. Wang 
et al., 2009).  
Besides GADD34, already mentioned previously, eIF2α phosphorylation is 
controlled by CReP, from Constitutive Repressor of eIF2a Phosphorylation. As the 
name indicates, CReP is constitutively expressed and exerts a baseline 
dephosphorylation activity to avoid over repression of translation (Ron & Walter, 
2007) 
In summary, the ISR is an extremely complex regulatory network (see 
Figure 16), with numerous possible outcomes that share many of the core effectors 
of the UPR, adding an extra layer of complexity to an already intricate phenomenon. 
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1.2.3 ACTIVATING TRANSCRIPTION FACTOR 6 
Activating Transcription Factor 6 is a type II transmembrane domain 
protein and it is present in two isoforms in mammalians: ATF6α and ATF6β (H. 
Yoshida et al., 2001). The first steps on the activation of the third branch of the UPR 
retains some similarities with IRE1 and PERK: BiP is associated with the ER terminal 
domain of Activating Transcription Factor 6 and, when it detects the accumulation 
Figure 16: Representation of the Integrated Stress Response. eIF2α can be phosphorylated by one of 
four kinases activated by the ISR: PERK, PKR, HRI or GCN2, where it allows transcription of ATF4. The 
outcomes of ATF4 transcritptional activation depend highly on the associations it keeps with additional 
transcription factors (not shown), but can vary from chaperone upregulation, antioxidant response or 
autoinhibition. Both GADD34 and CRep can be activated by ATF4 and dephosphorylate eIF2α, restarting 
translation. Source Ron & Walter 2007/ 
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of unfolded proteins it dissociates from ATF6 in favour of those (Marion Maurel & 
Chevet, 2013). However, instead of exposing an oligomerization domain, BiP 
dissociation exposes a Golgi localization sequence, that initiates ATF6 translocation 
to this organelle through its interaction with Coat Protein II (COPII) (Chen, Shen, & 
Prywes, 2002; Hetz, 2012). 
Once in the Golgi apparatus, ATF6 is cleaved in its luminal domain by Site-1 
Protease (S1P) and its N-terminal anchored portion is cleaved by Site-2 Protease 
within the lipid bilayer, releasing the cytosolic bZIP domain of ATF6 (ATF6f, of 
fraction), that translocates to the nucleus and activates UPR-related genes (Haze, 
Yoshida, Yanagi, Yura, & Mori, 1999; Ye et al., 2000). Among those are the 
transcription factor XBP1, the pro-apoptotic protein CHOP, the chaperone BiP (all 
mentioned previously), and Homocysteine Inducible ER Protein with Ubiquitin Like 
Domain 1 (Herp, homolog of S. cerevisiae Mif1), a protein that is associated with 
calcium homeostasis and the ERAD (Arnould, Michel, & Renard, 2015), shown on 
Figure 17. 
The importance of this branch of the UPR in mammalians is underscored by 
the fact that, while mice that lack either ATF6α or ATF6β are phenotypically normal, 
the deletion of both genes is embryonic lethal (Yamamoto et al., 2007).  
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1.2.4 ENDOPLASMIC RETICULUM-ASSOCIATED DEGRADATION - ERAD 
The Endoplasmic Reticulum-Associated Degradation (ERAD) is a mechanism 
of protein quality control that can be triggered by the UPR. In a series of relatively 
complex steps, misfolded proteins are identified with the help of chaperones (e.g. 
calnexin and calreticulin) in the ER lumen guided to retrotranslocation complexes 
whose composition varies according to the protein’s nature. When partially 
retrotranslocated E3 ubiquitin ligases polyubiquitinylates the damaged proteins and 
when transport to the cytoplasm is finished the proteasome recognizes them as a 
Figure 17: Main targets of ATF6 activation and biological effects. After cleavage, ATF6f translocates to 
the nucleus and activates several UPR genes, among them Herp, BiP, CHOP and XBP1. 
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substrate and degrades them, as can be seen in Figure 18 (Vembar & Brodsky, 
2008). 
As many other pathways, the UPR uses ERAD as one of many strategies to 
attain proteostasis and a large number of genes can be activated to elicit it (Travers 
et al., 2000). Activation of ERAD factors is shared by all branches of the UPR: the 
IRE1 branch activated EDEM (ER degradation- enhancing α-mannosidase-like lectin), 
which is directly responsible for recognition of terminally misfolded proteins and 
their retrotranslocation from the ER for degradation (Olivari & Molinari, 2007); 
Herp, a protein that putatively recruits the 26 S proteasome to the ER membrane 
during stress has its activation shared by both ATF4 and ATF6 and NRF2 (Y. Ma & 
Hendershot, 2004). 
Dysregulation of the ERAD is linked to debilitating degenerative diseases, 
either by loss of function mutations (e.g. familial Parkinson’s disease) or excessive 
degradation (e.g. cystic fibrosis) (Meusser, Hirsch, Jarosch, & Sommer, 2005; 
Tanaka, Suzuki, Hattori, & Mizuno, 2004). 
Figure 18: Schematic representation of the ERAD. A) Damaged or misfolded proteins are recognized by 
chaperones such as calnexin and calreticulin and protein disulphide isomerases (PDIs). B) The identified 
proteins are targeted to the retrotranslocation machinery/or E3 ligases. C) the retrotranslocation for the 
cytosol happens in an energy-depended mechanism that may require cell-division cycle 48 (Cdc48) 
and/or other components. D) Proteins are polyubiquitinylated by E3 ubiquitin ligases and finishes 
retrotranslocation. E) The polyubiquitinylated protein is recognized by the proteasome and degraded. 
Source: Vembar & Brodsky 2008.  
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As can be gathered from this simple introduction, the UPR is a vast and 
complex network that responds to wildly varied stimuli. Many animal models were 
developed so far to investigate the connections UPR dysregulation and disease 
(Table 3). The importance and range of action of these genes is highlighted by the 
fact that not only their absence can cause quite varied effects, but also that many of 
those are lethal. 
Table 3: Phenotypes for UPR knockout mice models.  
Phenotype IRE1α XBP1 ATF6α PERK ATF4 
Full knockout 
Embryonic lethal Yes Yes No No No 
Postnatal death – – No Yes No 
Tissue-specific effects 
Decreased Ig secretion by B cells Yes Yes – No - 
Exocrine pancreas alteration Mild Yes – Yes – 
Endocrine pancreas and insulin secretion alteration Yes Yes Yes Yes Yes 
Lipid abnormalities in liver Yes Yes Yes Yes – 
Altered bond formation – – – Yes Yes 
Blind, altered eye lens No No No No Yes 
Impaired glucose metabolism Mild Yes – Yes Yes 
*Published on Hetz et al. 2012. 
There is also an extensive body of evidence connecting ER disturbances in 
function and human pathologies as varied as the processes it controls: multiple 
myeloma, type 1 and 2 diabetes, amyotrophic lateral sclerosis, Parkinson’s Disease, 
Alzheimer’s Disease, obesity, cancer malignancy and resistance, among others (Hetz 
& Mollereau, 2014; Schönthal, 2012; Todd, Lee, & Glimcher, 2008; M. Wang & 
Kaufman, 2014). A summary of some of the evidence gathered so far can be seen 
on Table 4. 
Therefore, given the great importance to human health of both DNA repair 
and response to alkylation, as well the unfolded protein response for the 
maintenance of homeostasis, it is of paramount importance to understand the 
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interplay between these two apparently unrelated subjects. In this work, we show 
that Alkyladenine DNA Glycosylase not only modulates response to alkylation 
through its repair activity, but also affects the ER stress signalling in a hitherto 
unreported interface between a DNA repair glycosylase and the unfolded protein 
response. 
Table 4: Summary of the evidence connecting ER stress to human pathologies.  
Pathology Linkage to ER stress 
Type 2 Diabetes 
(i) Obesity induces ER stress  
(ii) Hyperlipidemia and hyperglycemia induce ER stress 
(iii) Free fatty acids (palmitate) induce beta cell apoptosis 
(iv) Deletion of CHOP improves beta cell function and survival 
Atherosclerosis 
(i) Oxidized lipids induce ER stress  
(ii) Hyperhomocysteinemia induces ER stress 
(iii) Cholesterol loading induces ER stress-mediated cell death 
(iv) Reduced plaque necrosis in mice lacking CHOP 
Non-alcoholic fatty liver 
disease 
(i) Forced GRP78 expression reduces hepatic steatosis in mice 
(ii) ER stress activates cholesterol and triglyceride biosynthesis  
(iii) Hyperlipidemia and hyperglycemia induce ER stress 
Alcoholic liver disease (i) Alcohol induces ER stress 
Heart disease 
(i) ER stress contributes to cardiomyocyte apoptosis  
(ii) Activation of ER stress in infarcted mouse heart 
(iii) GRP78 and GRP94 protect against ischemic injury 
HBV and HCV infection 
(i) HBV induces GRP78 and GRP94 
(ii) HCV suppresses IRE1/XBP1 pathway 
Alzheimer’s disease 
(i) Mutant presenilin 1 induces ER stress 
(ii) Mutant presenilin 1 sensitizes to ER stress-induced 
apoptosis  
(iii)  AD brains show ER stress features 
Parkinson’s disease 
(i) Parkin expression impacts ER stress 
(ii) ATF4 leads to increase in parkin expression 
Huntington disease 
(i) Polyglutamine induces ER stress 
(ii) ER stress markers are present in post-mortem HD brain 
Amyotrophic lateral 
sclerosis 
(i) Mutant SOD1 activates ER stress  
(ii) Mutant SOD1 interferes with ERAD 
(iii) ER stress markers detected in spinal cord of ALS patients 
Prion disease 
(i) ER stress markers detected in brains affected with prions  
(ii) ER chaperones are involved in regulation of misfolded prion 
protein 
Cancer 
(i) Tumour-specific microenvironment activates ER stress  
(ii) Cancer cells display chronic display of ER stress markers  
(iii) Knockdown of GRP78 or of CHOP affects chemosensitivity 
*Modified from Schönthal, 2012.  
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 PROBLEM STATEMENT AND OBJECTIVES 
Our main objective in this study was to describe and characterize the 
involvement of the Alkyladenine glycosylase in the ER stress response and 
understand the impact of AAG modulation in the elicitation of the Unfolded Protein 
Response. In order to achieve this aim, we proposed the following objectives. 
• Establish differentially modulated AAG cell lines and characterize 
their response to alkylation damage (Chapter 3); 
• Identify and characterize the participation of AAG in the ER 
response and the effect of said modulation on the UPR (Chapter 4); 
• Characterize the impact of AAG modulation on the proteome our 
cell models (Chapter 5).
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2 Evaluation of the 
phenotypes resulting from AAG 
expression in different 
subcellular compartments 
 INTRODUCTION  
DNA repair systems are ubiquitous and communicate with several 
fundamental cellular processes as replication, transcription and recombination, in 
order to protect and preserve the integrity of genomic information of all living 
organisms. However, even under optimal conditions, DNA damage cannot be 
completely avoided, being a result of its inherent chemical instability or of its 
interaction with a variety of chemical and/or physical agents.  
Some of the spontaneous damage can occur through spontaneous 
deamination and/or depurination events and by the action of endogenous oxidative 
or alkylative metabolic by-products derived from normal cell function. In 
mammalians, Base Excision Repair is responsible by the removal of such subtly 
modified bases and appears to be the preponderant repair mechanism in the 
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mitochondria (Druzhyna, Wilson, & LeDoux, 2008). Besides base damage repair, BER 
is also necessary to process single strand breaks derived from AP sites (Krokan & 
Bjørås, 2013). 
Being of such vital importance it is expected that issues with its activity 
may lead to disturbance of the cell homeostasis. In fact, defects in BER have been 
implicated in many pathological conditions as cancer, inflammation and 
neurological disfunction (Caldecott et al., 1995). Moreover, since BER is responsible 
for the repair of oxidative damage associated with ageing cells , its disfunction can 
also be implicated in such process (Xu, Herzig, Rotrekl, & Walter, 2008). 
The glycosylase that initiates BER for alkylated bases is the N-methylpurine 
DNA glycosylase (MPG), also known as AAG (alkyladenine DNA glycosylase). AAG 
has been reasonably well studied regarding its function. Gene targeting by 
homologous recombination was used to eliminate Aag expression in mouse 
embryonic stem cells (Engelward et al., 1996) and in adult animals (Engelward et al., 
1997a). As expected, embryonic stem cells lacking Aag activity are more sensitive to 
alkylation (Engelward et al., 1996). However, the opposite effect can be observed in 
vivo: in Aag-null animals or cells derived from them, the absence of Aag correlated 
with alkylation resistance (J. A. Calvo et al., 2013; Meira et al., 2009). There is no 
current consensus as to why this discrepancy arises and exactly how AAG/Aag can 
be beneficial or deleterious depending on the cellular context.  
To fill this gap in the knowledge we had proposed to investigate the effect 
of the modulation of AAG expression in a human model, using an immortalized 
retinal pigmented epithelial cell line. Assuming that in such cells an increase in 
alkylation sensitivity would correlate with high AAG expression, we were also 
interested in determining whether alkylation sensitivity would be associated with 
expression of the nuclear or the mitochondrial forms of the glycosylase. To address 
such question, a panel of cell lines overexpressing AAG in each one of these 
subcellular compartments (or both of them) and cells with low or no detectable 
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AAG expression was to be engineered and challenged with distinct alkylating and 
non-alkylating agents.  
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 AIM 
To assess whether AAG activity on mitochondrial DNA damage can 
contribute to a potential scenario of alkylation-induced energy depletion and cell 
death. 
 OBJECTIVES 
• Generate plasmid constructs to allow robust overexpression/silencing of 
human and mouse AAG activity in both rapidly dividing and quiescent cells; 
• Using these constructs, generate cell lines stably knocked-down or 
overexpressing human and mouse AAG; 
 MATERIALS AND METHODS 
2.4.1 CLONING STRATEGIES 
Firstly, two constructs were devised to analyse the impact of AAG 
overexpression:  one containing the full-length hAAG (NCBI NM_002424.3), cloned 
in a pEGFP-C3 backbone and a second plasmid containing hAAG with its 
mitochondrial targeting sequence (MTS) truncated (∆MTS.hAAG).  
The human AAG gene (NCBI NM_002424.3) was previously cloned into the 
high-expression eukaryotic pCAGIG plasmid (Hitoshi, Ken-ichi, & Jun-ichi, 1991) and 
gifted to the Meira Lab by Leona D. Samson (MIT, USA) (Klapacz et al., 2010) . For 
the purpose of tracking AAG subcellular location in a mammalian cell model (ARPE-
19) AAG had to be sub cloned into pEGFP-C3, that generates an N-terminal protein 
fusion between eGFP and the product of the cloned gene (Figure 19 A). 
To this end, approximately 50 µg of pCAGIG-hAAG were incubated 
overnight at 37℃ with the restriction enzyme XhoI (XhoI, Promega, Madison, USA). 
The 1 kb fragment containing the AAG gene was separated from its backbone by 
electrophoresis in an 0.8% ultrapure agarose gel (Invitrogen, Carlsbad, USA). The 
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fragment was then cut with a clean razor, weighed and purified using a PCR Cleanup 
and Gel Extraction kit (Macherey-Nagel, Düren, Germany), following the 
manufacturer’s instructions. After purification, the DNA concentration was 
measured by spectrophotometry using a NanoDrop (Thermo Fisher Scientific, 
Waltham, USA), ligated to the XhoI-restricted and dephosphorylated pEGFP-C3 
backbone. The restriction and dephosphorylation reactions were done concurrently, 
by adding 15 units of restriction enzyme/µg of DNA, 1x Multi-Core enzyme buffer, 1 
µL of Thermosensitive Alkaline Phosphatase (TSAP, Promega, Madison, USA) and 
incubating at 37ºC for 15 minutes. The enzymes were then inactivated by 
incubation at 75ºC for 15 minutes. For the ligation, the reaction was spun down and 
approximately 40 ng of vector was mixed with the insert (AAG fragment), 1x Fast 
Ligation Buffer and 6 units of T4 DNA Ligase (Promega, Madison, USA) and 
incubated at 25ºC for 15 minutes. Competent E. coli (DH5 strain) was then 
transformed with the products of the reaction. 
The transformation procedure was carried out as follows: 5 µL of the 
ligation mix was added to 50 µL of DH5α Subcloning Efficiency E. coli (Invitrogen, 
Carlsbad, USA) and kept on ice for 30 minutes. The cells were then heat shocked at 
42ºC for 20 seconds on a heat block and incubated on ice for an additional 2 
minutes. Then, 950 µL of prewarmed lysogeny broth (LB) was added and cells were 
incubated at 37ºC for one hour to allow expression of the antibiotic kanamycin 
resistance gene present on the vector. The cells were pelleted by low-speed 
centrifugation and approximately 900 µL of the supernatant was removed. The 
pellet was resuspended on the remainder of the liquid and spread on LB agar plates 
containing kanamycin at 50 µg/mL After overnight incubation, individual colonies 
were picked and reincubated overnight in LB broth containing the same 
concentration of kanamycin. The bacterial suspension was then harvested and 
plasmids were isolated using a NucleoSpin Plasmid miniprep kit (Macherey-Nagel, 
Düren, Germany). Finally, a small portion of the sample was restricted again with 
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XhoI to confirm insert integration and then sent for sequencing Source BioScience 
(Nottingham, UK) to confirm orientation and integrity of the construct. 
To generate the truncated AAG (ΔMTS.hAAG), pCAGIG-hAAG was 
linearized and underwent a PCR amplification with two specific primers. The 
forward primer annealed downstream from the MTS sequence, while the reverse 
primer annealed on the first stop codon, generating a truncated AAG without the 
MTS. To allow cloning both primers also introduced XhoI restriction sites flanking 
the amplified sequence.  
To insert the hAAG and ΔMTS.hAAG fragments into the pEGFP-C3 multiple 
cloning site, the plasmid was XhoI restricted and the fragments were posteriorly 
ligated to the pEGFP-C3 vector with T4 DNA ligase (Thermo Scientific) and the 
resulting constructs were then named C3-hAAG and C3-∆MTS.hAAG (Figure 19 B). 
   
Figure 19: Schematic representation of the AAG overexpression vectors used in this work. A) 
Diagram represents C3-hAAG, the overall AAG overexpression. B) Diagram represents the C3-
ΔMTS.hAAG, where a truncated version AAG (absent of its MTS) was cloned, what allows nuclear 
overexpression. C), a third construct, obtained elsewhere (Fishel, Seo et al. 2003), will also be used 
for directed mitochondrial overexpression. In this vector, the mitochondrial targeting sequence of 
MnSOD (a mitochondrial protein) was cloned in tandem with the hAAG gene.  
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Both the constructs were transformed into DH5α E. coli using a standard 
heat-shock protocol, consisting of incubation of the cells and DNA mixture for 30 
minutes in ice, followed by a 42oC incubation for 45 seconds and finalized by a 2-
minute ice incubation. The cells were then inoculated in LB media and incubated at 
37oC for 1 hour to allow the antibiotic resistance gene to be expressed. After this 
period, a small portion of inoculate was seeded into kanamycin selective plates and 
incubated for 16 hours. Single transformant colonies were picked and incubated in 
LB media also containing kanamycin and incubated overnight. The plasmids were 
then extracted with the NucleoSpin Plasmid EasyPure mini-prep kit (Macherey-
Nagel). Successful transformation was confirmed by cleaving the plasmids with XhoI 
and 0.8% agarose gel electrophoresis. The identity and orientation of the constructs 
were further confirmed by Sanger sequencing. 
To achieve AAG overexpression only on the mitochondria, the third 
construct was originally to be constructed using the full length AAG cDNA, with the 
addition of the mitochondrial targeting sequence (MTS)  found on the manganese 
superoxide dismutase gene (MnSOD, Figure 19 C) a very strong mitochondrial 
targeting signal that was first designed elsewhere (Fishel, Seo, Smith, Dna, & Kelley, 
2003). The stock for this plasmid was kindly donated by Dr Guido Lenz (UFRGS, 
Brazil). However, due to suboptimal plasmid yield it was decided to use instead a 
commercial mitochondrial overexpression system, the pCMV/Myc/Mito/GFP- 
pSHOOTER (Life Technologies, Carlsbad, USA). AAG was cloned on the XhoI I 
restriction site, localized in between the MTS and a myc epitope, in such a fashion 
that the plasmid expression would create a myc-tagged AAG, facilitating the 
subcellular tracking (Figure 20). 
 
Figure 20: schematic representation of the mitochondrial overexpression vector. AAG was cloned 
between the strong MTS and a myc epitope, generating a fusion protein containing the latter in 
order to facilitate cell tracking. 
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To complement the investigation on the effects of AAG modulation four 
knockdown shRNA AAG knockdown pGIPZ plasmids [Sh1, Sh2, Sh3, Sh4, 
NM_001015052, NM_001015054, NM_002434], obtained from Thermo Scientific - 
along with a GAPDH silencing positive control and a non-silencing negative control – 
were also included in the study (Figure 21). The plasmids were transformed into 
competent bacteria and extracted following the same procedures as the previous 
plasmids. 
 
Figure 21: Schematic representation of the shRNA silencing vectors. a) four pGIPZ vectors containing 
distinct AAG shRNA sequences. b) Non-silencing and GAPDH silencing shRNA vectors used as 
negative and positive controls. 
2.4.2 CELL CULTURE 
AAG modulation was carried out using ARPE-19, a human retinal 
pigmented epithelium cell line. ARPE-19 is a cell line spontaneously immortalised 
and derived from the eyes of 19-year old male donor.  
The cells were kindly donated by Dr Axel Nohturfft (St. George’s University 
of London, UK) and were cultivated using High Glucose Dulbecco’s modified Eagle’s 
medium (DMEM, Sigma Aldrich), supplemented with 10% of heat-inactivated FBS 
and 2.5 mM of L-glutamine, in a humidified incubator with 5% CO2. Experiments 
were performed with freshly thawed stocks of cells, kept after defrosting for a 
maximum of 3 passages. The parental cells were grown in the absence of 
antibiotics. 
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2.4.3 ISOGENIC CELL LINE GENERATION 
All transfections were carried out utilizing Lipofectamine LTX as 
transfection reagent, according to the manufacturer’s recommendations. Briefly, 
after optimization, 5x103 cells/well (96-well plate) were plated on the day prior to 
the transfection. On the day, 100 ng of plasmid DNA/well was diluted in serum-free 
DMEM, mixed with 0.1 µL of Plus reagent and incubated for 5 minutes. Next, the 
Lipofectamine was added (0.3 µL/ 100 ng of DNA) and incubated for an additional 
30 minutes to allow the formation of DNA:reagent complexes. Ten microliters of the 
mixture were added to each well and for a maximum of 6 hours to avoid excessive 
cell toxicity, when was then replaced by complete DMEM medium. 
Cells were visualized under an epifluorescence microscope to evaluate the 
presence of GFP (AAG overexpressors) positive cells, that were then trypsinized and 
transferred to a 24-well plate, in the presence of either 300 µg of geneticin or 1 µg 
of puromycin, respectively. Selection was maintained until all untransfected control 
cells were dead and the recombinant cells were passaged to increasingly larger 
flasks upon reaching 80-90% confluence, after which antibiotic concentrations were 
lowered to 200 µg of geneticin and 0.5 µg of puromycin for maintenance. 
For isogenic cell line generation, the cells were submitted to limiting 
dilution, by plating at an approximate concentration of 1 cell/well on a 96-well plate 
and inspected for colonies derived from a single cell. The selected wells were than 
expanded until confluent enough for expression analysis. 
2.4.4 CELL LINE CHARACTERIZATION 
Once the cell lines were selected and expanded, AAG expression levels 
were assessed either by RT-qPCR or western-blot. To investigate the impact of the 
manipulation on the phenotype, the cells were submitted to a clonogenic assay. 
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2.4.4.1 RNA ISOLATION AND CDNA SYNTHESIS 
The cells were grown in T25 cm2 flasks until they reached 80-90% 
confluency, whereupon they were harvested by trypsinization and pelleted. The 
pellet was processed for RNA isolation using the PureLink RNA Mini kit (Invitrogen, 
Carlsbad, USA) according to the manufacturer’s instructions. The RNA samples were 
quantified by spectrophotometry (NanoDrop, Invitrogen Carlsbad, USA) and either 
frozen at -80 ℃ or promptly used for first strand cDNA synthesis. 
For the synthesis, 1 µg of RNA was used per sample and the reaction was 
carried out using the Maxima First Strand cDNA Synthesis (Thermo Fisher Scientific, 
Waltham, USA) whose first step consists of the incubation of the RNA with a 
dsDNAse, therefore minimizing the risk of genomic DNA contamination. The 
procedure was carried out following the product manual. 
2.4.4.2 RT-QPCR 
To assess the efficacy of the AAG modulation on the overexpressor cell 
lines, a RT-qPCR was performed. AAG expression levels were quantified as a ratio 
using human β-actin (ACTB, NM_001101.3) as the reference gene (ΔΔCt). The 
sequences of the primers used for the both genes are as follows:  
human_beta_actin fwd - 5’ ATT GCC GAC AGG ATG CAG AA 3’,  
human_beta_actin rev - 5’ GCT GAT CCA CAT CTG CTG GAA 3’;  
hAAG1_498-517 fwd - CCC CGC AAC CGA GGC ATG TT 3’,  
hAAG1_610_591 rev - AGC AAG ACG CAA GCC CCG TC 3’.  
All reactions were singleplex in a 96-well plate in triplicate, using SYBR 
Green Luminaris Colour HiGreen qPCR Master Mix, low ROX (Thermo Fisher 
Scientific, Waltham, USA) for amplification detection and ROX as a fluorescence 
normalizer. The reaction total volume was 20 µL, of which 10 µL of master mix, 0.8 
µL of each primer, 1 µL of template and ultrapure water. The amplification was 
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done in the QuantStudio 7 Flex Real-Time PCR System (Life Technologies, Carlsbad, 
USA) using as cycling conditions 50ºC/2 minutes (UDG activation), 95ºC/10 minutes 
(denaturation/polymerase activation) followed by 40 cycles of 95ºC/15 seconds and 
60ºC/1 minute. At the end of the reaction, an additional cycle for melting curve 
analysis was added to confirm primer specificity. 
2.4.4.3 PROTEIN ISOLATION AND QUANTIFICATION 
Cells were grown until 80-90% confluence on a T75 cm2 flask, when they 
were trypsinized and pelleted by centrifugation at 300 x g for 5 minutes. The 
supernatant was then discarded and the pellet was resuspended in 1x PBS and 
centrifuged at 1200 x g, and the supernatant was removed again and replaced by 
100 µL of RIPA buffer (Sigma-Aldrich, St. Louis, USA) containing 1 x of Halt Protease 
Inhibitor Cocktail (Thermo Fisher Scientific, Waltham, USA). The contents were 
transferred to a microcentrifuge tube and underwent 3 freeze/thaw cycles and 
were sonicated in a cold sonic water bath for 10 minutes. Then the lysates were 
centrifuged at 16.000 x g for 5 minutes at 4ºC and the supernatant was transferred 
to a new pre-chilled tube and stored at -20ºC.   
Protein concentrations were determined through the bicinchoninic acid 
assay (BCA) supplied by Pierce (Thermo Fisher Scientific, Waltham, USA) using 10 µL 
of sample and standards as recommended by the supplier. 
2.4.4.4 WESTERN-BLOT 
To determine if indeed AAG was being expressed as a fusion protein the 
samples were analysed by western-blot. 20 µg of protein was prepared in 1x 
Laemmli buffer (Bio-Rad Laboratories, Hercules, USA) containing 355 µM of 2-
mercaptoethanol as a reducing agent. The samples were then boiled for 5 minutes 
at 95ºC and run in a precast gel Any kD Mini-Protean TGX (Bio-Rad Laboratories, 
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Hercules, USA). The electrophoresis was done for one hour at constant voltage of 
125 V. 
The transfer was done under semi-dry conditions using the Trans-Blot 
Turbo transfer pack, in Trans Blot turbo equipment (Bio-Rad Laboratories, Hercules, 
USA) for 30 minutes at 25 V. The PVDF membrane was then washed with 1xTBS and 
blocked with 1% milk/TBS for one hour. Next the membrane was washed again and 
incubated overnight at 4ºC with primary antibodies against human AAG (APNG 
[3D1]: sc-101237, Santa Cruz Biotechnology Inc., 1:250 or Anti-MPG, rabbit, 
HPA006531, Sigma Aldrich) and anti-human β-actin (Anti-β-Actin, mouse, A2228, 
Sigma Aldrich) in a dilution of 1:500 and 1:7000 in TBS, respectively. On the 
following day, the membrane was washed with TBST and TBS and incubated in the 
dark for an hour with the secondary antibodies IRDye 680RD green goat anti-mouse 
IgG and IRDye 800CW red Goat anti-rabbit IgM (LI-COR Biosciences, Lincoln, USA) at 
1:6000. At the end of the incubation, the membrane was washed a minimum of 4 
times, with TBST and TBS and was scanned in the Odyssey CLx IR imaging system (LI-
COR Biosciences, Lincoln, USA). 
2.4.4.5 SURVIVAL ANALYSIS – CLONOGENIC ASSAY. 
A total of 400 cells/well (6-well plate) were plated in the day before 
treatment. On the following day, complete media was replaced by serum-free 
medium containing dilutions (0.5 to 2.5 mM) of MMS and left to incubate for one 
hour, period after which the medium was replaced by complete DMEM and the 
cells were left to grow for 12 days, having their media refreshed on the 6th day. 
At the end of the incubation, the medium was removed and replaced by 
ice-cold methanol for 10 minutes to fix the colonies. To stain the plates, the 
methanol was removed and replaced by a solution of 50% methanol (v/v) and 0.5% 
crystal violet, for an additional 10 minutes with agitation. The excess stain was then 
stored and the plates were washed under running water and left to air-dry. 
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Colony counting was done manually, using as exclusion criteria colonies 
with less than 50 cells and not considering wells with number of colonies inferior to 
10. Survival fraction was calculated using the equations on Figure 22. 
 
PE =  
𝑛º 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑓𝑜𝑟𝑚𝑒𝑑
𝑛º 𝑐𝑒l𝑙𝑠 𝑝𝑙𝑎𝑡𝑒𝑑
 
SF =
𝑛º 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑎𝑓𝑡𝑒𝑟 𝑡𝑟𝑒𝑎𝑡𝑚e𝑛𝑡
𝑛º 𝑐𝑒𝑙𝑙𝑠 𝑠𝑒𝑒𝑑𝑒𝑑 𝑥 PE
 
Figure 22: Equations used for determination of clonogenic survival fraction. Firstly, Plating 
Efficiency (PE) is determined by dividing the number of colonies formed by the number of cells 
plated. Then, Survival Fraction (SF) is calculated by dividing the number of colonies formed after 
treatment divided by the number of cells seeded times the plating efficiency.  
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 RESULTS 
Our purpose was to assess whether AAG expression in distinct subcellular 
compartments (i.e. nucleus and mitochondria) played a role in alkylation-induced 
cell death. Thus, the first step was to develop cell lines that would selectively 
overexpress AAG in both nucleus and mitochondria, on nucleus only, mitochondria 
only or had expression totally or almost totally ablated (silenced). 
 
2.5.1 GENERATION AND CHARACTERIZATION OF THE AAG 
OVEREXPRESSING ISOGENIC CELL LINES 
Three isogenic cell lines were developed: a whole cell overexpressor 
(nucleus + mitochondria, WC OE) transfected with C3-hAAG, a nuclear 
overexpressor (N OE), transfected with C3-ΔMTS.hAAG and a negative control cell 
line, transfected only with the empty vector, pEGFP-C3  
The characterization of these cell lines is detailed on Figure 23. On panel A 
(left) the cells can be seen under light microscopy, presenting a similar morphology 
even though they represent distinct overexpression clones. On the right panels, 
however it becomes apparent that the cells expressing the empty plasmid show a 
diffuse fluorescence on the cellular body, while both Whole-cell overexpressors (WC 
OE) and Nuclear Overexpressors (Nuc OE) show a green fluorescence concentrated 
around the nuclei. To confirm overexpression, AAG expression was assessed by RT-
qPCR (Figure 23, panel B), where it was observed that both overexpressor cell lines 
had far superior AAG mRNA levels than their mock (empty vector) and wild-type 
counterparts. 
Finally, bearing in mind that the increase in mRNA levels does not 
necessarily constitute increase in protein levels, the whole-cell extracts were 
probed with an anti-AAG antibody (APNG [3D1]: sc-101237, Santa Cruz 
Biotechnology Inc., 1:250) that has shown a strong reactivity with a protein around 
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60 kDa, the predicted size for the GFP+AAG (17 + 33kDa) fusion, present only on the 
AAG-transfected cells. Therefore, we assumed that the overexpression was 
accomplished and proceeded to test whether the manipulation had any impact on 
cell phenotype.  
 
 
Figure 23: Morphologic and phenotypic characterization of the AAG overexpressing cell lines. On 
panel A) pictures of representative clones of each cell lines can be observed under both bright-field 
(left panels) and fluorescence microscopy (right panels), all 200 x magnification. B) AAG relative 
quantification suggesting a strong overexpression was achieved on both WC and Nuc OE, which was 
further confirmed by western-blot using anti-AAG antibodies (APNG [3D1]: sc-101237, Santa Cruz 
Biotechnology Inc., 1:250) as attested by the strong bands present in the recombinant cells 
(AAG+GFP panel) and not on the wild-type and control cell lines.  
The AAG knockdown clones were generated using a similar method: cells 
were transfected either with plasmids containing one of four sequences aimed at 
silencing AAG or negative controls (non-silencing and GAPHD), whose 
representation can be seen in (Figure 24 B). After selection and clonal expansion, 
the cells displayed a diffuse green fluorescence, as expected (Figure 24 A). However, 
some atypical morphology was also detected like polynucleated cells and cells 
greatly enlarged, the latter suggestive of a senescent phenotype. 
Chapter 2: Evaluation of the phenotypes resulting from AAG expression in different subcellular 
compartments 
 
86 
 
Despite that, AAG expression levels were measured by RT-qPCR and at first 
instance two of the clones, KD 6 and KD 7, had shown promising decrease in 
expression levels when compared to the parental cells (Figure 24 C). This decrease, 
though, could not be replicated on further experiments (data not shown) and 
coupled with the morphological changes, led us eventually to abandon the 
knockdown technique altogether. 
 
 
Figure 24: Morphologic and phenotypic characterization of the AAG-silencing cell lines. On panel A) 
pictures of representative clones of each cell lines can be observed under both bright-field (left 
panels) and fluorescence microscopy (right panels), all 200 x magnification. B) schematic 
representation of the four plasmids used for silencing (left) and the two negative controls (right, 
non-silencing and GAPDH silencing). C) quantification of AAG relative expression by RT-qPCR showing 
decrease on two of the four sequences tested (KD 6 and 7) when compared to the wild-type parental 
cell line. 
2.5.2 AAG OVEREXPRESSION SENSITIZES CELLS TO ALKYLATING 
DAMAGE  
Next, we assessed whether AAG expression modulation could impact 
cellular survival after alkylation treatment.  
Cells overexpressing AAG either on the whole-cell or the nucleus show 
increased alkylation sensitivity, if compared to the parental cell line (Figure 25). At 
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the intermediate dose of 1.25 mM of MMS, colonies can be observed on the wild-
type cells whereas on the overexpressing (OE) cells the number and size of the 
colonies is drastically altered (colonies contaned < 50 cells, Figure 25 A). 
 
Figure 25: Cell lines overexpressing AAG are more sensitive to alkylation treatment. A) is a 
representative picture of a plate clonogenic assay and B) is the plotted survival curves of said lines 
when treated with MMS. 
2.5.3  AAG KNOCKDOWN SEEMS TO DECREASE CELL FITNESS  
To evaluate whether the decrease in AAG expression would affect the cells’ 
ability to deal with alkylation damage, a clonogenic assay was to be carried out. This 
approach proved challenging with these silenced cells, as after two or three 
passages, the cells displayed altered morphology such as increase in size (Figure 26 
B) and/or membrane blebbing (Figure 26 C). Those changes were accompanied by a 
great reduction in cell fitness in such magnitude that prevented further clonogenic 
experiments, as there was complete or almost complete obliteration of the colonies 
even on the lowest doses (data not shown), despite testing negative for common 
pathogens such as Mycoplasma. Thus, a change in method of AAG modulation was 
proposed, in favour of the knockout approach.  
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Figure 26: Phenotypical aspects of the AAG knockdown cell lines. A) typical morphology presented 
by the parental ARPE-19 cell line. Most knockdown clones after sucessive passages presented altered 
morphologies that included B) greatly enlarged cells and/or C) membrane blebbing. Before the onset 
of these, the survival of the KDs showed a trend towards increased sensitivity to MMS in the higher 
doses. 
At this point in our investigation new data acquired by our group showing a 
novel and very promising putative role of AAG in modulating the endoplasmic 
reticulum stress and this, coupled with the several technical setbacks encountered 
during this first period of the project motivated a change of scope.  
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 DISCUSSION 
Although the role of AAG in cellular survival to alkylation damage has been 
studied before, the cellular determinants for AAG activity being cytoprotective or 
cytotoxic are still unclear. Therefore, despite being the main enzymatic activity for 
alkylated base repair (Meira et al., 2005), its activity can be deleterious to cell 
survival (Burns & Gold, 2007; J. A. Calvo et al., 2013; Roth & Samson, 2002).  
To define whether AAG subcellular location affects cellular outcome in 
response to alkylation, we generated a panel of genetically engineered cell lines 
with varying levels of AAG expression in distinct subcellular compartments. Cells 
overexpressing AAG in the nucleus (Nuc OE) or both nucleus and mitochondria (Wc 
OE) were challenged with increasing doses of MMS and were found to be far more 
sensitive to MMS than the wild-type MMS cells, regardless of overexpression 
location. Such finding is largely supported by the literature either on breast cancer 
cell lines or biopsies (Cerda et al., 1998; M Rinne, Caldwell, & Kelley, 2004) and 
gliomas (Liu et al., 2012) where elevated AAG levels were associated with increased 
alkylation sensitivity. Moreover, such observation is not limited only to in vitro 
models, but AAG-dependent alkylation-sensitivity can be also detected in certain 
tissues (thymus, spleen, bone marrow, cerebral granular cells) of Aag transgenic 
animals (J. A. Calvo et al., 2013) and retina (Meira et al., 2009). 
To explain the mechanism behind such sensitization, one can extrapolate 
from the BER imbalance hypothesis, that postulates that what drives the damage 
associated with AAG activity is that somehow its removal of damaged bases 
becomes uncoupled from the activity of the downstream enzymes such as AP 
endonuclease and Pol-β, resulting in the accumulation of highly toxic intermediates 
as AP sites, 5’-dRPs and SSB (Fu et al., 2012). Therefore, it is only logical to assume 
that a further increase in AAG levels would further sensitize cells to alkylation 
damage.  
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In contrast, what was found when evaluating selected AAG knockdown 
differed from what was expected, given the results obtained with the 
overexpression experiment: the reduction in AAG levels seemed to grant no 
advantage over the wild-type cells to alkylation treatment. Some reports indicate 
that AAG is important to protect from inflammation-derived alkylation in vivo 
(Meira et al., 2008) but also its absence protects from alkylation damage originated 
from alkylating agents such as streptozotocin (Burns & Gold, 2007) and 
methylmethane sulfonate (or MMS) (Calvo et al., 2013; Meira et al., 2009; Roth & 
Samson, 2002). Due to the issues encountered with change in cell fitness due to our 
knock-down approach, we employed instead the knockout approach using the 
CRISPR-Cas9 methodology, described in the following chapter. 
It is important to stress the work detailed in this chapter was exploratory in 
nature. The main subject of this dissertation arose from the investigation into the 
alkylation-induced transcriptional profile of Aag-proficient and deficient mice. We 
observed that alkylation treatment induced ER stress and the unfolded protein 
response in living animals. Surprisingly, alkylation-induced expression of ER stress 
genes was dependent on the Aag DNA repair enzyme. Thus, from the next chapter 
onwards, the data presented deals with the interplay between AAG, ER stress and 
UPR induction  
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3 AAG and the UPR: Cell Line 
Development and 
Characterization 
 INTRODUCTION  
It comes to no surprise that recently The Royal Swedish Academy of 
Sciences awarded the Nobel Prize in Chemistry to Tomas Lindahl, Paul Modrich and 
Aziz Sancar on 2015 for their discoveries on the field of DNA repair. It is almost 
commonplace to mention the importance of DNA repair pathways to the cell, which 
is under constant attack by endogenous and exogenous threats to its genomic 
stability. However, what makes this relatively old subject still very relevant is not 
only its importance for the integrity of genomic information, but its abundance of 
potential targets for drug development for the treatment of neoplasias.  
One of the best studied repair pathways is Base Excision Repair (BER), a 
highly active and conserved pathway that deals with damaged bases arising both 
from spontaneous and induced damage  (De Bont & van Larebeke, 2004), and that 
takes place in nucleus and mitochondria (Larsen, Rasmussen, & Rasmussen, 2005). 
In its “canonical” (also called short-patch) form, BER is a series of steps that start 
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with the recognition and cleavage of the damaged base by a glycosylase, proceeded 
by the incision of the resulting apurinic/pyrimidinic (AP) site by an AP endonuclease 
that cleaves the phosphodiester bond at 5’ of the AP site leaving in its place a 3’-
hydroxyl-nucleotide (3’ OH) and 5’ deoxyribose phosphate termini (5’dRP). This 
creates an adequate substrate for either polymerase β (nucleus) or pol ϒ 
(mitochondria) to act upon. The polymerase then uses its lyase activity to remove 
5’dRP and fills the gap with the appropriate base (Krokan & Bjørås, 2013). To finalize 
the repair, either DNA ligase I or IIIα, the latter mainly on the mitochondrial BER, 
seals the nicks left behind (Gao et al., 2011; Simsek et al., 2011).  
After BER initiation by a glycosylase, each one of the subsequent steps 
needs to be tightly coordinated, as they result in the creation of potentially 
cytotoxic substrates. AP sites, 5’dRPs, and single strand breaks (SSBs) represent a 
risk to the cell if left unrepaired. 
In this fact lays the crux of the discussion around the enzyme known as 
alkyl adenine glycosylase, or AAG (also known as MPG). AAG is responsible for the 
repair of a varied group of substrates: N3-methyladenine (3meA), N3-
methylguanine (3meG), hypoxanthine (deaminated adenine), N7-methylguanine 
(7MeG), ethenoadenine among others (Fu et al., 2012). It therefore deals with 
damaged bases generated by alkylation, oxidation and deamination within BER and 
the most straightforward expectation would be that its presence would be central 
to the survival of the cell when faced with such insults. 
Although its mechanism of action and substrates are relatively well known, 
there is no defined phenotypic outcome resulting from AAG-mediated repair. In 
some contexts, and cell types, its absence has the impact expected when a repair 
enzyme is no longer able to fulfil its role: sensitization to damage. Such sensitization 
was reported in mouse embryonic stem cells (Engelward et al., 1996). AAG activity 
was also found to be important in the protection against colon carcinogenesis 
induced by inflammatory-derived alkylation and oxidation damage in an animal 
model (J. a Calvo et al., 2012; Meira et al., 2008).  However, the results obtained 
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from in vivo studies using the animal models indicate that AAG activity in the 
presence of DNA damage, rather than always being cytoprotective, can sometimes 
be cytotoxic.  
Puzzlingly, Aag knock-out animals/tissues are more resistant than wild-type 
to cell death induced by alkylation, indicating Aag knockout  protects from alkylation 
damage, albeit in a tissue-specific manner (Burns & Gold, 2007; Roth & Samson, 
2002). One of the studies that explored the relationship of Aag and an increased 
alkylation-induced tissue damage was the investigation conducted by Meira, 
Moroski-Erkul et al. (2009), where a whole set mice strains with modulated levels of 
the Aag glycosylase (Aag -/-, Aag +/-, Aag WT and Aag Tg overexpressor) was 
assessed for their sensitivity to alkylation. Although alkylation was previously known 
to induce retinal damage and degeneration in rodents (Nakajima et al., 1996; 
Taomoto et al., 1998), the work by Meira and collaborators showed was that this 
alkylation-induced retinal damage is proportional to the levels of Aag expression in 
the animal, but somehow limited to a specific layer in the retina. A similar tissue-
specific degeneration was reported in another investigation, where alkylation-
treated Aag Tg animals (Aag overexpressors) suffered from a higher degree of 
tissue damage when compared to their WT counterparts and cerebellar granular 
cells were found to be hypersensitive to alkylation, whereas the adjacent Purkinje 
cells were not significantly impacted (J. A. Calvo et al., 2013). Other tissues 
specifically sensitive to alkylation in an Aag-dependent fashion were thymus, 
pancreas and bone marrow (J. A. Calvo et al., 2013)The reason for this seemingly 
tissue selective sensitivity remains to be elucidated. 
Given the opposing effects of AAG modulation in the response to alkylating 
agents, the initial aim of this study was to evaluate whether AAG subcellular 
expression, i.e. nuclear or mitochondrial expression, played a differential role in 
alkylation-induced cell death. For that, we originally proposed to construct a panel 
of human cell lines where AAG would be expressed either in the nucleus or 
mitochondria, and compare the responses of these cells to alkylation with AAG 
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knockout cells and with AAG wild type cells, where AAG is known to be expressed in 
both compartments. As a first step, we used the CRISPR/Cas technology to generate 
an AAG knockout cell line to be the host cell to our compartment-specific AAG 
expression system. However, instigating new findings from our group, suggesting a 
relationship between AAG and endoplasmic reticulum stress led us to repurpose 
these cells for the study of this putative connection. Therefore, the following 
chapter details the generation of AAG -/- and AAG overexpressing cell lines and 
explores their response to alkylation induced damage. 
 AIMS  
To develop and characterize cell lines with modulated AAG levels to allow 
further investigation into its involvement on the endoplasmic reticulum stress 
response. 
 OBJECTIVES  
• Establish isogenic cell lines derived from the retinal pigmented 
epithelium cell line ARPE-19 with modulated levels of AAG 
expression; 
• Characterize AAG-modulated cell lines regarding their AAG status 
and; 
• Assess their phenotype in terms of alkylation sensitivity. 
 
 MATERIALS & METHODS 
To better understand the impact of AAG on the induction of ER stress, a 
series of cell lines with varying levels of the glycosylase was engineered, selected 
and characterized. 
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3.4.1 GENERATION AND CHARACTERIZATION OF AAG-/- CELL LINES - 
CLONING 
• Knockout constructs 
To evaluate the impact of AAG absence in ER stress induction and eliminate 
any ambiguity potentially generated by any residual glycosylase activity usually 
present on knockdown models, it was decided that the CRISPR/Cas9 Knockout 
system would be the best approach. 
For this purpose, a commercial knockout system was obtained from Santa 
Cruz Biosciences (Dallas, USA), comprising of a pool of three plasmids, each 
containing a different 20 nt homologous sequence directed to the AAG gene. The 
system also contains a separate homology directed repair plasmid, containing an 
800 bp homologous sequence that corresponds to the flanking region of the 
induced double strand break generated by the CRISPR/Cas9 nuclease, thus serving 
as a template for homologous recombination repair and allowing the integration of 
a puromycin resistance marker and a red fluorescence protein (RFP) reporter gene, 
as seen on Figure 27. 
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Figure 27: Schematic representation of the mechanism of CRISPR/Cas9 Knockout. a) CRISPR/Cas9 
plasmid creates double-strand breaks in the target gene directed by a 20 nt sequence titled guide 
RNA; b) HDR plasmid, that when co-transfected with the CRISPR/Cas9 plasmid, drives homologous 
recombination repair and results in the insertion of a puromycin resistance and RFP reporter gene. 
Source: adapted from the manufacturer’s technical sheet. 
3.4.2 CELL CULTURE 
The cell culture parameters were followed as described on the previous 
chapter, using the same cell line, ARPE-19. 
3.4.3 ISOGENIC CELL LINE GENERATION  
Again, all procedures for cell line generation were described in the previous 
chapter, the only difference being that, instead GFP, cells were screened for RFP 
fluorescence. The presence of RFP signals the successful insertion of a 
puromycin/RFP cassette into the host genome. 
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3.4.4 CELL LINE CHARACTERIZATION 
Once the cell lines were selected and expanded, AAG expression levels 
were measured either by RT-qPCR, western-blot and/or glycosylase activity assay. 
To evaluate alkylation response, both the MTS and clonogenic assays were used. 
Below, both the glycosylase and the MTS are described, as all the other methods 
were described in the previous chapter. 
3.4.4.1 AAG ACTIVITY ASSAY 
AAG activity was determined using an oligonucleotide plate based assay 
developed and executed at the University of Surrey by Dr Ruan Elliot and PhD 
student Eleanor Healing (submitted). The assay consists in measuring glycosylase 
repair activity over plate-immobilized modified oligonucleotides and output is 
measured by the decrease generated by fluorescent probe degradation. Below are 
the assay procedures as supplied by the authors: 
 
Assay to measure alkyl adenine DNA glycosylase (AAG) activity 
Substrate preparation 
For all experiments, the initial oligonucleotide (HX02; sequence 
information provided in Table 1) was diluted from 10µM stock solutions into freshly 
prepared 0.1M bicarbonate buffer (pH 9.6) to a final concentration of 0.5nM, and 
100μl of this solution was incubated in each well of a Nunc® ImmobiliserTM amino 
96-well plate overnight at 4°C. The plate was then washed with phosphate-buffered 
saline containing 0.1% v/v Tween-20 (PBST) and 100µl of a 0.05pM solution of the 
appropriate complementary oligonucleotide (Loop01; sequence information 
provided in Table 1) was added following dilution in hybridisation buffer (6x saline 
sodium citrate (SSC) buffer, 5mM EDTA, 0.1% v/v Tween-20). Each plate was then 
sealed and heated to 95°C for ten minutes in a hybridisation oven, followed by 
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gradual cooling to 80°C, maintenance at 80°C for ten minutes, and then further 
gradual cooling to 21°C. 
 
Table 5. Sequences of oligonucleotides used in experiments. 
Name Sequence (5’ → 3’) Base modification 
Substrate 
for: 
HX02 (P)CACGAA(X)CAACTCAGCAACTCCtt(NH2)2,3,4 Hypoxanthine (X) AAG 
Loop01 
(Flc)ttGGAGTTGCTGAGTTGATTCGTGAGC
ACCAACCGGTGCT1 
X X 
1Flc indicates fluorescein; 2NH2 indicates amino group modification; 3P indicates phosphorylation; 
4lower case letters in the nucleotide sequence indicate nucleotides linked via phosphorothiate bonds 
which also serve as a two-nucleotide spacer between the plate and the start of the double stranded 
nucleotide complex. 
 
To measure alkyl adenine DNA glycosylase (AAG) activity, plates containing 
HX02 annealed to Loop01 were treated with 0.05U T4 DNA ligase in 100µl of T4 
DNA ligase buffer (30mM Tris-HCl pH 7.8, 30mM NaCl, 10mM MgCl2, 10mM DTT, 
1mM ATP) for one hour at 37°C. The liquid was decanted from the wells and 150μl 
of neutral denaturation buffer (0.1x SSC, 0.1% w/v sodium dodecyl sulphate) added 
to each well. Plates were incubated for ten minutes at 95°C before the hot liquid 
was decanted and wells washed with PBST. Oligonucleotides were reannealed in 
hybridisation buffer following the same heating and gradual cooling process 
described above, before decanting and washing with PBST.  This process produces 
double-stranded substrate containing a hairpin loop and one site of damage (Figure 
28).  
These substrates were then incubated with increasing concentrations of 
recombinant enzyme (hAAG1, from New England Biolabs and cell extract (at a 
concentration of 10μg/100μl) in an AAG reaction buffer (20mM Tris-HCl pH 7.5, 
100mM KCl, 5mM EDTA, 1mM EGTA, 5mM β-mercaptoethanol, 0.2μg/100μl Herring 
Sperm DNA) for two hours at 37oC before alkaline denaturation (for details see 
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protocol), followed by colorimetric detection of retained fluorescein (for details see 
protocol). 
 
Figure 28: Structure of oligonucleotide sequences in their expected orientation bound to the well 
of a 96-well plate. Structure shown is substrate for alkyl adenine DNA glycosylase. 
 
3.4.4.2 SURVIVAL ANALYSIS – MTS ASSAY 
For its uncomplicated experimental setup and fast results, our first choice 
to evaluate the effects of AAG modulation in situations of genotoxic stress was the 
MTS assay. MTS is a colorimetric quantification cell viability and proliferation. The 
assay is based on the reduction of MTS tetrazolium compound by viable cells to 
generate a coloured formazan product that is soluble in cell culture media. This 
conversion is thought to be carried out by NAD(P)H-dependent dehydrogenase 
enzymes in metabolically active cells. The formazan dye produced by viable cells can 
be quantified by measuring the absorbance at 490-500 nm. 
This MTS assay is performed by adding the reagent directly into the cell 
culture media without any extra steps normally required in the routine MTT assay. 
In addition, this high-throughput assay requires no washing or solubilisation step 
and can be performed in a 96-well microtiter plate. 
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On the day prior to treatment, 5000 cells were plated in a 96-well plate, on 
complete DMEM. On the following day, cells were treated with MMS in a range of 
concentrations (from 0.5 to 3.5 mM) diluted in serum-free medium, for a period of 
one hour. After which the medium was replaced for drug-free complete DMEM and 
the cells were left to recover for a period of 5 days (with a media change on the 3rd 
day). On the 5th day, cells were refed with fresh medium and 20 µL of CellTiter 96® 
was added (Promega, Madison, USA) and incubated at 37°C in the dark until colour 
development (around 1 hour). The absorbance was then measured in the FLUOstar 
Omega plate reader (BMG LABTECH GmbH, Ortenberg, Germany) at 490 nm. 
3.4.5 STATISTICAL ANALYSIS 
All data represented as mean ± standard error of the mean and analysis is 
the result of three or more independent experiments, each comprising three or 
more technical replicates, unless stated otherwise. Comparisons were made using 
two-way ANOVA, followed either by post-hoc Dunnet or Tukey test for multiple 
comparisons when appropriate. Significance was assumed when P ≤ 0.05. Statistical 
tests and graphical representations were carried out using GraphPad Prism version 
7. 
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 RESULTS 
3.5.1 GENERATION AND CHARACTERIZATION OF AAG -/- CELL LINES. 
Having successfully generated overexpressing clones, the next logical step 
to have the full spectrum of AAG modulation was to generate AAG KO cells. This 
was done through the co-transfection of the host cells (ARPE-19) with AAG 
CRISPR/Cas9 and a HDR plasmid set. On the cells where the CRISPR/Cas9 
successfully introduced nicks and they were repaired by homologous recombination 
facilitated by the HDR plasmid, a diffuse red fluorescence can be seen (Figure 29A, 
right panel), signalling the insertion of the RFP and puromycin resistance genes. The 
absence of AAG expression was confirmed when total protein extracts were probed 
with anti-AAG antibodies (Figure 29B). AAG cannot be detected in any of the three 
clones selected for evaluation (A2C1, A2C2 and B6C3), whereas a band around 32 
kDa can be seen in the WT ARPE-19 lysate (Figure 29B, top panel). To 
unambiguously determine the successful AAG KO, two of the clones were selected 
for further investigation and had its glycosylase activity measured (Figure 29C). On 
both clones A2C2 and B6C3, AAG activity has fallen well below the limit of detection 
(indicated by the red dotted line on the graph) while UDG activity (Figure 29C), used 
to indicate the viability of the cell extracts and as an assay positive control, 
remained unaffected by the genetic manipulation. 
 
Chapter3:AAG and the UPR: Cell Line Development and Characterization  
 
103 
 
 
Figure 29: Phenotypical and functional characterization of the AAG -/- cell lines. A) A diffuse red 
fluorescence can be detected on the cells in which the HDR plasmid has served as a template for 
homologous recombination, incorporating a RFP and puromycin resistance gene. B) AAG can be 
detected by western blot only on the original host cell line, but not on either KO clones A2C1, A2C2 
or B6C3. C) KO is further confirmed by the absence of AAG activity in two of the clones tested (red 
line represents the assay’s limit of detection) and D) is supported by normal levels of UDG activity on 
all cells, used as an assay control. 
3.5.2 AAG OVEREXPRESSION AND KNOCKOUT, THE LATTER TO A 
LESSER EXTENT, ARE ASSOCIATED WITH SENSITIZATION 
AGAINST ALKYLATION DAMAGE.  
After confirming the success of the genetic modulation, the next step to be 
undertaken was to evaluate if AAG modulation would bring any detectable 
phenotype (in the form of any deviation on the survival profile). Thus, at first, it was 
decided to utilize the MTS assay for survival assessment, given its ease of use and 
high throughput. 
All cell lines, ARPE-19 (WT), 3.2 (OE), A2C2 and B6C3 (AAG -/-) were treated 
as stated in the Methods section, with MMS doses ranging from 0.5 to 3.5 mM, 
during one hour in serum-free conditions and were left to recover for 5 days. The 
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modulation that seems to have a more prominent impact on cell survival is the 
overexpression, especially on the highest doses of MMS (Figure 30). Whilst hardly 
affecting the WT cells, the 2.5 and 3.5 mM doses killed a significant number of 
overexpressor cells (P<0.0001). Contrary to what was expected, both A2C2 and 
B6C3 lines also seem to be more sensitive to the effect of the alkylating agent than 
the WT (P=0.0010 and 0.0131), albeit in a smaller magnitude than 3.2 and only at 
the highest dose (Figure 30).  
Before drawing any conclusions about the alkylation sensitivity of the 
knockout cells, it was decided to confirm the results using the clonogenic assay 
which, despite being time-consuming and low throughput, remains as a gold 
standard for survival evaluation in mammalian cells. 
 
 
Figure 30: AAG modulation affects survival in some of the differentially expressed cell lines. When 
treated with acute doses of MMS, all cell lines seem resistant, except the OE (3.2) and the KO clone 
A2C2 at the highest doses. Values represent average survival relative to control ± SEM. N ≥ 3 
experiments. Significance levels given by Two-way ANOVA, with Dunnet’s multiple comparison test 
with assumed significance if P ≥ 0.05. Significance levels legend: * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 
0.001, **** P ≤ 0.0001. 
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3.5.3 AAG KNOCKOUT IS ASSOCIATED WITH DECREASE OF CELL 
SURVIVAL AGAINST ALKYLATION  
To ensure that the results given by the MTS assay were accurate, we tested 
the ability of the wild-type and AAG -/-  cells to form colonies after treatment with 
MMS. We found that despite the MTS assessment, the KO cells indeed have shown 
a significant susceptibility to alkylation even at lower doses when compared to the 
AAG-proficient ARPE-19 cells (Figure 31B). Although the curve for the clone A2C2 
seem to be slightly less resistant than B6C3 this difference is not statistically 
significant.  
The consistency of the response across both knock-out clones suggests that 
the phenotype observed is indeed due to AAG absence and thus, the glycosylase 
seems important to alkylation repair in this specific cell model. 
 
 
Figure 31: AAG knockout sensitizes cells to alkylation damage. A) Typical colony aspect for each of 
the cell lines. B) Average clonogenic survival curves for each cell line. Survival fraction was calculated 
taking into account plating efficiencies. Values represent average survival relative to control ± SEM. 
N ≥ 3 experiments. Significance levels given by Two-way ANOVA, with Dunnet’s multiple comparison 
post-hoc test with assumed significance if P ≤ 0.05. Significance levels legend: * P ≤ 0.05, ** P ≤ 0.01, 
*** P ≤ 0.001, **** P ≤ 0.0001. 
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 DISCUSSION 
More relevant than ever, the field of DNA repair is of paramount 
importance to the understanding of the mechanics that drive cell sensitivity to the 
plethora of threats it suffers from both environmental and endogenous sources. 
From a clinical standpoint, it gains an additional level of importance: most widely 
used tumour treatments are still based on drugs that have the capacity to damage 
DNA, leading these already encumbered (either by replicative stress or oxygen 
reactive species) cells to death. Therefore, more relevant than ever, is the study of 
the particulars that drive the response of cells to damaging agents. 
One of the most common approaches to such research is through gain or 
loss of function experiments, such as the AAG overexpressor and knockout 
strategies employed in our study. To evaluate the impact that AAG has over the 
phenotype of the cells, we successfully generated several clones that either 
overexpressed AAG (clones 3.1 to 3.4) or had it knocked out (clones A2C2 and 
B6C3). 
To evaluate whether the modulation would have any significant impact on 
the cell’s response to alkylation we performed two distinct methods to evaluate 
survival: MTS and clonogenic assays. 
Both techniques delivered somewhat different results. When assessing 
survival through the MTS assay, it was seen that most of the cell lines were 
somewhat resistant to the alkylating treatment alone, except the overexpressor cell 
line (3.2). This observation agrees with what is reported in the literature on the 
impact of AAG overexpression. Relative decrease in cell fitness against alkylation 
was observed in most cells artificially overexpressing it, such as ovarian cancer cells 
lines (Fishel et al., 2007), Chinese Hamster Ovary cells (Coquerelle, Dosch, & Kaina, 
1995) and breast cancer (M. L. Rinne et al., 2005), amongst others. Enhanced AAG 
activity was also shown to have a very striking effect in certain cell types in vivo, 
Chapter3:AAG and the UPR: Cell Line Development and Characterization  
 
107 
 
leading to accentuated alkylation-derived degeneration in specific mouse tissues, 
such as retina, cerebellum and thymus (J. A. Calvo et al., 2013; Meira et al., 2009). 
The main theory behind this observation is that the heightened AAG repair activity 
is unmatched by downstream BER enzymes, which leads to the accumulation of 
cytotoxic repair intermediates, such as 5’dRPs and AP sites, which, in turn, can lead 
to cell death (Fu et al., 2012). This theory of imbalanced BER gains additional 
support from experiments that have shown when BER rate-limiting enzymes such as 
Pol β are overexpressed in conjunction with AAG, the deleterious effects of the 
glycosylase are abrogated (Tang et al., 2011). 
The MTS assay showed a surprising absence of a clear phenotype regarding 
the survival of the knockout cells and this led us to question whether such results 
were not due to a technical artefact. It is known that despite its various advantages 
(as higher throughput) this test has its shortcomings (Huang, Chen, & Walker, 2004). 
Therefore, we performed a clonogenic assay, a method that is referred by several 
authors as the “gold standard” of cell survival assays (Braselmann, Michna, Heß, & 
Unger, 2015; Mirzayans, Andrais, Scott, Tessier, & Murray, 2007) to ensure that the 
previous results were consistent across distinct experimental methods. 
Interestingly, the clonogenic assay showed that both AAG -/- clones A2C2 
and B6C3 were more sensitive to MMS than its WT counterpart, indicating that, 
contrary to the results obtained by MTS, AAG genotype had a significant effect on 
the clonogenic survival to alkylation (P< 0.0001). Contrary to the data reported on 
the literature regarding overexpression, the effects of AAG elimination do not have 
such clear-cut phenotype. One of the oldest studies shows that in mouse Aag -/- ES 
cells, there is an increased sensitivity to the alkylating agents bis-
chloroethylnitrosourea (BCNU) and mitomycin C, in comparison to wild type mouse 
ES cells (Engelward et al., 1996). Some of the subsequent studies also showed that 
AAG deficiency could lead to sensitization in HeLa treated with MMS or BCNU (Paik 
et al., 2005) and in paediatric glioblastomas treated with temozolomide (Agnihotri 
et al., 2014). 
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However, there is also a significant body of evidence that shows the 
opposite effect, instead of sensitizing cells, there is an increase in resistance. Ex vivo 
studies of myeloid progenitors extracted from Aag null mice show that Aag null 
cells are more resistant to MMS when compared to WT cells (Roth & Samson, 
2002). Furthermore, Aag null pancreatic β-cells are protected from cell death 
induced by streptozotocin, an alkylating agent that induces selective β-cell death in 
the pancreas, compared to wild type (Burns & Gold, 2007).  
Some in vivo studies suggest that there are additional contributors to 
alkylation sensitivity, as some tissues seem to be greatly affected by alkylation 
when Aag is modulated whereas some are not. Such is the case of the investigation 
mentioned above, by Meira and colleagues in 2009, where the number of Aag 
copies seems to correlate with the severity of damage in certain retinal areas. 
Similar findings were reported on a subsequent study where specific tissues were 
vulnerable to alkylation-derived cell death, namely: cerebellar granule cells, 
splenocytes, thymocytes, bone marrow cells, pancreatic β-cells, and retinal 
photoreceptor cells (J. A. Calvo et al., 2013) 
Thus, taken together, the highly contradictory studies on AAG and its 
effects on alkylation response, suggest that more than one mechanism may be 
responsible for the phenotype, such as cellular context (proliferative status, tissue, 
BER capabilities), lesion nature, energetic status and subcellular source of 
imbalance (nuclear vs. mitochondrial AAG) may explain some of the varied 
outcomes. Therefore, to be able to pinpoint a causal effect for the sensitivity 
observed on the knockouts, an extensive investigation on these factors would be 
required, whose aims are beyond the scope of this work. 
Overall, this chapter shows that we were able to generate several cell lines 
either overexpressing or without expression of AAG, from which three clones were 
chosen for further investigations (OE 3.2, AAG -/- A2C2 and B6C3). It was found that 
the selected overexpressor clone presents an increased sensitivity to the alkylating 
agent MMS, whereas the KO clones presented no such phenotype when analysed 
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through MTS assay. However, when survival was assayed with the more sensitive 
clonogenic assay, it was found that those cell lines were also significantly 
susceptible to the treatment.  
The possession of such biological tools enabled us to investigate the impact 
of AAG in a different setting: endoplasmic reticulum stress, as will be further 
discussed in Chapter 4 
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Chapter 4 
INVESTIGATION ON THE 
PUTATIVE ROLE OF AAG IN THE 
ENDOPLASMIC RETICULUM 
STRESS 
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4 Investigation on the putative 
role of AAG in the endoplasmic 
reticulum stress  
 INTRODUCTION 
The search for compounds that allows the killing of tumour cells with 
minimal or no toxicity to healthy tissues is one of the holy grails of current 
pharmacology. Despite the development of targeted therapies exploiting the anti-
tumour immune responses and individual tumour characteristics, alkylating agents 
are still a widely used anticancer chemotherapeutic strategy, often in combination 
with other chemotherapeutic drugs and/or radiotherapy (Jones, 2015).  
Often in their path to malignancy, neoplastic cells acquire traits that allow 
rapid growth (e.g. the ability to bypass cell cycle checkpoints) in detriment of the 
ability to properly repair damage and at considerable replication stress. Both 
chemotherapy and radiotherapy can exploit these shortcomings to increase damage 
to tumours (Jones, 2015; J. Zhang, Dai, Park, & Deng, 2016).In this way, damage to 
the surrounding healthy tissue can be limited, since healthy cells should still have 
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functional repair pathways and checkpoints to deal with the damage caused by the 
therapies.  
To maximize cytotoxic effect, protocols usually combine drugs that target 
more than one of these vulnerabilities (e.g. one or more defective repair pathways, 
absence of or shortened cell cycle checkpoints) to increase efficacy (Dietlein & 
Reinhardt, 2014). Thus, to optimize cancer treatment, a better understanding of the 
cellular mechanisms of stress response elicited by both healthy and cancer cells to 
cope with cytotoxic stress is highly desirable. 
Thus, to add to the body of knowledge about the mammalian response to 
alkylation, members of the Meira group have been studying how the repair activity 
of alkyl-adenine glycosylase (AAG) can influence the outcome of alkylation 
treatment. As mentioned in Chapter 3, AAG-initiated repair is important in certain 
situations (e.g. protecting against inflammation-induced colon carcinogenesis or 
protecting mouse embryonic stem cells) (Engelward et al., 1997b; Meira et al., 
2008), However, it soon became evident that Aag repair is not always beneficial.  It 
can also lead to alkylation-induced cell death and tissue damage (J. A. Calvo et al., 
2013; Meira et al., 2009) and this attribute has therapeutic potential. 
Although its mechanism of action and substrates are relatively well known, 
there is no defined phenotypic outcome resulting from AAG-mediated repair. In 
some contexts and cell types, its absence has the impact expected when a repair 
enzyme is no longer able to fulfil its role: sensitization to damage. Such sensitization 
was reported in mouse embryonic stem cells (Engelward et al., 1996). AAG activity 
was also found to be important in the protection against colon carcinogenesis 
induced by inflammatory-derived alkylation and oxidation damage in an animal 
model (J. a Calvo et al., 2012; Meira et al., 2008).  However, the results obtained 
from in vivo studies using the animal models indicate that AAG activity in the 
presence of DNA damage, rather than always being cytoprotective, can sometimes 
be cytotoxic.  
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In the pursuit of an understanding of the mechanisms behind such 
disparate outcomes, our group studied the transcriptional response of a non-toxic 
dose of the directly acting alkylating agent methylmethane sulfonate (MMS) in 
livers from mice deficient in Aag (Aag null) compared to wild-type animals. The 
analysis revealed that MMS treatment elicits a more robust transcriptional response 
in Aag-proficient animals versus Aag-deficient animals (Figure 12A, 229 unique 
transcripts modulated in the wild type liver vs. 108 in the Aag null liver; fold change 
> 1.5, adj. p-value  0.05). Furthermore, it was evident that the nature of the 
response was quite dissimilar between genotypes, as there were very few 
transcripts commonly modulated between the two genotypes (26 commonly 
modulated transcripts). Strikingly, transcripts involved in the endoplasmic reticulum 
(ER) stress/unfolded protein response (UPR) were induced by MMS treatment only 
in wild-type animals (Figure 12 B).  
The notion that MMS can evoke the UPR should not be very surprising, 
despite the lack of research in the area. Alkylating agents are capable of damaging 
not only nucleic acids, but biological membranes and also proteins (Boffa, 
Bolognesi, & Mariani, 1987). The alkylation of structures such as thiol groups can 
lead to impaired enzymatic activity or even elicit autoimmune response (Lin et al., 
2012; Pumford & Halmes, 1997).  
The UPR is a complex network of responses with the primary goal of 
maintaining the cellular proteostasis or, if the proteome stress is irreversible or 
prolonged, to drive the cells to apoptosis.(Todd et al., 2008). The response itself is 
composed of three main branches, initiated by transmembrane proteins localized in 
the ER, namely: Activating Transcription Factor 6 (ATF6), Protein kinase RNA-like 
endoplasmic reticulum kinase (PERK) and Inositol-Requiring Enzyme 1(IRE1) 
(Harding, Calfon, Urano, Novoa, & Ron, 2002). 
ATF6 is a Leu zipper (bZIP) transcription factor that is activated upon ER 
stress. The chaperone BiP (Immunoglobulin Heavy Chain-Binding Protein) 
dissociates from ATF6 upon detection of unfolded proteins in the ER, and in doing 
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so exposes a Golgi-targeting sequence present in the ATF6 protein, causing it to be 
translocated to the Golgi apparatus, where is cleaved by site 1 and site 2 proteases. 
This cleavage event generates an ATF6 cytosolic fraction (ATF6f) that is able to 
translocate to the nucleus to interact with canonical ER stress responsive elements 
(ERSE) and type II ER stress responsive elements (ERSE-II) in the promoters of 
certain genes. These elements are present in several genes, among them CHOP - 
CCAAT/enhancer-binding protein homologous protein - and X-box binding protein 1 
-XBP1 (Hetz, 2012; Todd et al., 2008). 
PERK or PRKR-Like Endoplasmic Reticulum Kinase, is a type-I 
transmembrane ER resident protein. As ATF6, its activation is also triggered by 
dissociation of BiP, allowing its kinase activity to transphosphorylate other PERK 
molecules, what leads to its oligomerization. It also phosphorylates eukaryotic 
transcription factor 2 α (eIF2α) resulting in a global downregulation of transcription, 
except for some select genes possessing alternative uORFs, notably activating 
transcription factor 4 - ATF4 (Harding et al., 2002). ATF4 can activate GADD34 , BiP, 
CHOP, Herp and genes responsible for amino acid metabolism and oxidative stress 
response (Schröder & Kaufman, 2005; Todd et al., 2008). However, eIF2α can also 
be phosphorylated by at least three other kinases (double-stranded RNA-dependent 
protein kinase -PKR, heme-regulated eIF2a kinase -HRI; and general control non- 
derepressible 2 -GCN2) that respond to diverse stress stimuli (e.g. hypoxia, amino 
acid deprivation, viral infection) and can induce ATF4 translation, in a PERK-
independent manner. These kinases, together with PERK, participate on an very 
complex web of pathways entitled ISR -  Integrated Stress Response, that triggers a 
series of adaptive responses that vary according with the source of stress and 
cellular status (Pakos‐Zebrucka et al., 2016). 
IRE1 - inositol requiring enzyme 1 – can be expressed as two isoforms, 
IRE1α and  β and initiates the most conserved of all three UPR pathways (X. Wang 
et al., 1998; L. Zhang, Zhang, & Wang, 2016). Its activation follows a series of steps 
similar to PERK: the release of BiP from IRE1 leads to its oligomerization and 
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subsequent autotransphosphorylation, activating its site specific-endoribonuclease 
activity (Li, Korennykh, Behrman, & Walter, 2010). Not much is known about its 
kinase activity apart from the autophosphorylation property, but the 
endoribonuclease’s most known target is the transcription factor known as XBP1. 
IRE1’s endoribonuclease activity acts upon the full-length XBP1 transcript, 
performing a non-canonical splicing event that generates an XBP1 active form that 
codes for a transcription factor, spliced XBP1 (sXPB1). sXBP1 activates chaperones, 
protein quality control and ERAD-ER-associated degradation genes (Hetz, 2012). In 
addition, IRE1 endoribonuclease activity also degrades specific mRNAs in a process 
called IRE1-dependant decay (RIDD) and can elicit other stress pathways involving 
the nuclear factor kappaB (NF-κB) transcription factor and the JUN N-terminal 
kinase (or JNK) (Gardner, Pincus, Gotthardt, Gallagher, & Walter, 2013). 
Despite extensive research on the UPR, to our knowledge, there is no 
report so far describing the involvement of a DNA glycosylase in any step of the 
UPR. Even so, our findings indicate AAG somehow modulates the intensity of the 
UPR response, either through its DNA damage detection and/or processing or 
through some novel repair-independent function, whose mechanism still eludes 
detection.  
 
 AIMS 
• To confirm and to comprehend the putative role of the Alkyl 
Adenine Glycosylase in the Unfolded Protein Response. 
 OBJECTIVES  
• Confirm the ability of ARPE-19 to elicit UPR response using a 
classical ER stress inducer (thapsigargin) and evaluate the specificity 
of the response; 
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• Investigate if the alkylating agent methyl methanesulfonate is 
capable of inducing ER stress in ARPE-19; 
• Investigate how the modulation of AAG affects the induction of ER 
stress response, using AAG-proficient, AAG-deficient and AAG-
complemented knockout cells; 
• Investigate the main players behind the UPR on AAG-proficient and 
AAG-deficient cells; 
• Investigate the impact of AAG modulation in the transcriptional 
response of several ER stress markers. 
 
 MATERIALS AND METHODS 
4.4.1 CELL CULTURE 
As stated in the previous chapter, all AAG genetic modulation was carried 
out using ARPE-19 cells as hosts.  
The wild-type original ARPE-19 stock was donated by Dr Axel Nohturfft (St. 
George’s University of London, UK). Both ARPE-19 and Hep G2 cells were cultivated 
in High-Glucose DMEM (Sigma-Aldrich, St. Louis, USA), supplemented with 10% 
heat-inactivated GIBCO foetal bovine serum (Thermo Fisher Scientific, Waltham, 
USA) and 2.5mM of L-glutamine (Sigma-Aldrich, St. Louis, USA) in a humidified 
incubator, under 5% CO2. All cells, WT or otherwise, were cultured in the absence of 
antibiotics, except the complemented AAG Knockout (A2C2 AAG ++, see next 
section) that was grown with medium containing 200 µg/mL of geneticin. 
All experiments were performed with freshly thawed stocks of cells, kept 
after defrosting for a maximum of 3 passages.  
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4.4.2 AAG KNOCKOUT CLONE COMPLEMENTATION 
To address the question of whether the genetic manipulation per se or the 
absence of AAG expression was responsible for the phenotype observed during ER 
stress induction aa AAG complemented cell population was developed. Using as 
background the AAG -/- clone A2C2, a genetic complementation was carried out 
transfecting the cells with the AAG expressing plasmid pEGFP-C3. hAAG (C3-hAAG, 
Figure 19). The transfection was achieved in a similar fashion to the method applied 
for the overexpressor cell line generation. Briefly, 100 ng of the plasmid per well 
was diluted on serum-free medium and incubated with Lipofectamine LTX 
(Invitrogen Carlsbad, USA) for 30 minutes on a proportion of 3:1 (reagent:DNA). The 
mix was then applied to the cells plated on the prior day and incubated for a 
maximum of 6 hours and replaced with fresh supplemented medium (DMEM 10% 
FBS). 
Cells were left to recover for 24 h, whereupon the wells were inspected 
under an epifluorescence microscope to detect GFP-positive populations. Those 
populations were then trypsinized and expanded gradually under 300 µg/mL of 
geneticin selection for the first two weeks. After this period, antibiotic 
concentration was kept constant at 200 µg/mL to avoid excessive stress on the cells. 
4.4.3 ER-STRESS INVESTIGATION – LUCIFERASE ASSAYS  
4.4.3.1 ER STRESS CONSTRUCTS AND TRANSFECTION CONDITIONS 
For its convenience and high-throughput, the main approach chosen in this 
work to investigate the effect of AAG on ER stress induction was through the 
luciferase reporter assay. One of the most widely used versions of this assay 
transfects cells with a couple of luciferase-expressing plasmidial reporters, each 
expressing either firefly (p5xATF6-Luc2P) or Renilla luciferase (pRL-CMV). In this 
particular case, a firefly luciferase gene was placed under the command of a 5-
repeat ERSE element, that can be induced by several ER-stress signal transductors 
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as ATF6f, sXBP1 and CREB3/Luman. Thus, the firefly luciferase transcription 
induction was indirectly measured by luminescence increase when the target cell 
lysate was incubated with the luciferase substrate and the light emission was 
measured in an appropriate plate reader. To minimize the natural fluctuation of 
signal between cells, the firefly luciferase emission is normalized by the 
constitutively expressed Renilla firefly (i.e. under a CMV promoter). It is importante 
to note, however, that since the output (luminescence) relies on the cellular 
transcription and translation machinery to be activated, in theory there could be 
variations on signal intensity between distinct cell lines or between cells from the 
same parental cell line with differing genetic background (e. g. genetically 
engineered KOs). To address this issue, one of the experiments carried out 
consisted in co-transfecting cells with a constitutively expressed CREB3 plasmid in 
addition to the regular luciferase reporters, in order to highlight any discrepancies 
in signal output borne out of the diverse gentic background of our engineered cell 
lines. 
Additional experiments were also conducted in parallel to confirm the 
specificity of the ER stress induction. ARPE-19 cells were transfected with reporter 
plasmids either responsive to NF-kappaB (induced by a great variety of stress 
stimuli, such as inflammation) and ATPase H+ Transporting Accessory Protein 1 
(ATP6AP1) a subunit of vacuolar ATPase, whose expression is not predicted to 
fluctuate under stress. The choice of these plasmids rests on the fact that if ER 
stress were to be detected concomitantly with NF-kB, it would indicate a “dirty” 
induction (i.e. indirect or acting upon several cell components). Whereas ATP6AP1 
variation would indicate a spurious result resulting of methodological issues. A table 
listing all the reporter constructs, their function and their source is included in the 
Appendix of this chapter 
Cells were plated on the day prior to the experiment, at a density of 5 x 104 
cells/mL in complete DMEM. On the day of the experiment, a mix of 100 ng of the 
p5xATF6-Luc2P plus 1 ng of the pRL-CMV plasmid was transfected after incubation 
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with Lipofectamine LTX, following the manufacturer’s instructions. The medium 
containing the transfection reagent was replaced by complete DMEM after 4 hours 
and the transfected cells were left to recover for additional 24 hours(Figure 32). 
Raw and calculated data of the main luciferase experiments can be found on the 
Appendix at the end of this chapter. 
 
Figure 32: Experimental timeline for the luciferase ER stress experiments. Cells were plated at least 
12hours prior the experiment, after which were transfected with the appropriate luciferase plasmid 
reporters. After 4 hours, the medium was changed and cells were left to recover for 24 hours. Then, 
cells were treated either with MMS (for one hour in serum-free medium) or 6 hours with 
thapsigargin (TG), tunicamycin (TUN) or brefeldin A (BFA). 
4.4.3.2 DRUG TREATMENTS  
After the 24-hour recovery period, the cells were treated with a variety of 
ER stress inducers.  
For being such a potent ER stress inducer, Thapsigargin (TG) was used as a 
positive control. It acts by disrupting the cellular calcium balance, triggering its 
release from the ER by blocking SERCA pumps (sarco/endoplasmic reticulum Ca2+-
ATPase). The decrease on ER calcium prevents calcium-dependent chaperones from 
working, thus leading to accumulation of unfolded proteins in the ER (Oslowski & 
Urano, 2011). For the luciferase assays, a dose of 300 nM was used (all drugs were 
obtained from Sigma-Aldrich, St. Louis, USA, unless stated otherwise). The drug was 
resuspended in DMSO and then diluted in complete DMEM to the appropriate 
concentration. Cells were treated for 6 hours before luciferase levels were 
measured. 
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The second ER stress inducer used was tunicamycin, which causes 
accumulation of unfolded proteins in the ER, albeit through a different mechanism. 
It acts by impacting protein glycosylation, thus impeding proper protein folding 
(Foufelle & Fromenty, 2016). Cell treatment was done in the same fashion as TG, by 
diluting tunicamycin to the concentration of 50 µg/mL in complete DMEM and 
incubating cells for a period of 6 hours. 
Finally, the third classical ER stress inducer utilized was brefeldin A. It 
indirectly inhibits the ADP Ribosylation Factor 1 (ARF1), responsible for the 
recruitment of coat proteins involved in the formation of secretory vesicles, 
preventing traffic between ER and Golgi complex (Misumi et al., 1986). The lack of 
transport has a twofold effect: leads to accumulation of proteins in the ER and 
overexposure of vesicle-SNARES, which allows the Golgi cisternae to fuse with the 
ER redistributing their content therein (Fujiwara, Oda, Yokota, Takatsuki, & Ikehara, 
1988; Lippincott-Schwartz et al., 1990; Oslowski & Urano, 2011).  A dose of 10 
µg/mL was used and, as before, the incubation was done for 6 hours on complete 
medium. 
Given the relevance in the context of AAG-initiated repair and the 
preliminary microarray experimental results, it was decided to examine the 
response to methyl methanesulfonate, a SN2 alkylating agent. Doses ranging from 
0.5 to 3.5 mM were used for treatment. The procedure was done by diluting the 
drug in serum-free DMEM and treating the cells in serum-free conditions for 1 hour. 
The medium was then replaced by complete DMEM and cells were left to recover 
for additional 5 hours, when they promptly had the luciferase levels measured. 
4.4.3.3 LUCIFERASE MEASUREMENTS  
After a 6-hour period, the growth medium was removed from the plates 
and replaced with 30 µL of lysis buffer (20 mM Tris [pH 7.6], 10% glycerol, 0.5% 
Triton X-100), supplemented with 1 x protease inhibitor cocktail (Thermo Fisher 
Scientific, Waltham, USA) and 1 mM of DTT (Sigma-Aldrich, St. Louis, USA). The 
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plates were incubated for 30 minutes on ice, and then 10 µL of the lysate was 
transferred to a white 96-well plate. The luciferase levels on the lysates were then 
detected using the Promega Dual-Glo Luciferase Assay System (Promega, Madison, 
USA), following the manufacturer’s recommendations. 
To obtain the relative luminescence levels of ER stress induction, first each 
raw firefly luminescence (Fluc) value was divided by its respective Renilla 
luminescence (Rluc) value. The result was the corrected luminescence induction, as 
Renilla luminescence measurements are supposed to correct for experimental 
differences (e.g. different transfections efficiencies). Then, the corrected 
luminescence was normalised by dividing it by the average of the corrected 
luminesce values obtained for the untreated wells, as can be seen on Figure 33. 
(𝐹𝑙𝑢𝑐 𝑅𝑙𝑢𝑐⁄ )
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑈𝑇 (𝐹𝑙𝑢𝑐/𝑅𝑙𝑢𝑐)
 = 𝑁𝑜𝑟𝑚.  𝑟𝑒𝑙.  𝑙𝑢𝑚. 𝑖𝑛𝑑𝑢𝑐𝑡𝑖𝑜𝑛 
Figure 33: Equation for the determination of normalized luciferase induction. Each raw firefly 
luciferase value is first divided by its respective Renilla luciferase value to obtain corrected luciferase 
induction levels, which are, in turn, divided by the average of the corrected values (Fluc/Rluc) of the 
untreated wells, resulting in the normalized relative luminescence induction. 
4.4.4 ER-STRESS INVESTIGATION – RT-QPCR 
4.4.4.1 RNA ISOLATION AND CDNA SYNTHESIS 
The cells were grown in T25 cm2 flasks until they reached 90% confluence, 
whereupon they were harvested by trypsinization and pelleted. The pellet was 
processed for RNA isolation using the PureLink RNA Mini kit (Invitrogen, Carlsbad, 
USA) according to the manufacturer’s instructions. The samples were quantified by 
spectrophotometry (NanoDrop, Invitrogen Carlsbad, USA) and either frozen at -80 
ºC or promptly used for first strand cDNA synthesis. 
For the synthesis, 1 µg of total RNA was used per sample and the reaction 
was carried out using the Maxima First Strand cDNA Synthesis (Thermo Fisher 
Scientific, Waltham, USA) whose first step consists of the incubation of the RNA 
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with a dsDNAse, minimizing the risk of genomic DNA contamination. The procedure 
was carried out following the product manual. 
4.4.4.2 RT-QPCR 
To complement our investigation into the impact of AAG modulation in the 
ER stress induction, a number of ER stress markers had their transcription levels 
evaluated after MMS and TG treatment: Activating Transcription Factor 4 (ATF4), 
Immunoglobulin Heavy Chain-Binding Protein (BiP - HSPA5), X-Box Binding Protein 1 
(XBP1), Homocysteine-Inducible Endoplasmic Reticulum Stress-Inducible Ubiquitin-
Like Domain Member 1 Protein – HERP (HERPUD1). C/EBP homologous protein – 
CHOP (DDIT3) and p21 (CDKN1A) were also assessed. Primer sequences and their 
source can be seen on Appendix 1, S. Table 1. 
Expression levels were quantified as fold-expression using human β-actin 
(ACTB, NM_001101.3) as the reference gene (ΔΔCt). All reactions were singleplex in 
a 96-well plate (triplicate wells), using SYBR Green Luminaris Colour HiGreen qPCR 
Master Mix, low ROX (Thermo Fisher Scientific, Waltham, USA) for amplification 
detection and ROX as a fluorescence normalizer. The total volume of the reaction 
was of 20 µL, of which 10 µL of master mix, 0.8 µL of each primer, 1 µL of template 
and ultrapure water. The amplification was done in the QuantStudio 7 Flex Real-
Time PCR System (Life Technologies, Carlsbad, USA) using as cycling conditions 
50ºC/2 minutes (UDG activation), 95ºC/10 minutes (denaturation/polymerase 
activation) followed by 40 cycles of 95ºC/15 seconds and 60ºC/1 minute. At the end 
of the reaction, an additional cycle for melting curve analysis was added to confirm 
primer specificity. 
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4.4.4.3 WESTERN BLOTTING 
To further analyse ER stress induction in WT and AAG-/- cells, western 
blotting was performed to examine the expression levels of Xbp1 and BiP, proteins 
normally upregulated in the UPR.  
Cells were grown in T25 cm2 in triplicate until 80% confluent and were 
treated either 2.5mM of MMS or 300 nM of thapsigargin (Sigma-Aldrich, St. Louis, 
USA). Treatments were performed as stated prior: MMS was diluted to the 
appropriate concentration in serum-free media and treatment was done for one 
hour after which cells had the treatment medium replaced by complete medium. 
Treatment with thapsigargin was done in complete medium and drug was kept 
during the whole treatment period. Time points were started after this period (1, 6 
and 24 hours). Untreated controls were harvested after 24 hours. 
Cells were harvested by trypsinization and were centrifuged at 300 x g for 
five minutes for pelleting. The pellet was washed with 1x PBS and centrifuged again 
at the same speed/time, after which the supernatant was aspirated and the pellet 
frozen at ---80°C until further processing. 
Total cell protein was obtained by lysing cells in the pellet with 60 μl of 
MPER buffer (Thermo Fisher Scientific, Waltham, USA), supplemented with 1% 
Phosphatase inhibitor (Sigma-Aldrich, St. Louis, USA) and 1x protease inhibitor 
cocktail (Thermo Fisher Scientific, Waltham, USA) and submitted to three 
freeze/thaw cycles. After the final thaw, tubes were centrifuged at 14,000 x g for 7 
minutes and supernatant was transferred to a new tube and total protein was 
quantified. 
Protein concentrations were determined through bicinchoninic acid assay 
(BCA) supplied by Pierce (Thermo Fisher Scientific, Waltham, USA) using 10 µL of 
sample and standards as recommended by the supplier. 
For western blot analysis 15 µg of protein was diluted in 1x Laemmli buffer 
(Bio-Rad Laboratories, Hercules, USA) containing 1x 1,4-dithiothreitol (Sigma-
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Aldrich, St. Louis, USA) as a reducing agent. The samples were then boiled for 10 
minutes at 95ºC and separated in a TruPAGE™ 4-20% precast gel (Sigma-Aldrich, St. 
Louis, USA) for one hour at constant voltage of 150V. 
Proteins were then blotted by wet transfer in to a PVDF membrane (Merck 
Millipore, Darmstadt, Germany), previously equilibrated for 10 minutes with pure 
methanol and 10 minutes with 1x TruPAGE™ Transfer Buffer (Sigma-Aldrich, St. 
Louis, USA). Transfer was done at 100 V for 2 hours, using 1x TruPAGE™ Transfer 
Buffer with 20% methanol (Sigma-Aldrich, St. Louis, USA). 
Membrane was blocked overnight in a solution of TBS and 1% bovine 
serum albumin (Sigma-Aldrich, St. Louis, USA). Primary antibodies were diluted also 
in TBS and 1% BSA and incubated overnight at 4ºC. On the next day, membrane was 
washed three times (each for 5 minutes) in 1x TBST and incubated with fluorescent 
secondary antibodies for 1 hour shielded from light and under agitation, after which 
it was scanned in the Odyssey CLx IR imaging system (LI-COR Biosciences, Lincoln, 
USA) 
Antibodies and dilutions utilized were as follows: 1:1000 Rabbit anti-BiP 
mAb (Cell Signalling Technology, Danvers, Massachusetts), at 1:1000; mouse anti-
Xbp1 mAb (Santa Cruz Biosciences, Dallas, USA), at 1:500; mouse anti-β-Actin mAb 
(Sigma-Aldrich, St. Louis, USA) at 1: 10,000 and rabbit anti-peIF2α mAb (Cell 
Signalling Technology, Danvers, Massachusetts) at 1:100.  
IRDye 680RD green goat anti-mouse IgG, IRDye 680RD green goat anti-
rabbit IgG, IRDye 800CW red Goat anti-rabbit and IgM IRDye 800CW red Goat anti 
mouse (LI-COR Biosciences, Lincoln, USA) at 1:10,000. 
BiP and sXbp1 levels were quantified with the help of the software Image 
Studio Lite, version 5.2 (LI-COR Biosciences, Lincoln, USA). For quantification, all raw 
β-Actin values were first divided by the sample with the highest β-Actin raw signal 
to obtain a relative signal. Then, each of the target protein values were divided by 
its own relative β-Actin signal to obtain the normalized protein induction, according 
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to recommendation issue by the LI-COR technical bulletin (LI-COR Biosciences, 
2014) . 
 RESULTS 
4.5.1 MMS INDUCES ENDOPLASMIC RETICULUM STRESS IN A SPECIFIC 
AND DOSE-DEPENDENT MANNER 
The first step in the evaluation of ER stress in our cell model was to 
investigate if these cells were capable of inducing measurable ER stress. To such 
end, firstly cells were transfected with p5xATF6-Luc2P and pRL-CMV and treated 
with thapsigargin. To determine if the response detected was specific, a separate 
experiment was conducted, where cells were transfected either with a NF-kB or 
ATP6AP1-responsive plasmid.  
Unsurprisingly, when the ARPE-19 cells were treated with TG a high 
induction of luciferase (around 21-fold compared to untreated control) is seen, and 
this induction is limited to the ERSE-responsive plasmid (Figure 34, rightmost bars), 
indicating that not only these cells are proficient in the induction of ER stress, but 
that this induction is specific when thapsigargin is used. 
To investigate if MMS treatment would also induce ER stress, cells were 
transfected and treated as indicated previously, and a significant normalized 
increase in luciferase expression of 6.34 (0.02)-fold could be identified when the 
highest dose of MMS was used (3.5 mM). Moreover, the luciferase induction upon 
MMS treatment was shown to be: (i) specific to the ER stress responsive reporter 
(no change in either control plasmids) and (ii) dose-dependent, albeit MMS 
treatment induced the response in a smaller scale than thapsigargin. 
However, to confirm that this finding is not a particularity of our chosen 
ARPE-19 cell line, the assay was also conducted on HepG2 cells. Similarly, MMS 
treatment induced the ER stress responsive reporter in HepG2 cells, although the 
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induction was of a smaller magnitude than what measured on the ARPE-19 cells [in 
HepG2 cells, 3.9 (0.7)-fold at the highest MMS dose]. 
Thus, our first experiment has shown that not only ARPE-19 cells are UPR-
proficient, but that MMS can induce an ER stress response that is dose-dependent 
and specific. 
To further explore this response in the ARPE-19 cells and to investigate 
whether this response was somehow connected to AAG as the previous 
transcriptomic data suggested, we decided to compare the responses on AAG-
proficient and deficient cells employing the same luciferase reporter system. 
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Figure 34: MMS induces endoplasmic reticulum stress in a specific and dose-dependent manner. A) 
MMS treated ARPE-19 cells present a dose-dependent increase in luciferase induction, similar in its 
specificity to the treatment with 300 nM of Thapsigargin. B) A similar pattern can also be observed in 
Hep G2 cells. 
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4.5.2 AAG KNOCKOUT PARTIALLY ABROGATES THE ER STRESS 
RESPONSE TO ALKYLATION TREATMENT. 
Given the differential transcriptional response to alkylation treatment 
exhibited by Aag proficient versus Aag deficient mouse livers, it was only logical to 
interrogate if the same Aag-dependent response would be replicated on a human 
cell model. In order to examine whether alkylation-induced UPR depends on AAG, 
both ARPE-19 AAG +/+ and ARPE-19 AAG -/- cells were co-transfected with p5xATF6-
Luc2P and pRL-CMV and treated as already explained above. 
The difference in alkylation-induced luciferase expression observed 
between the cells with different AAG proficiencies was remarkable. At the highest 
MMS dose (3.5 mM), the wild-type cells displayed a significant (P=0.0015) luciferase 
induction of approximately 6.4 (4.3) fold compared to control levels, while the two 
tested AAG knockout clones consistently displayed a much lower luciferase activity 
level, very similar to those of the untreated controls (1.2-fold, Figure 35 A). We 
surmise that the differences in induction observed in the initial experiments (Figure 
34 when compared to those on Figure 35, are likely due to the precision of the 
latter, that had a higher number of experimental and biological repeats. However, it 
is worth mentioning that it was not possible to perform both experiment using a 
single batch of the drugs (MMS and thapsigargin) and some variation can be fruit of 
the different reagent stocks utilized. 
Strikingly, the response attenuation was also observed in the AAG 
knockout clones upon treatment with TG, where a significant 18 (6.1)-fold induction 
in luciferase expression is seen in the wild-type ARPE-19 cells (P<0.0001 when 
compared to untreated control) in contrast with the lower (P<0.0001) luciferase 
expression induction values measured in the two AAG -/- clones of a 7.4-fold (3.5) 
induction for clone A2C2 and a 6.7-fold (2.2) induction for clone B6C3, as seen in 
Figure 35 B. This finding leads us to propose that indeed AAG status seem to 
influence the degree of ER stress response, not only after alkylation treatment but 
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also after treatment with classical ER stress inducers, such as thapsigargin.  It is 
important to mention that we  
To corroborate the hypothesis of the involvement of AAG in the observed 
response, we restored AAG expression on the AAG -/- A2C2 clone by transfection 
with the plasmid pEGFP-C3.hAAG (Figure 35 D). When these AAG complemented 
cells were interrogated using the same luciferase assay, we could see a 
reestablishment of ER stress induction after treatment with both MMS and TG. The 
defect exhibited by the AAG knockout cells was eliminated by AAG expression and 
luciferase levels in the complemented cells were higher when treated with MMS 
(P<0.0001) or similar (when TG was used) when compared to the wild-type cells 
(Figure 35 A and B), lending strength to our proposal that AAG plays a role in UPR 
induction. 
To further evaluate whether AAG indeed plays a role in UPR induced by 
pharmacological activators of ER stress, our panel of cell lines was also treated with 
two additional ER stress inducers: tunicamycin and brefeldin A (Figure 35 C). With 
tunicamycin treatment, again we could see that the knockout cells had a dampened 
response when compared to the wild-type cells, just as before. WT cells had a 
significantly higher luciferase induction than both KOs (P<0.0001). However, 
contrary to A2C2 (P= 0.0004), B6C3 was not significantly induced by tunicamycin 
when compared to its untreated control.  
Despite leading to a similar trend in terms of defective luciferase induction 
in the AAG knockout cells, the treatment with brefeldin A did not induce a 
significant difference in luciferase expression either among the genotypes or among 
the knockout clones. Results obtained by the Meira group revealed that 
glioblastoma cells did not show a conventional dose-response curve after BFA 
treatment (data not shown), as there was a binary response to the concentrations 
of BFA used: either no cytotoxicity or almost complete cytotoxicity.  
There seems to be a cell type specificity in terms of BFA sensitivity. In MDA-
MB-231 the highest doses (up to 50µg/mL) failed to reduce more than 60% the 
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survival of the adherent cells. When used to treat epithelial ovarian cancer cells, 
however, it seems to decrease cell viability to 33% on a dose of 10 µg/mL  (S. A. Lee, 
Kim, & Lee, 2013). On the available literature, ARPE-19 has been treated with the 
dose utilized in this work, but not with the aim of evaluating survival or ER stress 
(Faghiri & Bazan, 2006; Reigada, Lu, & Mitchell, 2006). Therefore, the lack of 
response could be due to a resistance of the ARPE-19 to the compound, highlighting 
the need to use a range of doses to investigate the issue. 
However, it is also interesting to note that in most of the cited works, the 
length of treatment far exceeded the one used in the present investigation (6 hours 
vs. ~ 24 hours), so it could be also a matter of increasing the exposure to the drug. 
Next, it was verified if the differences in the levels of luciferase induction 
seen between the AAG knockout clones and wild-type cells did not result from off-
target effects of our genetic modulation that would impair the ability of the cells to 
properly induce luciferase. To test this hypothesis, we transfected the cells with the 
plasmid pCX-nCREB3-EGFP, which allows the expression of CREB3/Luman, a 
dominant positive activator of the luciferase reporter construct used in the study. 
By co-transfecting our cells with the luciferase reporter plasmids as above and pCX-
nCREB3-EGFP, and measuring the difference of expression efficiencies in the cells 
lines, we were able to address a potential defect in luciferase expression caused by 
AAG modulation.  
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Figure 35: AAG absence seems to partially abrogate ER stress response. A) When treated with MMS 
ERSE-responsive luciferase expression rises to approximately 6.4-fold (relative to untreated control) 
in the WT cells, where in the AAG -/- does not exceed 1.4-fold. B) The dampened response is also 
seen upon TG treatment. In both cases induction is restored to WT levels or above when AAG is 
complemented in the A2C2 AAG -/-. C) The significant difference in ATF6 induction is also seen when 
cells are treated with tunicamycin, but not with brefeldin A. D) Western-blot of AAG levels on wild-
type, knockout and complemented knockout: bottom panel shows b-actin levels, middle panel 
shows wild-type AAG (32 kDa) and top panel shows AAG-GFP fusion protein expressed generated by 
pEGFP-C3.hAAG. Values represent normalized fold-change firefly luciferase induction relative to 
control ± SEM. N ≥ 3 experiments. Significance levels given by Two-way ANOVA, with Tukey’s 
multiple comparison post-hoc test with assumed significance if P ≤ 0.05. Significance levels legend: * 
P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001.  
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4.5.3 DIFFERENCES IN EPISOMAL EXPRESSION OF CREB3 DO NOT 
SEEM RELATED TO THE DECREASE IN ERSE-DRIVEN LUCIFERASE 
EXPRESSION IN KNOCKOUT CELLS.  
As previously mentioned, to eliminate the possibility that the dampened ER 
stress response observed on the knockouts was driven by the inability to properly 
express luciferase, we next examined the effects of dominant expression of CREB3.  
To assess such possibility, cells were co-transfected with pCX-nCREB3-EGFP, 
p5xATF6-Luc2P and pRL-CMV. The experiment was devised to work as such: 
episomal expression of CREB3/Luman (from pCX-nCREB3-EGFP) would transactivate 
luciferase expression by binding to the ERSE repeats on p5xATF6-Luc2P. As such, 
any potential impairment on luciferase expression would be detected by decrease 
in the luciferase signal. 
The results of this experiment show that CREB3/Luman transfection 
induced luciferase expression relative to control conditions in all cell lines tested, 
albeit with different magnitudes. Despite all cell lines having the ARPE-19 genetic 
background, the levels of CREB3/Luman mediated luciferase induction observed 
varied amongst the cell lines (Figure 36). ARPE-19 presented an increase of 752 
(312)-fold induction against its untransfected control (P= 0.0013), whereas the AAG 
-/- A2C2 clone displayed a 152 (52) -fold increase (not significant) and the AAG -/-. 
The B6C3 clone showed a 1086 (358)-fold induction (P-<0.0001). Despite being 
slightly higher than the uncomplemented knockout, AAG++ A2C2 still achieved lower 
values of CREB3-mediated luciferase induction than ARPE-19 or AAG -/- B6C3, with a 
mean of 202 (90)-fold induction (not significant). The luciferase levels of the wild-
type cells were significantly higher than both AAG -/- A2C2 (P= 0.0105) and AAG++ 
A2C2 (P=0.0210), but no different (statistically) from AAG -/- B6C3. Although they 
have  a variation in fold induction, this experiment shows that none of the clones is 
uncapable of inducing luciferase expression. 
Thus, even though the AAG -/- A2C2 clone seems to induce luciferase at 
lower levels, clone AAG -/- B6C3 does not seem to be affected by the same issue, 
which indicates that, at least for this clone, the difference of ER induction between 
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wild-type cells and this clone when treated with either MMS or thapsigargin is 
caused by the knockout of AAG rather than any off-target effect of the CRISPR/Cas9 
manipulation or any inherent defect in luciferase expression. This is further 
supported by the fact that complemented clone AAG++ A2C2, despite having lower 
luciferase induction in this experiment, it is capable of inducing it at higher or 
comparable levels to the other cells when the expression is triggered by ER stress ( 
Figure 35  and Figure 36). 
Our next step was to dissect the response by investigating which 
transcription factors are mediating the luciferase reporter response. 
 
Figure 36: AAG -/-  and AAG ++ A2C2 present a diminished CREB3 luciferase-driven expression. When 
luciferase is driven by the episomal expression of CREB3, both the A2C2 knockout and the AAG-
complemented equivalent express much lower levels of luciferase, especially when compared to the 
knockout clone B6C3. Values represent normalized fold-change firefly luciferase induction relative to 
control ± SEM. N ≥ 3 experiments. Significance levels given by Two-way ANOVA, with Tukey’s 
multiple comparison post-hoc test with assumed significance if P ≤ 0.05. Significance levels legend: * 
P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. 
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4.5.4 CREB3 AND IRE1Α ARE RESPONSIBLE FOR A PORTION OF THE 
MMS-INDUCED ER STRESS SIGNALLING AND THEIR 
PARTICIPATION REMAINS MOSTLY CONSTANT, REGARDLESS OF 
TYPE OF STRESS STIMULUS. 
CREB3/Luman shares several similarities with ATF6: it is a basic domain 
leucine zipper (bZIP) transcription factor, and lies anchored in the ER membrane (R. 
Lu, Yang, O’Hare, & Misra, 1997). Moreover, CREB3/Luman is capable of interacting 
with a number of response elements as cAMP (cyclic AMP) response element and, 
more importantly, it shares with ATF6 the ability to bind to the ERSE (G. Liang et al., 
2006), although it is still not quite clear which exactly is its role in the ER stress or 
even what leads to its activation. 
To better discern the relative contributions of the different transcription 
factors that can transactivate the ER-responsive promoter used in our analysis, we 
co-transfected cells with different constructs expressing dominant negative mutants 
of ER stress-responsive transcription factors.  
Firstly, we used the construct pCX-nCreb3[57-218]-IRES-EGFP, a dominant 
negative form of CREB3/Luman. The protein expressed from this plasmid dimerises 
with the ATF6f, preventing it from interacting with the ERSE on the reporter plasmid 
(p5xATF6-Luc2P). Therefore, the remaining luciferase signal detected would be 
probably originating from IRE1/sXBP1. 
Remarkably, functional repression by a dominant negative CREB3 mutant 
attenuated MMS-induced luciferase expression, indicating that ATF6 and/or 
CREB3/Luman participate in MMS-induced ER stress induction. When treated with 
2.5 mM of MMS, both wild-type and AAG -/- A2C2 show a statistically significant 
decrease in luciferase induction after transfection with the dominant negative form 
of CREB3 (dnCREB3), as seen in Figure 37 A. The levels of induction on AAG -/-  B6C3, 
however, remain largely unaffected, since MMS treatment did not significantly 
induce the luciferase reporter in this cell line. Upon analysing the contribution of 
CREB3/Luman to the activation of the reporter, it can be seen that the dominant 
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negative CREB3 mutant inhibited luciferase induction by 57.02% in the wild-type, 
80.74% in the AAG -/- A2C2; and 24.08% AAG -/-  B6C3 (Figure 37 A). 
In addition, the dominant negative CREB3 also attenuated luciferase 
expression after treatment with thapsigargin. Significant signal decrease is detected 
in wild-type ARPE-19, AAG -/- A2C2 clone and AAG -/-  B6C3 (Figure 37 B). After 
thapsigargin treatment, the dominant negative CREB3 mutant inhibited luciferase 
expression by 59.03% in the wild-type, 70.57% in AAG -/- A2C2 and 71.14% AAG -/-  
B6C3 (Figure 37 B). We can see the response is remarkably similar to what was 
obtained with the MMS treatment and that both MMS and thapsigargin-mediated 
induction of the response depends on a functional CREB3/Luman, and 
consequently, ATF6 as well (if we consider ATF6 and CREB3 can be functional 
partners in ERSE-binding and activation).  
Next, using a similar approach, we investigated the contribution of IRE1α to 
the UPR on our cells. Cells were transfected with IRE1alphaKA-pcDNA3.EGFP 
(referred by dnIRE1α from this point forward). The plasmid encodes a kinase 
inactive form of IRE1α that dimerizes with its wild-type counterpart and prevents it 
from activating the downstream effectors of this UPR branch. 
The results are remarkably like those obtained on the dnCREB3 assay in 
that the vector expressing a dominant-negative form of IRE1 partially abolished the 
effect of MMS. After MMS treatment and dnIRE1α transfection, both wild-type cells 
and AAG -/- A2C2 knockout displayed a significant decrease in luciferase induction, 
whereas AAG -/-  B6C3 was not affected as such, because initial induction levels were 
not as high in this knock-out cell line (Figure 37 C). After MMS treatment, the 
dominant negative IRE1α partially abolished luciferase induction by 62.21% in the 
wild-type, 76.89% on AAG -/- A2C2 and 35.91% AAG -/-  B6C3 (Figure 37C). 
Again, when the cells were treated with thapsigargin, all three cell lines 
have shown a significant reduction in signal upon transfection with dnIRE1α, 
indicating that IRE1/XBP1 axis also participates in the transduction of ER stress 
signals in this case (Figure 37 D). When cells were treated with thapsigargin, 
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dnIRE1α partially abolished luciferase induction by 59.65% in the wild-type, 68.19% 
on AAG -/- A2C2 and 73.13% AAG -/-  B6C3 (Figure 37D). 
These results suggest that there is a high level of crosstalk between the 
distinct axes of the UPR response and that the source of activation, at least in this 
particular scenario, is not very relevant to most of the cell lines investigated. In an 
effort to tease apart the differences that lead to the initial divergence between the 
genotypes regarding ERSE activation we decided to examine the expression profile 
of some genes involved in the UPR. 
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Figure 37: CREB3/Luman and IRE1α participation in ER stress signalling remains mostly constant, 
regardless of type of stress stimulus. Cells transfected with dnCBREB3 present a decrease in 
detected luciferase signal proportional to its participation in its activation. A) After treatment with 
2.5 mM of MMS, both wild-type ARPE-19 and AAG -/- A2C2 cells transfected with dnCBREB3 show a 
significant decrease in luciferase expression. B) After 300 nM of thapsigargin treatment, all cell lines 
transfected with dnCBREB3 show a significant decrease in luciferase expression. C) After treatment 
with 2.5 mM of MMS, both wild-type ARPE-19 and AAG -/- A2C2 cells transfected with dnIRE1α show 
a significant decrease in luciferase expression. B) Relative contribution of dnIRE1α activation to the 
overall detected luciferase induction after MMS treatment. D) After 300 nM of thapsigargin 
treatment, all cell lines transfected with dnIRE1α also show a significant decrease in luciferase 
expression. Values represent normalized fold-change firefly luciferase induction relative to control ± 
SEM. N ≥ 3 experiments. Significance levels given by Two-way ANOVA, with Tukey’s multiple 
comparison post-hoc test with assumed significance if P ≤ 0.05. Significance levels legend: * P ≤ 0.05, 
** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. 
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4.5.5 AAG MODULATION AFFECTS THE TRANSCRIPTIONAL RESPONSE 
OF THE ATF4 GENE 
Our previous studies with the reporter system containing five ATF6α 
binding sites reflected UPR levels activated 6 hours post-treatment with ER stress 
inducers as well as MMS. However, as previously described, IRE1α, PERK and ATF6α 
are all involved in regulating transcription during ER stress. We therefore 
investigated if MMS and/or ER stress inducers also induced transcription for 
important UPR genes activated downstream to IRE1α, PERK or ATF6α.  
A total of six genes were chosen for transcriptional analysis by RT-qPCR to 
cover several distinct points of the unfolded protein response. Firstly, to represent 
the PERK branch of the response, Activating Transcription Factor 4 (ATF4) was 
analysed. As mentioned previously, ATF4 is preferentially transcribed when eIF2α is 
phosphorylated and it is responsible for activating a number of UPR genes involved 
in antioxidant response, lipid metabolism and, if the ER stress is irreversible, 
apoptosis (Schröder & Kaufman, 2005).  
The second analysed gene is HSPA5, the gene coding for the chaperone 
BiP, and it was selected given its central role as a chaperone and the activation of all 
three UPR branches (Todd et al., 2008).  
As a representative of the IRE1 pathway we selected XBP1. Its spliced 
mRNA is transcribed as the isoform 2 of the gene, a highly active transcription factor 
that activates ERAD and induces chaperones to re-establish ER homeostasis (H 
Yoshida et al., 2001).  
HERPUD1 (whose product is Herp), a downstream target of all three 
branches of the UPR and has antiapoptotic properties (G. Liang et al., 2006; Y. Ma & 
Hendershot, 2004), was chosen as an aggregator of all signalling cascades and as 
also a target for ATF6f and CREB3/Luman, investigated in the previous sections 
through the luciferase reporter assay (Denboer et al., 2005; Y. Ma & Hendershot, 
2004).  
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DDIT3 (CHOP) was chosen as the proapoptotic counterpart, activated by 
both PERK (via ATF4) and ATF6 signalling cascades (Nakanishi, Sudo, & Morishima, 
2005; Su & Kilberg, 2008).  
Finally, CDKN1A (p21) for its role in the DNA damage response (Dutto, 
Tillhon, Cazzalini, Stivala, & Prosperi, 2015; Karimian et al., 2016). Interestingly, 
there are reports that p21 levels can be downregulated by CHOP to cause a pro-
apoptotic shift in the UPR (Mihailidou et al., 2010). 
In general terms, all cell lines presented a very similar transcriptional 
response at 6 hours after treatment with MMS or the ER stress inducer TG for most 
of the genes examined, regardless of AAG status. There was no difference in the 
transcriptional response of ATF4 between the different cell lines (Figure 38). MMS 
treatment did not significantly induce ATF4 in wild-type cells, not even at the 
highest dose (2.5 mM). In contrast, treatment with MMS significantly induced ATF4 
in the AAG knockout cell lines when compared to their own untreated controls: on 
the MMS dose of 2.5 mM, AAG -/-  A2C2 had 2.9 (0.25)-fold induction (P=0.0003) 
and AAG-/- B6C3 had 2.5 (0.36)-fold induction (P=0.0182). Thapsigargin treatment 
led to an approximate 4-fold ATF4 induction in all cell lines, regardless of genotype 
(P. <0.0001, for all).  
Regarding XBP1 splicing none of the MMS doses was capable to elicit a 
significant transcriptional response in any of the cell lines. Notwithstanding, XBP1 
mRNA splicing does not seem to be impaired in ARPE19 cells, as TG was able to 
induce this splicing event at about 100-fold levels over untreated controls in all cell 
lines (P <0.0001 for all). Given this result, XPB1 splicing was also investigated using 
an alternative method, using RT-PCR and gel electrophoresis.  However, the results 
obtained by conventional reverse transcription-PCR and gel electrophoresis 
confirmed what was seen by qPCR and indicate that MMS does not induce 
significantly XBP1 splicing in ARPE19 cells (S. Figure 1). 
Similarly, MMS treatment did not significantly induce HSPA5 (BiP), but TG 
did so for all cell lines. ARPE-19 wild-type presented an average induction of 34.43 
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(4.43) fold, AAG -/- A2C2 40.05 (2.83) and AAG -/- B6C3 35.90 (3.94), none of those 
significantly different from each other, but significantly different from untreated 
controls (P <0.0001).  
Similarly, HERPUD1 (Herp) was only induced by thapsigargin treatment: in 
the wild-type ARPE-19 was induced 27.37 (2.82)-fold, AAG -/- A2C2 28.83 (4.02)-fold 
and AAG-/- B6C3 33.61 (2.55) fold all significantly different from untreated controls 
(P <0.0001). However, in this case the level of its induction was significantly 
different among the wild-type cells and clone AAG-/- B6C3 (P= 0.0051). 
DDIT3 (CHOP) expression, was not induced significantly in either cell line by 
MMS treatment, even at the highest dose. However, as expected, there was a 
substantial induction in all cell lines after TG treatment: 166.3 (4)-fold in the wild-
type cells, 185.3 (37)-fold in AAG-/- A2C2 and 188.5 (23) -fold in AAG-/- B6C3 when 
compared to untreated controls (P <0.0001). 
Unsurprisingly, given its participation in the DNA damage response (Dutto 
et al., 2015), CDKN1A (p21) was induced by MMS treatment, at least in the highest 
dose (2.5 mM). The only cells that transcriptionally induced p21 at the dose of 1.5 
mM of MMS was AAG -/- B6C3 (P= 0.0013). At 2.5 mM of MMS, CDKN1A was 
induced on wild-type cells at 4.31 (0.92)-fold, AAG -/- A2C2 5.67 (1.32)-fold and AAG 
-/- B6C3 4.04 (0.95) fold (P<0.0001 for the first two and P=0.0009 for the latter, all 
vs. untreated controls). When treated with 300 nM of thapsigargin, only AAG -/- 
B6C3 has shown a significant 3.5-fold p21 induction when compared to its own 
control (P= 0.0104). 
In summary, all ER stress markers except ATF4 remained mostly unchanged 
after MMS treatment, regardless of AAG status. Despite the lack of response, is 
clear that none of the cells is defective in the examined pathways, as all exhibited a 
considerable induction when treated thapsigargin. 
Moreover, the CDKN1A induction levels suggest that the doses chosen for 
the MMS treatment are indeed having a biological effect on the cells (possibly in the 
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form of DNA damage) and that thapsigargin does not elicit such response, except on 
AAG-/- B6C3 clone. 
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Figure 38. AAG modulation does not change the transcriptional response induced by ER stress. 
Relative gene expression in untreated, MMS treated (1.5 and 2.5 mM) and TG treated (300 nM). The 
relative quantification was done using the wild-type untreated samples but positive inductions were 
made through comparisons within each class (UT WT vs. Treated WT, UT AAG -/- A2C2 vs. Treated 
AAG -/- A2C2 and so on). Values represent normalized fold-change gene expression relative to control 
± SEM. N ≥ 3 experiments. Significance levels given by Two-way ANOVA, with Tukey’s multiple 
comparison post-hoc test with assumed significance if P ≤ 0.05. Significance levels legend: * P ≤ 0.05, 
** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001 
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4.5.6 AAG ABSENCE SEEMS TO DECREASE INDUCTION OF KEY UPR 
MARKERS  
Aware that the lack of transcriptional response could be due to a different 
time frame in the UPR induction, we decided to proceed with a western blot 
analysis of Xbp1, BiP, and phosphorylated eIF2α using time points covering 1, 6 and 
24 hours post-treatment.  
Due to time constraints only wild-type ARPE-19 and the knockout clone 
AAG -/- B6C3 were analysed. However, as can be seen in Figure 39, the results 
suggest that there is indeed a difference between the two genotypes. BiP is induced 
upon MMS treatment (2.5 mM) on the wild-type cells, peaking at 6 hours and 
decreasing to half the intensity at 24-hours (Figure 39). In counterpart, BiP 
induction AAG -/- B6C3 remains low throughout all timepoints, having a very slight 
increase at 24h (Figure 39, panels B and C). There was a clear BiP induction in both 
cell lines 6 hours post TG treatment, albeit AAG -/- B6C3 shows a lower induction 
when compared to the wild-type cells (6.84-fold in wild-type vs. 4.05-fold in the 
knockout). At 24 hours post-TG treatment, BiP induction is even higher than at 6 
hours and wild-type presents and induction of 60-fold against its untreated control, 
while AAG -/- B6C3 has 30-fold induction (Figure 39, panels B and C). It is interesting 
to notice how BiP activation is maintained for such an extended period post 
treatment in both cell lines, although at slightly different levels between genotypes. 
There was also a striking difference between genotypes regarding sXBP1 
splicing. On the wild-type cells it decreases slightly after 1 hour (relative to control) 
and after then steadily increases, peaking at 24h, while AAG -/- B6C3 has a very 
strong basal sXBP1 induction such that the levels seem to decrease upon treatment 
with MMS when compared to the untreated control (Figure 39, panels A and C). 
Regarding the TG treatment there is a 2-fold induction at 6 hours that falls by 0.5-
fold after at the 24-hour time point (Figure 39). Given the very strong basal 
induction of AAG -/- B6C3, the treatment with thapsigargin at 6 hours seem to 
decrease sXBP1 levels, however, there is actually an increase in signal when 
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compared to the MMS time points (Figure 39 C). The differences are more evident 
when the raw fluorescence data is observed (S. Figure 2). At 24h after treatment 
with TG fluorescence on AAG -/- B6C3 decreases further, reaching its lowest point, at 
levels similar to the ones obtained during MMS treatment. Therefore, we also see 
an interesting contrast between the duration of Xbp1 induction, with the wild-type 
still at its second-highest level after 24 hours, while AAG -/- B6C3 already decreased 
to its lowest level at this time. 
There is also a remarkable difference when we compare phosphorylation 
of eIF2α between genotypes. Wild-type cells show a somewhat strong signal on 
untreated conditions that almost disappears 1 hour after MMS treatment but 
increases again at 6 and 24 hours post-treatment (Figure 39 A). Curiously, in this 
specific experiment, TG treatment does not induce p-eIF2α very strongly, at least 
not 6 hours after treatment. What is very interesting about this marker is that there 
seems to be a complete absence of eIF2α phosphorylation on AAG -/- B6C3, even 
when the cells were treated with TG. 
Although these results were obtained from a single experiment and will 
need to be repeated to increase the robustness of the data, the pattern points to a 
clear difference in activation of key UPR markers. What can be seen is that AAG -/- 
B6C3 seems to present a lower induction of BiP, sXbp1 and pEIF2-α, corroborating 
our hypothesis that AAG is involved in the ER stress. 
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Figure 39: AAG absence seems to downregulate the induction of key UPR markers. Cells were 
treated with either 2.5 mM of MMS or 300 nM of Thapsigargin and harvested 1, 6 or 24 hours post-
treatment. A) AAG -/- B6C3 presents a lower induction of BiP, sXbp1 and p-eIF2α, at 1,6 and 24h post 
MMS treatment and 6 hours after TG treatment and B) results follow a similar trend 24 hours post 
TG treatment. C) quantification of BiP and sXbp1 levels normalized by β-actin signal. 
 
 DISCUSSION 
The Unfolded Protein Response encompasses a multitude of cellular 
reactions aimed at the reestablishment of the homeostasis on the endoplasmic 
reticulum. Although such response is dictated by a great variety of cellular cues, to 
our best knowledge this is the first observation of a repair glycosylase being 
involved in the UPR. 
By using a luciferase reporter assay, here we demonstrate a series of 
particularities regarding ER induction in ARPE-19 cells. Firstly, we were able to show 
that not only AAG-proficient cells are capable of eliciting the UPR successfully, but 
Chapter 4: Investigation on the putative role of AAG in the endoplasmic reticulum stress  
 
146 
 
that this response is also triggered to a considerable degree through treatment with 
the alkylating agent MMS. Although it is a known fact since 1987 that MMS not only 
reacts with the N7 atom of guanine and N3 of adenine, but also with sulfhydryl (-SH) 
group of cysteine and the 3 position in the imidazolic ring of histidine (Boffa et al., 
1987), very little research has been conducted on the connection between MMS 
and  the triggering  of the UPR. The only study linking MMS treatment to a direct 
effect in the ER stress response is the one conducted by van Laar and colleagues, in 
2000. 
Laar and colleagues (2000) identified a yeast gene that responds to both 
tunicamycin and MMS treatment, named Mif1 (MMS-inducible factor 1) at the time. 
(Van Laar et al., 2000). In the same year, a homolog of Mif1 was identified in 
HUVECs, and officially named as Herp - homocysteine-inducible, endoplasmic 
reticulum stress-inducible, ubiquitin-like domain member 1,  product of the 
HERPUD1 gene (Kokame, Agarwala, Kato, & Miyata, 2000). Herp is now known as a 
hub upon which several ER stress factors act. Not only it is inducible by MMS 
treatment, but it can be activated by XBP1, ATF6, CREB3/Luman and Nrf1 (Nuclear 
factor erythroid-derived 2-related factor 1). Although HERPUD1 was induced on the 
experiment that motivated this investigation - which compared mice post a 6-hour 
treatment with MMS – it is curious to observe a lack of induction of HERPUD1 
transcription on our cell model. There are possible explanations for this output: 
there could be a difference inherent to the model used (mouse vs. cell line), where 
the lack of response could be linked to a particularity of the ARPE-19 metabolism or 
it could be that the length of the treatment (6 hours) is too long (given the fact that 
the drug is in direct contact with the studied cells as opposed to mice where it has 
to diffuse through several layers of tissue or circulate in the bloodstream to reach 
the liver). It is also possible that in this model, ER stress activation follows a distinc 
pathway that bypasses Herp althogether. 
It is very likely that during our MMS treatment, one or more of these 
pathways were being activated. We have shown a specific ERSE-driven luciferase 
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activation by MMS that is not only dose-dependent, but also ER-stress specific, in 
both ARPE-19 and Hep G2 cells. Before investigating the source of the ERSE 
activation in our system, however, we endeavoured to first confirm if indeed the 
presence or absence of AAG was enough to modify the cells response to ER stress, 
as seen in vivo by our group. 
For this purpose, both AAG-proficient and AAG-deficient ARPE-19 cells 
were submitted to the same treatment and reporter assay used on the wild-type 
cells. Interestingly, our findings indicate that in the absence of AAG there was a 
considerable reduction in the ER-stress response, in both MMS and TG-treated cells 
and such defect was corrected by the reintroduction of AAG, via stable transfection. 
Within the time constraints of this work, one could only speculate how AAG may 
interfere with the triggering of the UPR. However, we propose two possible 
explanations for such outcome: a repair-dependent and a repair independent 
contribution. 
On the repair-dependent hypothesis, when AAG is absent, no toxic repair 
intermediates would be formed. As mentioned in Chapter 3, the participation of 
AAG in the alkylation-induced tissue degeneration was documented in different 
tissues, both in vivo (J. A. Calvo et al., 2013; Meira et al., 2009). In this scenario, the 
activation of the UPR could be a consequence of erroneous mRNA transcription 
caused by the accumulation of said repair intermediates, and those mRNAs could, in 
turn, cause transcription stalling (Edenberg et al., 2014) leading to an increase of 
truncated/misfolded proteins in the ER, triggering thus the UPR by the canonical 
pathway. 
It also cannot be dismissed the possibility that AAG activity in the 
mitochondria may also play a role in eliciting the UPR. Mitochondria have its own 
UPR that not only acts locally but also establishes a crosstalk with the nuclear UPR 
(Schulz & Haynes, 2015). Issues with mitochondrial protein folding and several other 
instances can lead to retrograde signalling, triggering the Integrated Stress 
Response (ISR) that ultimately leads to the phosphorylation of eIF2α without 
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necessarily involving PERK (Arnould et al., 2015; Baker, Nargund, Sun, Haynes, & 
Durbin, 2012). The connection between mtDNA damage and ER stress was 
established in rat L6 skeletal muscle cells whose mitochondrial DNA was damaged 
by palmitate, where overexpression of mitochondrial hOGG protected mtDNA and 
led to the decrease of several ER stress and autophagy markers (Yuzefovych, 
LeDoux, Wilson, Rachek, & Ryu, 2013).  
It is plausible that enough mtDNA damage would elicit a cell-wide 
response. Although mitochondrial DNA is responsible for coding only a small 
proportion of proteins in the cell, those are critical to the oxidative phosphorylation 
process and any perturbations in their function could lead to disastrous 
consequences, ranging from excessive ROS generation to energy depletion (Smits, 
Smeitink, & van den Heuvel, 2010). A small moleculue called ISRIB (ISR Inhibitor) 
was successfully used in the literature to determine eIF2α involvement in certain 
processes such as memory formation and traumatic brain injury (Chou et al., 2017; 
Sidrauski et al., 2013). It diminishes translation attenuation caused by eIF2α 
phosphorylation and could be, therefore, a useful tool to help determine the 
contribution of eIF2α in the response observed. 
The finding that restoration of AAG levels in our knockout system seems to 
reinstate ERSE activation on our reporter system in cells treated with MMS, might 
mean that the higher AAG activity translates in a higher proportion of repair 
intermediates and, therefore, in high levels of ER-stress induction for the reasons 
stated previously. The observation that the activation on the complemented cells 
treated with thapsigargin did not surpass the one obtained upon TG treatment in 
the wild-type ARPE-19, could strengthen further our hypothesis: as thapsigargin is 
not known to induce alkylating DNA damage, an increase in AAG levels would not 
translate as higher levels of toxic intermediates, and would not be detected as 
higher ER stress induction. However, if the repair activity of AAG somehow 
modulates the ER response, the reason for the decrease of ERSE activation in 
thapsigargin-treated AAG -/- cells would remain unexplained, as it is not a compound 
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known to induce DNA damage. Fact supported by the absence of transcriptional 
induction of p21 (CDKN1A) on AAG-proficient and AAG-deficient cells treated with 
this drug. 
Nonetheless, we are aware that these results need to be interpreted 
carefully. Part of the restoration of ERSE dependent activation may be since 
artificial overexpression may lead to accumulation and aggregation of excess 
protein in the ER, triggering the ER stress response independently of protein 
function. To address this possibility, it would be necessary to test whether the 
overexpression of a protein of similar size but devoid of any relevant activity would 
also lead to a similar increase. 
Furthermore, the possibility of the repair activity of AAG being responsible 
for eliciting the UPR could be addressed in a more definitive manner by 
complementing the same knockout cells with a mutant form of AAG with inactive 
repair activity, to evaluate whether its connection to the UPR might be related to a 
structural function or interaction with other proteins. 
To eliminate the possibility that decreased ERSE activation detected in both 
our knockout clones being borne out of a deficiency originated from an off-target 
disruption by the CRISPR/Cas9 manipulation, we carried the same reporter assay 
but expressing CREB3/Luman episomally. The results indicate that indeed the signal 
detected on one of our clones (AAG-/-A2C2) is significantly inferior to both wild-type 
cells and AAG-/- B6C3. However, as stated before, we do not believe this finding 
would affect our conclusions regarding the inability of the AAG-deficient cells to 
elicit a significant ER stress induction, as clone AAG-/- B6C3 had the highest 
luciferase levels when on this experiment, but during ER stress-induced ERSE 
activation remained on par with the other knockout clone, AAG-/-A2C2. 
Furthermore, AAG-/-A2C2, when complemented by transfection with a plasmid 
containing AAG, was able to activate the ERSE sequence upon treatment to levels 
similar or even superior to the wild-type ARPE-19 cells. 
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We also determined that the ER stress activation was caused by a 
combination of UPR pathways, rather than having an individual source. For such, we 
employed two dominant-negative expression plasmids coding for either truncated 
or inactive forms of CREB3/Luman and IRE1α. The system is engineered in a way 
that both plasmids prevent interaction or activity of its wild-type counterparts, and 
this allows for a functional analysis of transcriptional induction or repression upon 
different experimental conditions. Our findings indicate that there is a considerable 
overlap on the activation of the ERSE reporter system, with different transcription 
factors participating in the transactivation of the ERSE-promoter in response to 
alkylation treatment. It also indicates that the alkylation-induced response is no 
different from the response induced by a classical ER stress inducer. 
CREB3/Luman is a transcription factor first described through the 
interaction with simplex virus (HSV)-related host cellular factor (HCF)-1 (R. Lu et al., 
1997). It plays varied roles as chemotaxis and inflammation repression (Ko, 2004; 
Sanecka et al., 2012). Of special relevance in our context is its capacity to bind to an 
ERSE-II element on the promoter of the protein Herp (HERPUD1) and activate it. It is 
believed that HERP is a pro-survival factor that regulates calcium homeostasis, 
counteracting the activation of calpain/caspase 12 and it is also associated with 
ERAD (Arnould et al., 2015; Chan et al., 2004). However, despite HERP being a 
known target of ATF6f, ATF4 and CREB3/Luman (G. Liang et al., 2006; Y. Ma & 
Hendershot, 2004; Yamamoto, Yoshida, Kokame, Kaufman, & Mori, 2004), we were 
unable to detect a significant transcriptional response in HERPUD1 6 hours after 
treatment with MMS. In contrast, the treatment with 300 nM of TG induced a 27 
(3)-fold induction in wild-type and 29 (4) in AAG -/- A2C2, and a significantly higher 
induction of 34 (2) in AAG -/- B6C3. Several hypotheses could explain this finding.  
Firstly, ER stress induction by MMS could differ in terms of kinetics 
requiring either shorter or longer times for elicitation of a transcriptional response 
by ATF6f. In this case, making use of timepoints both earlier and later than 6 hours 
would be of great interest to elucidate if that is this question. 
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A second possibility is that CREB3/Luman, one of the ER factors that can 
transactivate our reporter might be inducing a UPR response by targeting other 
promoters than the one in HERPUD1. One such factor is the EDEM (ER degradation-
enhancing α-mannosidase-like protein) that is involved with upregulating ERAD and 
sequestering certain misfolded proteins to prevent aggregation (Hosokawa et al., 
2001; Hosokawa, Wada, Natsuka, & Nagata, 2006). Nonetheless, additional 
experiments would be required to confirm whether either of these two hypotheses 
are correct or the lack of transcriptional response by HERPUD1 is caused by a third 
and hitherto unknown cause.  
When trying to characterize the relative contribution of the distinct 
branches of the UPR on our model we could observe that both IRE1α and ATF6 (as 
mentioned before, measured through the dnCREB3 luciferase experiment) 
contribute to the signal detected, as both cell lines had signal loss when transfected 
with either plasmid. Curiously, the source of the stress (MMS vs. thapsigargin) also 
did not seem to influence the choice of pathway, as the proportional loss of signal 
was very similar with either treatment. To figure the effects of such pattern we 
quantified the levels of the most known downstream IRE1α effector: spliced XBP1 
(sXBP1). 
Again, in a manner similar to HERP we failed to detect any significant 
differences in sXBP1 in cells treated with MMS, although there is an apparent trend 
of higher relative induction on the AAG -/- cells. Here we also see two possible 
explanations for such (that would work in concert with the ERSE induction pattern 
seen previously). 
The first is that the lack of XBP1 splicing is a real occurrence. There are 
indications that the activation of the IRE1α is much more nuanced than previously 
thought. Depending on the type, source and duration of stress, IRE1α can activate a 
series of responses that may or may not involve the alternative splicing of XBP1. 
Though there is still divergence on the fact, certain authors affirm that in conditions 
of low ER the cell could entirely bypass XBP1 splicing and trigger the IRE1-
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dependent mRNA decay (RIDD) to alleviate the ER load (M. Maurel et al., 2014). 
RIDD is a complex and not completely understood response, but it is known to be 
responsible for the degradation of a great number pre-miRNAs that act upon 
innumerable targets in the cell (Marion Maurel & Chevet, 2013). So, it is entirely 
possible that MMS might not be inducing a strong enough ER stress to cause a shift 
of IRE1α signalling to the XPB1-centric branch of the response. 
A second explanation is that in our timeframe is not the most adequate to 
detect XBP1 splicing. By using a non-canonical ER stressor, we perhaps would have 
to employ a time course to better understand the kinetics and the sequence of 
events in which the ER stress is induced with such drug. It is known that the 
detection of the soluble activated form of ATF6 precedes the spliced XBP1, (H 
Yoshida et al., 2001). It is a possibility also that the shift of a RIDD-only IRE1α 
activation to the XBP1 splicing is also a matter of time. However, to be able to truly 
identify the contribution of ATF6 to the alkylation-mediated UPR induction it would 
be interesting to carry out additional experiments as the co-transfection of both 
dnCREB3 and dnIRE1α or a direct detection of the translocation of the activated 
ATF6 by western-blot analysis using fractionated extracts. 
 It is worthy to note as well that there are many layers that command the 
temporal response in the UPR. It comprehends an adaptive response aimed at first 
at processes that might attenuate the source of ER stress, cell fate regulation, that 
controls the shift from pro-adaptive to a pro-apoptotic response in case of extended 
or unresolvable stress, and finally the feedback control (Hetz, 2012). Feedback 
control regulates the intensity and length of the response by a series of feedback 
loops, negative or positive, to ensure that the response is maintained or inhibited as 
necessary and imbalance in these mechanisms are linked to a series of pathologies 
(Todd et al., 2008) . It is possible, that within the time of our transcriptional analysis, 
had already shifted towards attenuating the response.  
Although we were not able to detect the induction of sXBP1 we were able 
to observe an increase of the isoform 2 of Xbp1 (protein transcribed from sXBP1) by 
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western blot, and the induction seems to peak at 24 hours, giving support to the 
idea that the transcriptional response might follow a different timeframe. 
More importantly, with these experiments we also could distinguish a 
remarkable difference between genotypes not only regarding the induction of 
sXBP1, but also BiP and phosphorylated eIF2α, key players of the UPR. It is very 
clear that AAG-/ B6C3 has a diminished activation of these markers, that is apparent 
both upon treatment with MMS and, to a lesser extent, when treated with 
thapsigargin. - 
To eliminate the possibility of our MMS doses being inadequate to elicit a 
response on the cells, we also analysed p21 expression (CDKN1A) on our expression 
panel. It was observed that MMS induced p21 expression for all cells and none of 
the induction was significant different across genotypes. Given the role of p21 in 
coordinating cell-cycle arrest during DNA damage (Jaiswal & Narayan, 2002), we 
could say with a certain confidence that our MMS doses are in appropriate levels to 
drive DNA damage and that the positive response seen in TG treated for all the 
markers does not induce cell cycle arrest, at least not via p21. Nonetheless, in 
regard to p21 induction and TG treatment it is important to mention that there is 
evidence that CHOP expression downregulates p21 (Mihailidou et al., 2010) and 
that the cells treated with TG have shown a very high induction of CHOP. 
Thus, in summary, in this chapter we were able to show that:  
• MMS induces ER stress in a specific and dose-dependent manner in 
both ARPE-19 and Hep G2 cells; 
• The absence of AAG reduces ER stress induction, and that induction 
levels are restored when AAG is reintroduced in the system; 
• That ATF6f and IRE1α are part of the signalling network of this ER 
stress induction;  
• However, lack of transcriptional modulation of downstream 
effectors of ATF6f and IRE1 α indicate that either the induction 
follows a non-canonical mode of induction or different kinetics 
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when treated with MMS. The latter supported by preliminary 
western blot analysis; 
• These preliminary data also point to an attenuation of the induction 
of key ER stress proteins: BiP, Xbp1 isoform 2 (from sXBP1) and 
phosphorylated eIF2α.  
Hoping to understand better how would AAG modulation would change 
the cell response to ER stress, we conducted a proteomic analysis of both AAG-
proficient and deficient cells in their basal state and the results for such analysis are 
presented in the following chapter. 
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APPENDIX CHAPTER 4 
S. Table 1: RT-qPCR primers used on Chapter 4. 
Gene Sequence Source 
hATF4 
(NM_001675) 
Fwd 5’ TTCTCCAGCGACAAGGCTAAGG 3’ 
Rev 5’ CTCCAACATCCAATCTGTCCCG 3’ 
OriGene 
Technologies, 
Rockville, USA 
hHSPA5 
(NM_005347) 
Fwd 5’ CTGTCCAGGCTGGTGTGCTCT 3’ 
Rev 5’ CTTGGTAGGCACCACTGTGTTC 3’ 
OriGene 
Technologies, 
Rockville, USA 
sXBP1 
(NM_005080) 
412–431 5’ CCTTGTAGTTGAGAACCAGG 3’ 
834– 853 5’ GGGGCTTGGTATATATGTGG 3’ 
(H Yoshida et al., 
2001) 
hHERPUD1 
(NM_001010989) 
Fwd 5’ CCAATGTCTCAGGGACTTGCTTC  3’ 
Rev 5’ CGATTAGAACCAGCAGGCTCCT 3’ 
OriGene 
Technologies, 
Rockville, USA 
hDDIT3 
(NM_004083) 
Fwd 5’ GGTATGAGGACCTGCAAGAGGT  3’ 
Rev 5’ CTTGTGACCTCTGCTGGTTCTG  3’ 
OriGene 
Technologies, 
Rockville, USA 
hCDKN1A 
(NM_000389) 
Fwd 5’ AGGTGGACCTGGAGACTCTCAG 3’ 
Rev 5’ TCCTCTTGGAGAAGATCAGCCG 3’ 
OriGene 
Technologies, 
Rockville, USA 
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S. Table 2: Reporter constructs utilized on luciferase-based assays for ER stress detection. 
Construct Function Author/Source 
p5xATF6-Luc2P Firefly luciferase gene under a 5-repeat promoter of an ATF6-responsive 
element. Can be activated by ATF6, CREB3 or spliced XBP1. Acts as an ER 
stress indicator. 
Optimized by Dr Axel Nohturfft on the plasmid 
developed by Dr Ron Pryweses and colleagues 
(Y. Wang et al., 2000). 
pRL-CMV Constitutively expresses Renilla luciferase. Acts as a control for fluorescence 
normalization. 
Obtained from Promega, Madison, USA. 
pCX-nCREB3-EGFP Encodes amino acids 1-219 of human CREB3 fused to EGFP A gift from Dr Axel Nohturfft (St. George’s 
University, London, UK). 
pCX-dnCREB3-IRES-EGFP Expresses amino acids 57-218 of human CREB3 and EGFP from a bi-cistronic 
mRNA, dimerizing with endogenous CREB3 and preventing it from binding to 
the ATF6 responsive (ERSE) elements on the firefly luciferase promoter. 
A gift from Dr Axel Nohturfft (St. George’s 
University, London, UK). 
IRE1 alpha-pcDNA3.EGFP Encodes a kinase-dead form of IRE1α that dimerizes with the endogenous 
IRE1α and prevents its activation. 
A  gift from Dr Fumihiko Urano (Addgene 
plasmid # 13010), published on (Lipson et al., 
2006). 
pGL4.32[luc2P/NF-κB-RE/Hygro] Contains five copies of an NF-κB response element (NF-κB-RE) that drives 
transcription of the luciferase reporter gene luc2P (Photinus pyralis), 
indicator of unspecific. cellular stress. 
Obtained from Promega, Madison, USA. 
ATP6AP1 Vacuolar ATPase gene, not subject to variation upon stress (negative 
control). 
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S. Figure 1: Analysis of XBP1 Splicing by semi-quantitative RT-PCR. By running the product of the 
RT-PCR XBP1 splicing can be detected by the presence of two bands: the heavier represents the 
unspliced product [XBP1 (u)] and the lighter the spliced mRNA [XPB1 (s)] 
 
 S. Figure 2: Comparison between raw Xbp1 fluorescence levels. High basal sXbp1 levels can mask 
some of the treatment effects, especially on AAG-/- B6C3. 
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S. Table 3: Luciferase raw and calculated fold inductions (WT vs clone A2C2). 
WT RAW FIREFLY LUMINESCENCE 
 
09/06/2016 23/06/2016 14/07/2016 Average 
UT 260 443 285 369 277 229 342 131 450 700 511 600 440 516 493 472 322 439 269 219 337 403 243 145 409.9375 
0.5 488 1202 653 1208 660 566 372 574 663 1005 1304 1074 1689 831 1259 836 302 218 505 810 284 298 690 907 792.1875 
1.5 1246 2159 3511 2666 2740 3766 1525 362 2034 3463 1986 3295 1824 3301 2903 2281 418 1880 992 1866 1539 1323 1434 1433 1998.25 
2.5 1622 1328 2544 1941 1798 1684 1172 191 3443 6146 2986 1583 3123 3133 3193 1376 880 1396 906 1673 1362 1195 1063 1060 2157.375 
3.5 591 1254 2775 1036 1728 1173 1708 318 1891 2209 2507 2282 1398 2601 2419 1361 480 600 760 1025 758 740 923 1905 1491.1875 
TG 1798 5323 7923 6735 6585 6543 6649 3139 88 11667 13976 16492 9987 11591 15312 9897 4993 8791 9000 8069 6537 7641 5797 3370 8950.5 
BLK 68 68 68 68 68 68 68 68 100 100 100 100 100 100 100 100 49 49 49 49 49 49 49 49 74.5 
 
A2C2 RAW FIREFLY LUMINESCENCE 
 
23/06/2016 14/07/2016 28/07/2016 Average 
UT 425 291 483 271 233 234 341 60 103 226 91 185 118 135 143 243 122 282 201 198 73 151 143 80 155.875 
0.5 582 685 612 805 490 1083 464 928 136 204 208 111 105 134 276 222 77 266 230 260 195 308 253 225 200.625 
1.5 584 1683 1590 1522 1242 1197 1312 209 233 358 397 282 576 604 253 412 49 210 373 276 473 415 340 268 344.9375 
2.5 385 1055 836 1055 694 1255 562 132 570 229 393 406 388 400 242 437 106 318 338 533 288 467 296 370 361.3125 
3.5 294 694 1234 725 576 638 467 296 89 239 431 222 413 267 300 503 58 212 190 285 306 217 315 235 267.625 
TG 527 4012 2868 3821 4103 5722 7410 1987 2092 3969 2562 2515 1905 2910 3496 4191 150 379 875 1898 2011 4077 1900 1864 2299.625 
BLK 25 25 25 25 25 25 25 25 57 57 57 57 57 57 57 57 261 261 261 261 261 261 261 261 159 
 
WT RAW Renilla LUMINESCENCE 
 
09/06/2016 23/06/2016 14/07/2016 Average 
UT 1373 4670 4600 3445 8694 5995 4905 2052 6949 14847 12722 16052 12164 10841 13340 12974 5986 4490 4227 6331 5247 5033 7691 6753 9102.9375 
0.5 3612 4670 6975 6592 6556 1990 6541 3609 13826 16715 19645 16175 20857 16509 24122 22145 5879 6353 8926 9397 7069 7480 8403 12432 13495.8125 
1.5 1164 1654 4208 6480 5954 6645 8336 2055 15772 24300 12191 17398 14247 17664 17410 15936 4904 10230 8940 10740 10090 11506 10403 13076 13425.4375 
2.5 2790 2627 4656 4973 4964 4502 5032 677 18459 22218 14608 11224 14791 12054 14675 11700 6084 7704 7137 8545 7451 8070 8963 11934 11601.0625 
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3.5 741 964 1801 1690 1415 1792 2598 811 7684 15044 10661 13018 9013 12974 10982 7611 5882 4096 4571 5168 4719 5505 4239 8731 8118.625 
TG 1520 3549 5462 5096 5855 8267 6769 4213 85 10613 15296 19202 10820 4794 10556 8361 7861 8215 9051 8081 9358 8155 8397 2861 8856.625 
BLK 76 76 76 76 76 76 76 76 86 86 86 86 86 86 86 86 79 79 79 79 79 79 79 79 82.5 
 
A2C2 RAW RENILLA LUMINESCENCE 
 
23/06/2016 14/07/2016 28/07/2016 Average 
UT 5409 13559 8659 12132 11582 10074 12233 6138 4085 4170 2159 4186 4637 3162 4451 3752 264 4002 3773 2486 1786 3893 2808 358 3123.25 
0.5 11226 19127 20491 17856 20440 18540 20747 11088 3602 6310 5446 5909 4521 7225 5047 7972 983 4444 4434 5911 3662 6652 8267 2096 5155.0625 
1.5 9018 20278 21608 16209 18852 16318 15932 3498 3779 5277 6174 5680 7325 6469 6096 7986 144 3890 5471 6140 5824 4706 4450 1528 5058.6875 
2.5 7158 14121 12350 14277 13415 16580 10176 1634 1943 7554 7135 8480 7228 6785 4470 7654 200 2524 4592 4400 4662 4467 4137 3497 4983 
3.5 4714 14032 22937 13572 16223 13375 9785 4013 2367 5443 4191 5471 6843 5451 4244 6096 122 2248 3735 5078 4427 4543 2279 1999 4033.5625 
TG 2099 11196 11137 10387 15864 13296 16655 7936 3732 7339 8749 8338 5798 7148 8449 8750 94 846 2943 5075 4054 6460 6249 4091 5507.1875 
BLK 164 164 164 164 164 164 164 164 64 64 64 64 64 64 64 64 164 164 164 164 164 164 164 164 114 
 
Fluc/Rluc (wild-type) 
 
09/06/2016 23/06/2016 24/06/2016 
UT 
0.189
366 
0.094
861 
0.061
957 
0.107
112 
0.031
861 
0.038
198 
0.069
725 
0.063
84 
0.064
758 
0.047
148 
0.040
167 
0.037
379 
0.036
172 
0.047
597 
0.036
957 
0.036
38 
0.053
792 
0.097
773 
0.063
639 
0.034
592 
0.064
227 
0.080
072 
0.031
595 
0.021
472 
0.5 
0.135
105 
0.257
388 
0.093
62 
0.183
252 
0.100
671 
0.284
422 
0.056
872 
0.159
047 
0.047
953 
0.060
126 
0.066
378 
0.066
399 
0.080
98 
0.050
336 
0.052
193 
0.037
751 
0.051
369 
0.034
314 
0.056
576 
0.086
198 
0.040
175 
0.039
84 
0.082
114 
0.072
957 
1.5 
1.070
447 
1.305
32 
0.834
363 
0.411
42 
0.460
195 
0.566
742 
0.182
941 
0.176
156 
0.128
963 
0.142
51 
0.162
907 
0.189
39 
0.128
027 
0.186
877 
0.166
743 
0.143
135 
0.085
237 
0.183
773 
0.110
962 
0.173
743 
0.152
527 
0.114
983 
0.137
845 
0.109
59 
2.5 
0.581
362 
0.505
52 
0.546
392 
0.390
308 
0.362
208 
0.374
056 
0.232
909 
0.282
127 
0.186
521 
0.276
623 
0.204
409 
0.141
037 
0.211
142 
0.259
914 
0.217
581 
0.117
607 
0.144
642 
0.181
205 
0.126
944 
0.195
787 
0.182
794 
0.148
079 
0.118
599 
0.088
822 
3.5 
0.797
571 
1.300
83 
1.540
811 
0.613
018 
1.221
201 
0.654
576 
0.657
429 
0.392
109 
0.246
096 
0.146
836 
0.235
156 
0.175
296 
0.155
109 
0.200
478 
0.220
27 
0.178
82 
0.081
605 
0.146
484 
0.166
266 
0.198
336 
0.160
627 
0.134
423 
0.217
74 
0.218
188 
TG 
1.182
895 
1.499
859 
1.450
568 
1.321
625 
1.124
68 
0.791
46 
0.982
272 
0.745
075 
1.035
294 
1.099
312 
0.913
703 
0.858
869 
0.923
013 
2.417
814 
1.450
549 
1.183
71 
0.635
161 
1.070
116 
0.994
365 
0.998
515 
0.698
547 
0.936
971 
0.690
366 
1.177
91 
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Fluc/Rluc (A2C2) 
 
23/06/2016 23/06/2016 28/07/2016 
UT 
0.0785
73 
0.0214
62 
0.0557
8 
0.0223
38 
0.0201
17 
0.0232
28 
0.0278
75 
0.0097
75 
0.0252
14 
0.0541
97 
0.0421
49 
0.0441
95 
0.0254
47 
0.0426
94 
0.0321
28 
0.0647
65 
0.4621
21 
0.0704
65 
0.0532
73 
0.0796
46 
0.0408
73 
0.0387
88 
0.0509
26 
0.2234
64 
0.5 
0.0518
44 
0.0358
13 
0.0298
67 
0.0450
83 
0.0239
73 
0.0584
14 
0.0223
65 
0.0836
94 
0.0377
57 
0.0323
3 
0.0381
93 
0.0187
85 
0.0232
25 
0.0185
47 
0.0546
86 
0.0278
47 
0.0783
32 
0.0598
56 
0.0518
72 
0.0439
86 
0.0532
5 
0.0463
02 
0.0306
04 
0.1073
47 
1.5 
0.0647
59 
0.0829
96 
0.0735
84 
0.0938
98 
0.0658
82 
0.0733
55 
0.0823
5 
0.0597
48 
0.0616
57 
0.0678
42 
0.0643
02 
0.0496
48 
0.0786
35 
0.0933
68 
0.0415
03 
0.0515
9 
0.3402
78 
0.0539
85 
0.0681
78 
0.0449
51 
0.0812
16 
0.0881
85 
0.0764
04 
0.1753
93 
2.5 
0.0537
86 
0.0747
11 
0.0676
92 
0.0738
95 
0.0517
33 
0.0756
94 
0.0552
28 
0.0807
83 
0.2933
61 
0.0303
15 
0.0550
81 
0.0478
77 
0.0536
8 
0.0589
54 
0.0541
39 
0.0570
94 
0.53 
0.1259
9 
0.0736
06 
0.1211
36 
0.0617
76 
0.1045
44 
0.0715
49 
0.1058
05 
3.5 
0.0623
67 
0.0494
58 
0.0538 
0.0534
19 
0.0355
05 
0.0477
01 
0.0477
26 
0.0737
6 
0.0376 
0.0439
1 
0.1028
39 
0.0405
78 
0.0603
54 
0.0489
82 
0.0706
88 
0.0825
13 
0.4754
1 
0.0943
06 
0.0508
7 
0.0561
24 
0.0691
21 
0.0477
66 
0.1382
19 
0.1175
59 
TG 
0.2510
72 
0.3583
42 
0.2575
2 
0.3678
64 
0.2586
36 
0.4303
55 
0.4449
11 
0.2503
78 
0.5605
57 
0.5408
09 
0.2928
33 
0.3016
31 
0.3285
62 
0.4071
07 
0.4137
77 
0.4789
71 
1.5957
45 
0.4479
91 
0.2973
16 
0.3739
9 
0.4960
53 
0.6311
15 
0.3040
49 
0.4556
34 
 
Fluc / Wild-type 
09/06/2016 23/06/2016 24/06/2016 Mean SD 
0.701
518 
1.195
278 
0.768
971 
0.995
616 
0.747
386 
0.617
875 
0.922
766 
0.353
457 
1.214
165 
1.888
702 
1.378
752 
1.618
887 
1.187
184 
1.392
243 
1.330
185 
1.273
524 
0.868
803 
1.184
486 
0.725
801 
0.590
894 
0.909
275 
1.087
352 
0.655
649 
0.391
231 
1 
0.381
538 
1.316
695 
3.243
17 
1.761
889 
3.259
359 
1.780
776 
1.527
15 
1.003
71 
1.548
735 
1.788
87 
2.711
636 
3.518
381 
2.897
808 
4.557
167 
2.242
159 
3.396
965 
2.255
649 
0.814
84 
0.588
196 
1.362
563 
2.185
497 
0.766
273 
0.804
047 
1.861
72 
2.447
218 
2.068
353 
1.027
83 
3.361
889 
5.825
295 
9.473
187 
7.193
255 
7.392
917 
10.16
121 
4.114
671 
0.976
728 
5.488
027 
9.343
676 
5.358
516 
8.890
388 
4.921
417 
8.906
577 
7.832
715 
6.154
469 
1.127
825 
5.072
513 
2.676
56 
5.034
739 
4.152
445 
3.569
646 
3.869
14 
3.866
442 
5.615
177 
2.580
503 
4.376
391 
3.583
137 
6.864
081 
5.237
099 
4.851
265 
4.543
676 
3.162
226 
0.515
346 
9.289
713 
16.58
28 
8.056
661 
4.271
164 
8.426
307 
8.453
288 
8.615
177 
3.712
648 
2.374
368 
3.766
61 
2.444
519 
4.513
997 
3.674
874 
3.224
283 
2.868
128 
2.860
034 
5.261
158 
3.349
592 
1.594
604 
3.383
474 
7.487
352 
2.795
278 
4.662
395 
3.164
924 
4.608
432 
0.858
01 
5.102
192 
5.960
202 
6.764
25 
6.157
167 
3.772
007 
7.017
875 
6.526
813 
3.672
175 
1.295
11 
1.618
887 
2.050
59 
2.765
599 
2.045
194 
1.996
627 
2.490
388 
5.139
966 
3.872
063 
2.016
145 
4.851
265 
14.36
223 
21.37
74 
18.17
201 
17.76
728 
17.65
396 
17.93
997 
8.469
477 
0.237
437 
31.47
926 
37.70
927 
44.49
781 
26.94
637 
31.27
42 
41.31
4 
26.70
354 
13.47
184 
23.71
939 
24.28
331 
21.77
133 
17.63
777 
20.61
653 
15.64
115 
9.092
749 
21.12
456 
10.86
755 
 
Fluc / B6C3 
09/06/2016 
 
24/06/2016 Mean SD SEM 
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2.110
927 
1.445
364 
2.399
007 
1.346
026 
1.157
285 
1.162
252 
1.693
709 
0.298
013 
0.511
589 
1.122
517 
0.451
987 
0.918
874 
0.586
093 
0.670
53 
0.710
265 
1.206
954 
0.605
96 
1.400
662 
0.998
344 
0.983
444 
0.362
583 
0.75 
0.710
265 
0.397
351 
1 
0.541
08 
0.156
196 
2.890
728 
3.402
318 
3.039
735 
3.998
344 
2.433
775 
5.379
139 
2.304
636 
4.609
272 
0.675
497 
1.013
245 
1.033
113 
0.551
325 
0.521
523 
0.665
563 
1.370
861 
1.102
649 
0.382
45 
1.321
192 
1.142
384 
1.291
391 
0.968
543 
1.529
801 
1.256
623 
1.117
55 
1.833
402 
1.375
823 
0.397
166 
2.900
662 
8.359
272 
7.897
351 
7.559
603 
6.168
874 
5.945
364 
6.516
556 
1.038
079 
1.157
285 
1.778
146 
1.971
854 
1.400
662 
2.860
927 
3 
1.256
623 
2.046
358 
0.243
377 
1.043
046 
1.852
649 
1.370
861 
2.349
338 
2.061
258 
1.688
742 
1.331
126 
3.074
917 
2.484
588 
0.717
239 
1.912
252 
5.240
066 
4.152
318 
5.240
066 
3.447
02 
6.233
444 
2.791
391 
0.655
629 
2.831
126 
1.137
417 
1.951
987 
2.016
556 
1.927
152 
1.986
755 
1.201
987 
2.170
53 
0.526
49 
1.579
47 
1.678
808 
2.647
351 
1.430
464 
2.319
536 
1.470
199 
1.837
748 
2.432
74 
1.464
122 
0.422
656 
1.460
265 
3.447
02 
6.129
139 
3.600
993 
2.860
927 
3.168
874 
2.319
536 
1.470
199 
0.442
053 
1.187
086 
2.140
728 
1.102
649 
2.051
325 
1.326
159 
1.490
066 
2.498
344 
0.288
079 
1.052
98 
0.943
709 
1.415
563 
1.519
868 
1.077
815 
1.564
57 
1.167
219 
1.905
215 
1.258
015 
0.363
158 
2.617
55 
19.92
715 
14.24
503 
18.97
848 
20.37
914 
28.42
053 
36.80
464 
9.869
205 
10.39
073 
19.71
358 
12.72
517 
12.49
172 
9.461
921 
14.45
364 
17.36
424 
20.81
623 
0.745
033 
1.882
45 
4.346
026 
9.427
152 
9.988
411 
20.25 
9.437
086 
9.258
278 
13.91
639 
8.440
014 
2.436
422 
 
Rluc / Wild-type 
09/06/2016 23/06/2016 24/06/2016 Mean SD SEM 
0.181
673 
0.617
926 
0.608
664 
0.455
836 
1.150
374 
0.793
247 
0.649
021 
0.271
517 
0.919
479 
1.964
528 
1.683
352 
2.123
971 
1.609
518 
1.434
461 
1.765
124 
1.716
696 
0.792
056 
0.594
109 
0.559
309 
0.837
706 
0.694
273 
0.665
957 
1.017
659 
0.893
545 
1 
0.549
932 
0.158
752 
0.477
933 
0.617
926 
0.922
919 
0.872
241 
0.867
478 
0.263
313 
0.865
493 
0.477
536 
1.829
431 
2.211
698 
2.599
39 
2.140
246 
2.759
76 
2.184
44 
3.191
779 
2.930
186 
0.777
898 
0.840
617 
1.181
072 
1.243
394 
0.935
357 
0.989
74 
1.111
869 
1.644
979 
1.414
029 
0.855
192 
0.246
873 
0.154
018 
0.218
854 
0.556
795 
0.857
422 
0.787
822 
0.879
254 
1.103
004 
0.271
914 
2.086
922 
3.215
331 
1.613
091 
2.302
071 
1.885
137 
2.337
268 
2.303
659 
2.108
622 
0.648
888 
1.353
615 
1.182
924 
1.421
097 
1.335
09 
1.522
453 
1.376
506 
1.730
192 
1.385
498 
0.773
37 
0.223
253 
0.369
168 
0.347
6 
0.616
073 
0.658
018 
0.656
827 
0.595
696 
0.665
825 
0.089
579 
2.442
461 
2.939
845 
1.932
904 
1.485
139 
1.957
118 
1.594
963 
1.941
769 
1.548
122 
0.805
024 
1.019
379 
0.944
355 
1.130
659 
0.985
903 
1.067
808 
1.185
968 
1.579
085 
1.189
97 
0.700
423 
0.202
195 
0.098
048 
0.127
555 
0.238
305 
0.223
618 
0.187
23 
0.237
114 
0.343
763 
0.107
31 
1.016
733 
1.990
594 
1.410
644 
1.722
518 
1.192
584 
1.716
696 
1.453
118 
1.007
074 
0.778
295 
0.541
975 
0.604
826 
0.683
82 
0.624
409 
0.728
411 
0.560
897 
1.155
27 
0.781
284 
0.569
318 
0.164
348 
0.201
124 
0.469
597 
0.722
722 
0.674
293 
0.774
723 
1.093
874 
0.895
662 
0.557
456 
0.011
247 
1.404
293 
2.023
939 
2.540
773 
1.431
682 
0.634
333 
1.396
75 
1.106
312 
1.040
153 
1.086
994 
1.197
612 
1.069
263 
1.238
233 
1.079
055 
1.111
076 
0.378
562 
1.005
822 
0.549
103 
0.158
512 
 
Rluc / B6C3 
09/06/2016 23/06/2016 24/06/2016 Mean SD SEM 
1.000
447 
2.507
868 
1.601
566 
2.243
931 
2.142
203 
1.863
284 
2.262
612 
1.135
283 
0.755
56 
0.771
282 
0.399
328 
0.774
241 
0.857
658 
0.584
843 
0.823
256 
0.693
969 
0.048
829 
0.740
209 
0.697
853 
0.459
81 
0.330
338 
0.720
048 
0.519
367 
0.066
216 
1 
0.712
367 
0.205
643 
2.076 3.537 3.790 3.302 3.780 3.429 3.837 2.050 0.666 1.167 1.007 1.092 0.836 1.336 0.933 1.474 0.181 0.821 0.820 1.093 0.677 1.230 1.529 0.387 1.710 1.205 0.347
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358 724 009 64 576 153 359 833 225 096 29 927 203 334 492 499 815 961 111 297 322 352 062 676 846 362 958 
1.667
967 
3.750
613 
3.996
609 
2.998
012 
3.486
86 
3.018
172 
2.946
778 
0.646
989 
0.698
963 
0.976
032 
1.141
941 
1.050
571 
1.354
83 
1.196
504 
1.127
514 
1.477
088 
0.026
634 
0.719
493 
1.011
914 
1.135
653 
1.077
205 
0.870
42 
0.823
071 
0.282
618 
1.561
769 
1.136
69 
0.328
134 
1.323
941 
2.611
816 
2.284
252 
2.640
67 
2.481
234 
3.066
632 
1.882
15 
0.302
224 
0.359
377 
1.397
186 
1.319
687 
1.568
458 
1.336
889 
1.254
952 
0.826
77 
1.415
681 
0.036
992 
0.466
838 
0.849
335 
0.813
823 
0.862
282 
0.826
215 
0.765
178 
0.646
804 
1.305
808 
0.818
336 
0.236
233 
0.871
9 
2.595
354 
4.242
421 
2.510
273 
3.000
601 
2.473
836 
1.809
831 
0.742
243 
0.437
8 
1.006
736 
0.775
166 
1.011
914 
1.265
679 
1.008
215 
0.784
969 
1.127
514 
0.022
565 
0.415
789 
0.690
824 
0.939
225 
0.818
817 
0.840
272 
0.421
523 
0.369
734 
1.257
633 
1.007
489 
0.290
837 
0.388
23 
2.070
809 
2.059
896 
1.921
176 
2.934
201 
2.459
224 
3.080
504 
1.467
84 
0.690
27 
1.357
419 
1.618
212 
1.542
194 
1.072
396 
1.322
092 
1.562
724 
1.618
397 
0.017
386 
0.156
476 
0.544
336 
0.938
67 
0.749
827 
1.194
84 
1.155
813 
0.756
67 
1.361
65 
0.795
424 
0.229
619 
 
 
Fold induction WT 
09/06/2016 23/06/2016 
 
Mean SD SEM 
3.132
962 
1.569
42 
1.025
036 
1.772
105 
0.527
124 
0.631
973 
1.153
558 
1.056
2 
1.071
377 
0.780
031 
0.664
535 
0.618
407 
0.598
451 
0.787
467 
0.611
425 
0.601
894 
0.889
962 
1.617
597 
1.052
864 
0.572
3 
1.062
603 
1.324
739 
0.522
728 
0.355
241 
1 
0.331
203 
0.095
61 
2.235
241 
4.258
335 
1.548
892 
3.031
81 
1.665
548 
4.705
607 
0.940
916 
2.631
342 
0.793
358 
0.994
745 
1.098
191 
1.098
531 
1.339
769 
0.832
784 
0.863
505 
0.624
572 
0.849
876 
0.567
714 
0.936
024 
1.426
094 
0.664
68 
0.659
124 
1.358
523 
1.207
031 
1.513
842 
0.274
565 
0.079
26 
17.70
995 
21.59
58 
13.80
408 
6.806
712 
7.613
669 
9.376
432 
3.026
665 
2.914
399 
2.133
617 
2.357
754 
2.695
207 
3.133
346 
2.118
135 
3.091
781 
2.758
675 
2.368
09 
1.410
191 
3.040
426 
1.835
804 
2.874
482 
2.523
479 
1.902
338 
2.280
567 
1.813
107 
5.049
363 
0.512
514 
0.147
95 
9.618
313 
8.363
542 
9.039
749 
6.457
424 
5.992
529 
6.188
549 
3.853
357 
4.667
636 
3.085
895 
4.576
567 
3.381
826 
2.333
38 
3.493
226 
4.300
129 
3.599
756 
1.945
74 
2.393
017 
2.997
929 
2.100
22 
3.239
188 
3.024
23 
2.449
89 
1.962
15 
1.469
508 
4.188
906 
0.867
036 
0.250
292 
13.19
537 
21.52
151 
25.49
186 
10.14
204 
20.20
41 
10.82
96 
10.87
68 
6.487
218 
4.071
519 
2.429
32 
3.890
529 
2.900
171 
2.566
197 
3.316
796 
3.644
238 
2.958
48 
1.350
108 
2.423
503 
2.750
772 
3.281
358 
2.657
489 
2.223
958 
3.602
388 
3.609
801 
6.934
38 
0.713
006 
0.205
827 
19.57
034 
24.81
434 
23.99
884 
21.86
555 
18.60
72 
13.09
427 
16.25
115 
12.32
685 
17.12
837 
18.18
751 
15.11
671 
14.20
951 
15.27
074 
40.00
139 
23.99
854 
19.58
383 
10.50
839 
17.70
447 
16.45
122 
16.51
988 
11.55
707 
15.50
167 
11.42
172 
19.48
787 
18.04
906 
6.859
2 
1.980
08 
 
 
 
Fold induction A2C2 
09/06/2016 23/06/2016 24/06/2016 Mean SD SEM 
1.171
639 
0.320
027 
0.831
766 
0.333
088 
0.299
981 
0.346
366 
0.415
665 
0.145
763 
0.375
982 
0.808
154 
0.628
508 
0.659
014 
0.379
461 
0.636
64 
0.479
071 
0.965
751 
6.890
928 
1.050
737 
0.794
385 
1.187
643 
0.609
485 
0.578
381 
0.759
383 
3.332
182 
1 
1.653
51 
0.477
327 
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0.773
072 
0.534
03 
0.445
359 
0.672
254 
0.357
468 
0.871
045 
0.333
491 
1.248
006 
0.563
011 
0.482
084 
0.569
518 
0.280
111 
0.346
319 
0.276
56 
0.815
45 
0.415
248 
1.168
044 
0.892
544 
0.773
489 
0.655
895 
0.794
032 
0.690
431 
0.456
346 
1.600
711 
0.667
272 
0.345
487 
0.099
734 
0.965
66 
1.237
601 
1.097
247 
1.400
168 
0.982
395 
1.093
828 
1.227
963 
0.890
94 
0.919
392 
1.011
621 
0.958
839 
0.740
325 
1.172
564 
1.392
264 
0.618
867 
0.769
289 
5.074
058 
0.804
992 
1.016
632 
0.670
29 
1.211
049 
1.314
976 
1.139
307 
2.615
371 
1.263
568 
1.099
477 
0.317
392 
0.802
03 
1.114
061 
1.009
395 
1.101
888 
0.771
419 
1.128
706 
0.823
533 
1.204
602 
4.374
454 
0.452
044 
0.821
335 
0.713
924 
0.800
452 
0.879
087 
0.807
29 
0.851
363 
7.903
104 
1.878
709 
1.097
581 
1.806
327 
0.921
175 
1.558
916 
1.066
911 
1.577
713 
1.477
751 
1.886
364 
0.544
546 
0.929
993 
0.737
499 
0.802
233 
0.796
555 
0.529
436 
0.711
293 
0.711
669 
1.099
878 
0.560
678 
0.654
759 
1.533
492 
0.605
073 
0.899
964 
0.730
393 
1.054
066 
1.230
396 
7.089
082 
1.406
246 
0.758
551 
0.836
901 
1.030
703 
0.712
26 
2.061
048 
1.752
98 
1.218
131 
1.570
667 
0.453
412 
3.743
863 
5.343
427 
3.840
013 
5.485
405 
3.856
654 
6.417
246 
6.634
304 
3.733
516 
8.358
76 
8.064
288 
4.366
591 
4.497
777 
4.899
351 
6.070
581 
6.170
039 
7.142
19 
23.79
497 
6.680
218 
4.433
427 
5.576
76 
7.396
907 
9.410
875 
4.533
826 
6.794
199 
6.551
883 
4.637
856 
1.338
834 
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S. Table 4: Luciferase raw and calculated fold inductions (WT vs clone B6C3). 
WT RAW FIREFLY LUMINESCENCE 
 
09/06/2016 23/06/2016 14/07/2016 Average 
UT 260 443 285 369 277 229 342 131 450 700 511 600 440 516 493 472 322 439 269 219 337 403 243 145 409.9375 
0.5 488 1202 653 1208 660 566 372 574 663 1005 1304 1074 1689 831 1259 836 302 218 505 810 284 298 690 907 792.1875 
1.5 1246 2159 3511 2666 2740 3766 1525 362 2034 3463 1986 3295 1824 3301 2903 2281 418 1880 992 1866 1539 1323 1434 1433 1998.25 
2.5 1622 1328 2544 1941 1798 1684 1172 191 3443 6146 2986 1583 3123 3133 3193 1376 880 1396 906 1673 1362 1195 1063 1060 2157.375 
3.5 591 1254 2775 1036 1728 1173 1708 318 1891 2209 2507 2282 1398 2601 2419 1361 480 600 760 1025 758 740 923 1905 1491.188 
TG 1798 5323 7923 6735 6585 6543 6649 3139 88 11667 13976 16492 9987 11591 15312 9897 4993 8791 9000 8069 6537 7641 5797 3370 8950.5 
BLK 68 68 68 68 68 68 68 68 100 100 100 100 100 100 100 100 49 49 49 49 49 49 49 49 74.5 
 
B6C3 RAW FIREFLY LUMINESCENCE 
 
14/07/2016 23/06/2016 24/06/2016 Average 
UT 1989 2210 2181 3760 2201 1906 2893 2138 1400 1955 3223 2898 4344 4584 3003 1813 580 3955 1562 726 1992 3194 2526 948 2418.938 
0.5 2808 4102 2002 3700 2948 4236 4220 4894 3496 3096 4265 3377 3146 4582 2892 2303 645 5316 2000 5213 3737 2905 6187 685 3365.313 
1.5 2782 6001 5934 5407 7549 7928 7484 4354 3719 4925 5755 6893 6603 5974 7391 4390 1233 5376 4263 5453 4918 4705 3390 890 4742.375 
2.5 2681 6333 4721 3112 4970 4748 6195 3309 4167 6733 8049 5955 5924 8372 8402 3682 846 3367 3235 4004 2946 4211 2976 708 4598.563 
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3.5 3510 3556 3624 5484 4353 5521 4460 2393 2152 3613 3767 5941 6080 4656 3456 2240 738 2299 2270 2828 2182 3854 2649 783 3094.25 
TG 57754 66578 66422 76589 72896 96811 104900 75483 27574 38189 35452 39347 31569 40390 41223 33449 2224 8566 11817 12879 14485 24152 17594 3217 23882.94 
BLK 471 471 471 471 471 471 471 471 159 159 159 159 159 159 159 159 87 87 87 87 87 87 87 87 123 
 
WT RAW Renilla LUMINESCENCE 
 
09/06/2016 23/06/2016 14/07/2016 Average 
UT 1373 4670 4600 3445 8694 5995 4905 2052 6949 14847 12722 16052 12164 10841 13340 12974 5986 4490 4227 6331 5247 5033 7691 6753 9102.938 
0.5 3612 4670 6975 6592 6556 1990 6541 3609 13826 16715 19645 16175 20857 16509 24122 22145 5879 6353 8926 9397 7069 7480 8403 12432 13495.81 
1.5 1164 1654 4208 6480 5954 6645 8336 2055 15772 24300 12191 17398 14247 17664 17410 15936 4904 10230 8940 10740 10090 11506 10403 13076 13425.44 
2.5 2790 2627 4656 4973 4964 4502 5032 677 18459 22218 14608 11224 14791 12054 14675 11700 6084 7704 7137 8545 7451 8070 8963 11934 11601.06 
3.5 741 964 1801 1690 1415 1792 2598 811 7684 15044 10661 13018 9013 12974 10982 7611 5882 4096 4571 5168 4719 5505 4239 8731 8118.625 
TG 1520 3549 5462 5096 5855 8267 6769 4213 85 10613 15296 19202 10820 4794 10556 8361 7861 8215 9051 8081 9358 8155 8397 2861 8856.625 
BLK 76 76 76 76 76 76 76 76 86 86 86 86 86 86 86 86 79 79 79 79 79 79 79 79 82.5 
 
B6C3 RAW Renilla LUMINESCENCE 
 
14/07/2016 23/06/2016 24/06/2016 Average 
UT 10301 15608 18289 19990 21361 18994 18477 13643 5682 12591 12743 11881 11399 11123 13276 6931 6057 1706 6044 1040 2810 2405 2707 691 61375.8
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6 4 7 0 9 3 7 2 3 2 6 4 1 3 1 5 1 9 3 9 9 6 1 
0.5 
13600
1 
20365
9 
22395
6 
25144
6 
24588
2 
21318
9 
22877
8 
12432
0 
9280
5 
98471 
12179
7 
13107
4 
12544
0 
11519
2 
13138
1 
6663
9 
4381 
3629
3 
2344
2 
3535
5 
4262
2 
4477
4 
3787
7 
331
7 
69428.7
5 
1.5 97589 
20078
1 
21342
9 
25897
9 
24342
5 
24702
8 
19580
4 
17232
9 
4710
5 
97644 
11393
9 
13422
6 
14532
4 
13330
0 
95573 
4934
5 
1014
5 
3673
6 
4066
5 
4955
0 
5779
7 
3808
3 
3435
2 
543
4 
68076.1
3 
2.5 86037 
18790
6 
19386
9 
19134
9 
16195
6 
16400
1 
18875
1 
94826 
4621
0 
99763 
10542
7 
12198
2 
96203 98817 
10436
4 
5397
0 
7481 
3203
9 
3581
9 
2314
4 
3464
1 
3922
3 
2980
5 
540
2 
58393.1
3 
3.5 81325 
10756
0 
14078
5 
16242
9 
13180
9 
14501
0 
13044
7 
71821 
4144
4 
86208 73413 
11049
0 
10845
2 
85834 70294 
4245
7 
7450 
1834
0 
2842
6 
2045
2 
2886
2 
2748
9 
1677
2 
420
0 
48161.4
4 
TG 
12746
0 
22315
5 
23685
4 
26533
5 
26518
5 
25266
1 
26233
5 
20982
3 
7270
1 
12157
9 
13298
2 
13394
0 
14143
3 
17577
5 
14921
0 
8324
3 
3109 
1453
4 
2242
6 
2268
2 
2963
4 
4210
2 
3485
2 
700
4 
74200.3
8 
BL
K 
1333 1333 1333 1333 1333 1333 1333 1333 686 686 686 686 686 686 686 686 164 164 164 164 164 164 164 164 425 
 
Fluc/Rluc (wild-type) 
 
09/06/2016 23/06/2016 24/06/2016 
U
T 
0.189
366 
0.094
861 
0.061
957 
0.107
112 
0.031
861 
0.038
198 
0.069
725 
0.063
84 
0.064
758 
0.047
148 
0.040
167 
0.037
379 
0.036
172 
0.047
597 
0.036
957 
0.036
38 
0.053
792 
0.097
773 
0.063
639 
0.034
592 
0.064
227 
0.080
072 
0.031
595 
0.021
472 
0. 0.135 0.257 0.093 0.183 0.100 0.284 0.056 0.159 0.047 0.060 0.066 0.066 0.080 0.050 0.052 0.037 0.051 0.034 0.056 0.086 0.040 0.039 0.082 0.072
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5 105 388 62 252 671 422 872 047 953 126 378 399 98 336 193 751 369 314 576 198 175 84 114 957 
1.
5 
1.070
447 
1.305
32 
0.834
363 
0.411
42 
0.460
195 
0.566
742 
0.182
941 
0.176
156 
0.128
963 
0.142
51 
0.162
907 
0.189
39 
0.128
027 
0.186
877 
0.166
743 
0.143
135 
0.085
237 
0.183
773 
0.110
962 
0.173
743 
0.152
527 
0.114
983 
0.137
845 
0.109
59 
2.
5 
0.581
362 
0.505
52 
0.546
392 
0.390
308 
0.362
208 
0.374
056 
0.232
909 
0.282
127 
0.186
521 
0.276
623 
0.204
409 
0.141
037 
0.211
142 
0.259
914 
0.217
581 
0.117
607 
0.144
642 
0.181
205 
0.126
944 
0.195
787 
0.182
794 
0.148
079 
0.118
599 
0.088
822 
3.
5 
0.797
571 
1.300
83 
1.540
811 
0.613
018 
1.221
201 
0.654
576 
0.657
429 
0.392
109 
0.246
096 
0.146
836 
0.235
156 
0.175
296 
0.155
109 
0.200
478 
0.220
27 
0.178
82 
0.081
605 
0.146
484 
0.166
266 
0.198
336 
0.160
627 
0.134
423 
0.217
74 
0.218
188 
T
G 
1.182
895 
1.499
859 
1.450
568 
1.321
625 
1.124
68 
0.791
46 
0.982
272 
0.745
075 
1.035
294 
1.099
312 
0.913
703 
0.858
869 
0.923
013 
2.417
814 
1.450
549 
1.183
71 
0.635
161 
1.070
116 
0.994
365 
0.998
515 
0.698
547 
0.936
971 
0.690
366 
1.177
91 
 
Fluc/Rluc (B6C3) 
 
 
09/06/2016 23/06/2016 24/06/2016 
U
T 
0.019
308 
0.014
159 
0.011
925 
0.018
809 
0.010
303 
0.010
035 
0.015
657 
0.015
671 
0.024
638 
0.015
527 
0.025
291 
0.024
391 
0.038
108 
0.041
211 
0.022
62 
0.026
156 
0.095
757 
0.231
815 
0.258
438 
0.069
747 
0.070
882 
0.132
757 
0.093
283 
0.137
073 
0.
5 
0.020
647 
0.020
142 
0.008
939 
0.014
715 
0.011
989 
0.019
87 
0.018
446 
0.039
366 
0.037
67 
0.031
441 
0.035
017 
0.025
764 
0.025
08 
0.039
777 
0.022
012 
0.034
559 
0.147
227 
0.146
475 
0.085
317 
0.147
447 
0.087
678 
0.064
881 
0.163
345 
0.206
512 
1.
5 
0.028
507 
0.029
888 
0.027
803 
0.020
878 
0.031
012 
0.032
094 
0.038
222 
0.025
266 
0.078
951 
0.050
438 
0.050
509 
0.051
354 
0.045
436 
0.044
816 
0.077
334 
0.088
965 
0.121
538 
0.146
341 
0.104
832 
0.110
05 
0.085
091 
0.123
546 
0.098
684 
0.163
784 
2. 0.031 0.033 0.024 0.016 0.030 0.028 0.032 0.034 0.090 0.067 0.076 0.048 0.061 0.084 0.080 0.068 0.113 0.105 0.090 0.173 0.085 0.107 0.099 0.131
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5 161 703 351 263 687 951 821 895 175 49 347 819 578 722 507 223 086 091 315 004 044 36 849 063 
3.
5 
0.043
16 
0.033
061 
0.025
741 
0.033
762 
0.033
025 
0.038
073 
0.034
19 
0.033
319 
0.051
925 
0.041
91 
0.051
312 
0.053
77 
0.056
062 
0.054
244 
0.049
165 
0.052
759 
0.099
06 
0.125
354 
0.079
856 
0.138
275 
0.075
601 
0.140
202 
0.157
942 
0.186
429 
T
G 
0.453
115 
0.298
349 
0.280
434 
0.288
65 
0.274
887 
0.383
166 
0.399
87 
0.359
746 
0.379
28 
0.314
109 
0.266
592 
0.293
766 
0.223
208 
0.229
782 
0.276
275 
0.401
824 
0.715
343 
0.589
377 
0.526
933 
0.567
807 
0.488
797 
0.573
654 
0.504
82 
0.459
309 
 
Fluc / Wild-type 
09/06/2016 23/06/2016 24/06/2016 Mean SD SEM 
0.701
518 
1.195
278 
0.768
971 
0.995
616 
0.747
386 
0.617
875 
0.922
766 
0.353
457 
1.214
165 
1.888
702 
1.378
752 
1.618
887 
1.187
184 
1.392
243 
1.330
185 
1.273
524 
0.868
803 
1.184
486 
0.725
801 
0.590
894 
0.909
275 
1.087
352 
0.655
649 
0.391
231 
1 
0.396
122 
0.114
35 
1.316
695 
3.243
17 
1.761
889 
3.259
359 
1.780
776 
1.527
15 
1.003
71 
1.548
735 
1.788
87 
2.711
636 
3.518
381 
2.897
808 
4.557
167 
2.242
159 
3.396
965 
2.255
649 
0.814
84 
0.588
196 
1.362
563 
2.185
497 
0.766
273 
0.804
047 
1.861
72 
2.447
218 
2.068
353 
1.125
018 
0.324
765 
3.361
889 
5.825
295 
9.473
187 
7.193
255 
7.392
917 
10.16
121 
4.114
671 
0.976
728 
5.488
027 
9.343
676 
5.358
516 
8.890
388 
4.921
417 
8.906
577 
7.832
715 
6.154
469 
1.127
825 
5.072
513 
2.676
56 
5.034
739 
4.152
445 
3.569
646 
3.869
14 
3.866
442 
5.615
177 
2.341
899 
0.676
048 
4.376
391 
3.583
137 
6.864
081 
5.237
099 
4.851
265 
4.543
676 
3.162
226 
0.515
346 
9.289
713 
16.58
28 
8.056
661 
4.271
164 
8.426
307 
8.453
288 
8.615
177 
3.712
648 
2.374
368 
3.766
61 
2.444
519 
4.513
997 
3.674
874 
3.224
283 
2.868
128 
2.860
034 
5.261
158 
3.823
278 
1.103
685 
1.594
604 
3.383
474 
7.487
352 
2.795
278 
4.662
395 
3.164
924 
4.608
432 
0.858
01 
5.102
192 
5.960
202 
6.764
25 
6.157
167 
3.772
007 
7.017
875 
6.526
813 
3.672
175 
1.295
11 
1.618
887 
2.050
59 
2.765
599 
2.045
194 
1.996
627 
2.490
388 
5.139
966 
3.872
063 
2.044
798 
0.590
282 
4.851 14.36 21.37 18.17 17.76 17.65 17.93 8.469 0.237 31.47 37.70 44.49 26.94 31.27 41.31 26.70 13.47 23.71 24.28 21.77 17.63 20.61 15.64 9.092 21.12 11.71 3.380
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265 223 74 201 728 396 997 477 437 926 927 781 637 42 4 354 184 939 331 133 777 653 115 749 456 043 511 
 
Fluc / B6C3 
09/06/2016 23/06/2016 24/06/2016 Mean SD SEM 
0.823
304 
0.914
782 
0.902
778 
1.556
372 
0.911
057 
0.788
948 
1.197
496 
0.884
98 
0.579
5 
0.809
231 
1.334
092 
1.199
565 
1.798
106 
1.897
449 
1.243
028 
0.750
453 
0.240
079 
1.637
088 
0.646
557 
0.300
512 
0.824
546 
1.322
088 
1.045
584 
0.392
404 
1 
0.518
44 
0.149
661 
1.162
312 
1.697
936 
0.828
685 
1.531
536 
1.220
262 
1.753
402 
1.746
779 
2.025
767 
1.447
095 
1.281
523 
1.765
406 
1.397
837 
1.302
22 
1.896
621 
1.197
082 
0.953
278 
0.266
984 
2.200
445 
0.827
857 
2.157
81 
1.546
852 
1.202
463 
2.560
977 
0.283
541 
1.427
278 
0.639
11 
0.184
495 
1.151
55 
2.483
986 
2.456
253 
2.238
112 
3.124
748 
3.281
627 
3.097
842 
1.802
246 
1.539
401 
2.038
599 
2.382
16 
2.853
211 
2.733
171 
2.472
81 
3.059
347 
1.817
147 
0.510
374 
2.225
281 
1.764
578 
2.257
153 
2.035
701 
1.947
535 
1.403
218 
0.368
397 
2.126
852 
0.748
157 
0.215
974 
1.109
743 
2.621
41 
1.954
157 
1.288
146 
2.057
226 
1.965
333 
2.564
288 
1.369
69 
1.724
841 
2.786
982 
3.331
712 
2.464
945 
2.452
114 
3.465
411 
3.477
829 
1.524
085 
0.350
184 
1.393
698 
1.339
059 
1.657
371 
1.219
434 
1.743
054 
1.231
852 
0.293
062 
1.891
068 
1.004
014 
0.289
834 
1.452
89 
1.471
93 
1.500
078 
2.269
985 
1.801
832 
2.285
3 
1.846
122 
0.990
531 
0.890
775 
1.495
524 
1.559
269 
2.459
15 
2.516
687 
1.927
252 
1.430
538 
0.927
2 
0.305
479 
0.951
622 
0.939
618 
1.170
59 
0.903
192 
1.595
281 
1.096
497 
0.324
106 
1.421
31 
0.639
579 
0.184
631 
23.90
604 
27.55
855 
27.49
397 
31.70
239 
30.17
375 
40.07
285 
43.42
112 
31.24
458 
11.41
367 
15.80
752 
14.67
46 
16.28
685 
13.06
732 
16.71
858 
17.06
338 
13.84
55 
0.920
577 
3.545
713 
4.891
395 
5.330
988 
5.995
757 
9.997
206 
7.282
662 
1.331
609 
17.23
944 
5.696
027 
1.644
301 
 
Rluc / Wild-type 
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09/06/2016 23/06/2016 24/06/2016 Mean SD SEM 
0.181
673 
0.617
926 
0.608
664 
0.455
836 
1.150
374 
0.793
247 
0.649
021 
0.271
517 
0.919
479 
1.964
528 
1.683
352 
2.123
971 
1.609
518 
1.434
461 
1.765
124 
1.716
696 
0.792
056 
0.594
109 
0.559
309 
0.837
706 
0.694
273 
0.665
957 
1.017
659 
0.893
545 
1 
0.535
576 
0.154
608 
0.477
933 
0.617
926 
0.922
919 
0.872
241 
0.867
478 
0.263
313 
0.865
493 
0.477
536 
1.829
431 
2.211
698 
2.599
39 
2.140
246 
2.759
76 
2.184
44 
3.191
779 
2.930
186 
0.777
898 
0.840
617 
1.181
072 
1.243
394 
0.935
357 
0.989
74 
1.111
869 
1.644
979 
1.414
029 
0.806
841 
0.232
915 
0.154
018 
0.218
854 
0.556
795 
0.857
422 
0.787
822 
0.879
254 
1.103
004 
0.271
914 
2.086
922 
3.215
331 
1.613
091 
2.302
071 
1.885
137 
2.337
268 
2.303
659 
2.108
622 
0.648
888 
1.353
615 
1.182
924 
1.421
097 
1.335
09 
1.522
453 
1.376
506 
1.730
192 
1.385
498 
0.607
426 
0.175
349 
0.369
168 
0.347
6 
0.616
073 
0.658
018 
0.656
827 
0.595
696 
0.665
825 
0.089
579 
2.442
461 
2.939
845 
1.932
904 
1.485
139 
1.957
118 
1.594
963 
1.941
769 
1.548
122 
0.805
024 
1.019
379 
0.944
355 
1.130
659 
0.985
903 
1.067
808 
1.185
968 
1.579
085 
1.189
97 
0.592
167 
0.170
944 
0.098
048 
0.127
555 
0.238
305 
0.223
618 
0.187
23 
0.237
114 
0.343
763 
0.107
31 
1.016
733 
1.990
594 
1.410
644 
1.722
518 
1.192
584 
1.716
696 
1.453
118 
1.007
074 
0.778
295 
0.541
975 
0.604
826 
0.683
82 
0.624
409 
0.728
411 
0.560
897 
1.155
27 
0.781
284 
0.468
114 
0.135
133 
0.201
124 
0.469
597 
0.722
722 
0.674
293 
0.774
723 
1.093
874 
0.895
662 
0.557
456 
0.011
247 
1.404
293 
2.023
939 
2.540
773 
1.431
682 
0.634
333 
1.396
75 
1.106
312 
1.040
153 
1.086
994 
1.197
612 
1.069
263 
1.238
233 
1.079
055 
1.111
076 
0.378
562 
1.005
822 
0.582
758 
0.168
228 
 
Rluc / B6C3 
09/06/2016 23/06/2016 24/06/2016 Mean SD SEM 
1.052
669 
1.594
945 
1.868
933 
2.042
678 
2.182
866 
1.940
933 
1.888
144 
1.394
131 
0.580
646 
1.286
632 
1.302
205 
1.214
101 
1.164
817 
1.136
635 
1.356
618 
0.708
295 
0.061
893 
0.174
338 
0.061
761 
0.106
364 
0.287
171 
0.245
847 
0.276
707 
0.070
671 
1 
0.524
948 
0.151
539 
1.389 2.081 2.288 2.569 2.512 2.178 2.337 1.270 0.948 1.006 1.244 1.339 1.281 1.177 1.342 0.680 0.044 0.370 0.239 0.361 0.435 0.457 0.387 0.033 1.165 0.474 0.136
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726 09 495 401 546 472 768 364 328 226 583 38 809 09 517 951 767 86 542 275 533 523 046 895 799 235 9 
0.997
213 
2.051
681 
2.180
925 
2.646
377 
2.487
439 
2.524
256 
2.000
823 
1.760
944 
0.481
343 
0.997
775 
1.164
286 
1.371
589 
1.484
993 
1.362
126 
0.976
613 
0.504
232 
0.103
667 
0.375
387 
0.415
535 
0.506
327 
0.590
599 
0.389
151 
0.351
026 
0.055
527 
1.157
493 
0.461
691 
0.133
279 
0.879
169 
1.920
118 
1.981
051 
1.955
3 
1.654
948 
1.675
844 
1.928
752 
0.968
98 
0.472
197 
1.019
428 
1.077
306 
1.246
473 
0.983
05 
1.009
762 
1.066
444 
0.551
493 
0.076
445 
0.327
391 
0.366
017 
0.236
497 
0.353
979 
0.400
8 
0.304
562 
0.055
2 
0.937
967 
0.399
332 
0.115
277 
0.831
02 
1.099
102 
1.438
612 
1.659
781 
1.346
89 
1.481
785 
1.332
973 
0.733
903 
0.423
496 
0.880
917 
0.750
171 
1.129
042 
1.108
217 
0.877
095 
0.718
299 
0.433
847 
0.076
128 
0.187
407 
0.290
471 
0.208
989 
0.294
926 
0.280
896 
0.171
385 
0.042
918 
0.741
595 
0.363
808 
0.105
022 
1.302
45 
2.280
31 
2.420
293 
2.711
326 
2.709
793 
2.581
817 
2.680
671 
2.144
077 
0.742
895 
1.242
355 
1.358
877 
1.368
666 
1.445
233 
1.796
157 
1.524
703 
0.850
619 
0.031
769 
0.148
516 
0.229
16 
0.231
776 
0.302
815 
0.430
219 
0.356
135 
0.071
57 
1.290
092 
0.606
523 
0.175
088 
 
Fold inductions WT 
09/06/2016 23/06/2016 24/06/2016 Mean SD SEM 
3.132
962 
1.569
42 
1.025
036 
1.772
105 
0.527
124 
0.631
973 
1.153
558 
1.056
2 
1.071
377 
0.780
031 
0.664
535 
0.618
407 
0.598
451 
0.787
467 
0.611
425 
0.601
894 
0.889
962 
1.617
597 
1.052
864 
0.572
3 
1.062
603 
1.324
739 
0.522
728 
0.355
241 
1 
0.331
203 
0.095
61 
2.235
241 
4.258
335 
1.548
892 
3.031
81 
1.665
548 
4.705
607 
0.940
916 
2.631
342 
0.793
358 
0.994
745 
1.098
191 
1.098
531 
1.339
769 
0.832
784 
0.863
505 
0.624
572 
0.849
876 
0.567
714 
0.936
024 
1.426
094 
0.664
68 
0.659
124 
1.358
523 
1.207
031 
1.513
842 
0.274
565 
0.079
26 
17.70
995 
21.59
58 
13.80
408 
6.806
712 
7.613
669 
9.376
432 
3.026
665 
2.914
399 
2.133
617 
2.357
754 
2.695
207 
3.133
346 
2.118
135 
3.091
781 
2.758
675 
2.368
09 
1.410
191 
3.040
426 
1.835
804 
2.874
482 
2.523
479 
1.902
338 
2.280
567 
1.813
107 
5.049
363 
0.512
514 
0.147
95 
9.618 8.363 9.039 6.457 5.992 6.188 3.853 4.667 3.085 4.576 3.381 2.333 3.493 4.300 3.599 1.945 2.393 2.997 2.100 3.239 3.024 2.449 1.962 1.469 4.188 0.867 0.250
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313 542 749 424 529 549 357 636 895 567 826 38 226 129 756 74 017 929 22 188 23 89 15 508 906 036 292 
13.19
537 
21.52
151 
25.49
186 
10.14
204 
20.20
41 
10.82
96 
10.87
68 
6.487
218 
4.071
519 
2.429
32 
3.890
529 
2.900
171 
2.566
197 
3.316
796 
3.644
238 
2.958
48 
1.350
108 
2.423
503 
2.750
772 
3.281
358 
2.657
489 
2.223
958 
3.602
388 
3.609
801 
6.934
38 
0.713
006 
0.205
827 
19.57
034 
24.81
434 
23.99
884 
21.86
555 
18.60
72 
13.09
427 
16.25
115 
12.32
685 
17.12
837 
18.18
751 
15.11
671 
14.20
951 
15.27
074 
40.00
139 
23.99
854 
19.58
383 
10.50
839 
17.70
447 
16.45
122 
16.51
988 
11.55
707 
15.50
167 
11.42
172 
19.48
787 
18.04
906 
6.859
2 
1.980
08 
 
Fold inductions B6C3 
09/06/2016 23/06/2016 24/06/2016 Mean SD SEM 
0.325
511 
0.238
709 
0.201
041 
0.317
11 
0.173
706 
0.169
174 
0.263
959 
0.264
196 
0.415
374 
0.261
767 
0.426
386 
0.411
212 
0.642
472 
0.694
778 
0.381
347 
0.440
967 
1.614
38 
3.908
204 
4.357
043 
1.175
88 
1.195
011 
2.238
168 
1.572
664 
2.310
94 
1 
1.263
514 
0.364
745 
0.348
089 
0.339
568 
0.150
708 
0.248
08 
0.202
132 
0.334
986 
0.310
981 
0.663
679 
0.635
09 
0.530
063 
0.590
361 
0.434
36 
0.422
822 
0.670
607 
0.371
109 
0.582
641 
2.482
114 
2.469
434 
1.438
37 
2.485
834 
1.478
171 
1.093
844 
2.753
847 
3.481
612 
1.021
604 
1.029
242 
0.297
116 
0.480
609 
0.503
891 
0.468
737 
0.351
987 
0.522
829 
0.541
069 
0.644
388 
0.425
957 
1.331
05 
0.850
347 
0.851
546 
0.865
779 
0.766
018 
0.755
562 
1.303
777 
1.499
88 
2.049
02 
2.467
19 
1.767
38 
1.855
355 
1.434
559 
2.082
878 
1.663
73 
2.761
249 
1.176
866 
0.621
565 
0.179
43 
0.525
348 
0.568
204 
0.410
545 
0.274
188 
0.517
362 
0.488
09 
0.553
334 
0.588
308 
1.520
277 
1.137
822 
1.287
139 
0.823
041 
1.038
154 
1.428
344 
1.357
273 
1.150
182 
1.906
54 
1.771
738 
1.522
636 
2.916
694 
1.433
764 
1.810
005 
1.683
368 
2.209
601 
1.205
082 
0.504
551 
0.145
651 
0.727
643 
0.557
373 
0.433
977 
0.569
206 
0.556
774 
0.641
882 
0.576
416 
0.561
729 
0.875
419 
0.706
571 
0.865
083 
0.906
508 
0.945
151 
0.914
511 
0.828
878 
0.889
475 
1.670
073 
2.113
367 
1.346
311 
2.331
197 
1.274
57 
2.363
677 
2.662
762 
3.143
024 
1.185
899 
0.783
797 
0.226
263 
7.639 5.029 4.727 4.866 4.634 6.459 6.741 6.065 6.394 5.295 4.494 4.952 3.763 3.873 4.657 6.774 12.06 9.936 8.883 9.572 8.240 9.671 8.510 7.743 6.707 2.515 0.726
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S. Table 5: Luciferase raw and calculated fold inductions (WT vs clone AAG++A2C2) 
WT RAW FIREFLY LUMINESCENCE 
 
09/06/2016 23/06/2016 14/07/2016 Average 
UT 260 443 285 369 277 229 342 131 450 700 511 600 440 516 493 472 322 439 269 219 337 403 243 145 409.9375 
2.5 1622 1328 2544 1941 1798 1684 1172 191 3443 6146 2986 1583 3123 3133 3193 1376 880 1396 906 1673 1362 1195 1063 1060 2157.375 
3.5 591 1254 2775 1036 1728 1173 1708 318 1891 2209 2507 2282 1398 2601 2419 1361 480 600 760 1025 758 740 923 1905 1491.188 
TG 1798 5323 7923 6735 6585 6543 6649 3139 88 11667 13976 16492 9987 11591 15312 9897 4993 8791 9000 8069 6537 7641 5797 3370 8950.5 
BLK 68 68 68 68 68 68 68 68 100 100 100 100 100 100 100 100 49 49 49 49 49 49 49 49 74.5 
 
A2C2 RAW FIREFLY LUMINESCENCE 
 
23/06/2016 14/07/2016 
 
Average 
UT 976 290 191 343 131 287 657 116 3243 2885 5061 4582 6702 4091 2638 3239 4633 4147 4644 3156 2896 3177 2551 2461 3756.625 
2.5 3066 1359 3046 2521 1485 2607 1511 5020 25310 38291 28513 41445 25534 26126 20065 29406 2846 3274 5120 3647 3526 4839 3833 3002 16548.56 
3.5 1104 722 429 587 591 295 305 1207 12194 15537 20344 8186 15013 22096 14222 10097 3712 5396 3986 3316 4165 3925 3227 2858 9267.125 
TG 7175 21745 19721 11601 20610 18923 9871 15732 106243 147987 98954 112321 74098 111589 114022 90108 1609 1810 1642 2060 1516 1644 1726 1484 54300.81 
BLK 578 613 472 491 
    
871 971 1115 654 
    
57 41 64 57 
    
478.75 
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WT RAW Renilla LUMINESCENCE 
 
09/06/2016 23/06/2016 14/07/2016 Average 
UT 1373 4670 4600 3445 8694 5995 4905 2052 6949 14847 12722 16052 12164 10841 13340 12974 5986 4490 4227 6331 5247 5033 7691 6753 9102.938 
2.5 2790 2627 4656 4973 4964 4502 5032 677 18459 22218 14608 11224 14791 12054 14675 11700 6084 7704 7137 8545 7451 8070 8963 11934 11601.06 
3.5 741 964 1801 1690 1415 1792 2598 811 7684 15044 10661 13018 9013 12974 10982 7611 5882 4096 4571 5168 4719 5505 4239 8731 8118.625 
TG 1520 3549 5462 5096 5855 8267 6769 4213 85 10613 15296 19202 10820 4794 10556 8361 7861 8215 9051 8081 9358 8155 8397 2861 8856.625 
BLK 76 76 76 76 76 76 76 76 86 86 86 86 86 86 86 86 79 79 79 79 79 79 79 79 82.5 
 
A2C2 RAW RENILLA LUMINESCENCE 
 
23/06/2016 14/07/2016 28/07/2016 Average 
UT 91627 57910 
5273
2 
7018
3 
60625 
4050
6 
74543 32434 
57017
2 
43692
6 
36038
5 
51772
1 
44139
1 
38679
3 
44585
0 
62898
9 
77443 71643 70389 57727 
5579
5 
55320 52688 61404 
268164.
8 
2.5 62057 61343 
7194
2 
3780
7 
28321 
3670
9 
44313 83733 
38382
8 
38104
8 
36780
6 
37489
2 
30648
4 
29927
1 
27177
3 
27878
3 
57240 57094 51971 41940 
4082
2 
50574 40542 59451 
191469.
9 
3.5 18299 14172 
1096
5 
1316
9 
18580 
1629
0 
14294 21565 
27027
0 
25376
5 
21928
6 
18794
2 
23932
2 
28606
7 
21554
9 
26774
7 
56785 38843 49575 51277 
4637
8 
42257 41795 67800 
145916.
1 
TG 
11009
5 
13365
6 
5242
6 
6273
1 
11549
7 
8624
0 
10456
6 
14653
3 
72602
4 
77172
2 
55038
0 
71707
4 
46933
7 
49979
0 
50246
8 
60550
6 
14757
8 
13810
9 
10899
5 
11370
6 
9844
5 
10403
9 
11526
4 
12327
3 
361981.
9 
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BL
K 
578 613 472 491 
    
5182 5194 5140 4686 
    
866 927 952 737 
    
2960.5 
 
Fluc/Rluc (wild-type) 
 
09/06/2016 23/06/2016 24/06/2016 
U
T 
0.189
366 
0.094
861 
0.061
957 
0.107
112 
0.031
861 
0.038
198 
0.069
725 
0.063
84 
0.064
758 
0.047
148 
0.040
167 
0.037
379 
0.036
172 
0.047
597 
0.036
957 
0.036
38 
0.053
792 
0.097
773 
0.063
639 
0.034
592 
0.064
227 
0.080
072 
0.031
595 
0.021
472 
2
.
5 
0.581
362 
0.505
52 
0.546
392 
0.390
308 
0.362
208 
0.374
056 
0.232
909 
0.282
127 
0.186
521 
0.276
623 
0.204
409 
0.141
037 
0.211
142 
0.259
914 
0.217
581 
0.117
607 
0.144
642 
0.181
205 
0.126
944 
0.195
787 
0.182
794 
0.148
079 
0.118
599 
0.088
822 
3
.
5 
0.797
571 
1.300
83 
1.540
811 
0.613
018 
1.221
201 
0.654
576 
0.657
429 
0.392
109 
0.246
096 
0.146
836 
0.235
156 
0.175
296 
0.155
109 
0.200
478 
0.220
27 
0.178
82 
0.081
605 
0.146
484 
0.166
266 
0.198
336 
0.160
627 
0.134
423 
0.217
74 
0.218
188 
T
G 
1.182
895 
1.499
859 
1.450
568 
1.321
625 
1.124
68 
0.791
46 
0.982
272 
0.745
075 
1.035
294 
1.099
312 
0.913
703 
0.858
869 
0.923
013 
2.417
814 
1.450
549 
1.183
71 
0.635
161 
1.070
116 
0.994
365 
0.998
515 
0.698
547 
0.936
971 
0.690
366 
1.177
91 
 
Fluc/Rluc (B6C3) 
 
23/06/2016 23/06/2016 28/07/2016 
U 0.010 0.005 0.003 0.004 0.002 0.007 0.008 0.003 0.005 0.006 0.014 0.008 0.015 0.010 0.005 0.005 0.059 0.057 0.065 0.054 0.051 0.057 0.048 0.040
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T 652 008 622 887 161 085 814 576 688 603 043 85 184 577 917 15 825 884 976 671 904 43 417 079 
2.
5 
0.049
406 
0.022
154 
0.042
34 
0.066
681 
0.052
435 
0.071
018 
0.034
098 
0.059
952 
0.065
941 
0.100
489 
0.077
522 
0.110
552 
0.083
313 
0.087
299 
0.073
83 
0.105
48 
0.049
72 
0.057
344 
0.098
516 
0.086
958 
0.086
375 
0.095
682 
0.094
544 
0.050
495 
3.
5 
0.060
331 
0.050
946 
0.039
124 
0.044
574 
0.031
808 
0.018
109 
0.021
338 
0.055
97 
0.045
118 
0.061
226 
0.092
774 
0.043
556 
0.062
731 
0.077
241 
0.065
98 
0.037
711 
0.065
369 
0.138
918 
0.080
403 
0.064
668 
0.089
806 
0.092
884 
0.077
21 
0.042
153 
T
G 
0.065
171 
0.162
694 
0.376
168 
0.184
932 
0.178
446 
0.219
423 
0.094
4 
0.107
361 
0.146
335 
0.191
762 
0.179
792 
0.156
638 
0.157
878 
0.223
272 
0.226
924 
0.148
814 
0.010
903 
0.013
106 
0.015
065 
0.018
117 
0.015
399 
0.015
802 
0.014
974 
0.012
038 
 
Fluc / Wild-type 
09/06/2016 23/06/2016 24/06/2016 Mean SD SEM 
0.701
518 
1.195
278 
0.768
971 
0.995
616 
0.747
386 
0.617
875 
0.922
766 
0.353
457 
1.214
165 
1.888
702 
1.378
752 
1.618
887 
1.187
184 
1.392
243 
1.330
185 
1.273
524 
0.868
803 
1.184
486 
0.725
801 
0.590
894 
0.909
275 
1.087
352 
0.655
649 
0.391
231 
1 
0.381
538 
0.110
14 
4.376
391 
3.583
137 
6.864
081 
5.237
099 
4.851
265 
4.543
676 
3.162
226 
0.515
346 
9.289
713 
16.58
28 
8.056
661 
4.271
164 
8.426
307 
8.453
288 
8.615
177 
3.712
648 
2.374
368 
3.766
61 
2.444
519 
4.513
997 
3.674
874 
3.224
283 
2.868
128 
2.860
034 
5.261
158 
3.349
592 
0.966
944 
1.594
604 
3.383
474 
7.487
352 
2.795
278 
4.662
395 
3.164
924 
4.608
432 
0.858
01 
5.102
192 
5.960
202 
6.764
25 
6.157
167 
3.772
007 
7.017
875 
6.526
813 
3.672
175 
1.295
11 
1.618
887 
2.050
59 
2.765
599 
2.045
194 
1.996
627 
2.490
388 
5.139
966 
3.872
063 
2.016
145 
0.582
011 
4.851
265 
14.36
223 
21.37
74 
18.17
201 
17.76
728 
17.65
396 
17.93
997 
8.469
477 
0.237
437 
31.47
926 
37.70
927 
44.49
781 
26.94
637 
31.27
42 
41.31
4 
26.70
354 
13.47
184 
23.71
939 
24.28
331 
21.77
133 
17.63
777 
20.61
653 
15.64
115 
9.092
749 
21.12
456 
10.86
755 
3.137
19 
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Fluc / B6C3 
09/06/2016 
 
24/06/2016 Mean SD SEM 
0.371
238 
0.110
306 
0.072
65 
0.130
466 
0.049
828 
0.109
165 
0.249
901 
0.044
123 
1.233
529 
1.097
358 
1.925
036 
1.742
84 
2.549
218 
1.556
08 
1.003
407 
1.232
008 
1.762
239 
1.577
381 
1.766
423 
1.200
437 
1.101
542 
1.208
425 
0.970
316 
0.936
083 
1 
0.716
606 
0.206
866 
1.166
204 
0.516
918 
1.158
597 
0.958
905 
0.564
845 
0.991
616 
0.574
734 
1.909
441 
9.627
082 
14.56
462 
10.84
54 
15.76
43 
9.712
284 
9.937
461 
7.632
059 
11.18
506 
1.082
524 
1.245
321 
1.947
478 
1.387
197 
1.341
173 
1.840
595 
1.457
946 
1.141
861 
4.523
068 
5.032
971 
1.452
894 
0.419
925 
0.274
625 
0.163
177 
0.223
275 
0.224
797 
0.112
208 
0.116
012 
0.459
103 
4.638
192 
5.909
758 
7.738
181 
3.113
682 
5.710
446 
8.404
583 
5.409
576 
3.840
563 
1.411
921 
2.052
459 
1.516
142 
1.261
296 
1.584
227 
1.492
939 
1.227
443 
1.087
088 
2.432
984 
2.548
184 
0.735
597 
2.729
131 
8.271
075 
7.501
212 
4.412
635 
7.839
358 
7.197
68 
3.754
6 
5.983
93 
40.41
13 
56.28
933 
37.63
881 
42.72
317 
28.18
441 
42.44
474 
43.37
018 
34.27
409 
0.612
01 
0.688
464 
0.624
562 
0.783
555 
0.576
636 
0.625
323 
0.656
513 
0.564
464 
15.75
655 
18.71
381 
5.402
211 
 
Rluc / Wild-type 
09/06/2016 23/06/2016 24/06/2016 Mean SD SEM 
0.181
673 
0.617
926 
0.608
664 
0.455
836 
1.150
374 
0.793
247 
0.649
021 
0.271
517 
0.919
479 
1.964
528 
1.683
352 
2.123
971 
1.609
518 
1.434
461 
1.765
124 
1.716
696 
0.792
056 
0.594
109 
0.559
309 
0.837
706 
0.694
273 
0.665
957 
1.017
659 
0.893
545 
1 
0.549
932 
0.158
752 
0.369
168 
0.347
6 
0.616
073 
0.658
018 
0.656
827 
0.595
696 
0.665
825 
0.089
579 
2.442
461 
2.939
845 
1.932
904 
1.485
139 
1.957
118 
1.594
963 
1.941
769 
1.548
122 
0.805
024 
1.019
379 
0.944
355 
1.130
659 
0.985
903 
1.067
808 
1.185
968 
1.579
085 
1.189
97 
0.700
423 
0.202
195 
0.098
048 
0.127
555 
0.238
305 
0.223
618 
0.187
23 
0.237
114 
0.343
763 
0.107
31 
1.016
733 
1.990
594 
1.410
644 
1.722
518 
1.192
584 
1.716
696 
1.453
118 
1.007
074 
0.778
295 
0.541
975 
0.604
826 
0.683
82 
0.624
409 
0.728
411 
0.560
897 
1.155
27 
0.781
284 
0.569
318 
0.164
348 
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0.201
124 
0.469
597 
0.722
722 
0.674
293 
0.774
723 
1.093
874 
0.895
662 
0.557
456 
0.011
247 
1.404
293 
2.023
939 
2.540
773 
1.431
682 
0.634
333 
1.396
75 
1.106
312 
1.040
153 
1.086
994 
1.197
612 
1.069
263 
1.238
233 
1.079
055 
1.111
076 
0.378
562 
1.005
822 
0.549
103 
0.158
512 
 
Rluc / A2C2 
 
23/06/2016 24/06/2016 Mean SD SEM 
0.460
901 
0.291
298 
0.265
252 
0.353
033 
0.304
955 
0.203
753 
0.374
965 
0.163
149 
2.868
071 
2.197
819 
1.812
803 
2.604
233 
2.220
279 
1.945
64 
2.242
708 
3.163
931 
0.389
553 
0.360
378 
0.354
07 
0.290
378 
0.280
659 
0.278
27 
0.265
03 
0.308
873 
1 
1.031
821 
0.297
861 
0.312
158 
0.308
567 
0.361
882 
0.190
176 
0.142
46 
0.184
653 
0.222
903 
0.421
193 
1.930
726 
1.916
742 
1.850
132 
1.885
776 
1.541
671 
1.505
389 
1.367
069 
1.402
33 
0.287
928 
0.287
193 
0.261
424 
0.210
966 
0.205
342 
0.254
397 
0.203
934 
0.299
05 
0.731
419 
0.697
109 
0.201
238 
0.092
047 
0.071
288 
0.055
156 
0.066
243 
0.093
461 
0.081
942 
0.071
901 
0.108
476 
1.359
508 
1.276
485 
1.103
049 
0.945
383 
1.203
834 
1.438
97 
1.084
251 
1.346
817 
0.285
639 
0.195
387 
0.249
371 
0.257
933 
0.233
29 
0.212
561 
0.210
237 
0.341
047 
0.516
011 
0.522
08 
0.150
712 
0.553
798 
0.672
314 
0.263
712 
0.315
549 
0.580
971 
0.433
803 
0.525
986 
0.737
088 
3.652
035 
3.881
905 
2.768
513 
3.607
015 
2.360
852 
2.514
036 
2.527
507 
3.045
807 
0.742
345 
0.694
714 
0.548
265 
0.571
962 
0.495
197 
0.523
335 
0.579
799 
0.620
086 
1.384
025 
1.248
357 
0.360
37 
                           
 
WT induction fold-change 
09/06/2016 23/06/2016 
 
Mean SD SEM 
3.132
962 
1.569
42 
1.025
036 
1.772
105 
0.527
124 
0.631
973 
1.153
558 
1.056
2 
1.071
377 
0.780
031 
0.664
535 
0.618
407 
0.598
451 
0.787
467 
0.611
425 
0.601
894 
0.889
962 
1.617
597 
1.052
864 
0.572
3 
1.062
603 
1.324
739 
0.522
728 
0.355
241 
0.897
435 
0.331
203 
0.095
61 
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9.618
313 
8.363
542 
9.039
749 
6.457
424 
5.992
529 
6.188
549 
3.853
357 
4.667
636 
3.085
895 
4.576
567 
3.381
826 
2.333
38 
3.493
226 
4.300
129 
3.599
756 
1.945
74 
2.393
017 
2.997
929 
2.100
22 
3.239
188 
3.024
23 
2.449
89 
1.962
15 
1.469
508 
2.897
041 
0.867
036 
0.250
292 
13.19
537 
21.52
151 
25.49
186 
10.14
204 
20.20
41 
10.82
96 
10.87
68 
6.487
218 
4.071
519 
2.429
32 
3.890
529 
2.900
171 
2.566
197 
3.316
796 
3.644
238 
2.958
48 
1.350
108 
2.423
503 
2.750
772 
3.281
358 
2.657
489 
2.223
958 
3.602
388 
3.609
801 
2.979
789 
0.713
006 
0.205
827 
19.57
034 
24.81
434 
23.99
884 
21.86
555 
18.60
72 
13.09
427 
16.25
115 
12.32
685 
17.12
837 
18.18
751 
15.11
671 
14.20
951 
15.27
074 
40.00
139 
23.99
854 
19.58
383 
10.50
839 
17.70
447 
16.45
122 
16.51
988 
11.55
707 
15.50
167 
11.42
172 
19.48
787 
17.66
556 
6.859
2 
1.980
08 
                           
 
A2C2 induction fold-change 
 
23/06/2016 24/06/2016 Mean SD SEM 
0.461
451 
0.216
942 
0.156
913 
0.211
72 
0.093
609 
0.306
946 
0.381
819 
0.154
938 
0.246
4 
0.286
047 
0.608
372 
0.383
406 
0.657
78 
0.458
195 
0.256
322 
0.223
083 
2.591
67 
2.507
609 
2.858
163 
2.368
414 
2.248
551 
2.487
909 
2.097
482 
1.736
259 
1 
1.050
958 
0.303
385 
6.709
575 
3.008
625 
5.749
91 
9.055
538 
7.120
845 
9.644
553 
4.630
703 
8.141
805 
8.955
073 
13.64
679 
10.52
78 
15.01
342 
11.31
422 
11.85
556 
10.02
643 
14.32
463 
6.752
256 
7.787
568 
13.37
897 
11.80
921 
11.73
01 
12.99
397 
12.83
948 
6.857
49 
9.744
772 
2.571
266 
0.742
261 
8.193
234 
6.918
623 
5.313
275 
6.053
394 
4.319
718 
2.459
317 
2.897
742 
7.601
012 
6.127
199 
8.314
748 
12.59
909 
5.915
092 
8.519
194 
10.48
961 
8.960
419 
5.121
314 
8.877
445 
18.86
57 
10.91
913 
8.782
245 
12.19
598 
12.61
405 
10.48
548 
5.724
613 
8.261
151 
3.455
151 
0.997
416 
8.850
503 
22.09
452 
51.08
529 
25.11
463 
24.23
377 
29.79
853 
12.81
989 
14.58
015 
19.87
298 
26.04
212 
24.41
655 
21.27
211 
21.44
052 
30.32
128 
30.81
725 
20.20
964 
1.480
635 
1.779
796 
2.045
88 
2.460
353 
2.091
314 
2.145
948 
2.033 
1.634
856 
16.61
009 
11.92
32 
3.441
931 
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5 COMPARATIVE PROTEOMICS 
ON DIFFERENTIALLY EXPRESSED 
AAG CELL LINES 
 INTRODUCTION 
The confirmation that AAG modulates the ER stress response was very 
surprising.  In order to better understand how this modulation occurs and the 
nature of the changes that caused such striking dampening of the ER stress 
response in AAG-deficient cells, we decided to utilise proteomic analyses in our cell 
models. 
Historically, analysing the protein content of highly complex samples (as 
cell lysates) and extracting whole-proteome information was a daunting task that 
involved multiple rounds of sample fractionation in an effort to reduce sample 
complexity prior to mass spectrometry.  In addition, earlier instrumentation had 
relatively low spectral resolution, that reduced mass accuracy.  During the last 15 
years or so, however, protein mass spectrometry has advanced considerably, in 
particular with the advent of the orbitrap mass analyser with considerably improved 
mass accuracy (ref 1999). However, unlike genomic approaches, it is still not 
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possible to quantitatively analyse an entire proteome in a single run (Cox & Mann, 
2007; Hu, Noble, & Wolf-Yadlin, 2016).  
Until very recently, the main approach for data acquisition during tandem mass 
spectrometry for discovery proteomics (also termed shotgun proteomics) has been 
Data-Dependent Acquisition, DDA (Gillet et al., 2012) Essentially during DDA the 
most abundant ions that reach the detector during the first round of mass 
spectrometry (MS1) are chosen for subsequent fragmentation in the second round 
of mass spectrometry (MS2).  This generates individual MS2 scans that can be 
queried against a database with the help of search algorithms in specialized 
software (Hu et al., 2016). However, therein lies its biggest flaw: in selecting 
abundant ions it biases the data towards more abundant peptides limiting the 
quantification of low abundance peptides and ultimately proteins (Mueller, 
Brusniak, Mani, & Aebersold, 2008). Numerous strategies have been devised to 
allow more accurate quantitation using DDA that involve the labelling of the 
samples prior to analysis. Two examples of such techniques are the isobaric 
labelling, that allows to chemically tag peptides post-metabolically (e.g. iTRAQ, that 
produce in the MS2 spectrum specific fragments that can be quantified) and 
isotopic labels that are metabolically incorporated in the sample and allow 
quantitation through the ratio of “heavy” (labelled) and “light” (normally occurring) 
peptides (Mueller et al., 2008). Of the isotopic labelling approaches, the SILAC 
(Stable Isotopic Labelling with Amino acids in Cell culture) is by far the most 
popular, however it can be cost-prohibitive and demand considerable optimization 
(Schilling et al., 2012). 
Thus, the search for precise and cost-effective methods led to the 
development of the label-free Data-Independent Acquisition (DIA), technique that 
operates by fragmenting and scanning (MS2) all the precursor ions detected within 
contiguous limited m/z windows (Gillet et al., 2012). This ‘sequential window 
acquisition of all theoretical spectra’ was initially termed SWATH in reference to the 
series of isolation windows acquired (Gillet et al., 2012). DIA results in highly 
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complex spectra, due to the number of co-eluting and concurrent fragmentation of 
several peptides in each of the isolation windows, and thus requires more 
sophisticated analytic tools than DDA data (Hu et al., 2016). SWATH combines the 
DIA strategy of sweeping and fragmenting the ions in a set of predefined isolation 
windows, the raw spectra are annotated with the help of a spectral library , where 
their relative intensities and chromatographic concurrence can be obtained (Gillet 
et al., 2012). In 2014, this method gave origin to the Wide Selected-Ion Monitoring, 
Data-Independent Acquisition (WiSIM-DIA), a method specially tailored for use 
with the Orbitrap Fusion Tribrid Mass Spectrometer (Thermo Fisher Scientific, 
Waltham, USA) a state of the art mass spectrometer recently acquired by the 
Southern Four Proteomic Consortium (Universities of Southampton, Surrey, Reading 
and Portsmouth) and housed at the Laboratory of Proteomics in the University of 
Southampton, led by Dr Paul Skipp. The method itself consists of three high 
resolution (240,000 FWHM) selected ion monitoring scans and wide isolation 
windows of 200 m/z (Kiyonami et al., 2014). The equipment allows simultaneous 
detection of high-resolution, accurate-mass (HRAM) MS/MS data in the Orbitrap 
detector and Collision Induced Dissociation (CID) in the linear ion trap detector 
(Kiyonami et al., 2014). 
Given access to this new high-resolution mass spectrometer, WiSIM-DIA 
was an appealing approach for analysing our samples, as relatively inexpensive and 
billed as not requiring extensive optimization.  As mentioned previously, the 
method requires the compilation of a spectral library for quantification of peptides. 
To assemble the libraries the same samples were acquired initially by DDA with the 
annotated spectra being utilised for spectral library generation with the help of the 
spectral analyser software Skyline 
Skyline is an open-source, multi-platform and freely available software for 
proteomic analysis (MacLean et al., 2010). It supports the creation of spectral 
libraries for analysis and quantitation of spectra, has a user-friendly interface and 
abundant online resources (video and written tutorials) that facilitates its 
Chapter 5: COMPARATIVE PROTEOMICS ON DIFFERENTIALLY EXPRESSED AAG CELL LINES 
 
185 
 
application by less experienced users. As Skyline is better equipped to be used as a 
hypothesis-driven software instead of a discovery tool, we decided to compile two 
limited libraries using the acquired DDA runs, one comprising a set of putative AAG 
interactors (66 proteins) and the set of proteins retrieved by search on Uniprot 
using UPR as query (212 proteins). These libraries were then used to assess the 
utility of the WiSIM-DIA method, alongside an in-depth qualitative analysis of the 
data obtained using the DDA method. Hence, we employed a series of approaches 
comprising gene-ontology and R language scripts to characterize and tease apart 
differences in our AAG-proficient and deficient models.  
 AIMS 
Evaluate the impact of AAG modulation on the proteomic landscape on 
basal conditions. 
 OBJECTIVES 
• Characterize qualitatively the proteomic composition of AAG-
proficient and AAG-deficient cells; 
• To examine the utility of a label-free wide selected-ion monitoring 
data-independent acquisition (WiSIM-DIA) for quantitative 
proteomic analysis of AAG-proficient and –deficient cells; 
 MATERIAL & METHODS 
5.4.1 CELL CULTURE 
As described in the previous chapters, the cell lines utilized to assess AAG 
function were ARPE-19, a human retinal pigmented epithelium cell line expressing 
AAG (WT), or AAG -/- developed using ARPE-19 as original host. 
The ARPE-19 cells were kindly donated by Dr Axel Nohturfft (St. George’s 
University, London, UK) and were cultivated using high glucose Dulbecco’s modified 
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Eagle’s medium (DMEM, Sigma Aldrich), supplemented with 10% of heat-
inactivated FBS and 2.5 mM of L-glutamine without the presence of antibiotics, in a 
humidified incubator under 5% CO2. Experiments were performed with freshly 
thawed stocks of cells, kept after defrosting for a maximum of 2 passages.  
After the isogenic selection, when they were cultivated in the presence of 1 
µg of puromycin, AAG-/- were grown under the same conditions as the host WT 
cells. 
5.4.2 PROTEIN ISOLATION FOR MASS SPECTROMETRY 
The WT and AAG-/- cells were grown in T75 flasks until about 80% 
confluence, whereupon they were harvested by trypsinization and centrifuged at 
300 x g for 5 minutes. When finished, the supernatant was discarded and the pellet 
was suspended again in 5 mL of 1x PBS centrifuged again at 4,200 x g. the 
supernatant was discarded and replaced by 200 µL of TABC lysis buffer [100mM 
triethylammoniumbicarbonate, 0.1% (v/v) SDS (both Sigma-Aldrich, St. Louis, USA)], 
and 1 x Halt Protease Inhibitor Cocktail (Thermo Fisher Scientific, Waltham, USA). 
The lysate then underwent 4 freeze/thaw cycles, was loaded on a 
Qiashredder column (Qiagen, Hilden, Germany) to shear nucleic acids thereby 
reducing sample viscosity and spun at 10,000 x g for 2 minutes under refrigeration. 
The protein content was quantified by micro BCA assay (Thermo Fisher Scientific, 
Waltham, USA), aliquoted and stored at -80ºC for further processing. 
5.4.3 IN-SOLUTION PROTEIN DIGESTION 
The digestion procedures were followed based on the Solution Protein 
Digest protocol published on the Cold Spring Harbour protocols (Link & LaBaer, 
2011) with some adaptations. Briefly, an aliquot of 25 µg of protein was defrosted 
on ice and diluted in HPLC-grade water to a concentration of 0.5 µg/µL. Then 0.5 
µg/mL of freshly diluted DTT was added to the protein, which was incubated for 5 
minutes at 65ºC to reduce disulphide bonds. Subsequently, alkylation was done by 
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adding 2.5 µg of iodoacetamide (IAA) and incubating for 30 minutes at 30ºC, in the 
dark. 
After reduction and alkylation, the samples were subjected to tryptic 
digestion, using 0.5 µg of mass spectrometry-grade trypsin (Trypsin Gold, Promega, 
Madison, USA) overnight at 37ºC. The following day, the reaction was stopped by 
adjusting the pH of the sample to 6 with the addition of 0.5 % (v/v) acetic acid 
(Sigma-Aldrich, St. Louis, USA). The resulting solution was lyophilized on a SpeedVac 
Concentrator (Thermo Fisher Scientific, Waltham, USA) until no solvent was 
observed in the tube and peptide samples were stored at -80ºC. 
Prior to mass spectrometry, the samples were desalted by filtration on C18 
columns with a protein capacity of 1000 µg (C18 SpinTips Sample Prep Kit, Protea 
Biosciences, Morgantown, USA), according to the manufacturer’s directions. At the 
end of the purification process, the samples were ready to be analysed by Nano LC-
MS/MS. 
5.4.4 NANO LC-MS/MS ANALYSIS 
The sample were analysed in the Laboratory of Proteomics, at the 
University of Southampton, under supervision of Dr Paul Skipp and with the help of 
Dr Erika Parkinson. 
The chromatographic separation was carried out in an EASY-nLC™ 1000 
Thermo Scientific™ EASY-Spray™ PepMap™ system equipped with an EASYspray ion 
source. (Thermo Fisher Scientific, Waltham, USA). Samples (1 μL) were injected onto 
an Acclaim PepMap C-18 RP trap column (3μm, 0.075mm x 50mm, Thermo Fisher 
Scientific) at 300 nL/min at 50°C, and eluted in a 140 min (60 min for blanks) 
gradient of 5–35% ACN in 0.1% FA, followed by a 5-min ramping to 90% ACN-0.1% 
FA and a 5 min hold at 90% ACN-0.1% FA. Hela digests were also run for quality 
control purposes. Wild-type ARPE-19, AAG -/-A2C2 and AAG -/- B6C were run in the 
same day, using biological triplicates. 
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The Orbitrap Fusion was operated in positive ion mode with the spray 
voltage set at 1950 V and source temperature at 275°C. For generation of the 
reference spectral library, the instrument was operated in “top speed” data-
dependent mode. Briefly, a full scan was acquired in the Orbitrap mass analyser at a 
resolving power of 120,000 (full width at half maximum: FWHM at m/z 200) over 
m/z 400–1800, followed by 3s of CID MS/MS acquired in the ion trap mass analyser 
using the “rapid” scan rate at 35% normalized collision energy. Quadrupole isolation 
of 2m/z and a precursor intensity threshold of 5,000 were utilized. Dynamic 
exclusion parameters were set at repeat count 1, an exclusion list size of 500, 60 s 
of exclusion duration with ±10 ppm exclusion mass width. The activation time was 
10 ms for CID analysis. All data were acquired with Xcalibur 3.0 operation software 
(Thermo Fisher Scientific). 
For the WiSIM-DIA mode, 3x SIM scans covering m/z 400–600, m/z 600–
800, and m/z 800–1000 (see Figure 40) at 240,000 resolving power were acquired in 
parallel with seventeen 12-amu wide sequential CID ion trap MS/MS scans. 
Quadrupole isolation was used for all isolation events. 
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Figure 40: Diagrammatic view of the proprietary WiSIM method used for DIA acquisition. 3x SIM scans covering m/z 400–600, m/z 600–800, and m/z 800–1000 at 
240,000 resolving power were acquired in parallel with seventeen 12-amu wide sequential CID ion trap MS/MS scans. Source: Thermo Scientific Webpage - 
https://www.thermofisher.com.
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5.4.5 QUANTITATIVE AND QUALITATIVE MS DATA ANALYSIS 
Samples were run in in a Orbitrap Fusion Tribrid mass spectrometer in DDA 
and DIA modes Firstly samples were run using a traditional shotgun proteomics DDA 
approach and the resulting spectra were analysed on Proteome Discoverer v 2.0 
(Thermo Fisher Scientific, Waltham, USA) using Sequest-HT (Eng, McCormack, & 
Yates, 1994) for peptide identification, allowing for a maximum of 2 missed 
cleavages and a fragment mass tolerance of 0.6 kDa. Percolator set for a 1% False 
Discovery Rate (FDR) was used for peptide identity validation. DDA. Annotated DDA 
spectra were used both for spectral library compilation in Skyline and qualitative 
proteomic analysis. 
DIA spectra were acquired to quantify proteins against the spectral library 
compiled with DDA spectra in Skyline. The general workflow for sample analysis can 
be seen on Figure 42. 
5.4.5.1 QUANTITATIVE PROTEOMICS 
DDA annotated spectra obtained with Proteome Discoverer 2.0 (see 
procedure above) were used to compile a spectral library on Skyline v 3.6 for label-
free quantitation based on spectral matching. A library was built with a cut-off score 
of 0.99, to allow only peptides identified with high confidence by Percolator. Protein 
assignment was done with a custom build FASTA file containing the sequences of 
known AAG interactors. To build such file, firstly a search on the Unified Human 
Interactome website was done (Kalathur et al., 2014)The sequences of the resulting 
physical interactors (66 proteins) were the retrieved from the collection of Uniprot 
databases (UniProt, 2017). For stringency purposes, only proteins with at least 2 
unique peptides were included and the ion match tolerance was set at 0.6 m/z. The 
Swiss-Prot human proteome, downloaded on November 2016 was used for protein 
identification as background proteome to help with transition identification. After 
all, DDA spectra were parsed and all filters applied, a total of 51 proteins of the 
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original 66 were detected on the library. After the compilation, the WiSIM-DIA (3 
replicates of WT and AAG-/-cell lines) data was imported and had their spectra 
aligned to those of the library. A similar approach was followed to generate a 
second and broader library comprising the proteins involved in the human UPR. For 
such, a query with “UPR” was conducted on the Uniprot website (UniProt, 2017), 
also in November 2016,  retrieving a total of 212 proteins whose sequences were 
used in the library. After the spectra were loaded, a total of 161 proteins were 
identified in the DDA run. 
For relative quantification, a report was generated with total MS1 area 
under (AUC). As exclusion parameters, only transitions present in all replicates, 
spectra with idot ≥ 0.6, transitions present in all three replicates and whose 
variation coefficient did not exceed 30% were analysed. 
5.4.5.2 QUALITATIVE PROTEOMICS 
As previously mentioned, the DDA spectra were analysed on Proteome 
Discoverer v 2.0 (Thermo Fisher Scientific, Waltham, USA). The Uniport human 
proteome was used as protein database for peptide identification. Sequest-HT was 
employed (Eng et al., 1994) for peptide identification, allowing for a maximum of 2 
missed cleavages, with minimum peptide length of 6 and maximum of 144 residues, 
precursor mass tolerance of 10 ppm and fragment mass tolerance of 0.6 kDa. 
Percolator was set for cut-off of 1% False Discovery Rate (FDR). 
To discriminate between shared and unique protein groups, protein group 
*.CSV files were exported from Proteome Discoverer protein group IDs for each cell 
line were extracted (the three replicates were combined and any redundancy was 
removed). The ID lists were then input on the InteractiVenn website (Heberle, 
Meirelles, da Silva, Telles, & Minghim, 2015) to generate Venn diagram of 
overlapping and unique protein group content. 
For gene ontology analysis and overrepresentation analysis, protein ID lists 
for each of the cell lines were exported from Proteome Discoverer as *.CSV files 
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and, as before, replicates were combined and had redundancies removed. ID lists 
(consisting of 5072, 6173 and 6239 entries for ARPE-19 wild-type AAG-/- A2C2 and 
AAG-/-B6C3, respectively) were extracted from those files and input on the 
PANTHER (Protein ANalysis THrough Evolutionary Relationships) Classification 
System website (Mi et al., 2016) for functional GO-slim (gene ontology) 
classification analysis. The proportion of terms within the domains of Molecular 
Function (GO 0003674) and Biological Process (GO 0008150) were first analysed and 
the as well as second level of the predominant GO categories (Figure 41).  
To investigate any interesting categorical trends within our samples an 
overrepresentation analysis was run. The overrepresentation analysis consists of 
the statistical comparison between ID lists (queries and reference) do determine 
over or under-representation of ontology categories, using binomial distribution 
test with Bonferroni correction multiple testing. For the overrepresentation tests 
the IDs were also run on PANTHER, but using the whole manually annotated human 
proteome (downloaded on March 2017) as reference list. Heatmaps with fold-
changes superior to 1.5 were then created on GraphPad Prism v. 7.0 (GraphPad 
Software, 2017). 
To identify presence/absence of proteins we compared the proteomics 
data obtained for ARPE19 (wild-type) versus AAG-/- clones A2C2 and B6C3 using 
data manipulation and calculations performed with R v. 3.4 scripts (Core Team, 
2016), performed by Dr Axel Nohturfft. Firstly, only proteins identified by at least 
two peptides per protein, and where protein presence was confirmed in at least 
two replicates were considered for further analysis. A second high-stringency list 
was also generated, composed of only proteins identified by at least two peptides 
per protein, but where protein presence was confirmed in all three replicates in one 
genotype compared to no positive identification in the other genotype. 
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Figure 41: Hierarchical relationship of analysed GO terms. A) Hierarchy of Biological Process Domain (green) and the GO-slim analysed terms and B) Molecular function domain 
and the analysed GO-slim terms 
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Figure 42: Workflow for qualitative and quantitative proteomic analysis. Quantitative data analysis 
procedures were done by acquiring DDA spectral library data and WiSIM-DIA samples for querying. 
DDA data was also used for qualitative analysis using PANTHER, InteractiVenn and R scripts. 
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  RESULTS 
Proteomic analysis was performed using two different approaches. The 
quantitative approach was done by first acquiring DDA spectra and retrieving 
spectral annotation with the help of Proteome Discoverer 2.0. Annotated spectra 
were then loaded on Skyline 3.6 for spectral library compilation, against which the 
subsequent WiSIM-DIA runs would be quantified (Figure 42). 
For the qualitative analysis, information about protein groups and protein 
lists were exported from the information retrieved by Proteome Discoverer 2.0 
from DDA runs and analysed on InteractiVenn, PANTHER and with the help of R 
language scripts (Figure 42). 
5.5.1 QUANTITATIVE PROTEOMICS 
Our next aim was to examine whether the absence of AAG would modulate 
the levels of putative AAG interactors and/or UPR proteins. As mentioned before, 
our approach to proteomic quantification was to compile a Skyline spectral library 
from annotated DDA data retrieved from Proteome Discoverer analysis against 
which the WiSIM-DIA data would be quantified.  
The first library, comprised all the putative AAG interactors retrieved from 
the Unified Human Interactome website (Kalathur et al., 2014). After removing 
redundant IDs, their corresponding sequences were downloaded from the UniProt 
database and, together with the annotated DDA spectra obtained from Proteome 
Discoverer 2.0, were used to successfully create a spectral library on Skyline 
.(MacLean et al., 2010). The UPR library was created on a similar manner but 
instead using the set of proteins (and respective sequences) retrieved after 
querying for “UPR” directly on the UniProt knowledgebase (UniProt, 2017), as seen 
on Figure 44. 
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Both libraries were created successfully, the “AAG interactors” library 
consisting of 51 proteins and 2,393 transitions identified in the DDA runs and the 
“UPR” library consisting of 161 proteins and 15,825 transitions (Figure 43A). 
However, despite being able to compile the libraries, it was not possible to 
properly quantify the WiSIM-DIA runs due to the poor quality of the chromatograms 
(Figure 43 B). The poor definition of the spectra proved to be a big challenge to the 
peak-picking algorithm on Skyline. When relying solely on the automated algorithm 
the quantification was deeply compromised, sometimes showing coefficients of 
variation between replicates higher than 300% (data not shown). Upon visual 
inspection, it was possible to observe that at least for some of those cases the 
algorithm failed to set adequate boundaries for quantification on the test samples. 
A possible workaround such problem would be manually adjusting some of the 
peaks, but in libraries with such elevated number of transitions, the task would 
prove to be too time-intensive and, in cases such as the chromatogram of Figure 43 
B, futile. 
To achieve our original objective of quantifying proteomic changes on 
differentially modulated AAG cell lines, either would require extensive time to 
manually curate most peptides using the current data, or reacquisition of DDA and 
WiSIM-DIA data with optimized methods.  
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Figure 43 Comparison between chromatography profiles of DDA and WiSIM-DIA acquisitions. A) 
Representative chromatogram obtained from a DDA run and B) representative chromatogram 
obtained from a DIA run 
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Figure 44: Workflow for DDA spectral library compilation on Skyline 3.6 and WiSIM-DIA acquisition 
for protein quantification. 
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5.5.2 QUALITATIVE PROTEOMICS 
Given the differences found in the response of AAG-proficient and deficient 
cells when eliciting ER stress, we decided to investigate if AAG knockout had 
impacted the cellular proteomic landscape. Hence, cells were harvested in their 
basal condition (i.e. no drug treatment) and had their proteomic content analysed 
by LC-MS/MS. The resulting spectra were then analysed on Proteome Discoverer 
2.0, as stated before, using a workflow that included SequestHT for protein 
identification and Percolator for validation. 
Reflecting the high resolution of the Fusion mass spectrometer, utilising 
relatively stringent criteria (≥2 peptides, FDR< 0.1%) a remarkable average of ~5,373 
protein groups were identified across all three cell lines. As can be seen by Venn 
analysis in Figure 45, 5480 protein groups were identified in the WT ARPE-19 cells, 
511 of which were only found in those cells. In the AAG -/- A2C2 cells, 5377 protein 
groups were identified and 425 of those were unique to these cells. Finally, 5264 IDs 
were identified in the AAG -/- B6C3 cell line with 560 unique hits.  A significant 
portion (4209) of the proteins was shared by all three proteomes, while 239 were 
shared between both the AAG -/- clones. Proteins identified solely in WT and solely 
in the 2 AAG -/- lines represent candidates of functional interest as potentially either 
disrupted or induced by the loss of AAG.  
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Figure 45: Venn diagram of identified proteins across the three analysed cell lines. Analysis was 
carried out using three replicates of each cell line and filtered for high confidence identifications (2 
or more unique peptides and 1% FDR on Percolator). 
 
5.5.2.1 GENE ONTOLOGY ANALYSIS 
The total protein sets were then analysed by gene ontology, with the help 
of the PANTHER website (version 11.1), using the Molecular Function and Biological 
Process domains.  
Under the Molecular Function GO-slim domain (GO:0003674), all three cell 
lines are remarkably similar. The preponderant GO term is “catalytic activity” 
(GO:0003824) in both wild-type and AAG -/- cells. On ARPE-19 wild-type, 35.4% of 
the proteins mapped corresponded to this category, where on AAG -/-A2C2 it was 
34.2% and 33.2% on AAG -/- B6C3 (left charts on ). The second highest proportion 
was from GO-slim term “binding” (GO:0005488), 30.3% on ARPE-19 wild-type, 
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29.4% in AAG -/-A2C2 and 29.7% on AAG -/- B6C3. The least represented category 
was “channel regulator activity” with 0.1% for all cell lines.  
A similar outcome was observed under the Biological Process 
(GO:0008150) GO-slim domain, in that the distribution of ontologies was largely 
similar (), charts on the right). Most of the proteins were classified under “cellular 
process” (GO:0009987), whose percentages were 46.8% for ARPE-19 wild-type, 
45.7% AAG -/-A2C2 and 45.5% for AAG -/- B6C3.  This term was followed immediately 
by “metabolic process” with 43.7% on ARPE-19 wild-type, 42.4% on AAG -/-A2C2 and 
42.6% AAG -/- B6C3. The least represented GO-terms were “growth” (GO:0040007) 
and “cell-killing” (GO:0001906) with only two hits across all cell lines, representing 
less than 0.05% of the evaluated data sets (data not shown).  
The majority of GO terms were then submitted to a further analysis, to 
identify their individual composition of 2nd level hierarchical GO terms (Figure 47, 
inset). Under “catalytic activity” the largest contribution in all cell lines was done by 
the “hydrolase activity” (GO:0016787) accounting for 38.3% in the wild-type cells, 
38.2% in AAG -/-A2C2 and 38.9% AAG -/- B6C3. The smallest percentage was given by 
the “deaminase activity” (GO:0019239) with 0.5% in the wild-type cells, 0.6% in the 
AAG -/-A2C2 and again 0.5% for the AAG -/- B6C3 clone. 
Again, under the “cellular process” term, the distribution of ontologies was 
quite similar amongst the cell lines. “Cell communication” (GO:0007154) was the 
term with the highest contribution: 24.5% in ARPE-19 wild type, 25.3% in AAG -/-
A2C2 and 24.3% for AAG -/- B6C3. The least represented category was “cell 
recognition” (GO:0008037), totalizing 0.3% in wild-type cells, 0.2% and 0.3% in AAG 
-/-A2C2 and AAG -/- B6C3, respectively.  
Based on these observations it appeared that AAG modulation does not 
seem to affect drastically the qualitative composition, at least on basal cellular 
conditions. Therefore, given the lack of difference among the distinct genotypes, we 
investigated how similar our ontology distribution would be against a reference 
human proteome using the statistical overrepresentation test. 
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Figure 46: Gene ontology analysis of the proteome of AAG-proficient and deficient cells. On the 
left are the contributions of each term in the category Molecular Function (GO:0003674) and on 
the right, are the contributions of terms in the Biological Process (GO:0008150) category 
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Figure 47: Second-level hierarchical representation of the majoritarian GO terms of the Molecular 
Function and Biological Process domains. Inset: representation of the hierarchical relation between 
the represented GO terms. Representation of the 2nd level hierarchical categories of the GO term 
“Catalytic Activity”- GO:0003824 (left) and “Cellular Process” GO:0009987 (right) and their 
contribution to the proteomic composition of the investigated cell lines.  
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5.5.2.2 OVERREPRESENTATION ANALYSIS 
To evaluate how our proteomic sample would compare against a reference 
human sample, the protein lists generated by the search on Proteome Discoverer 
2.0, were used to conduct a statistical overrepresentation analysis using PANTHER 
11.1 (Mi et al., 2016). As the name suggests, the test is aimed at identifying possible 
clusters of IDs (genes, transcripts or proteins) that might be overrepresented in the 
sample when compared with a given list, either supplied by the user or annotated 
by the GO ontology community (Ashburner et al., 2000). The ontology domain 
utilized on the first analysis was Biological Process (GO:0008150) and the reference 
list used for comparison was the Swiss-Prot human proteome, last modified in 19 of 
January 2017 and comprised of 20,185 entries, obtained from UniProt 
knowledgebase (UniProt, 2017). 
The results of the analysis can be visualized on Figure 48. The first two 
highest-ranking overrepresentations on the wild-type cells are from ontologies 
related to energetic metabolism: glycolysis (GO:0006096), with a 3.62-fold 
overrepresentation, followed by tricarboxylic acid cycle (GO:0006099) with 3.34-
fold overrepresentation. The third rank is lysosomal transport (GO:0007041) with 
3.19-fold change. The highest rankings on AAG -/-A2C2, however, are somewhat 
different: the first category is RNA splicing, via transesterification reactions 
(GO:0000375) with 2.89-fold change, followed by regulation of carbohydrate 
metabolic process (GO:0006109), with 2.83-fold and tricarboxylic acid cycle 
(GO:0006099), with 2.74-fold. The highest category on AAG -/- B6C3 is, like the wild-
type cells, related with energy generation: tricarboxylic acid cycle, with 2.84-fold, 
followed by RNA splicing, via transesterification reactions with 2.68-fold and 
glycolysis 2.65-fold. 
Next, using the same set of target proteomes and reference list, we ran an 
analysis of overrepresentation using the PANTHER pathway annotation to highlight 
potential differences on cellular pathways (Figure 49). Unsurprisingly, the most 
overrepresented pathway in the ARPE-19 wild-type cells was glycolysis (P00024) 
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with a 3.54-fold, followed by de novo pyrimidine ribonucleotides biosynthesis 
(P02740) with 3.51-fold and ubiquitin proteasome pathway (P00060) 3.47-fold 
overrepresentation. However, the most represented pathway in AAG -/-A2C2 is DNA 
replication (P00017) with 3.18-fold, followed by Glycolysis, with 3.06 and by 
Ubiquitin proteasome pathway, with 2.95-fold. Similarly, AAG -/- B6C3 the two most 
represented pathways are DNA replication (3.05-fold) and Glycolysis (3.03-fold), but 
the third highest is Cytoskeletal regulation by Rho GTPase (P00016), with 2.89-fold. 
Although most of them share Glycolysis as an overrepresented term there 
is a difference of almost 1-fold lower in the level of overrepresentation between 
wild-type and the knockout cells (Figure 49). In contrast, there is an interesting 
difference regarding the level of overrepresentation on the oxidative 
phosphorylation (GO:0006119). The levels of overrepresentation are lower in the 
wild-type cells (1.69-fold) than in AAG -/-A2C2 (2.31-fold) and AAG -/- B6C3 (2.16-
fold). 
Regarding the pathway analysis, the largest difference of 
overrepresentation between wild type and the clone AAG -/-A2C2 is the Insulin/IGF 
pathway-mitogen activated protein kinase kinase/MAP kinase cascade (P00032) 
with 0.87-fold lower induction on the knockout. On the other hand, when 
comparing the wild-type and the AAG -/- B6C3 clone, the largest difference is 
between the levels of overrepresentation of the de novo pyrimidine ribonucleotides 
biosynthesis (P02740), where the wild-type is 0.89-fold higher. 
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Figure 48: Gene ontology proteomic overrepresentation analysis of investigated the cell lines. The 
protein lists of each cell line were compared with the human annotated reference proteome 
obtained from the UniProt database. For clarity purposes, only fold-enrichments ≥1.5 were included 
in the graph. 
Chapter 5: COMPARATIVE PROTEOMICS ON DIFFERENTIALLY EXPRESSED AAG CELL LINES 
 
207 
 
Figure 49: Pathway proteomic overrepresentation analysis of investigated the cell lines. The 
protein lists of each cell line were compared with the human annotated reference proteome 
obtained from the UniProt database, using the PANTHER pathways annotation list. For clarity 
purposes, only fold-enrichments ≥1.5 were included in the graph. 
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5.5.2.3 PRESENCE/ABSENCE ANALYSIS 
We compared the proteomics data obtained for ARPE19 (wild-type) versus 
clones AAG -/- A2C2 and AAG -/- B6C3 in order to identify present or absent proteins 
on our proteomics dataset between wild-type and AAG -/- ARPE-19 cells.  
Only proteins identified by at least two peptides per protein, and where 
protein presence was confirmed in at least two replicates were considered for 
further analysis. Following these parameters, we identified that: 
• 297 proteins were present in the wild type but not in either mutant 
(Table S4); 
• 99 proteins were expressed in both AAG knockouts and not in the 
wild type; 
• 63 proteins were expressed in either mutant and not in the wild 
type. 
To increase the likelihood of finding biologically relevant differences, we 
performed the same analysis but with higher stringency settings, comparing wild 
type and knockout samples by considering, once again, only proteins identified by 
at least two peptides per protein, but this time where protein expression was 
confirmed in all three replicates in one genotype compared to no positive 
identification in the other genotype.  
Following these parameters, we identified that: 
• 13 proteins are present in the wild type but not in either mutant 
(Table 4.1); 
• 0 mutant-specific proteins were identified. 
The 13 proteins identified in all three replicates are presented in Table 6. 
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Table 6: High stringency list of proteins present in ARPE-19 and absent in the AAG -/- clones 
UniProtKB IDs Gene name/symbol PANTHER Family/Subfamily PANTHER protein class 
Q96L14 CEP170P1 Cep170-like protein; CEP170P1 
CENTROSOMAL PROTEIN OF 170 KDA PROTEIN 
B-RELATED (PTHR15715:SF34)  
Q9Y6G5 COMMD10 
COMM domain-containing protein 
10; COMMD10 
COMM DOMAIN-CONTAINING PROTEIN 10 
(PTHR12333:SF1)  
P46734 MAP2K3 
Dual specificity mitogen-activated 
protein kinase kinase 3; MAP2K3 
DUAL SPECIFICITY MITOGEN-ACTIVATED 
PROTEIN KINASE KINASE 3 (PTHR24361:SF432)  
Q9P0L2 MARK1 
Serine/threonine-protein kinase 
MARK1; MARK1 
SERINE/THREONINE-PROTEIN KINASE MARK1 
(PTHR24346:SF36) 
non-receptor serine/threonine 
protein kinase (PC00167) 
P27448 MARK3 
MAP/microtubule affinity-regulating 
kinase 3; MARK3  
MAP/MICROTUBULE AFFINITY-REGULATING 
KINASE 3 (PTHR24346:SF30) 
non-receptor serine/threonine 
protein kinase (PC00167) 
Q96L34 MARK4 
MAP/microtubule affinity-regulating 
kinase 4; MARK4 
MAP/MICROTUBULE AFFINITY-REGULATING 
KINASE 4 (PTHR24346:SF32) 
non-receptor serine/threonine 
protein kinase (PC00167) 
Q99707 MTR Methionine synthase; MTR METHIONINE SYNTHASE (PTHR21091:SF149) 
Decarboxylase (PC00089); 
methyltransferase (PC00155); 
reductase (PC00198) 
Q6XQN6 NAPRT1 
Nicotinate 
phosphoribosyltransferase; NAPRT 
NICOTINATE PHOSPHORIBOSYLTRANSFERASE 
(PTHR11098:SF21) 
Glycosyltransferase (PC00111) 
O43164 PJA2 
E3 ubiquitin-protein ligase Praja-2; 
PJA2 
E3 UBIQUITIN-PROTEIN LIGASE PRAJA-2 
(PTHR15710:SF6) 
ubiquitin-protein ligase (PC00234) 
Q12972 PPP1R8 
Nuclear inhibitor of protein 
phosphatase 1; PPP1R8 
NUCLEAR INHIBITOR OF PROTEIN 
PHOSPHATASE 1 (PTHR23308:SF39)  
Q9H974 QTRTD1 
Queuine tRNA-ribosyltransferase 
subunit QTRTD1 
QUEUINE TRNA-RIBOSYLTRANSFERASE 
SUBUNIT QTRTD1 (PTHR21148:SF38) 
G-protein modulator (PC00022); 
chaperone (PC00072) 
UniProtKB IDs Gene name/symbol PANTHER Family/Subfamily PANTHER protein class 
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P57729 RAB38 Ras-related protein Rab-38; RAB38 
RAS-RELATED PROTEIN RAB-38 
(PTHR24073:SF636)  
P51151 RAB9A Ras-related protein Rab-9A; RAB9A;  
RAS-RELATED PROTEIN RAB-9A 
(PTHR24073:SF717)  
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 DISCUSSION 
Mass spectrometry is a very powerful tool that can allow us to have a 
glimpse of the vast complexity of mammalian cell. With the development of more 
sensitive and accurate instrumentation and implementation of user-friendlier 
human interface (e.g. software), its application in the field of life sciences has 
increased. 
One of the most promising of emerging quantitative methods for MS 
acquisition is DIA (Bantscheff, Lemeer, Savitski, & Kuster, 2012). One of the 
approaches for DIA data acquisition, is the wide selected-ion monitoring (WiSIM) 
workflow, that employs a series of contiguous scans of the whole mass spectrum, 
allowing the detection of a large quantity of peptides in highly complex samples 
(Kiyonami et al., 2014). The use of such workflow in conjunction with Skyline, allows 
the quantification of protein abundance through the comparison with DDA 
annotated spectral library created from the same set of analysed samples 
(Egertson, MacLean, Johnson, Xuan, & MacCoss, 2015). 
Such approach, however, requires not only the compilation of a robust 
DDA spectral library to allow precise quantification in the absence of prior 
knowledge of the peptide elution times, but also a good chromatographic profile 
with few interfering peaks. Once these requirements are met, label-free 
quantification is a relatively straightforward task. In less than optimal conditions, 
peak interference may prove too great to allow automatic peak detection, requiring 
manual adjustment that is time-consuming relatively larger libraries (in Skyline’s 
parameters) such as the ones compiled for this study and can lead to biased 
quantification. Perhaps for future experiments, would be beneficial to employ 
metabolic labels as SILAC, that count with extensive user support and publications, 
as opposed to WiSIM-DIA, a very recent technology developed for used only in 
conjunction with the Orbitrap Fusion Tribrid equipment (Kiyonami et al., 2014). 
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Notwithstanding, we were able to acquire DDA data from all samples with 
an acceptable degree of reproducibility and complexity and therefore utilized the 
data for a series of qualitative characterization of the cell lines. 
The first of such analysis was the Gene Ontology search within the 
Molecular Function domain. Overall, the GO profile composition of all cell lines was 
strikingly similar, which is somewhat expected, given both the AAG -/- clones 
descend from the same wild-type host, ARPE-19. The lack of pronounced changes 
suggest that is unlikely that the technique used for the knockout (CRISPR/Cas9) had 
off-target effects. 
The largest proportion of proteins was classified under the GO term 
catalytic activity, that is a very broad definition and encompasses all the biologically 
catalysed reactions, whether by enzymes or ribozymes (Smith, 2000). It accounted 
on average 34% of the distribution and it could be further subdivided in to 9 
categories of which hydrolase activity amasses the highest proportion on all cells 
(roughly 38%), comprising all enzymes that catalyse the hydrolysis of various bonds. 
It is again a quite vast category whose quick search on the GO ontology website 
AmiGO 2.0 (Gene Ontology Consortium, 2015), tool established by the Gene 
Ontology Consortium, returns a total of 275,426 entries. AAG, for example, can be 
included in this category, as it catalyses the hydrolysis of the N-glycosidic bond 
between the damaged base and the DNA backbone (UniProt, 2017). 
Cellular Process, under the Biological Process domain, had an average of 
46% on all cells. Such high proportion is understandable, as the category includes 
“Any process that is carried out at the cellular level, but not necessarily restricted to 
a single cell” (Gene Ontology Consortium, 2015), entry with almost two million 
annotations, 105,825 of those referring exclusively to Homo sapiens. According to 
our data, within this category half of all the GO terms can be attributed to “cell 
communication” that refers no only to the signalling between cells, but also 
attachment and any form of interaction with its environment. 
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The comparison between the Biological Process ontologies frequencies and 
the human reference proteome reveals several overrepresented terms on our 
dataset. Glycolysis (also named as “glycolytic process” on the AmiGO database) is 
indicated as the highest overrepresented in the wild-type cells and figures on the 
first three categories in one of the knockouts (AAG -/- B6C3) and it is also amongst 
the three first overrepresented cellular pathways in the PANTHER pathway 
overrepresentation test. The metabolic shift toward the aerobic glycolysis, known 
as Warburg effect, is a well-known phenomenon that affects most cells in 
continuous culture along with primary tumour cells (Gatenby & Gillies, 2004; Young, 
2013). Apart from the possibility of a mitochondrial dysfunction that would lead to 
the reliance on the glycolysis as main energy source; it is hypothesized that, in 
favouring such wasteful energy generation method (2 moles of ATP/mole of glucose 
against up to 36 moles of ATP/mole of glucose in the oxidative phosphorylation) the 
cell repurposes the glycolytic by-products as carbon source for the synthesis of 
macromolecules required for cell proliferation (Lunt & Vander Heiden, 2011). The 
mitochondria may also be repurposed in highly proliferating cells, where 
intermediates of the TCA cycle are exported from the mitochondria for use in lipid 
or nucleotide biosynthesis, for example, explaining at least partially on the reliance 
on aerobic glycolysis as energy source. (DeBerardinis et al., 2007) 
The Warburg effect likely also explains the appearance of the tricarboxylic 
acid cycle as a prominent term on our analysis. Our cell lines were always harvested 
for analysis when at approximately 80% of confluence, while they would still be 
actively growing and probably relying on aerobic glycolysis for the reasons stated 
above. 
The finding that, apart from Glycolysis, the highest overrepresentation 
terms in all three cell lines were de novo pyrimidine ribonucleotides biosynthesis (in 
ARPE-19 wild-type) and DNA replication (AAG-/- A2C2 and AAG-/- B6C3) also does not 
come as surprise. Immortalized cell lines have not only a high metabolic demand 
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but are also in constant division, thus requiring robust pathways to deal with DNA 
replication and RNA synthesis. 
It is interesting to note that the term Lysosomal Transport is among the 
three highest overrepresented only on the wild-type cells (it figures as the 9th on 
AAG-/- A2C2 and 6th on AAG-/- B6C3). This accommodates the diverse functions of 
lysosomal activities, such as any trafficking between the organelle and the Golgi 
apparatus, ER and mitochondria (Gene Ontology Consortium, 2015). These 
categories, in turn, encompass processes that are very relevant to protein 
homeostasis, as the lysosomal protein degradation and macroautophagy (Sasaki & 
Yoshida, 2015). The lysosomal degradation pathway is particularly important in 
cases where the proteins are not good ERAD substrates, as the case in 
glycosylphosphatidylinositol (GPI)-anchored proteins (e.g. mammalian prion 
protein, PrP), and instead are targeted to the Golgi and subsequently degraded by 
the lysosome (Satpute-Krishnan et al., 2014). Disruptions to this pathway can lead 
to accumulation of PrP and its aggregation, a hallmark of some neurodegenerative 
diseases (Aguzzi & Calella, 2009). Macroautophagy also seem to play a role in the 
alleviation of ER stress and it is particularly responsive to the PERK pathway, via 
ATF4 (Rashid, Yadav, Kim, & Chae, 2015). 
The Ubiquitin proteasome pathway, also one of the three most 
represented pathway terms in almost all cell lines (3rd on the wild-type cells and 
AAG-/- A2C2 and 4th on AAG-/- B6C3) is an integral part of the ERAD, degrading 
defective or overabundant proteins (Christianson & Ye, 2014).  
Taken together the gene ontology analyses do not indicate very 
remarkable changes when compared to the reference human proteome. Most of 
the changes observed (especially the ones pointed by the overrepresentation 
analysis) could well be explained by the fact that although our cell model is of non 
tumoural origin its behaviour and metabolic requirements (e.g. reliance on aerobic 
glycolysis, continuous growth) are still more closely related to pathological tissue 
than of a healthy individual. Within this methodology is impossible to discern 
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between changes originating from the intrinsic inadequacies of our biological model 
and changes caused by the absence of AAG expression.  
We also used an alternative approach to identify possible differentially 
expressed proteins across the AAG genotypes. By performing a high stringency 
search using R scripts we compiled a list of 13 proteins present in all three replicates 
of the wild-type ARPE-19, with no hits in any of the replicates in both AAG-/- clones. 
The first ID on the list is CEP170P1 or Cep170-like protein, a product of the 
centrosomal protein 170 pseudogene 1 (O’Leary et al., 2016). The product of the 
functional gene is a component of the centrosome that interacts with polo-like-
kinase 1 and works in the maintenance of microtubule organization (O’Leary et al., 
2016). 
The second ID on the list is the copper metabolism MURR1 domain-
containing protein 1 (COMMD10). The precise function of this protein is still not 
very well-defined, but it seems to regulate hepatic copper excretion in dogs, 
possibly participating in the ATP7B-mediated transport of copper from the trans-
Golgi to the bile canaliculus, as its deletion seems to cause an hepatic copper 
overload phenotype in these organisms (O’Leary et al., 2016; Tao, Liu, Klomp, 
Wijmenga, & Gitlin, 2003). It is also suggested to be involved in the regulation of 
NF-κB-mediated transcription by preventing its interaction with the chromatin in 
the neighbourhood of a NF-κB-responsive promoter (Burstein et al., 2005). More 
interestingly it also prevents the formation of a complex between CAND1 (Cullin-
associated Nedd8-dissociated) and Cullin RING ligases (Mao et al., 2011). The 
formation of this complex abrogates the ubiquitin ligase function of the Cullin-RING 
ligases (Mao et al., 2011). The Cullin RING ligases regulate (by ubiquitination) 
processes that range from glucose sensing and DNA replication to limb patterning 
and circadian rhythms (Petroski & Deshaies, 2005) and are deeply intertwined with 
the UPR, as one of the major protein degradation pathways (Fan et al., 2016; 
Sarikas, Hartmann, & Pan, 2011).  
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The next ID on the list is PJA2, the gene that codes for the Praja Ring Finger 
Ubiquitin Ligase 2, also has a connection with cellular proteolysis. It is a RING E3 
ligase, class that serves as scaffolds to align the substrate and the E2 ligases. It is 
extremely important to PKA (protein kinase A) mediated long-term memory 
formation (Lignitto et al., 2011). It is also required for activation of calcium entry 
and insulin secretion, playing an important role in the regulation of β-cell function 
(Sakamaki et al., 2014). Praja2 also is overexpressed in high-grade glioblastomas 
(GBM), and ubiquitinates MOB1, a protein that controls its growth. 
PJA2 is followed by the Mitogen-Activated Protein Kinase Kinase 3 
(MAP2K3, MEK3 or MKK3), a kinase belonging to the MAP kinase family, activated 
by mitogenic and environmental stress (O’Leary et al., 2016). It activates the 
p38/MAPK which plays a role in immune response as well as regulation of cell 
survival and differentiation (Cuadrado & Nebreda, 2010). MAP2K3 is also essential 
to tumour necrosis factor induced increase in cytokine expression (Wysk, Yang, Lu, 
Flavell, & Davis, 1999) and its loss in diabetic mice models seems to protect against 
diabetic renal injury (Tesch & Lim, 2011). It also recognized as a pro-senescence 
factor in mammary epithelial cell lines (Jia et al., 2010) and inhibits tumour growth 
by upregulating cyclin-dependent kinase (CDK) inhibitors p21 and p27 (MacNeil et 
al., 2014). 
MARK1, 3 and 4, from map/microtubule affinity-regulating kinase, are 
members of a highly conserved group of kinases (Bright, Thornton, & Carling, 2009) 
of great importance for the establishment of cell polarity, migration, neuronal 
differentiation (Matenia & Mandelkow, 2009). From studies with the Drosophila 
MARK ortholog Par-1, the MARK-mediated phosphorylation of tau has been linked 
to the formation of neurofibrillary tangles observed in Alzheimer’s disease (Wu et 
al., 2011). They are also involved in the migration and invasion of neoplastic cells 
(McDonald, 2014) and have varied isoform-specific functions (Bright et al., 2009). 
Methionine Synthase (MTR, also known as 5-Methyltetrahydrofolate-
Homocysteine Methyltransferase and cobalamin-dependent methionine synthase)  
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catalyses the last step of the methionine synthesis transferring a methyl group from 
methyl-cobalamin (a form of vitamin B12) to homocysteine, yielding enzyme-bound 
cob(I)alamin and methionine (UniProt, 2017). Methionine is not only important in 
the protein synthesis, but is the precursor of S-adeno-sylmethionine (SAM), a donor 
for methylation of many substrates (Guéant et al., 2013). Accordingly, it was found 
that in a rat model of B12 deficiency there is a global hypomethylation of DNA 
(Brunaud et al., 2003). The MTR KO mice are lethal, with embryo development 
blocked at the stage of 20 somites (Guéant et al., 2013). 
Nicotinate phosphoribosyltransferase transcribed from NAPRT1 is 
responsible for the conversion of nicotinic acid (NA, niacin, vitamin B3) in to NA 
mononucleotide (NaMN), that in its turn is converted in to nicotinamide adenine 
dinucleotide (NAD), which is a cofactor for a wide number of cellular processes 
(Hara et al., 2007). Cells are able to generate NAD either through a de novo pathway 
from tryptophan or through the salvage pathways from nicotinamide (Nam), 
through the Nicotinamide Phosphoribosyltransferase (NAMPT) or NA through 
NAPRT1 but it seems that NAD generation from NA is more efficient in raising NAD 
levels (Hara et al., 2007). However, despite the redundancy in the salvage pathways, 
NAPRT1 requires exogenous sources of NA supplementation to produce NAD in the 
absence of NAMPT (Shames et al., 2013). Together with the fact that a high 
proportion of tumours have NAPRT1 inactivated by hypermethylation of its 
promoter, the inhibition of NAMPT presents a promising therapeutical target, as it 
obliterates the NAD salvage pathway (Roulston & Shore, 2016). Interestingly, our 
group recently reported that Aag -/- MEFs when treated with the Nampt inhibitor 
FK866, suffer not only NAD depletion, but also a severe ATP depletion as well, while 
similarly treated wild-type MEFs, while NAD depleted, are protected from ATP 
depletion (Alhumaydhi et al., 2017). Together with our observation that NAPRT1 
could only be detected on the AAG-proficient ARPE-19 may suggest that somehow 
AAG-deficient cells are unable to rely on the NAPRT1 as an alternative salvage 
pathway when unable to use NAMPT. The same work also found that Aag-deficient 
Chapter 5: COMPARATIVE PROTEOMICS ON DIFFERENTIALLY EXPRESSED AAG CELL LINES 
 
218 
 
MEFs have lower basal levels of ATP, indicating that Aag absence may be impacting 
the metabolic balance in those cells. 
The Nuclear inhibitor of protein phosphatase 1 (PPP1R8, NIPP-1), forms a 
heterodimer with Ser/Thr protein phosphatase type I (PP1) and acts as its inhibitor 
(Martin-granados et al., 2012).PP1 is a ubiquitous enzyme that plays an important 
role  in a variety of cellular processes including protein synthesis, RNA splicing, cell-
cycle progression and glycogen metabolism (Ceulemans, 2004). NIPP-1 itself has 
also a function in pre-mRNA processing, being essential to the late spliceosome 
assembly (Beullens & Bollen, 2002). Its knockout is embryonic lethal, suggesting it 
has implications in cell lineage differentiation (Eynde et al., 2004). One of its 
isoforms also has endoribonuclease function, cleaving A+U-rich regions (O’Leary et 
al., 2016).  
Queuine tRNA-Ribosyltransferase Accessory Subunit 2 (QTRTD1 and 
QTRTD1), as the name indicates, is a subunit of queuine tRNA-rybosyltransferase, 
responsible for substituting guanosine nucleotides for the queuine, a specially 
modified nucleoside present in the wobble codon of some tRNAs (Q-tRNAs) 
(Langgut & Reisser, 1995). PP1 (see prior paragraph), together with protein kinase 
C, regulates the uptake o queosine in to the cell and therefore, its incorporation in 
tRNAs (Morris, Galicia, Clase, & Elliott, 1999). Q-tRNAs seem to participate indirectly 
in a broad range of processes as inhibition of cell proliferation, apoptosis induction, 
and suppression of anaerobic metabolism (Vinayak & Pathak, 2009). 
RAB38 and RAB9A code for the Ras-Related Protein Rab-38 and Ras-
Related Protein Rab-9A. Rab proteins exist in all eukaryotic cells and form the 
largest branch of the small G protein superfamily that regulates intracellular 
vesicular transport (Osanai et al., 2005; Takai, Sasaki, & Matozaki, 2001). Data 
suggests that RAB38 localizes in the endoplasmic reticulum and regulates vesicle 
traffic in this organelle (Osanai et al., 2005). Associated with RAB32, it participates 
in the biogenesis of the melanosomes (Bultema, Ambrosio, Burek, & Di Pietro, 
2012), organelles that store melanin in the retinal pigmented epithelial cell, among 
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others (Raposo & Marks, 2009). In cancer RAB GTPases were implicated in cell 
migration, invasion, proliferation and RAB38 appears to be overexpressed in high-
grade gliomas, and in this setting has a positive correlation with tumour cell-
migration (H. Wang & Jiang, 2013). RAD9A seems to be involved in non-canonical 
macroautophagy (Atg5/Atg7-independent) reportedly that has a role in erythroid 
cell maturation (Ao et al., 2014; Nishida et al., 2009).  
Curiously, none of the proteins identified among the 13 wild-type exclusive 
are present in the putative AAG interactors list compiled from the UNiHI database  
(Kalathur et al., 2014). However, at least two of the components are closely related 
to proteins listed there. RAB7A, present on the AAG interactors list, RAB38 and 
RAB9A (from the 13 wild-type exclusive proteins) are all from the family of the RAB 
GTPases (Takai et al., 2001). They are also  involved in lysosomal biogenesis and are 
important in the maturation of late autophagic vacuoles (Jager, 2004; Zhou et al., 
2015).  
The second related ID is PPP1R10 or PNUTS (from the AAG interactors list), 
as NIPP-1 (PPP1R8, wild-type exclusive list) is also a PP1 interacting protein, 
regulating diverse factors as M-phase entry and exit (Fisher, Wang, Wu, & Peng, 
2014) and regulates early events in the DDR response (Landsverk et al., 2010). PP1 
has ties to the UPR by its interaction with GADD34, that induces PP1 to 
dephosphorylate eIF2α and causing the cell to resume translation (Blais et al., 
2004). 
Whether these relationships are of biological importance is still unknown. 
A search on STRING (Jensen et al., 2009) for interactions between RAB7A, 38 and 9A 
revealed a low-confidence interaction (minimum required interaction score of 
0.150), while the interaction between PNUTS and NIPP-1 had a high score of more 
than 0.9 (data not shown). It would be interesting to evaluate whether these 
proteins indeed interact in our models and if their function is related to the AAG 
related elicitation of the UPR.  
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To address such question, it would be highly desirable not only conduct 
experiments were the levels of such proteins could be ascertained across genotypes 
(as was our original purpose) but also in cells under stress (ER-related or otherwise). 
Moreover, it would be also very informative to investigate by co-
immunoprecipitation and mass spectrometry analysis potential AAG interactors 
that could explain the findings described on Chapter 4.
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APPENDIX CHAPTER 5 
S. Table 6: Complete results of the overrepresentation analysis based on the GO-Slim Biological Process domain. FE – Fold Enrichment 
PANTHER GO-
Slim  
Biological 
Process 
Human 
Prot  
REFLIST 
(20795) 
ARPE19 
(5072) 
ARPE19 
(exp.) 
ARPE
19 
(FE) 
ARPE19 
(P-value) 
A2C2 
(6173) 
A2C2 
(exp.) 
A2C2 
(FE) 
A2C2  
(P-value) 
B6C3 
(6239) 
B6C3 
(exp.) 
B6C3 
(FE) 
B6C3 
(P-value) 
glycolysis 
(GO:0006096) 
34 30 8.29 3.62 1.08E-06 27 10.09 2.68 1.78E-03 27 10.2 2.65 2.14E-03 
tricarboxylic 
acid cycle 
(GO:0006099) 
27 22 6.59 3.34 4.11E-04 22 8.01 2.74 8.15E-03 23 8.1 2.84 3.27E-03 
lysosomal 
transport 
(GO:0007041) 
27 21 6.59 3.19 1.40E-03 21 8.01 2.62 2.29E-02 21 8.1 2.59 2.65E-02 
RNA splicing, via 
transesterificati
on reactions 
(GO:0000375) 
133 101 32.44 3.11 7.97E-20 114 39.48 2.89 6.37E-20 107 39.9 2.68 2.06E-16 
chromatin 
assembly 
(GO:0031497) 
30 22 7.32 3.01 2.10E-03 24 8.91 2.69 4.92E-03 22 9 2.44 4.17E-02 
nuclear 
transport 
(GO:0051169) 
106 77 25.85 2.98 6.58E-14 83 31.47 2.64 3.55E-12 84 31.8 2.64 2.31E-12 
regulation of 
carbohydrate 
metabolic 
process 
(GO:0006109) 
25 18 6.1 2.95 1.65E-02 21 7.42 2.83 7.92E-03 19 7.5 2.53 7.24E-02 
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PANTHER GO-
Slim  
Biological 
Process 
Human 
Prot  
REFLIST 
(20795) 
ARPE19 
(5072) 
ARPE19 
(exp.) 
ARPE
19 
(FE) 
ARPE19 
(P-value) 
A2C2 
(6173) 
A2C2 
(exp.) 
A2C2 
(FE) 
A2C2  
(P-value) 
B6C3 
(6239) 
B6C3 
(exp.) 
B6C3 
(FE) 
B6C3 
(P-value) 
mRNA splicing, 
via spliceosome 
(GO:0000398) 
173 122 42.2 2.89 1.78E-21 140 51.36 2.73 2.23E-22 133 51.9 2.56 5.90E-19 
tRNA 
aminoacylation 
for protein 
translation 
(GO:0006418) 
47 33 11.46 2.88 3.79E-05 38 13.95 2.72 1.86E-05 37 14.1 2.62 6.63E-05 
mRNA 
processing 
(GO:0006397) 
241 161 58.78 2.74 3.65E-26 184 71.54 2.57 9.17E-27 175 72.31 2.42 1.38E-22 
protein 
targeting 
(GO:0006605) 
158 104 38.54 2.7 3.78E-16 113 46.9 2.41 3.83E-14 114 47.4 2.4 3.20E-14 
regulation of 
gene 
expression, 
epigenetic 
(GO:0040029) 
51 31 12.44 2.49 1.58E-03 33 15.14 2.18 1.12E-02 29 15.3 1.9 2.74E-01 
RNA localization 
(GO:0006403) 
71 43 17.32 2.48 3.31E-05 48 21.08 2.28 7.79E-05 47 21.3 2.21 2.40E-04 
translation 
(GO:0006412) 
321 191 78.29 2.44 3.06E-25 211 95.29 2.21 1.01E-22 211 96.31 2.19 3.58E-22 
protein folding 
(GO:0006457) 
130 77 31.71 2.43 1.50E-09 85 38.59 2.2 1.60E-08 85 39 2.18 2.64E-08 
protein complex 
biogenesis 
167 99 40.73 2.43 1.53E-12 110 49.57 2.22 1.80E-11 107 50.1 2.14 3.75E-10 
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PANTHER GO-
Slim  
Biological 
Process 
Human 
Prot  
REFLIST 
(20795) 
ARPE19 
(5072) 
ARPE19 
(exp.) 
ARPE
19 
(FE) 
ARPE19 
(P-value) 
A2C2 
(6173) 
A2C2 
(exp.) 
A2C2 
(FE) 
A2C2  
(P-value) 
B6C3 
(6239) 
B6C3 
(exp.) 
B6C3 
(FE) 
B6C3 
(P-value) 
(GO:0070271) 
protein complex 
assembly 
(GO:0006461) 
166 98 40.49 2.42 2.67E-12 109 49.28 2.21 2.81E-11 106 49.8 2.13 5.77E-10 
glycogen 
metabolic 
process 
(GO:0005977) 
83 48 20.24 2.37 2.47E-05 50 24.64 2.03 1.09E-03 47 24.9 1.89 1.17E-02 
tRNA metabolic 
process 
(GO:0006399) 
111 63 27.07 2.33 5.72E-07 73 32.95 2.22 2.64E-07 73 33.3 2.19 4.08E-07 
RNA catabolic 
process 
(GO:0006401) 
58 33 14.15 2.33 3.05E-03 42 17.22 2.44 7.31E-05 40 17.4 2.3 5.67E-04 
cellular amino 
acid 
biosynthetic 
process 
(GO:0008652) 
78 44 19.02 2.31 1.56E-04 42 23.15 1.81 6.38E-02 44 23.4 1.88 2.16E-02 
cellular 
component 
biogenesis 
(GO:0044085) 
490 271 119.51 2.27 2.73E-31 317 145.46 2.18 1.51E-33 315 147.01 2.14 4.95E-32 
cellular amino 
acid catabolic 
process 
(GO:0009063) 
58 32 14.15 2.26 7.28E-03 36 17.22 2.09 1.20E-02 34 17.4 1.95 6.50E-02 
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PANTHER GO-
Slim  
Biological 
Process 
Human 
Prot  
REFLIST 
(20795) 
ARPE19 
(5072) 
ARPE19 
(exp.) 
ARPE
19 
(FE) 
ARPE19 
(P-value) 
A2C2 
(6173) 
A2C2 
(exp.) 
A2C2 
(FE) 
A2C2  
(P-value) 
B6C3 
(6239) 
B6C3 
(exp.) 
B6C3 
(FE) 
B6C3 
(P-value) 
rRNA metabolic 
process 
(GO:0016072) 
116 64 28.29 2.26 1.23E-06 81 34.43 2.35 2.08E-09 84 34.8 2.41 2.42E-10 
protein 
localization 
(GO:0008104) 
241 131 58.78 2.23 5.29E-14 145 71.54 2.03 2.59E-12 150 72.31 2.07 1.47E-13 
chromatin 
organization 
(GO:0006325) 
262 142 63.9 2.22 3.74E-15 165 77.77 2.12 7.24E-16 155 78.61 1.97 2.85E-12 
cellular amino 
acid metabolic 
process 
(GO:0006520) 
261 134 63.66 2.1 1.63E-12 147 77.48 1.9 2.25E-10 146 78.31 1.86 9.18E-10 
coenzyme 
metabolic 
process 
(GO:0006732) 
114 58 27.81 2.09 8.45E-05 64 33.84 1.89 5.57E-04 62 34.2 1.81 2.79E-03 
purine 
nucleobase 
metabolic 
process 
(GO:0006144) 
75 38 18.29 2.08 8.64E-03 37 22.26 1.66 6.20E-01 40 22.5 1.78 1.28E-01 
generation of 
precursor 
metabolites and 
energy 
(GO:0006091) 
224 108 54.63 1.98 2.26E-08 125 66.49 1.88 1.89E-08 127 67.21 1.89 9.76E-09 
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PANTHER GO-
Slim  
Biological 
Process 
Human 
Prot  
REFLIST 
(20795) 
ARPE19 
(5072) 
ARPE19 
(exp.) 
ARPE
19 
(FE) 
ARPE19 
(P-value) 
A2C2 
(6173) 
A2C2 
(exp.) 
A2C2 
(FE) 
A2C2  
(P-value) 
B6C3 
(6239) 
B6C3 
(exp.) 
B6C3 
(FE) 
B6C3 
(P-value) 
nucleobase-
containing 
compound 
transport 
(GO:0015931) 
73 35 17.81 1.97 4.77E-02 42 21.67 1.94 1.62E-02 42 21.9 1.92 2.03E-02 
organelle 
organization 
(GO:0006996) 
749 351 182.68 1.92 2.03E-27 426 222.34 1.92 4.02E-33 410 224.72 1.82 1.45E-27 
chromosome 
segregation 
(GO:0007059) 
121 54 29.51 1.83 7.60E-03 73 35.92 2.03 8.05E-06 63 36.3 1.74 8.38E-03 
mitosis 
(GO:0007067) 
370 164 90.24 1.82 2.90E-10 210 109.83 1.91 1.47E-15 193 111.01 1.74 1.64E-10 
cellular 
component 
organization or 
biogenesis 
(GO:0071840) 
1695 747 413.42 1.81 3.33E-52 907 503.16 1.8 5.44E-63 868 508.54 1.71 2.85E-50 
cytokinesis 
(GO:0000910) 
113 50 27.56 1.81 1.78E-02 68 33.54 2.03 2.53E-05 61 33.9 1.8 4.04E-03 
catabolic 
process 
(GO:0009056) 
788 346 192.2 1.8 2.81E-22 396 233.92 1.69 8.91E-21 392 236.42 1.66 4.80E-19 
DNA repair 
(GO:0006281) 
172 75 41.95 1.79 5.86E-04 89 51.06 1.74 2.05E-04 76 51.6 1.47 2.00E-01 
cellular 
component 
1555 664 379.27 1.75 1.84E-41 802 461.6 1.74 6.76E-49 763 466.54 1.64 2.12E-37 
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PANTHER GO-
Slim  
Biological 
Process 
Human 
Prot  
REFLIST 
(20795) 
ARPE19 
(5072) 
ARPE19 
(exp.) 
ARPE
19 
(FE) 
ARPE19 
(P-value) 
A2C2 
(6173) 
A2C2 
(exp.) 
A2C2 
(FE) 
A2C2  
(P-value) 
B6C3 
(6239) 
B6C3 
(exp.) 
B6C3 
(FE) 
B6C3 
(P-value) 
organization 
(GO:0016043) 
protein 
transport 
(GO:0015031) 
1044 442 254.64 1.74 8.62E-26 516 309.91 1.66 4.80E-26 533 313.23 1.7 3.98E-29 
intracellular 
protein 
transport 
(GO:0006886) 
1021 434 249.03 1.74 1.26E-25 508 303.08 1.68 3.13E-26 524 306.32 1.71 4.06E-29 
oxidative 
phosphorylation 
(GO:0006119) 
51 21 12.44 1.69 1.00E+00 35 15.14 2.31 2.06E-03 33 15.3 2.16 1.37E-02 
cytoskeleton 
organization 
(GO:0007010) 
155 63 37.81 1.67 2.51E-02 80 46.01 1.74 7.75E-04 79 46.5 1.7 1.98E-03 
DNA metabolic 
process 
(GO:0006259) 
372 148 90.73 1.63 3.76E-06 188 110.43 1.7 1.78E-09 159 111.61 1.42 2.82E-03 
vesicle-
mediated 
transport 
(GO:0016192) 
860 333 209.76 1.59 1.39E-13 388 255.29 1.52 3.90E-13 399 258.02 1.55 1.22E-14 
regulation of 
cell cycle 
(GO:0051726) 
109 42 26.59 1.58 8.14E-01 55 32.36 1.7 4.15E-02 49 32.7 1.5 1.00E+00 
DNA replication 
(GO:0006260) 
154 59 37.56 1.57 1.69E-01 76 45.71 1.66 5.82E-03 68 46.2 1.47 3.65E-01 
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PANTHER GO-
Slim  
Biological 
Process 
Human 
Prot  
REFLIST 
(20795) 
ARPE19 
(5072) 
ARPE19 
(exp.) 
ARPE
19 
(FE) 
ARPE19 
(P-value) 
A2C2 
(6173) 
A2C2 
(exp.) 
A2C2 
(FE) 
A2C2  
(P-value) 
B6C3 
(6239) 
B6C3 
(exp.) 
B6C3 
(FE) 
B6C3 
(P-value) 
carbohydrate 
metabolic 
process 
(GO:0005975) 
475 177 115.85 1.53 1.31E-05 210 141 1.49 5.70E-06 197 142.51 1.38 1.70E-03 
exocytosis 
(GO:0006887) 
219 81 53.42 1.52 5.89E-02 90 65.01 1.38 4.39E-01 103 65.71 1.57 2.74E-03 
cell cycle 
(GO:0007049) 
897 328 218.78 1.5 2.53E-10 406 266.27 1.52 5.16E-14 379 269.12 1.41 1.38E-08 
cellular 
component 
morphogenesis 
(GO:0032989) 
545 197 132.93 1.48 1.97E-05 253 161.78 1.56 2.50E-09 238 163.51 1.46 4.31E-06 
protein 
metabolic 
process 
(GO:0019538) 
2028 729 494.64 1.47 2.34E-23 848 602.01 1.41 2.01E-21 834 608.45 1.37 6.76E-18 
endocytosis 
(GO:0006897) 
393 140 95.85 1.46 2.79E-03 159 116.66 1.36 2.36E-02 152 117.91 1.29 3.18E-01 
nitrogen 
compound 
metabolic 
process 
(GO:0006807) 
2012 701 490.74 1.43 4.91E-19 839 597.26 1.4 7.72E-21 886 603.65 1.47 6.91E-28 
respiratory 
electron 
transport chain 
(GO:0022904) 
155 53 37.81 1.4 1.00E+00 72 46.01 1.56 5.40E-02 74 46.5 1.59 2.76E-02 
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PANTHER GO-
Slim  
Biological 
Process 
Human 
Prot  
REFLIST 
(20795) 
ARPE19 
(5072) 
ARPE19 
(exp.) 
ARPE
19 
(FE) 
ARPE19 
(P-value) 
A2C2 
(6173) 
A2C2 
(exp.) 
A2C2 
(FE) 
A2C2  
(P-value) 
B6C3 
(6239) 
B6C3 
(exp.) 
B6C3 
(FE) 
B6C3 
(P-value) 
phosphate-
containing 
compound 
metabolic 
process 
(GO:0006796) 
1246 423 303.91 1.39 3.40E-09 500 369.88 1.35 4.15E-09 490 373.83 1.31 4.04E-07 
PANTHER GO-
Slim Biological 
Process 
Human 
Prot - 
REFLIST 
(20795) 
ARPE19 
(5072) 
ARPE19 
(expected) 
ARPE
19 
(fold 
Enric
hmen
t) 
ARPE19 
(P-value) 
A2C2 
(6173) 
A2C2 
(expect
ed) 
A2C2 
(fold 
Enrichme
nt) 
A2C2 
(P-value) 
B6C3 
(6239) 
B6C3 
(expect
ed) 
B6C3 
(fold 
Enric
hmen
t) 
B6C3 
(P-value) 
primary 
metabolic 
process 
(GO:0044238) 
5732 1931 1398.06 1.38 6.55E-57 2274 
1701.5
5 
1.34 2.70E-54 2317 
1719.7
4 
1.35 2.09E-58 
nucleobase-
containing 
compound 
metabolic 
process 
(GO:0006139) 
3151 1061 768.54 1.38 1.03E-25 1265 935.37 1.35 4.97E-27 1317 945.38 1.39 8.30E-34 
transport 
(GO:0006810) 
1918 634 467.81 1.36 2.00E-12 768 569.36 1.35 1.02E-14 770 575.45 1.34 5.61E-14 
localization 
(GO:0051179) 
2113 692 515.37 1.34 5.91E-13 838 627.24 1.34 2.77E-15 836 633.95 1.32 6.60E-14 
metabolic 
process 
6774 2215 1652.21 1.34 9.34E-59 2620 
2010.8
6 
1.3 8.59E-57 2655 
2032.3
6 
1.31 1.07E-58 
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PANTHER GO-
Slim  
Biological 
Process 
Human 
Prot  
REFLIST 
(20795) 
ARPE19 
(5072) 
ARPE19 
(exp.) 
ARPE
19 
(FE) 
ARPE19 
(P-value) 
A2C2 
(6173) 
A2C2 
(exp.) 
A2C2 
(FE) 
A2C2  
(P-value) 
B6C3 
(6239) 
B6C3 
(exp.) 
B6C3 
(FE) 
B6C3 
(P-value) 
(GO:0008152) 
cellular 
component 
movement 
(GO:0006928) 
412 134 100.49 1.33 1.75E-01 166 122.3 1.36 2.05E-02 157 123.61 1.27 4.72E-01 
biosynthetic 
process 
(GO:0009058) 
1515 480 369.52 1.3 1.38E-06 567 449.73 1.26 4.10E-06 641 454.54 1.41 1.17E-15 
cellular protein 
modification 
process 
(GO:0006464) 
981 310 239.27 1.3 9.53E-04 387 291.21 1.33 5.50E-06 367 294.32 1.25 3.73E-03 
RNA metabolic 
process 
(GO:0016070) 
2045 606 498.79 1.21 1.21E-04 738 607.06 1.22 7.27E-06 813 613.55 1.33 6.34E-14 
cellular process 
(GO:0009987) 
8156 2374 1989.29 1.19 8.13E-26 2824 
2421.1
1 
1.17 2.85E-23 2836 2447 1.16 1.92E-21 
regulation of 
nucleobase-
containing 
compound 
metabolic 
process 
(GO:0019219) 
532 132 129.76 1.02 1.00E+00 143 157.92 -0.91 1.00E+00 210 159.61 1.32 1.53E-02 
skeletal system 
development 
(GO:0001501) 
194 10 47.32 -0.21 1.15E-08 12 57.59 -0.21 6.92E-11 10 58.2 < 0.2 1.56E-12 
Chapter 5: COMPARATIVE PROTEOMICS ON DIFFERENTIALLY EXPRESSED AAG CELL LINES 
 
230 
 
PANTHER GO-
Slim  
Biological 
Process 
Human 
Prot  
REFLIST 
(20795) 
ARPE19 
(5072) 
ARPE19 
(exp.) 
ARPE
19 
(FE) 
ARPE19 
(P-value) 
A2C2 
(6173) 
A2C2 
(exp.) 
A2C2 
(FE) 
A2C2  
(P-value) 
B6C3 
(6239) 
B6C3 
(exp.) 
B6C3 
(FE) 
B6C3 
(P-value) 
B cell mediated 
immunity 
(GO:0019724) 
188 10 45.85 -0.22 3.71E-08 12 55.81 -0.22 2.88E-10 12 56.4 -0.21 1.79E-10 
angiogenesis 
(GO:0001525) 
118 8 28.78 -0.28 1.16E-03 12 35.03 -0.34 1.50E-03 10 35.4 -0.28 1.13E-04 
cytokine-
mediated 
Signalling 
pathway 
(GO:0019221) 
175 13 42.68 -0.3 2.28E-05 22 51.95 -0.42 5.13E-04 22 52.5 -0.42 3.69E-04 
cell recognition 
(GO:0008037) 
79 6 19.27 -0.31 1.02E-01 5 23.45 -0.21 1.14E-03 8 23.7 -0.34 4.36E-02 
sensory 
perception 
(GO:0007600) 
665 52 162.2 -0.32 3.87E-22 74 197.41 -0.37 4.33E-22 72 199.52 -0.36 1.43E-23 
blood 
coagulation 
(GO:0007596) 
91 8 22.2 -0.36 1.20E-01 12 27.01 -0.44 2.38E-01 10 27.3 -0.37 3.18E-02 
immune 
response 
(GO:0006955) 
661 62 161.22 -0.38 3.16E-17 81 196.22 -0.41 7.26E-19 76 198.32 -0.38 1.77E-21 
blood 
circulation 
(GO:0008015) 
140 13 34.15 -0.38 7.40E-03 24 41.56 -0.58 5.30E-01 19 42 -0.45 1.34E-02 
heart 
development 
(GO:0007507) 
143 14 34.88 -0.4 1.21E-02 17 42.45 -0.4 1.81E-03 17 42.9 -0.4 1.37E-03 
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PANTHER GO-
Slim  
Biological 
Process 
Human 
Prot  
REFLIST 
(20795) 
ARPE19 
(5072) 
ARPE19 
(exp.) 
ARPE
19 
(FE) 
ARPE19 
(P-value) 
A2C2 
(6173) 
A2C2 
(exp.) 
A2C2 
(FE) 
A2C2  
(P-value) 
B6C3 
(6239) 
B6C3 
(exp.) 
B6C3 
(FE) 
B6C3 
(P-value) 
anion transport 
(GO:0006820) 
237 24 57.81 -0.42 8.84E-05 40 70.35 -0.57 1.33E-02 39 71.11 -0.55 5.12E-03 
cell proliferation 
(GO:0008283) 
144 16 35.12 -0.46 5.88E-02 24 42.75 -0.56 3.07E-01 21 43.2 -0.49 3.25E-02 
ion transport 
(GO:0006811) 
351 39 85.61 -0.46 2.64E-06 68 104.19 -0.65 2.19E-02 61 105.31 -0.58 4.02E-04 
cellular defence 
response 
(GO:0006968) 
207 23 50.49 -0.46 2.72E-03 34 61.45 -0.55 2.19E-02 39 62.1 -0.63 2.61E-01 
gamete 
generation 
(GO:0007276) 
286 34 69.76 -0.49 3.33E-04 45 84.9 -0.53 3.11E-04 47 85.81 -0.55 7.20E-04 
reproduction 
(GO:0000003) 
370 45 90.24 -0.5 2.02E-05 63 109.83 -0.57 1.70E-04 62 111.01 -0.56 5.54E-05 
segment 
specification 
(GO:0007379) 
128 16 31.22 -0.51 4.91E-01 18 38 -0.47 5.71E-02 16 38.4 -0.42 8.65E-03 
neurological 
system process 
(GO:0050877) 
1144 149 279.03 -0.53 3.85E-16 190 339.6 -0.56 2.06E-17 192 343.23 -0.56 1.30E-17 
cell 
differentiation 
(GO:0030154) 
441 60 107.56 -0.56 7.78E-05 68 130.91 -0.52 1.80E-07 68 132.31 -0.51 8.95E-08 
system process 
(GO:0003008) 
1364 194 332.69 -0.58 3.50E-15 250 404.9 -0.62 2.35E-15 247 409.23 -0.6 8.09E-17 
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PANTHER GO-
Slim  
Biological 
Process 
Human 
Prot  
REFLIST 
(20795) 
ARPE19 
(5072) 
ARPE19 
(exp.) 
ARPE
19 
(FE) 
ARPE19 
(P-value) 
A2C2 
(6173) 
A2C2 
(exp.) 
A2C2 
(FE) 
A2C2  
(P-value) 
B6C3 
(6239) 
B6C3 
(exp.) 
B6C3 
(FE) 
B6C3 
(P-value) 
multicellular 
organismal 
process 
(GO:0032501) 
1830 265 446.35 -0.59 7.39E-20 323 543.24 -0.59 3.47E-24 322 549.04 -0.59 1.50E-25 
single-
multicellular 
organism 
process 
(GO:0044707) 
1814 265 442.44 -0.6 4.21E-19 323 538.49 -0.6 2.86E-23 322 544.24 -0.59 1.32E-24 
response to 
external 
stimulus 
(GO:0009605) 
310 45 75.61 -0.6 2.17E-02 62 92.02 -0.67 1.28E-01 57 93.01 -0.61 8.61E-03 
pattern 
specification 
process 
(GO:0007389) 
168 25 40.98 -0.61 1.00E+00 28 49.87 -0.56 1.25E-01 25 50.4 -0.5 1.33E-02 
immune system 
process 
(GO:0002376) 
1213 182 295.86 -0.62 4.22E-11 228 360.08 -0.63 2.93E-12 224 363.93 -0.62 8.59E-14 
regulation of 
transcription 
from RNA 
polymerase II 
promoter 
(GO:0006357) 
975 151 237.81 -0.63 1.16E-07 197 289.43 -0.68 5.95E-07 212 292.52 -0.72 6.25E-05 
regulation of 
biological 
1872 301 456.59 -0.66 9.20E-14 363 555.7 -0.65 1.47E-17 346 561.65 -0.62 3.14E-22 
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PANTHER GO-
Slim  
Biological 
Process 
Human 
Prot  
REFLIST 
(20795) 
ARPE19 
(5072) 
ARPE19 
(exp.) 
ARPE
19 
(FE) 
ARPE19 
(P-value) 
A2C2 
(6173) 
A2C2 
(exp.) 
A2C2 
(FE) 
A2C2  
(P-value) 
B6C3 
(6239) 
B6C3 
(exp.) 
B6C3 
(FE) 
B6C3 
(P-value) 
process 
(GO:0050789) 
system 
development 
(GO:0048731) 
1063 174 259.27 -0.67 1.28E-06 206 315.55 -0.65 2.53E-09 197 318.93 -0.62 9.22E-12 
cell surface 
receptor 
signalling 
pathway 
(GO:0007166) 
1273 207 310.49 -0.67 2.01E-08 270 377.89 -0.71 2.65E-07 250 381.93 -0.65 2.02E-11 
cell-cell 
signalling 
(GO:0007267) 
480 78 117.07 -0.67 1.63E-02 90 142.49 -0.63 3.07E-04 93 144.01 -0.65 7.04E-04 
response to 
stimulus 
(GO:0050896) 
2522 421 615.13 -0.68 2.30E-16 518 748.66 -0.69 4.98E-19 498 756.66 -0.66 4.05E-24 
nervous system 
development 
(GO:0007399) 
667 114 162.68 -0.7 6.51E-03 134 198 -0.68 1.48E-04 123 200.12 -0.61 4.31E-07 
mesoderm 
development 
(GO:0007498) 
446 76 108.78 -0.7 1.22E-01 106 132.4 -0.8 1.00E+00 93 133.81 -0.7 2.52E-02 
biological 
regulation 
(GO:0065007) 
2262 392 551.71 -0.71 6.47E-12 478 671.48 -0.71 1.70E-14 470 678.65 -0.69 6.76E-17 
ectoderm 
development 
404 70 98.54 -0.71 3.40E-01 81 119.93 -0.68 2.18E-02 79 121.21 -0.65 5.82E-03 
Chapter 5: COMPARATIVE PROTEOMICS ON DIFFERENTIALLY EXPRESSED AAG CELL LINES 
 
234 
 
PANTHER GO-
Slim  
Biological 
Process 
Human 
Prot  
REFLIST 
(20795) 
ARPE19 
(5072) 
ARPE19 
(exp.) 
ARPE
19 
(FE) 
ARPE19 
(P-value) 
A2C2 
(6173) 
A2C2 
(exp.) 
A2C2 
(FE) 
A2C2  
(P-value) 
B6C3 
(6239) 
B6C3 
(exp.) 
B6C3 
(FE) 
B6C3 
(P-value) 
(GO:0007398) 
G-protein 
coupled 
receptor 
signalling 
pathway 
(GO:0007186) 
551 100 134.39 -0.74 2.46E-01 116 163.56 -0.71 1.09E-02 110 165.31 -0.67 5.61E-04 
developmental 
process 
(GO:0032502) 
1930 366 470.74 -0.78 2.13E-05 440 572.92 -0.77 2.02E-07 427 579.05 -0.74 6.31E-10 
Unclassified 
(UNCLASSIFIED) 
8541 1646 2083.19 -0.79 0.00E+00 2089 2535.4 -0.82 0.00E+00 2128 
2562.5
1 
-0.83 0.00E+00 
transcription, 
DNA-dependent 
(GO:0006351) 
1517 300 370 -0.81 1.35E-02 365 450.32 -0.81 2.30E-03 447 455.14 -0.98 1.00E+00 
cell 
communication 
(GO:0007154) 
2647 582 645.62 -0.9 8.55E-01 715 785.76 -0.91 8.01E-01 690 794.16 -0.87 7.30E-03 
signal 
transduction 
(GO:0007165) 
2363 524 576.35 -0.91 1.00E+00 649 701.46 -0.93 1.00E+00 617 708.96 -0.87 2.44E-02 
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S. Table 7: Proteins detected exclusively in ARPE-19 wild-type cells (two replicates or more).  
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
RALYL RNA-binding Raly-like protein 
RNA-BINDING RALY-LIKE PROTEIN 
(PTHR13968:SF27) 
mRNA processing factor(PC00147); 
ribonucleoprotein(PC00201) 
CDK11A Cyclin-dependent kinase 11A 
CYCLIN-DEPENDENT KINASE 11A-RELATED 
(PTHR24056:SF238) 
non-receptor serine/threonine protein 
kinase(PC00167); non-receptor tyrosine protein 
kinase(PC00168) 
ARHGAP29 
Rho GTPase-activating protein 
29 
RHO GTPASE-ACTIVATING PROTEIN 29 
(PTHR15228:SF31)  
GNAO1 
Guanine nucleotide-binding 
protein G(o) subunit alpha 
GUANINE NUCLEOTIDE-BINDING PROTEIN 
G(O) SUBUNIT ALPHA (PTHR10218:SF248) 
heterotrimeric G-protein(PC00117) 
H3F3A Histone H3.3 HISTONE H3.3 (PTHR11426:SF92) histone(PC00118) 
H3F3C Histone H3.3C 
HISTONE H3.3-RELATED 
(PTHR11426:SF121) 
histone(PC00118) 
SETD7 
Histone-lysine N-
methyltransferase SETD7 
HISTONE-LYSINE N-METHYLTRANSFERASE 
SETD7 (PTHR23084:SF179) 
kinase(PC00137) 
NUP50 
Nuclear pore complex protein 
Nup50 
NUCLEAR PORE COMPLEX PROTEIN 
NUP50 (PTHR23138:SF118) 
transporter(PC00227) 
MARK2 
Serine/threonine-protein kinase 
MARK2 
SERINE/THREONINE-PROTEIN KINASE 
MARK2 (PTHR24346:SF37) 
non-receptor serine/threonine protein 
kinase(PC00167) 
KIRREL Kin of IRRE-like protein 1 
KIN OF IRRE-LIKE PROTEIN 1 
(PTHR11640:SF70) 
cell junction protein(PC00070) 
GCLC 
Glutamate--cysteine ligase 
catalytic subunit 
GLUTAMATE--CYSTEINE LIGASE 
CATALYTIC SUBUNIT (PTHR11164:SF2) 
ligase(PC00142) 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
PHF3 PHD finger protein 3 
PHD FINGER PROTEIN 3 
(PTHR11477:SF22) 
nucleic acid binding(PC00171); transcription 
factor(PC00218) 
SDPR 
Serum deprivation-response 
protein 
SERUM DEPRIVATION-RESPONSE 
PROTEIN (PTHR15240:SF10) 
transcription factor(PC00218) 
UAP1L1 
UDP-N-acetylhexosamine 
pyrophosphorylase-like protein 1 
UDP-N-ACETYLHEXOSAMINE 
PYROPHOSPHORYLASE-LIKE PROTEIN 1 
(PTHR11952:SF15) 
nucleotidyltransferase(PC00174) 
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
FCGRT 
IgG receptor FcRn large subunit 
p51 
IGG RECEPTOR FCRN LARGE SUBUNIT P51 
(PTHR16675:SF221) 
immunoglobulin receptor superfamily(PC00124); 
major histocompatibility complex antigen(PC00149) 
DMD Dystrophin DYSTROPHIN (PTHR11915:SF339) non-motor actin binding protein(PC00165) 
PFDN5 Prefoldin subunit 5 PREFOLDIN SUBUNIT 5 (PTHR12674:SF6) 
 
PABPN1 Polyadenylate-binding protein 2 
POLYADENYLATE-BINDING PROTEIN 2 
(PTHR24012:SF667)  
LTBP2 
Latent-transforming growth 
factor beta-binding protein 2 
LATENT-TRANSFORMING GROWTH 
FACTOR BETA-BINDING PROTEIN 2 
(PTHR24034:SF66) 
; annexin(PC00050); calmodulin(PC00061); cell 
adhesion molecule(PC00069); extracellular matrix 
glycoprotein(PC00100); extracellular matrix 
structural protein(PC00103); signalling 
molecule(PC00207) 
ECI1 
Enoyl-CoA delta isomerase 1, 
mitochondrial 
ENOYL-COA DELTA ISOMERASE 1, 
MITOCHONDRIAL (PTHR11941:SF102) 
acetyltransferase(PC00038); 
acyltransferase(PC00042); 
dehydrogenase(PC00092); 
epimerase/racemase(PC00096); 
hydratase(PC00120); ligase(PC00142) 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
SPTLC2 Serine palmitoyltransferase 2 
SERINE PALMITOYLTRANSFERASE 2 
(PTHR13693:SF70) 
transaminase(PC00216) 
H2AFX Histone H2AX HISTONE H2AX (PTHR23430:SF121) histone(PC00118) 
GLRX Glutaredoxin-1 GLUTAREDOXIN-1 (PTHR10168:SF167) oxidoreductase(PC00176) 
ISOC1 
Isochorismatase domain-
containing protein 1 
ISOCHORISMATASE DOMAIN-
CONTAINING PROTEIN 1 
(PTHR14119:SF14)  
SRSF10 
Serine/arginine-rich splicing 
factor 10 
SERINE/ARGININE-RICH SPLICING FACTOR 
10 (PTHR23147:SF34) 
mRNA splicing factor(PC00148) 
RQCD1 
Cell differentiation protein RCD1 
homolog 
CELL DIFFERENTIATION PROTEIN RCD1 
HOMOLOG (PTHR12262:SF5)  
LTBP3 
Latent-transforming growth 
factor beta-binding protein 3 
LATENT-TRANSFORMING GROWTH 
FACTOR BETA-BINDING PROTEIN 3 
(PTHR24034:SF69) 
annexin(PC00050); calmodulin(PC00061); cell 
adhesion molecule(PC00069); extracellular matrix 
glycoprotein(PC00100); extracellular matrix 
structural protein(PC00103); signaling 
molecule(PC00207) 
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
HIST2H3PS2 Histone H3 
HISTONE H3-RELATED 
(PTHR11426:SF110) 
histone(PC00118) 
UBR2 E3 ubiquitin-protein ligase UBR2 
E3 UBIQUITIN-PROTEIN LIGASE UBR2 
(PTHR21497:SF36)  
MARK3 
MAP/microtubule affinity-
regulating kinase 3 
MAP/MICROTUBULE AFFINITY-
REGULATING KINASE 3 (PTHR24346:SF30) 
non-receptor serine/threonine protein 
kinase(PC00167) 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
GPD2 
Glycerol-3-phosphate 
dehydrogenase, mitochondrial 
GLYCEROL-3-PHOSPHATE 
DEHYDROGENASE, MITOCHONDRIAL 
(PTHR11985:SF19)  
MCMBP 
Mini-chromosome maintenance 
complex-binding protein 
MINI-CHROMOSOME MAINTENANCE 
COMPLEX-BINDING PROTEIN 
(PTHR13489:SF1)  
ST5 
Suppression of tumorigenicity 5 
protein 
SUPPRESSION OF TUMORIGENICITY 5 
PROTEIN (PTHR15288:SF12)  
IPO8 Importin-8 IMPORTIN-8 (PTHR10997:SF42) small GTPase(PC00208); transporter(PC00227) 
HLTF Helicase-like transcription factor 
HELICASE-LIKE TRANSCRIPTION FACTOR 
(PTHR10799:SF915) 
DNA helicase(PC00011) 
DNPH1 
2'-deoxynucleoside 5'-phosphate 
N-hydrolase 1 
2'-DEOXYNUCLEOSIDE 5'-PHOSPHATE N-
HYDROLASE 1 (PTHR15364:SF3)  
KDELC1 KDEL motif-containing protein 1 
KDEL MOTIF-CONTAINING PROTEIN 1 
(PTHR12203:SF46)  
GINS3 
DNA replication complex GINS 
protein PSF3 
DNA REPLICATION COMPLEX GINS 
PROTEIN PSF3 (PTHR22768:SF1)  
CTGF Connective tissue growth factor 
CONNECTIVE TISSUE GROWTH FACTOR 
(PTHR11348:SF30) 
growth factor(PC00112) 
HIST1H2AA Histone H2A type 1-A 
HISTONE H2A TYPE 1-A 
(PTHR23430:SF182) 
histone(PC00118) 
PDS5B 
Sister chromatid cohesion 
protein PDS5 homolog B 
SISTER CHROMATID COHESION PROTEIN 
PDS5 HOMOLOG B (PTHR12663:SF13) 
chromatin/chromatin-binding protein(PC00077) 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
ANAPC4 
Anaphase-promoting complex 
subunit 4 
ANAPHASE-PROMOTING COMPLEX 
SUBUNIT 4 (PTHR13260:SF1)  
PHKB 
Phosphorylase b kinase 
regulatory subunit beta 
PHOSPHORYLASE B KINASE REGULATORY 
SUBUNIT BETA (PTHR10749:SF11) 
kinase activator(PC00138) 
GRIPAP1 GRIP1-associated protein 1 
GRIP1-ASSOCIATED PROTEIN 1 
(PTHR18978:SF2)  
COMMD9 
COMM domain-containing 
protein 9 
COMM DOMAIN-CONTAINING PROTEIN 9 
(PTHR15663:SF6)  
GPKOW 
G patch domain and KOW 
motifs-containing protein 
G PATCH DOMAIN AND KOW MOTIFS-
CONTAINING PROTEIN (PTHR15818:SF3) 
nucleic acid binding(PC00171) 
COBLL1 Cordon-bleu protein-like 1 
CORDON-BLEU PROTEIN-LIKE 1 
(PTHR21557:SF12)  
RAB9A Ras-related protein Rab-9A 
RAS-RELATED PROTEIN RAB-9A 
(PTHR24073:SF717)  
PBK 
Lymphokine-activated killer T-
cell-originated protein kinase 
LYMPHOKINE-ACTIVATED KILLER T-CELL-
ORIGINATED PROTEIN KINASE 
(PTHR43289:SF3) 
protein kinase(PC00193) 
RTKN Rhotekin RHOTEKIN (PTHR21538:SF29) 
 
CUX1 Homeobox protein cut-like 1 
HOMEOBOX PROTEIN CUT-LIKE 1 
(PTHR14043:SF18) 
homeobox transcription factor(PC00119); nucleic 
acid binding(PC00171) 
EXOSC7 
Exosome complex component 
RRP42 
EXOSOME COMPLEX COMPONENT RRP42 
(PTHR11097:SF16) 
exoribonuclease(PC00099); hydrolase(PC00121) 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
AFAP1 
Actin filament-associated protein 
1 
ACTIN FILAMENT-ASSOCIATED PROTEIN 1 
(PTHR14338:SF10)  
SPTLC1 Serine palmitoyltransferase 1 
SERINE PALMITOYLTRANSFERASE 1 
(PTHR13693:SF72) 
transaminase(PC00216) 
FN1 Fibronectin FIBRONECTIN (PTHR19143:SF308) signaling molecule(PC00207) 
BRAT1 
BRCA1-associated ATM activator 
1 
BRCA1-ASSOCIATED ATM ACTIVATOR 1 
(PTHR21331:SF3)  
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
FAM96B 
Mitotic spindle-associated 
MMXD complex subunit MIP18 
MITOTIC SPINDLE-ASSOCIATED MMXD 
COMPLEX SUBUNIT MIP18 
(PTHR12377:SF4)  
GABPA GA-binding protein alpha chain 
GA-BINDING PROTEIN ALPHA CHAIN 
(PTHR11849:SF215) 
nucleic acid binding(PC00171); signaling 
molecule(PC00207); transcription factor(PC00218) 
CDK3 Cyclin-dependent kinase 3 
CYCLIN-DEPENDENT KINASE 3 
(PTHR24056:SF313) 
non-receptor serine/threonine protein 
kinase(PC00167); non-receptor tyrosine protein 
kinase(PC00168) 
SBF1 Myotubularin-related protein 5 
MYOTUBULARIN-RELATED PROTEIN 5 
(PTHR10807:SF91) 
phosphatase(PC00181) 
PIK3C2A 
Phosphatidylinositol 4-
phosphate 3-kinase C2 domain-
containing subunit alpha 
PHOSPHATIDYLINOSITOL 4-PHOSPHATE 3-
KINASE C2 DOMAIN-CONTAINING 
SUBUNIT ALPHA (PTHR10048:SF88) 
kinase(PC00137) 
PHF5A 
PHD finger-like domain-
containing protein 5A 
PHD FINGER-LIKE DOMAIN-CONTAINING 
PROTEIN 5A (PTHR13120:SF3)  
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
H3F3A Histone H3.3 
HISTONE H3.3-RELATED 
(PTHR11426:SF121) 
histone(PC00118) 
MTR Methionine synthase 
METHIONINE SYNTHASE 
(PTHR21091:SF149) 
decarboxylase(PC00089); 
methyltransferase(PC00155); reductase(PC00198) 
CKS1B 
Cyclin-dependent kinases 
regulatory subunit 1 
CYCLIN-DEPENDENT KINASES 
REGULATORY SUBUNIT 1 
(PTHR23415:SF24) 
kinase modulator(PC00140) 
MARK4 
MAP/microtubule affinity-
regulating kinase 4 
MAP/MICROTUBULE AFFINITY-
REGULATING KINASE 4 (PTHR24346:SF32) 
non-receptor serine/threonine protein 
kinase(PC00167) 
BAG5 
BAG family molecular chaperone 
regulator 5 
BAG FAMILY MOLECULAR CHAPERONE 
REGULATOR 5 (PTHR12329:SF21)  
EXOSC4 
Exosome complex component 
RRP41 
EXOSOME COMPLEX COMPONENT RRP41 
(PTHR11953:SF4) 
exoribonuclease(PC00099); hydrolase(PC00121); 
nucleotidyltransferase(PC00174) 
PLXND1 Plexin-D1 PLEXIN-D1 (PTHR22625:SF48) 
 
PEF1 Peflin PEFLIN (PTHR10183:SF361) 
annexin(PC00050); calmodulin(PC00061); cysteine 
protease(PC00081) 
DNAJB6 
DnaJ homolog subfamily B 
member 6 
DNAJ HOMOLOG SUBFAMILY B MEMBER 
6 (PTHR24078:SF483)  
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
NUP160 
Nuclear pore complex protein 
Nup160 
NUCLEAR PORE COMPLEX PROTEIN 
NUP160 (PTHR21286:SF1) 
transporter(PC00227) 
KDELC2 KDEL motif-containing protein 2 
KDEL MOTIF-CONTAINING PROTEIN 2 
(PTHR12203:SF37)  
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
RAB3B Ras-related protein Rab-3B 
RAS-RELATED PROTEIN RAB-3B 
(PTHR24073:SF773)  
ALAD 
Delta-aminolevulinic acid 
dehydratase 
DELTA-AMINOLEVULINIC ACID 
DEHYDRATASE (PTHR11458:SF3) 
dehydratase(PC00091) 
RBM12B RNA-binding protein 12B 
RNA-BINDING PROTEIN 12B 
(PTHR13976:SF57) 
ribosomal protein(PC00202) 
EHD2 EH domain-containing protein 2 
EH DOMAIN-CONTAINING PROTEIN 2 
(PTHR11216:SF106) 
G-protein modulator(PC00022); calcium-binding 
protein(PC00060); membrane traffic 
protein(PC00150) 
RANBP9 Ran-binding protein 9 
RAN-BINDING PROTEIN 9 
(PTHR12864:SF30) 
transfer/carrier protein(PC00219); 
transporter(PC00227) 
EHBP1 EH domain-binding protein 1 
EH DOMAIN-BINDING PROTEIN 1 
(PTHR11915:SF416) 
non-motor actin binding protein(PC00165) 
IGFBP7 
Insulin-like growth factor-binding 
protein 7 
INSULIN-LIKE GROWTH FACTOR-BINDING 
PROTEIN 7 (PTHR14186:SF24)  
ZNF622 Zinc finger protein 622 
ZINC FINGER PROTEIN 622 
(PTHR13182:SF16) 
RNA binding protein(PC00031) 
INPP1 
Inositol polyphosphate 1-
phosphatase 
INOSITOL POLYPHOSPHATE 1-
PHOSPHATASE (PTHR43028:SF3) 
phosphatase(PC00181) 
MICAL1 
Protein-methionine sulfoxide 
oxidase MICAL1 
PROTEIN-METHIONINE SULFOXIDE 
OXIDASE MICAL1 (PTHR11915:SF387) 
non-motor actin binding protein(PC00165) 
LEPREL2 Prolyl 3-hydroxylase 3 
PROLYL 3-HYDROXYLASE 3 
(PTHR14049:SF16) 
extracellular matrix glycoprotein(PC00100) 
TANC1 Protein TANC1 PROTEIN TANC1 (PTHR24166:SF39) non-receptor serine/threonine protein 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
kinase(PC00167) 
ACOX3 
Peroxisomal acyl-coenzyme A 
oxidase 3 
PEROXISOMAL ACYL-COENZYME A 
OXIDASE 3 (PTHR10909:SF358) 
dehydrogenase(PC00092); oxidase(PC00175); 
transferase(PC00220) 
LEPREL1 Prolyl 3-hydroxylase 2 
PROLYL 3-HYDROXYLASE 2 
(PTHR14049:SF17) 
extracellular matrix glycoprotein(PC00100) 
VPS37B 
Vacuolar protein sorting-
associated protein 37B 
VACUOLAR PROTEIN SORTING-
ASSOCIATED PROTEIN 37B 
(PTHR13678:SF17)  
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
ANP32C 
Acidic leucine-rich nuclear 
phosphoprotein 32 family 
member C 
ACIDIC LEUCINE-RICH NUCLEAR 
PHOSPHOPROTEIN 32 FAMILY MEMBER 
A-RELATED (PTHR11375:SF9) 
phosphatase inhibitor(PC00183) 
SPC24 Kinetochore protein Spc24 
KINETOCHORE PROTEIN SPC24 
(PTHR22142:SF3)  
ZCCHC8 
Zinc finger CCHC domain-
containing protein 8 
ZINC FINGER CCHC DOMAIN-CONTAINING 
PROTEIN 8 (PTHR13316:SF4) 
nucleic acid binding(PC00171) 
PTPRF 
Receptor-type tyrosine-protein 
phosphatase F 
RECEPTOR-TYPE TYROSINE-PROTEIN 
PHOSPHATASE F (PTHR19134:SF343) 
protein phosphatase(PC00195); receptor(PC00197) 
KPNA5 Importin subunit alpha-6 
IMPORTIN SUBUNIT ALPHA-6 
(PTHR23316:SF44) 
transfer/carrier protein(PC00219) 
PPP1R8 
Nuclear inhibitor of protein 
phosphatase 1 
NUCLEAR INHIBITOR OF PROTEIN 
PHOSPHATASE 1 (PTHR23308:SF39)  
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
ALDH16A1 
Aldehyde dehydrogenase family 
16 member A1 
ALDEHYDE DEHYDROGENASE FAMILY 16 
MEMBER A1 (PTHR11699:SF228) 
dehydrogenase(PC00092) 
CDK11B Cyclin-dependent kinase 11B 
CYCLIN-DEPENDENT KINASE 11A-RELATED 
(PTHR24056:SF238) 
non-receptor serine/threonine protein 
kinase(PC00167); non-receptor tyrosine protein 
kinase(PC00168) 
IFT27 
Intraflagellar transport protein 
27 homolog 
INTRAFLAGELLAR TRANSPORT PROTEIN 
27 HOMOLOG (PTHR24073:SF625)  
HCRT Orexin OREXIN (PTHR15173:SF3) 
 
ADPRH 
[Protein ADP-ribosylarginine] 
hydrolase 
[PROTEIN ADP-RIBOSYLARGININE] 
HYDROLASE (PTHR22957:SF407) 
G-protein modulator(PC00022); hydrolase(PC00121) 
ECE1 Endothelin-converting enzyme 1 
ENDOTHELIN-CONVERTING ENZYME 1 
(PTHR11733:SF162) 
metalloprotease(PC00153) 
ATG4B Cysteine protease ATG4B 
CYSTEINE PROTEASE ATG4B 
(PTHR22624:SF45) 
hydrolase(PC00121) 
WAPAL 
Wings apart-like protein 
homolog 
WINGS APART-LIKE PROTEIN HOMOLOG 
(PTHR22100:SF16)  
SGTB 
Small glutamine-rich 
tetratricopeptide repeat-
containing protein beta 
SMALL GLUTAMINE-RICH 
TETRATRICOPEPTIDE REPEAT-
CONTAINING PROTEIN BETA 
(PTHR22904:SF452) 
chaperone(PC00072) 
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
CBS Cystathionine beta-synthase 
CYSTATHIONINE BETA-SYNTHASE 
(PTHR10314:SF149) 
deaminase(PC00088); dehydratase(PC00091); 
epimerase/racemase(PC00096) 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
RAB38 Ras-related protein Rab-38 
RAS-RELATED PROTEIN RAB-38 
(PTHR24073:SF636)  
ACYP1 Acylphosphatase-1 ACYLPHOSPHATASE-1 (PTHR10029:SF15) phosphatase(PC00181) 
REPS1 
RalBP1-associated Eps domain-
containing protein 1 
RALBP1-ASSOCIATED EPS DOMAIN-
CONTAINING PROTEIN 1 
(PTHR11216:SF102) 
G-protein modulator(PC00022); membrane traffic 
protein(PC00150) 
ARIH1 E3 ubiquitin-protein ligase ARIH1 
E3 UBIQUITIN-PROTEIN LIGASE ARIH1 
(PTHR11685:SF182) 
ubiquitin-protein ligase(PC00234); calcium-binding 
protein(PC00060) 
MIER1 
Mesoderm induction early 
response protein 1 
MESODERM INDUCTION EARLY 
RESPONSE PROTEIN 1 (PTHR10865:SF36) 
chromatin/chromatin-binding protein(PC00077); 
histone(PC00118) 
COMMD7 
COMM domain-containing 
protein 7 
COMM DOMAIN-CONTAINING PROTEIN 7 
(PTHR16231:SF9)  
MARK1 
Serine/threonine-protein kinase 
MARK1 
SERINE/THREONINE-PROTEIN KINASE 
MARK1 (PTHR24346:SF36) 
non-receptor serine/threonine protein 
kinase(PC00167) 
PTRHD1 
Putative peptidyl-tRNA hydrolase 
PTRHD1 
PEPTIDYL-TRNA HYDROLASE PTRHD1-
RELATED (PTHR11717:SF25) 
protein phosphatase(PC00195); reductase(PC00198) 
CCDC50 
Coiled-coil domain-containing 
protein 50 
COILED-COIL DOMAIN-CONTAINING 
PROTEIN 50 (PTHR22115:SF5)  
PTGES2 Prostaglandin E synthase 2 
PROSTAGLANDIN E SYNTHASE 2 
(PTHR12782:SF9) 
reductase(PC00198) 
PREPL Prolyl endopeptidase-like 
PROLYL ENDOPEPTIDASE-LIKE 
(PTHR11757:SF16) 
serine protease(PC00203) 
HSPG2 
Basement membrane-specific 
heparan sulphate proteoglycan 
BASEMENT MEMBRANE-SPECIFIC 
HEPARAN SULFATE PROTEOGLYCAN CORE 
extracellular matrix linker protein(PC00101); 
receptor(PC00197) 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
core protein PROTEIN (PTHR10574:SF343) 
GSDMD Gasdermin-D GASDERMIN-D (PTHR16399:SF22) 
 
NR2C2AP 
Nuclear receptor 2C2-associated 
protein 
NUCLEAR RECEPTOR 2C2-ASSOCIATED 
PROTEIN (PTHR31535:SF2)  
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
AP2S1 AP-2 complex subunit sigma 
AP-2 COMPLEX SUBUNIT SIGMA 
(PTHR11753:SF21) 
vesicle coat protein(PC00235) 
PTGIS Prostacyclin synthase 
PROSTACYCLIN SYNTHASE 
(PTHR24306:SF9) 
isomerase(PC00135); oxidoreductase(PC00176) 
SAMHD1 
Deoxynucleoside triphosphate 
triphosphohydrolase SAMHD1 
DEOXYNUCLEOSIDE TRIPHOSPHATE 
TRIPHOSPHOHYDROLASE SAMHD1 
(PTHR11373:SF35)  
RPRD2 
Regulation of nuclear pre-mRNA 
domain-containing protein 2 
REGULATION OF NUCLEAR PRE-MRNA 
DOMAIN-CONTAINING PROTEIN 2 
(PTHR12460:SF14) 
kinase inhibitor(PC00139) 
COL4A1 Collagen alpha-1(IV) chain 
COLLAGEN ALPHA-1(IV) CHAIN 
(PTHR24023:SF662)  
NNMT 
Nicotinamide N-
methyltransferase 
NICOTINAMIDE N-METHYLTRANSFERASE 
(PTHR10867:SF22) 
methyltransferase(PC00155) 
AP1G2 
AP-1 complex subunit gamma-
like 2 
AP-1 COMPLEX SUBUNIT GAMMA-LIKE 2 
(PTHR22780:SF36) 
transmembrane receptor regulatory/adaptor 
protein(PC00226) 
BIN1 
Myc box-dependent-interacting 
protein 1 
MYC BOX-DEPENDENT-INTERACTING 
PROTEIN 1 (PTHR10663:SF287) 
actin family cytoskeletal protein(PC00041); guanyl-
nucleotide exchange factor(PC00113) 
Chapter 5: COMPARATIVE PROTEOMICS ON DIFFERENTIALLY EXPRESSED AAG CELL LINES 
 
247 
 
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
HIST3H3 Histone H3.1t 
HISTONE H3.1-RELATED 
(PTHR11426:SF145) 
histone(PC00118) 
PNMA2 Paraneoplastic antigen Ma2 
PARANEOPLASTIC ANTIGEN MA2 
(PTHR23095:SF26) 
defence/immunity protein(PC00090) 
NUP35 Nucleoporin NUP53 NUCLEOPORIN NUP53 (PTHR21527:SF9) 
 
RTCA 
RNA 3'-terminal phosphate 
cyclase 
RNA 3'-TERMINAL PHOSPHATE CYCLASE 
(PTHR11096:SF2) 
RNA binding protein(PC00031); cyclase(PC00079) 
RFC5 Replication factor C subunit 5 
REPLICATION FACTOR C SUBUNIT 5 
(PTHR11669:SF33) 
DNA-directed DNA polymerase(PC00018); 
nucleotidyltransferase(PC00174); 
nucleotidyltransferase(PC00174) 
STAG1 Cohesin subunit SA-1 
COHESIN SUBUNIT SA-1 
(PTHR11199:SF18) 
chromatin/chromatin-binding protein(PC00077) 
NAA30 N-alpha-acetyltransferase 30 
N-ALPHA-ACETYLTRANSFERASE 30 
(PTHR23091:SF289) 
acetyltransferase(PC00038) 
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
RB1 
Retinoblastoma-associated 
protein 
RETINOBLASTOMA-ASSOCIATED PROTEIN 
(PTHR13742:SF26) 
nucleic acid binding(PC00171); transcription 
factor(PC00218) 
PMEPA1 Protein TMEPAI PROTEIN TMEPAI (PTHR16514:SF8) 
 
RFC2 Replication factor C subunit 2 
REPLICATION FACTOR C SUBUNIT 2 
(PTHR11669:SF44) 
DNA-directed DNA polymerase(PC00018), 
nucleotidyltransferase(PC00174) 
DRAP1 Dr1-associated corepressor 
DR1-ASSOCIATED COREPRESSOR 
(PTHR10252:SF51) 
DNA-directed DNA polymerase(PC00018); 
chromatin/chromatin-binding protein(PC00077); 
transcription factor(PC00218) 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
MORF4L1 Mortality factor 4-like protein 1 
MORTALITY FACTOR 4-LIKE PROTEIN 1 
(PTHR10880:SF38) 
chromatin/chromatin-binding protein(PC00077) 
ZAK 
Mitogen-activated protein kinase 
kinase kinase MLT 
MITOGEN-ACTIVATED PROTEIN KINASE 
KINASE KINASE MLT (PTHR23257:SF591) 
non-receptor serine/threonine protein 
kinase(PC00167); transcription factor(PC00218); 
non-receptor tyrosine protein kinase(PC00168) 
PRIM2 DNA primase large subunit 
DNA PRIMASE LARGE SUBUNIT 
(PTHR10537:SF4)  
WDR61 WD repeat-containing protein 61 
  
HIST2H3A Histone H3.2 HISTONE H3.2 (PTHR11426:SF135) histone(PC00118) 
HIST2H2BC Putative histone H2B type 2-C 
HISTONE H2B TYPE 2-C-RELATED 
(PTHR23428:SF131) 
histone(PC00118) 
FBXO30 F-box only protein 30 
F-BOX ONLY PROTEIN 30 
(PTHR15933:SF19)  
LMO7 LIM domain only protein 7 
LIM DOMAIN ONLY PROTEIN 7 
(PTHR15551:SF6) 
actin family cytoskeletal protein(PC00041) 
MAP2K3 
Dual specificity mitogen-
activated protein kinase kinase 3 
DUAL SPECIFICITY MITOGEN-ACTIVATED 
PROTEIN KINASE KINASE 3 
(PTHR24361:SF432)  
PRKAG1 
5'-AMP-activated protein kinase 
subunit gamma-1 
5'-AMP-ACTIVATED PROTEIN KINASE 
SUBUNIT GAMMA-1 (PTHR13780:SF81) 
kinase modulator(PC00140) 
CBLB E3 ubiquitin-protein ligase CBL-B 
E3 UBIQUITIN-PROTEIN LIGASE CBL-B 
(PTHR23007:SF16) 
ligase(PC00142) 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
COL4A2 Collagen alpha-2(IV) chain 
COLLAGEN ALPHA-2(IV) CHAIN 
(PTHR24023:SF657)  
RPL3L 60S ribosomal protein L3-like 
60S RIBOSOMAL PROTEIN L3-LIKE 
(PTHR11363:SF9) 
ribosomal protein(PC00202) 
COMMD3 
COMM domain-containing 
protein 3 
COMM DOMAIN-CONTAINING PROTEIN 3 
(PTHR31159:SF2)  
NT5DC2 
5'-nucleotidase domain-
containing protein 2 
5'-NUCLEOTIDASE DOMAIN-CONTAINING 
PROTEIN 2 (PTHR12103:SF28) 
nucleotide phosphatase(PC00173) 
ATE1 
Arginyl-tRNA--protein 
transferase 1 
ARGINYL-TRNA--PROTEIN TRANSFERASE 1 
(PTHR21367:SF2) 
acetyltransferase(PC00038) 
BCR Breakpoint cluster region protein 
BREAKPOINT CLUSTER REGION PROTEIN 
(PTHR23182:SF10) 
guanyl-nucleotide exchange factor(PC00113) 
RIF1 
Telomere-associated protein 
RIF1 
TELOMERE-ASSOCIATED PROTEIN RIF1 
(PTHR22928:SF4)  
H1F0 Histone H1.0 HISTONE H1.0 (PTHR11467:SF59) histone(PC00118) 
RBBP9 Putative hydrolase RBBP9 
HYDROLASE RBBP9-RELATED 
(PTHR15394:SF4)  
TNS1 Tensin-1 TENSIN-1 (PTHR12305:SF70) protein phosphatase(PC00195) 
EMC3 
ER membrane protein complex 
subunit 3 
ER MEMBRANE PROTEIN COMPLEX 
SUBUNIT 3 (PTHR13116:SF9)  
PJA2 E3 ubiquitin-protein ligase Praja- E3 UBIQUITIN-PROTEIN LIGASE PRAJA-2 ubiquitin-protein ligase(PC00234) 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
2 (PTHR15710:SF6) 
GTPBP1 GTP-binding protein 1 
GTP-BINDING PROTEIN 1 
(PTHR43721:SF11) 
G-protein(PC00020); hydrolase(PC00121); 
translation elongation factor(PC00222); translation 
initiation factor(PC00224) 
SERPINB8 Serpin B8 SERPIN B8 (PTHR11461:SF265) serine protease inhibitor(PC00204) 
HIST2H3A Histone H3.2 
HISTONE H3-RELATED 
(PTHR11426:SF110) 
histone(PC00118) 
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
KIF1A Kinesin-like protein KIF1A 
KINESIN-LIKE PROTEIN KIF1A 
(PTHR24115:SF616) 
microtubule binding motor protein(PC00156) 
FN3K Fructosamine-3-kinase 
FRUCTOSAMINE-3-KINASE 
(PTHR12149:SF12)  
HIST2H3A Histone H3.2 HISTONE H3.2 (PTHR11426:SF157) histone(PC00118) 
GNE 
Bifunctional UDP-N-
acetylglucosamine 2-
epimerase/N-
acetylmannosamine kinase 
BIFUNCTIONAL UDP-N-
ACETYLGLUCOSAMINE 2-EPIMERASE/N-
ACETYLMANNOSAMINE KINASE 
(PTHR18964:SF152) 
carbohydrate kinase(PC00065); 
epimerase/racemase(PC00096); transcription 
factor(PC00218) 
GFRA1 GDNF family receptor alpha-1 
GDNF FAMILY RECEPTOR ALPHA-1 
(PTHR10269:SF21)  
HDHD2 
Haloacid dehalogenase-like 
hydrolase domain-containing 
protein 2 
HALOACID DEHALOGENASE-LIKE 
HYDROLASE DOMAIN-CONTAINING 
PROTEIN 2 (PTHR19288:SF46)  
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
QTRTD1 
Queuine tRNA-ribosyltransferase 
subunit QTRTD1 
QUEUINE TRNA-RIBOSYLTRANSFERASE 
SUBUNIT QTRTD1 (PTHR21148:SF38) 
G-protein modulator(PC00022); 
chaperone(PC00072) 
RPS6KA4 
Ribosomal protein S6 kinase 
alpha-4 
RIBOSOMAL PROTEIN S6 KINASE ALPHA-4 
(PTHR24351:SF123) 
annexin(PC00050); calmodulin(PC00061); cysteine 
protease(PC00081); non-receptor serine/threonine 
protein kinase(PC00167); transfer/carrier 
protein(PC00219) 
COL18A1 Collagen alpha-1(XVIII) chain 
COLLAGEN ALPHA-1(XVIII) CHAIN 
(PTHR24023:SF733)  
INSL6 Insulin-like peptide INSL6 
INSULIN-LIKE PEPTIDE INSL6 
(PTHR12004:SF7) 
peptide hormone(PC00179) 
SAAL1 Protein SAAL1 PROTEIN SAAL1 (PTHR23424:SF12) 
 
LYAR 
Cell growth-regulating nucleolar 
protein 
CELL GROWTH-REGULATING NUCLEOLAR 
PROTEIN (PTHR13100:SF11)  
COL8A1 Collagen alpha-1(VIII) chain 
COLLAGEN ALPHA-1(VIII) CHAIN 
(PTHR24023:SF634) 
cell adhesion molecule(PC00069); extracellular 
matrix structural protein(PC00103) 
SH3GLB2 Endophilin-B2 ENDOPHILIN-B2 (PTHR10663:SF305) guanyl-nucleotide exchange factor(PC00113) 
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
ANP32D 
Acidic leucine-rich nuclear 
phosphoprotein 32 family 
member D 
ACIDIC LEUCINE-RICH NUCLEAR 
PHOSPHOPROTEIN 32 FAMILY MEMBER 
A-RELATED (PTHR11375:SF9) 
phosphatase inhibitor(PC00183) 
HMOX2 Heme oxygenase 2 HEME OXYGENASE 2 (PTHR10720:SF6) oxygenase(PC00177) 
ARFGEF2 
Brefeldin A-inhibited guanine 
nucleotide-exchange protein 2 
BREFELDIN A-INHIBITED GUANINE 
NUCLEOTIDE-EXCHANGE PROTEIN 2 
guanyl-nucleotide exchange factor(PC00113) 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
(PTHR10663:SF231) 
SNRPD2 
Small nuclear ribonucleoprotein 
Sm D2 
SMALL NUCLEAR RIBONUCLEOPROTEIN 
SM D2 (PTHR12777:SF2) 
mRNA processing factor(PC00147) 
STK4 
Serine/threonine-protein kinase 
4 
SERINE/THREONINE-PROTEIN KINASE 4 
(PTHR24361:SF538)  
COMMD8 
COMM domain-containing 
protein 8 
COMM DOMAIN-CONTAINING PROTEIN 8 
(PTHR16231:SF8)  
CDKN2B 
Cyclin-dependent kinase 4 
inhibitor B 
CYCLIN-DEPENDENT KINASE 4 INHIBITOR 
B (PTHR24148:SF53) 
kinase inhibitor(PC00139) 
LRIF1 
Ligand-dependent nuclear 
receptor-interacting factor 1 
LIGAND-DEPENDENT NUCLEAR 
RECEPTOR-INTERACTING FACTOR 1 
(PTHR16131:SF3)  
PRPSAP2 
Phosphoribosyl pyrophosphate 
synthase-associated protein 2 
PHOSPHORIBOSYL PYROPHOSPHATE 
SYNTHASE-ASSOCIATED PROTEIN 2 
(PTHR10210:SF78) 
carbohydrate kinase(PC00065); ligase(PC00142); 
nucleotide kinase(PC00172) 
STK33 
Serine/threonine-protein kinase 
33 
SERINE/THREONINE-PROTEIN KINASE 33 
(PTHR24347:SF269) 
non-receptor serine/threonine protein 
kinase(PC00167) 
TRIP4 Activating signal cointegrator 1 
ACTIVATING SIGNAL COINTEGRATOR 1 
(PTHR12963:SF3) 
transcription cofactor(PC00217) 
TRAPPC4 
Trafficking protein particle 
complex subunit 4 
TRAFFICKING PROTEIN PARTICLE 
COMPLEX SUBUNIT 4 (PTHR23249:SF17) 
membrane traffic protein(PC00150) 
CEP170P1 Cep170-like protein 
CENTROSOMAL PROTEIN OF 170 KDA 
PROTEIN B-RELATED (PTHR15715:SF34)  
ANAPC1 Anaphase-promoting complex ANAPHASE-PROMOTING COMPLEX ligase(PC00142) 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
subunit 1 SUBUNIT 1 (PTHR12827:SF4) 
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
GTF3C1 
General transcription factor 3C 
polypeptide 1 
GENERAL TRANSCRIPTION FACTOR 3C 
POLYPEPTIDE 1 (PTHR15180:SF3)  
FHL3 
Four and a half LIM domains 
protein 3 
FOUR AND A HALF LIM DOMAINS 
PROTEIN 3 (PTHR24205:SF9) 
zinc finger transcription factor(PC00244) 
ANKMY2 
Ankyrin repeat and MYND 
domain-containing protein 2 
ANKYRIN REPEAT AND MYND DOMAIN-
CONTAINING PROTEIN 2 
(PTHR24150:SF11)  
ASRGL1 
Isoaspartyl peptidase/L-
asparaginase 
ISOASPARTYL PEPTIDASE/L-
ASPARAGINASE (PTHR10188:SF32) 
protease(PC00190) 
PMVK Phosphomevalonate kinase 
PHOSPHOMEVALONATE KINASE 
(PTHR13101:SF2)  
CMTR1 
Cap-specific mRNA (nucleoside-
2'-O-)-methyltransferase 1 
CAP-SPECIFIC MRNA (NUCLEOSIDE-2'-O-)-
METHYLTRANSFERASE 1 (PTHR16121:SF3)  
HYI 
Putative hydroxypyruvate 
isomerase 
HYDROXYPYRUVATE ISOMERASE-
RELATED (PTHR43489:SF9) 
DNA binding protein(PC00009), isomerase(PC00135) 
RNASEH2C Ribonuclease H2 subunit C 
RIBONUCLEASE H2 SUBUNIT C 
(PTHR21726:SF70) 
glycosyltransferase(PC00111) 
CDC42EP2 Cdc42 effector protein 2 
CDC42 EFFECTOR PROTEIN 2 
(PTHR15344:SF17)  
EXOSC10 Exosome component 10 
EXOSOME COMPONENT 10 
(PTHR12124:SF54) 
exoribonuclease(PC00099); hydrolase(PC00121) 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
BCAT2 
Branched-chain-amino-acid 
aminotransferase, mitochondrial 
BRANCHED-CHAIN-AMINO-ACID 
AMINOTRANSFERASE, MITOCHONDRIAL 
(PTHR11825:SF68) 
transaminase(PC00216) 
HINT1 
Histidine triad nucleotide-
binding protein 1 
HISTIDINE TRIAD NUCLEOTIDE-BINDING 
PROTEIN 1 (PTHR23089:SF20) 
nucleotide phosphatase(PC00173) 
SNRPC 
U1 small nuclear 
ribonucleoprotein C 
U1 SMALL NUCLEAR 
RIBONUCLEOPROTEIN C (PTHR31148:SF5)  
WDR44 WD repeat-containing protein 44 
WD REPEAT-CONTAINING PROTEIN 44 
(PTHR14221:SF17)  
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
SSH1 
Protein phosphatase Slingshot 
homolog 1 
PROTEIN PHOSPHATASE SLINGSHOT 
HOMOLOG 1 (PTHR10159:SF434)  
SLC1A4 Neutral amino acid transporter A 
NEUTRAL AMINO ACID TRANSPORTER A 
(PTHR11958:SF78) 
cation transporter(PC00068) 
POLR2C 
DNA-directed RNA polymerase II 
subunit RPB3 
DNA-DIRECTED RNA POLYMERASE II 
SUBUNIT RPB3 (PTHR11800:SF14) 
DNA-directed RNA polymerase(PC00019) 
GLUL Glutamine synthetase 
GLUTAMINE SYNTHETASE 
(PTHR20852:SF67) 
ligase(PC00142) 
OPLAH 5-oxoprolinase 5-OXOPROLINASE (PTHR11365:SF13) 
 
GUSB Beta-glucuronidase 
BETA-GLUCURONIDASE 
(PTHR10066:SF76) 
galactosidase(PC00104) 
TRAPPC12 
Trafficking protein particle 
complex subunit 12 
TRAFFICKING PROTEIN PARTICLE 
COMPLEX SUBUNIT 12 (PTHR21581:SF13) 
protease(PC00190) 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
DNAJC1 
DnaJ homolog subfamily C 
member 1 
DNAJ HOMOLOG SUBFAMILY C MEMBER 
1 (PTHR24078:SF510)  
DLGAP4 Disks large-associated protein 4 
DISKS LARGE-ASSOCIATED PROTEIN 4 
(PTHR12353:SF25) 
transmembrane receptor regulatory/adaptor 
protein(PC00226) 
STRN Striatin STRIATIN (PTHR15653:SF6) 
 
THOC6 THO complex subunit 6 homolog 
THO COMPLEX SUBUNIT 6 HOMOLOG 
(PTHR22847:SF555) 
esterase(PC00097), kinase inhibitor(PC00139); 
mRNA splicing factor(PC00148) 
COASY 
Bifunctional coenzyme A 
synthase 
BIFUNCTIONAL COENZYME A SYNTHASE 
(PTHR10695:SF42) 
kinase(PC00137) 
ACP2 Lysosomal acid phosphatase 
LYSOSOMAL ACID PHOSPHATASE 
(PTHR11567:SF155) 
phosphatase(PC00181) 
COMMD10 
COMM domain-containing 
protein 10 
COMM DOMAIN-CONTAINING PROTEIN 
10 (PTHR12333:SF1)  
SRSF11 
Serine/arginine-rich splicing 
factor 11 
SERINE/ARGININE-RICH SPLICING FACTOR 
11 (PTHR32343:SF9) 
RNA binding protein(PC00031) 
SEC14L2 SEC14-like protein 2 SEC14-LIKE PROTEIN 2 (PTHR23324:SF92) 
transfer/carrier protein(PC00219); 
transporter(PC00227) 
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
DIAPH3 Protein diaphanous homolog 3 
PROTEIN DIAPHANOUS HOMOLOG 3 
(PTHR23213:SF299) 
non-motor actin binding protein(PC00165) 
PPT1 Palmitoyl-protein thioesterase 1 
PALMITOYL-PROTEIN THIOESTERASE 1 
(PTHR11247:SF36) 
esterase(PC00097) 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
MAGT1 
Magnesium transporter protein 
1 
MAGNESIUM TRANSPORTER PROTEIN 1 
(PTHR12692:SF5) 
glycosyltransferase(PC00111) 
HIST2H2BD Putative histone H2B type 2-D 
HISTONE H2B TYPE 2-C-RELATED 
(PTHR23428:SF131) 
histone(PC00118) 
VAV2 
Guanine nucleotide exchange 
factor VAV2 
GUANINE NUCLEOTIDE EXCHANGE 
FACTOR VAV2 (PTHR22826:SF164) 
guanyl-nucleotide exchange factor(PC00113); 
signaling molecule(PC00207) 
RPS24 40S ribosomal protein S24 
40S RIBOSOMAL PROTEIN S24 
(PTHR10496:SF6) 
ribosomal protein(PC00202) 
AAR2 Protein AAR2 homolog 
PROTEIN AAR2 HOMOLOG 
(PTHR12689:SF5)  
PPP2R1B 
Serine/threonine-protein 
phosphatase 2A 65 kDa 
regulatory subunit A beta 
isoform 
SERINE/THREONINE-PROTEIN 
PHOSPHATASE 2A 65 KDA REGULATORY 
SUBUNIT A BETA ISOFORM 
(PTHR10648:SF14) 
protein phosphatase(PC00195) 
CTR9 
RNA polymerase-associated 
protein CTR9 homolog 
RNA POLYMERASE-ASSOCIATED PROTEIN 
CTR9 HOMOLOG (PTHR14027:SF3)  
SNRPD1 
Small nuclear ribonucleoprotein 
Sm D1 
SMALL NUCLEAR RIBONUCLEOPROTEIN 
SM D1 (PTHR23338:SF31) 
mRNA splicing factor(PC00148); 
ribonucleoprotein(PC00201) 
AKAP8 A-kinase anchor protein 8 
A-KINASE ANCHOR PROTEIN 8 
(PTHR12190:SF7)  
PML Protein PML PROTEIN PML (PTHR24103:SF465) 
 
AHCTF1 Protein ELYS PROTEIN ELYS (PTHR21583:SF9) 
 
TACC3 
Transforming acidic coiled-coil-
containing protein 3 
TRANSFORMING ACIDIC COILED-COIL-
CONTAINING PROTEIN 3  
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
(PTHR13924:SF16) 
CDKN2AIP CDKN2A-interacting protein 
CDKN2A-INTERACTING PROTEIN 
(PTHR16148:SF8) 
DNA binding protein(PC00009) 
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
LSM2 
U6 snRNA-associated Sm-like 
protein LSm2 
U6 SNRNA-ASSOCIATED SM-LIKE PROTEIN 
LSM2 (PTHR13829:SF3) 
ribonucleoprotein(PC00201) 
FADS2 Fatty acid desaturase 2 
FATTY ACID DESATURASE 2 
(PTHR19353:SF37)  
CBL E3 ubiquitin-protein ligase CBL 
E3 UBIQUITIN-PROTEIN LIGASE CBL 
(PTHR23007:SF15) 
ligase(PC00142) 
CD2BP2 
CD2 antigen cytoplasmic tail-
binding protein 2 
CD2 ANTIGEN CYTOPLASMIC TAIL-
BINDING PROTEIN 2 (PTHR13138:SF4) 
chromatin/chromatin-binding protein(PC00077) 
NAPRT 
Nicotinate 
phosphoribosyltransferase 
NICOTINATE 
PHOSPHORIBOSYLTRANSFERASE 
(PTHR11098:SF21) 
glycosyltransferase(PC00111) 
PPOX Protoporphyrinogen oxidase 
PROTOPORPHYRINOGEN OXIDASE 
(PTHR42923:SF1) 
DNA methyltransferase(PC00013); 
oxidase(PC00175) 
S. Table 8: Proteins detected exclusively on AAG -/- A2C2 cells (on 2 replicates or more). 
Gene Symbol Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
MAGOHB 
Protein mago nashi 
homolog 2 
PROTEIN MAGO NASHI HOMOLOG 2 
(PTHR12638:SF5)  
DPYD 
Dihydropyrimidine 
dehydrogenase 
DIHYDROPYRIMIDINE DEHYDROGENASE [NADP (+)] 
(PTHR43073:SF2) 
dehydrogenase(PC00092); reductase(PC00198) 
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Gene Symbol Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
[NADP (+)] 
SUGP1 
SURP and G-patch 
domain-containing 
protein 1 
SURP AND G-PATCH DOMAIN-CONTAINING 
PROTEIN 1 (PTHR23340:SF5) 
mRNA splicing factor(PC00148) 
ATP13A1 
Manganese-
transporting ATPase 
13A1 
MANGANESE-TRANSPORTING ATPASE 13A1 
(PTHR24093:SF402) 
cation transporter(PC00068); hydrolase(PC00121); ion 
channel(PC00133) 
EDF1 
Endothelial 
differentiation-
related factor 1 
ENDOTHELIAL DIFFERENTIATION-RELATED FACTOR 
1 (PTHR10245:SF69) 
nucleic acid binding(PC00171); transcription cofactor(PC00217) 
TOP2B 
DNA topoisomerase 
2-beta 
DNA TOPOISOMERASE 2-BETA (PTHR10169:SF56) 
DNA topoisomerase (PC00017); enzyme modulator(PC00095); 
isomerase(PC00135) 
DYSF Dysferlin DYSFERLIN (PTHR12546:SF53) membrane traffic protein(PC00150) 
ARMT1 
Protein-glutamate 
O-
methyltransferase 
PROTEIN-GLUTAMATE O-METHYLTRANSFERASE 
(PTHR12260:SF9)  
NAA11 
N-alpha-
acetyltransferase 11 
N-ALPHA-ACETYLTRANSFERASE 11 
(PTHR23091:SF295) 
acetyltransferase(PC00038) 
MYO18A 
Unconventional 
myosin-XVIIIa 
UNCONVENTIONAL MYOSIN-XVIIIA 
(PTHR13140:SF575) 
G-protein modulator(PC00022); actin binding motor 
protein(PC00040); cell junction protein(PC00070) 
KIAA1524 Protein CIP2A PROTEIN CIP2A (PTHR23161:SF6) 
 
PACSIN3 
Protein kinase C and 
casein kinase 
substrate in neurons 
protein 3 
PROTEIN KINASE C AND CASEIN KINASE SUBSTRATE 
IN NEURONS PROTEIN 3 (PTHR23065:SF41) 
actin family cytoskeletal protein(PC00041); membrane trafficking 
regulatory protein(PC00151) 
TMED7-
TICAM2 
Protein TMED7-
TICAM2 
PROTEIN TMED7-TICAM2-RELATED 
(PTHR22811:SF96) 
transfer/carrier protein(PC00219); vesicle coat protein(PC00235) 
RCL1 
RNA 3'-terminal 
phosphate cyclase-
like protein 
RNA 3'-TERMINAL PHOSPHATE CYCLASE-LIKE 
PROTEIN (PTHR11096:SF3) 
RNA binding protein(PC00031); cyclase(PC00079) 
C17orf85 
Uncharacterized 
protein C17orf85 
SUBFAMILY NOT NAMED (PTHR16291:SF1) 
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Gene Symbol Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
ATXN3 Ataxin-3 ATAXIN-3 (PTHR14159:SF3) transcription factor(PC00218) 
EXOSC3 
Exosome complex 
component RRP40 
EXOSOME COMPLEX COMPONENT RRP40 
(PTHR21321:SF6) 
esterase(PC00097); exoribonuclease(PC00099) 
MYO1F 
Unconventional 
myosin-If 
UNCONVENTIONAL MYOSIN-IF (PTHR13140:SF593) 
G-protein modulator(PC00022); actin binding motor 
protein(PC00040); cell junction protein(PC00070) 
RRP1B 
Ribosomal RNA 
processing protein 1 
homolog B 
RIBOSOMAL RNA PROCESSING PROTEIN 1 
HOMOLOG B (PTHR13026:SF3)  
RACGAP1 
Rac GTPase-
activating protein 1 
RAC GTPASE-ACTIVATING PROTEIN 1 
(PTHR23176:SF84) 
G-protein modulator(PC00022) 
SFXN3 Sideroflexin-3 SIDEROFLEXIN-3 (PTHR11153:SF34) cation transporter(PC00068); transfer/carrier protein(PC00219) 
TMED7 
Transmembrane 
emp24 domain-
containing protein 7 
PROTEIN TMED7-TICAM2-RELATED 
(PTHR22811:SF96) 
transfer/carrier protein(PC00219); vesicle coat protein(PC00235) 
STXBP6 
Syntaxin-binding 
protein 6 
SYNTAXIN-BINDING PROTEIN 6 (PTHR16092:SF24) transfer/carrier protein(PC00219) 
TOM1L1 TOM1-like protein 1 TOM1-LIKE PROTEIN 1 (PTHR13856:SF113) membrane traffic protein(PC00150); transporter(PC00227) 
SLC25A11 
Mitochondrial 2-
oxoglutarate/malate 
carrier protein 
MITOCHONDRIAL 2-OXOGLUTARATE/MALATE 
CARRIER PROTEIN (PTHR24089:SF424) 
amino acid transporter(PC00046); calmodulin(PC00061); 
mitochondrial carrier protein(PC00158); ribosomal 
protein(PC00202); transfer/carrier protein(PC00219) 
PYCR2 
Pyrroline-5-
carboxylate 
reductase 2 
PYRROLINE-5-CARBOXYLATE REDUCTASE 2 
(PTHR11645:SF31)  
FYN 
Tyrosine-protein 
kinase Fyn 
TYROSINE-PROTEIN KINASE FYN (PTHR24418:SF291) non-receptor tyrosine protein kinase(PC00168) 
GOLM1 
Golgi membrane 
protein 1 
GOLGI MEMBRANE PROTEIN 1 (PTHR15896:SF10) 
 
MAGOH 
Protein mago nashi 
homolog 
PROTEIN MAGO NASHI HOMOLOG (PTHR12638:SF4) 
 
TMEM30A 
Cell cycle control 
protein 50A 
CELL CYCLE CONTROL PROTEIN 50A 
(PTHR10926:SF33)  
WDR36 
WD repeat-
containing protein 
WD REPEAT-CONTAINING PROTEIN 36 
(PTHR22840:SF16) 
mRNA splicing factor(PC00148) 
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Gene Symbol Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
36 
KIF1BP KIF1-binding protein KIF1-BINDING PROTEIN (PTHR20956:SF11) 
 
FAM120B 
Constitutive 
coactivator of 
peroxisome 
proliferator-
activated receptor 
gamma 
CONSTITUTIVE COACTIVATOR OF PEROXISOME 
PROLIFERATOR-ACTIVATED RECEPTOR GAMMA 
(PTHR15976:SF19) 
 
WFS1 Wolframin WOLFRAMIN (PTHR13098:SF7) 
 
EIF4E 
Eukaryotic 
translation initiation 
factor 4E 
EUKARYOTIC TRANSLATION INITIATION FACTOR 4E 
(PTHR11960:SF36) 
translation initiation factor(PC00224) 
TMED5 
Transmembrane 
emp24 domain-
containing protein 5 
TRANSMEMBRANE EMP24 DOMAIN-CONTAINING 
PROTEIN 5 (PTHR22811:SF80) 
transfer/carrier protein(PC00219); vesicle coat protein(PC00235) 
SMTN Smoothelin SMOOTHELIN (PTHR11915:SF421) non-motor actin binding protein(PC00165) 
CACNA2D1 
Voltage-dependent 
calcium channel 
subunit alpha-
2/delta-1 
VOLTAGE-DEPENDENT CALCIUM CHANNEL SUBUNIT 
ALPHA-2/DELTA-1 (PTHR10166:SF46)  
PES1 Pescadillo homolog PESCADILLO HOMOLOG (PTHR12221:SF8) ribosomal protein(PC00202) 
QSOX1 Sulfhydryl oxidase 1 SULFHYDRYL OXIDASE 1 (PTHR22897:SF16) oxidase(PC00175) 
ITGB4 Integrin beta-4 INTEGRIN BETA-4 (PTHR10082:SF51) 
cell adhesion molecule(PC00069); extracellular matrix 
glycoprotein(PC00100); receptor(PC00197) 
NOSIP 
Nitric oxide 
synthase-interacting 
protein 
NITRIC OXIDE SYNTHASE-INTERACTING PROTEIN 
(PTHR13063:SF11)  
TBC1D5 
TBC1 domain family 
member 5 
TBC1 DOMAIN FAMILY MEMBER 5 
(PTHR22957:SF351) 
G-protein modulator(PC00022); hydrolase(PC00121) 
SMARCA2 
Probable global 
transcription 
GLOBAL TRANSCRIPTION ACTIVATOR SNF2L2-
RELATED (PTHR10799:SF870) 
DNA helicase(PC00011) 
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activator SNF2L2 
STX5 Syntaxin-5 SYNTAXIN-5 (PTHR19957:SF182) SNARE protein(PC00034) 
ATAD3B 
ATPase family AAA 
domain-containing 
protein 3B 
ATPASE FAMILY AAA DOMAIN-CONTAINING 
PROTEIN 3B (PTHR23075:SF7) 
hydrolase(PC00121) 
NDUFA5 
NADH 
dehydrogenase 
[ubiquinone] 1 
alpha subcomplex 
subunit 5 
NADH DEHYDROGENASE [UBIQUINONE] 1 ALPHA 
SUBCOMPLEX SUBUNIT 5 (PTHR12653:SF1) 
oxidoreductase(PC00176) 
YKT6 
Synaptobrevin 
homolog YKT6 
SYNAPTOBREVIN HOMOLOG YKT6 
(PTHR21136:SF154) 
SNARE protein(PC00034) 
CDKN2AIPNL 
CDKN2AIP N-
terminal-like protein 
CDKN2AIP N-TERMINAL-LIKE PROTEIN 
(PTHR16148:SF9) 
DNA binding protein(PC00009) 
SLC25A10 
Mitochondrial 
dicarboxylate carrier 
MITOCHONDRIAL DICARBOXYLATE CARRIER 
(PTHR24089:SF592) 
amino acid transporter(PC00046); calmodulin(PC00061); 
mitochondrial carrier protein(PC00158); ribosomal 
protein(PC00202); transfer/carrier protein(PC00219) 
LARP4B 
La-related protein 
4B 
LA-RELATED PROTEIN 4B (PTHR22792:SF84) ribonucleoprotein(PC00201) 
TRIP10 
Cdc42-interacting 
protein 4 
CDC42-INTERACTING PROTEIN 4 
(PTHR10663:SF295) 
cytoskeletal protein(PC00085); guanyl-nucleotide exchange 
factor(PC00113); signaling molecule(PC00207) 
RBM5 
RNA-binding protein 
5 
RNA-BINDING PROTEIN 5 (PTHR13948:SF28) RNA binding protein(PC00031) 
CAV1 Caveolin-1 CAVEOLIN-1 (PTHR10844:SF23) 
G-protein modulator(PC00022); membrane traffic protein(PC00150); 
structural protein(PC00211); transmembrane receptor 
regulatory/adaptor protein(PC00226) 
S. Table 9: Proteins detected exclusively on AAG-/- B6C3 (2 replicates or more). 
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
MAGOHB Protein mago nashi homolog 2 PROTEIN MAGO NASHI HOMOLOG 2 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
(PTHR12638:SF5) 
SF3B14 Splicing factor 3B subunit 6 
SPLICING FACTOR 3B SUBUNIT 6 
(PTHR12785:SF10) 
mRNA splicing factor(PC00148) 
ATP13A1 Manganese-transporting ATPase 13A1 
MANGANESE-TRANSPORTING ATPASE 13A1 
(PTHR24093:SF402) 
cation transporter(PC00068); hydrolase(PC00121); ion 
channel(PC00133) 
IQGAP2 
Ras GTPase-activating-like protein 
IQGAP2 
RAS GTPASE-ACTIVATING-LIKE PROTEIN IQGAP2 
(PTHR14149:SF21) 
G-protein modulator(PC00022) 
IMPAD1 Inositol monophosphatase 3 
INOSITOL MONOPHOSPHATASE 3 
(PTHR43028:SF6) 
phosphatase(PC00181) 
TOP2B DNA topoisomerase 2-beta DNA TOPOISOMERASE 2-BETA (PTHR10169:SF56) 
DNA topoisomerase(PC00017); enzyme 
modulator(PC00095); isomerase(PC00135) 
DYSF Dysferlin DYSFERLIN (PTHR12546:SF53) membrane traffic protein(PC00150) 
WNK4 
Serine/threonine-protein kinase 
WNK4 
SERINE/THREONINE-PROTEIN KINASE WNK4 
(PTHR13902:SF91) 
non-receptor serine/threonine protein 
kinase(PC00167) 
MAP1A Microtubule-associated protein 1A 
MICROTUBULE-ASSOCIATED PROTEIN 1A 
(PTHR13843:SF13) 
non-motor microtubule binding protein(PC00166) 
ARMT1 
Protein-glutamate O-
methyltransferase 
PROTEIN-GLUTAMATE O-METHYLTRANSFERASE 
(PTHR12260:SF9)  
RNF31 E3 ubiquitin-protein ligase RNF31 
E3 UBIQUITIN-PROTEIN LIGASE RNF31 
(PTHR16004:SF6)  
TSPAN10 Tetraspanin-10 TETRASPANIN-10 (PTHR19282:SF355) 
cell adhesion molecule(PC00069); membrane-bound 
signaling molecule(PC00152); receptor(PC00197) 
MAN2B1 Lysosomal alpha-mannosidase 
LYSOSOMAL ALPHA-MANNOSIDASE 
(PTHR11607:SF38) 
glycosidase(PC00110) 
NAA11 N-alpha-acetyltransferase 11 
N-ALPHA-ACETYLTRANSFERASE 11 
(PTHR23091:SF295) 
acetyltransferase(PC00038) 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
PSMG3 Proteasome assembly chaperone 3 
PROTEASOME ASSEMBLY CHAPERONE 3 
(PTHR31051:SF2)  
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
MYO18A Unconventional myosin-XVIIIa 
UNCONVENTIONAL MYOSIN-XVIIIA 
(PTHR13140:SF575) 
G-protein modulator(PC00022); actin binding motor 
protein(PC00040); cell junction protein(PC00070) 
VPS11 
Vacuolar protein sorting-associated 
protein 11 homolog 
VACUOLAR PROTEIN SORTING-ASSOCIATED 
PROTEIN 11 HOMOLOG (PTHR23323:SF28) 
membrane trafficking regulatory protein(PC00151) 
SMAD3 
Mothers against decapentaplegic 
homolog 3 
MOTHERS AGAINST DECAPENTAPLEGIC 
HOMOLOG 3 (PTHR13703:SF55) 
transcription factor(PC00218) 
AGTRAP 
Type-1 angiotensin II receptor-
associated protein 
TYPE-1 ANGIOTENSIN II RECEPTOR-ASSOCIATED 
PROTEIN (PTHR16521:SF4)  
M6PR 
Cation-dependent mannose-6-
phosphate receptor 
CATION-DEPENDENT MANNOSE-6-PHOSPHATE 
RECEPTOR (PTHR15071:SF11) 
receptor(PC00197) 
RPS6KA2 Ribosomal protein S6 kinase alpha-2 
RIBOSOMAL PROTEIN S6 KINASE ALPHA-2 
(PTHR24351:SF138) 
annexin(PC00050); calmodulin(PC00061); non-receptor 
serine/threonine protein kinase(PC00167); 
transfer/carrier protein(PC00219) 
AKR1C1 
Aldo-keto reductase family 1 member 
C1 
ALDO-KETO REDUCTASE FAMILY 1 MEMBER C1 
(PTHR11732:SF324) 
reductase(PC00198) 
TMED7-
TICAM2 
Protein TMED7-TICAM2 
PROTEIN TMED7-TICAM2-RELATED 
(PTHR22811:SF96) 
transfer/carrier protein(PC00219); vesicle coat 
protein(PC00235) 
BRIX1 
Ribosome biogenesis protein BRX1 
homolog 
RIBOSOME BIOGENESIS PROTEIN BRX1 HOMOLOG 
(PTHR13634:SF3) 
ribosomal protein(PC00202) 
NUDT3 
Diphosphoinositol polyphosphate 
phosphohydrolase 1 
DIPHOSPHOINOSITOL POLYPHOSPHATE 
PHOSPHOHYDROLASE 1 (PTHR12629:SF31) 
phosphatase(PC00181) 
ARHGEF6 Rho guanine nucleotide exchange RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 6 guanyl-nucleotide exchange factor(PC00113); signaling 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
factor 6 (PTHR22826:SF182) molecule(PC00207) 
VPS16 
Vacuolar protein sorting-associated 
protein 16 homolog 
VACUOLAR PROTEIN SORTING-ASSOCIATED 
PROTEIN 16 HOMOLOG (PTHR12811:SF1)  
ITGA4 Integrin alpha-4 INTEGRIN ALPHA-4 (PTHR23220:SF98) 
 
MPZL1 Myelin protein zero-like protein 1 
MYELIN PROTEIN ZERO-LIKE PROTEIN 1 
(PTHR13869:SF27) 
cell adhesion molecule(PC00069); voltage-gated 
sodium channel(PC00243) 
GGCX 
Vitamin K-dependent gamma-
carboxylase 
VITAMIN K-DEPENDENT GAMMA-CARBOXYLASE 
(PTHR12639:SF9)  
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
DTNB Dystrobrevin beta DYSTROBREVIN BETA (PTHR11915:SF361) non-motor actin binding protein(PC00165) 
C17orf85 Uncharacterized protein C17orf85 SUBFAMILY NOT NAMED (PTHR16291:SF1) 
 
GPRC5A Retinoic acid-induced protein 3 
RETINOIC ACID-INDUCED PROTEIN 3 
(PTHR14511:SF21) 
G-protein coupled receptor(PC00021) 
FAM82B 
Regulator of microtubule dynamics 
protein 1 
REGULATOR OF MICROTUBULE DYNAMICS 
PROTEIN 1 (PTHR16056:SF26)  
UBE2E1 Ubiquitin-conjugating enzyme E2 E1 
UBIQUITIN-CONJUGATING ENZYME E2 E1 
(PTHR24068:SF83) 
ligase(PC00142) 
GNAL 
Guanine nucleotide-binding protein 
G(olf) subunit alpha 
GUANINE NUCLEOTIDE-BINDING PROTEIN G(OLF) 
SUBUNIT ALPHA (PTHR10218:SF258) 
heterotrimeric G-protein(PC00117) 
RBM28 RNA-binding protein 28 RNA-BINDING PROTEIN 28 (PTHR24012:SF659) 
 
M6PR 
Cation-independent mannose-6-
phosphate receptor 
CATION-INDEPENDENT MANNOSE-6-PHOSPHATE 
RECEPTOR (PTHR15071:SF15) 
receptor(PC00197) 
CYB5R1 NADH-cytochrome b5 reductase 1 
NADH-CYTOCHROME B5 REDUCTASE 1 
(PTHR19370:SF138) 
reductase(PC00198) 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
RAB4A Ras-related protein Rab-4A 
RAS-RELATED PROTEIN RAB-4A 
(PTHR24073:SF662)  
RRP1B 
Ribosomal RNA processing protein 1 
homolog B 
RIBOSOMAL RNA PROCESSING PROTEIN 1 
HOMOLOG B (PTHR13026:SF3)  
CLTA Clathrin light chain A CLATHRIN LIGHT CHAIN A (PTHR10639:SF14) vesicle coat protein(PC00235) 
RHOT1 Mitochondrial Rho GTPase 1 
MITOCHONDRIAL RHO GTPASE 1 
(PTHR24072:SF185) 
small GTPase(PC00208) 
DCAF13 DDB1- and CUL4-associated factor 13 
DDB1- AND CUL4-ASSOCIATED FACTOR 13 
(PTHR22851:SF1) 
RNA binding protein(PC00031) 
COX6C Cytochrome c oxidase subunit 6C 
CYTOCHROME C OXIDASE SUBUNIT 6C 
(PTHR12916:SF3)  
DHX38 
Pre-mRNA-splicing factor ATP-
dependent RNA helicase PRP16 
PRE-MRNA-SPLICING FACTOR ATP-DEPENDENT 
RNA HELICASE PRP16 (PTHR18934:SF178) 
RNA helicase(PC00032) 
SFXN3 Sideroflexin-3 SIDEROFLEXIN-3 (PTHR11153:SF34) 
cation transporter(PC00068); transfer/carrier 
protein(PC00219) 
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
TMED7 
Transmembrane emp24 domain-
containing protein 7 
PROTEIN TMED7-TICAM2-RELATED 
(PTHR22811:SF96) 
transfer/carrier protein(PC00219); vesicle coat 
protein(PC00235) 
MDC1 
Mediator of DNA damage checkpoint 
protein 1 
MEDIATOR OF DNA DAMAGE CHECKPOINT 
PROTEIN 1 (PTHR23196:SF16)  
ITGA7 Integrin alpha-7 INTEGRIN ALPHA-7 (PTHR23220:SF96) 
 
TOM1L1 TOM1-like protein 1 TOM1-LIKE PROTEIN 1 (PTHR13856:SF113) 
membrane traffic protein(PC00150); 
transporter(PC00227) 
WDR43 WD repeat-containing protein 43 
WD REPEAT-CONTAINING PROTEIN 43 
(PTHR22847:SF533) 
esterase(PC00097); kinase inhibitor(PC00139); mRNA 
splicing factor(PC00148) 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
NBEA Neurobeachin NEUROBEACHIN (PTHR13743:SF87) 
 
LPIN1 Phosphatidate phosphatase LPIN1 
PHOSPHATIDATE PHOSPHATASE LPIN1 
(PTHR12181:SF47)  
APOOL MICOS complex subunit MIC27 
MICOS COMPLEX SUBUNIT MIC27 
(PTHR14564:SF5)  
DMXL2 DmX-like protein 2 DMX-LIKE PROTEIN 2 (PTHR13950:SF14) 
 
SLC25A11 
Mitochondrial 2-oxoglutarate/malate 
carrier protein 
MITOCHONDRIAL 2-OXOGLUTARATE/MALATE 
CARRIER PROTEIN (PTHR24089:SF424) 
amino acid transporter(PC00046); 
calmodulin(PC00061); mitochondrial carrier 
protein(PC00158); ribosomal protein(PC00202); 
transfer/carrier protein(PC00219) 
MFN2 Mitofusin-2 MITOFUSIN-2 (PTHR10465:SF9) nucleotide phosphatase(PC00173) 
UQCRB Cytochrome b-c1 complex subunit 7 
CYTOCHROME B-C1 COMPLEX SUBUNIT 7 
(PTHR12022:SF1) 
reductase(PC00198) 
JAM3 Junctional adhesion molecule C 
JUNCTIONAL ADHESION MOLECULE C 
(PTHR12231:SF157)  
DDRGK1 DDRGK domain-containing protein 1 
DDRGK DOMAIN-CONTAINING PROTEIN 1 
(PTHR13270:SF5)  
SNCA Alpha-synuclein ALPHA-SYNUCLEIN (PTHR13820:SF12) 
chaperone(PC00072); membrane traffic 
protein(PC00150) 
BDH2 
3-hydroxybutyrate dehydrogenase 
type 2 
3-HYDROXYBUTYRATE DEHYDROGENASE TYPE 2 
(PTHR43477:SF4)  
EPB41 Protein 4.1 PROTEIN 4.1 (PTHR23280:SF38) 
 
PYCR2 Pyrroline-5-carboxylate reductase 2 
PYRROLINE-5-CARBOXYLATE REDUCTASE 2 
(PTHR11645:SF31)  
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
LRP10 
Low-density lipoprotein receptor-
related protein 10 
LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED 
PROTEIN 10 (PTHR10529:SF300) 
extracellular matrix glycoprotein(PC00100); 
receptor(PC00197) 
RPTOR 
Regulatory-associated protein of 
mTOR 
REGULATORY-ASSOCIATED PROTEIN OF MTOR 
(PTHR12848:SF18)  
CCDC25 
Coiled-coil domain-containing protein 
25 
COILED-COIL DOMAIN-CONTAINING PROTEIN 25 
(PTHR13049:SF6)  
ARMC9 
LisH domain-containing protein 
ARMC9 
LISH DOMAIN-CONTAINING PROTEIN ARMC9 
(PTHR14881:SF5)  
CXADR 
Coxsackievirus and adenovirus 
receptor 
COXSACKIEVIRUS AND ADENOVIRUS RECEPTOR 
(PTHR12231:SF211)  
CALB2 Calretinin CALRETININ (PTHR19972:SF12) calcium-binding protein(PC00060) 
ATG5 Autophagy protein 5 AUTOPHAGY PROTEIN 5 (PTHR13040:SF3) membrane trafficking regulatory protein(PC00151) 
TSC2 Tuberin TUBERIN (PTHR10063:SF12) 
 
DDT D-dopachrome decarboxylase 
D-DOPACHROME DECARBOXYLASE 
(PTHR11954:SF30) 
cytokine(PC00083); isomerase(PC00135) 
MINK1 Misshapen-like kinase 1 MISSHAPEN-LIKE KINASE 1 (PTHR24361:SF463) 
 
PALMD Palmdelphin PALMDELPHIN (PTHR10498:SF14) 
 
SSFA2 Sperm-specific antigen 2 SPERM-SPECIFIC ANTIGEN 2 (PTHR17469:SF17) 
 
MAGOH Protein mago nashi homolog 
PROTEIN MAGO NASHI HOMOLOG 
(PTHR12638:SF4)  
THYN1 Thymocyte nuclear protein 1 
THYMOCYTE NUCLEAR PROTEIN 1 
(PTHR14087:SF10)  
TMEM33 Transmembrane protein 33 TRANSMEMBRANE PROTEIN 33 (PTHR12703:SF7) 
 
HEG1 Protein HEG homolog 1 PROTEIN HEG HOMOLOG 1 (PTHR24037:SF6) 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
SOGA2 Microtubule cross-linking factor 1 
MICROTUBULE CROSS-LINKING FACTOR 1 
(PTHR15742:SF9)  
WDR36 WD repeat-containing protein 36 
WD REPEAT-CONTAINING PROTEIN 36 
(PTHR22840:SF16) 
mRNA splicing factor(PC00148) 
BCAR1 
Breast cancer anti-oestrogen 
resistance protein 1 
BREAST CANCER ANTI-ESTROGEN RESISTANCE 
PROTEIN 1 (PTHR10654:SF24)  
CPA4 Carboxypeptidase A4 CARBOXYPEPTIDASE A4 (PTHR11705:SF83) metalloprotease(PC00153) 
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
NAA38 
N-alpha-acetyltransferase 38, NatC 
auxiliary subunit 
N-ALPHA-ACETYLTRANSFERASE 38, NATC 
AUXILIARY SUBUNIT (PTHR10701:SF6)  
GIT1 ARF GTPase-activating protein GIT1 
ARF GTPASE-ACTIVATING PROTEIN GIT1 
(PTHR23180:SF363) 
G-protein modulator(PC00022); nucleic acid 
binding(PC00171) 
AKR1C3 
Aldo-keto reductase family 1 member 
C3 
ALDO-KETO REDUCTASE FAMILY 1 MEMBER C3 
(PTHR11732:SF316) 
reductase(PC00198) 
DDX54 ATP-dependent RNA helicase DDX54 
ATP-DEPENDENT RNA HELICASE DDX54 
(PTHR24031:SF501) 
RNA helicase(PC00032) 
VAC14 Protein VAC14 homolog PROTEIN VAC14 HOMOLOG (PTHR16023:SF1) receptor(PC00197) 
EIF4E 
Eukaryotic translation initiation factor 
4E 
EUKARYOTIC TRANSLATION INITIATION FACTOR 
4E (PTHR11960:SF36) 
translation initiation factor(PC00224) 
ZMPSTE24 CAAX prenyl protease 1 homolog 
CAAX PRENYL PROTEASE 1 HOMOLOG 
(PTHR10120:SF25) 
metalloprotease(PC00153) 
POR NADPH--cytochrome P450 reductase 
NADPH--CYTOCHROME P450 REDUCTASE 
(PTHR19384:SF104)  
SYPL1 Synaptophysin-like protein 1 
SYNAPTOPHYSIN-LIKE PROTEIN 1 
(PTHR10306:SF21) 
membrane trafficking regulatory protein(PC00151) 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
RRAGD Ras-related GTP-binding protein D 
RAS-RELATED GTP-BINDING PROTEIN D 
(PTHR11259:SF11) 
small GTPase(PC00208) 
MMP2 72 kDa type IV collagenase 
72 KDA TYPE IV COLLAGENASE 
(PTHR10201:SF199)  
FOXO3 Forkhead box protein O3 FORKHEAD BOX PROTEIN O3 (PTHR11829:SF243) 
DNA binding protein(PC00009); transcription 
factor(PC00218) 
ANK2 Ankyrin-2 ANKYRIN-2 (PTHR24123:SF39) cytoskeletal protein(PC00085) 
PES1 Pescadillo homolog PESCADILLO HOMOLOG (PTHR12221:SF8) ribosomal protein(PC00202) 
UBAP1 Ubiquitin-associated protein 1 
UBIQUITIN-ASSOCIATED PROTEIN 1 
(PTHR15960:SF8)  
PPP1R18 Phostensin PHOSTENSIN (PTHR21685:SF5) 
 
C7orf50 Uncharacterized protein C7orf50 SUBFAMILY NOT NAMED (PTHR22306:SF3) 
 
DNAJC11 DnaJ homolog subfamily C member 11 
DNAJ HOMOLOG SUBFAMILY C MEMBER 11 
(PTHR24078:SF404)  
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
PAG1 
Phosphoprotein associated with 
glycosphingolipid-enriched 
microdomains 1 
PHOSPHOPROTEIN ASSOCIATED WITH 
GLYCOSPHINGOLIPID-ENRICHED MICRODOMAINS 
1 (PTHR16322:SF1)  
VPS13A 
Vacuolar protein sorting-associated 
protein 13A 
VACUOLAR PROTEIN SORTING-ASSOCIATED 
PROTEIN 13A (PTHR16166:SF120)  
SPCS1 Signal peptidase complex subunit 1 
SIGNAL PEPTIDASE COMPLEX SUBUNIT 1 
(PTHR13202:SF1) 
signaling molecule(PC00207) 
TBC1D5 TBC1 domain family member 5 
TBC1 DOMAIN FAMILY MEMBER 5 
(PTHR22957:SF351) 
G-protein modulator(PC00022); hydrolase(PC00121) 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
AGO2 Protein argonaute-2 PROTEIN ARGONAUTE-2 (PTHR22891:SF86) 
 
RP2 Protein XRP2 PROTEIN XRP2 (PTHR15440:SF1) nucleotide kinase(PC00172) 
ERO1LB ERO1-like protein beta ERO1-LIKE PROTEIN BETA (PTHR12613:SF6) oxidoreductase(PC00176) 
GRN Granulins GRANULINS (PTHR12274:SF6) 
 
FAM83H Protein FAM83H PROTEIN FAM83H (PTHR16181:SF21) 
 
GDAP1 
Ganglioside-induced differentiation-
associated protein 1 
GANGLIOSIDE-INDUCED DIFFERENTIATION-
ASSOCIATED PROTEIN 1 (PTHR11260:SF391) 
cytoskeletal protein(PC00085); 
epimerase/racemase(PC00096); reductase(PC00198); 
signaling molecule(PC00207); transferase(PC00220); 
translation elongation factor(PC00222) 
AP1M2 AP-1 complex subunit mu-2 
AP-1 COMPLEX SUBUNIT MU-2 
(PTHR10529:SF286) 
extracellular matrix glycoprotein(PC00100); 
receptor(PC00197) 
ATAD3C 
ATPase family AAA domain-containing 
protein 3C 
ATPASE FAMILY AAA DOMAIN-CONTAINING 
PROTEIN 3C (PTHR23075:SF8) 
hydrolase(PC00121) 
FUCA2 Plasma alpha-L-fucosidase PLASMA ALPHA-L-FUCOSIDASE (PTHR10030:SF34) 
 
GALNT1 
Polypeptide N-
acetylgalactosaminyltransferase 1 
POLYPEPTIDE N-
ACETYLGALACTOSAMINYLTRANSFERASE 1 
(PTHR11675:SF78) 
glycosyltransferase(PC00111) 
SNRPB2 U2 small nuclear ribonucleoprotein B'' 
U2 SMALL NUCLEAR RIBONUCLEOPROTEIN B'' 
(PTHR10501:SF30) 
mRNA splicing factor(PC00148) 
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
GALNT12 
Polypeptide N-
acetylgalactosaminyltransferase 12 
POLYPEPTIDE N-
ACETYLGALACTOSAMINYLTRANSFERASE 12 
(PTHR11675:SF82) 
glycosyltransferase(PC00111) 
CNOT3 
CCR4-NOT transcription complex 
subunit 3 
CCR4-NOT TRANSCRIPTION COMPLEX SUBUNIT 3 
(PTHR23326:SF7) 
transcription factor(PC00218) 
Chapter 5: COMPARATIVE PROTEOMICS ON DIFFERENTIALLY EXPRESSED AAG CELL LINES 
 
271 
 
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
GNA13 
Guanine nucleotide-binding protein 
subunit alpha-13 
GUANINE NUCLEOTIDE-BINDING PROTEIN 
SUBUNIT ALPHA-13 (PTHR10218:SF271) 
heterotrimeric G-protein(PC00117) 
SPAG7 Sperm-associated antigen 7 SPERM-ASSOCIATED ANTIGEN 7 (PTHR13498:SF4) nucleic acid binding(PC00171) 
NDUFA13 
NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 13 
NADH DEHYDROGENASE [UBIQUINONE] 1 ALPHA 
SUBCOMPLEX SUBUNIT 13 (PTHR12966:SF1) 
dehydrogenase(PC00092) 
LRP10 
Low-density lipoprotein receptor-
related protein 4 
LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED 
PROTEIN 4 (PTHR10529:SF278) 
extracellular matrix glycoprotein(PC00100); 
receptor(PC00197) 
PSD3 
PH and SEC7 domain-containing 
protein 3 
PH AND SEC7 DOMAIN-CONTAINING PROTEIN 3 
(PTHR10663:SF234) 
guanyl-nucleotide exchange factor(PC00113) 
PTDSS1 Phosphatidylserine synthase 1 
PHOSPHATIDYLSERINE SYNTHASE 1 
(PTHR15362:SF16) 
transferase(PC00220) 
GAR1 
H/ACA ribonucleoprotein complex 
subunit 1 
H/ACA RIBONUCLEOPROTEIN COMPLEX SUBUNIT 
1 (PTHR23237:SF9) 
ribosomal protein(PC00202) 
MAPRE3 
Microtubule-associated protein RP/EB 
family member 3 
MICROTUBULE-ASSOCIATED PROTEIN RP/EB 
FAMILY MEMBER 3 (PTHR10623:SF23) 
non-motor microtubule binding protein(PC00166) 
ATAD3B 
ATPase family AAA domain-containing 
protein 3B 
ATPASE FAMILY AAA DOMAIN-CONTAINING 
PROTEIN 3B (PTHR23075:SF7) 
hydrolase(PC00121) 
NDUFA5 
NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 5 
NADH DEHYDROGENASE [UBIQUINONE] 1 ALPHA 
SUBCOMPLEX SUBUNIT 5 (PTHR12653:SF1) 
oxidoreductase(PC00176) 
GJA1 Gap junction alpha-1 protein 
GAP JUNCTION ALPHA-1 PROTEIN 
(PTHR11984:SF70) 
gap junction(PC00105) 
S100A16 Protein S100-A16 PROTEIN S100-A16 (PTHR11639:SF93) calmodulin(PC00061); signaling molecule(PC00207) 
EML1 
Echinoderm microtubule-associated 
protein-like 1 
ECHINODERM MICROTUBULE-ASSOCIATED 
PROTEIN-LIKE 1 (PTHR13720:SF40)  
STX7 Syntaxin-7 SYNTAXIN-7 (PTHR19957:SF157) SNARE protein(PC00034) 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
METTL13 Methyltransferase-like protein 13 
METHYLTRANSFERASE-LIKE PROTEIN 13 
(PTHR12176:SF39)  
RAB23 Ras-related protein Rab-23 
RAS-RELATED PROTEIN RAB-23 
(PTHR24073:SF722)  
SNX27 Sorting nexin-27 SORTING NEXIN-27 (PTHR12431:SF23) 
 
FAM82A2 
Regulator of microtubule dynamics 
protein 3 
REGULATOR OF MICROTUBULE DYNAMICS 
PROTEIN 3 (PTHR16056:SF25)  
NF1 Neurofibromin NEUROFIBROMIN (PTHR10194:SF101) G-protein modulator(PC00022) 
SRP14 
Signal recognition particle 14 kDa 
protein 
SIGNAL RECOGNITION PARTICLE 14 KDA PROTEIN 
(PTHR12013:SF1) 
RNA binding protein(PC00031) 
CAMK2A 
Calcium/calmodulin-dependent 
protein kinase type II subunit alpha 
CALCIUM/CALMODULIN-DEPENDENT PROTEIN 
KINASE TYPE II SUBUNIT ALPHA 
(PTHR24347:SF318) 
non-receptor serine/threonine protein 
kinase(PC00167) 
ATP6V0A1 
V-type proton ATPase 116 kDa subunit 
a isoform 1 
V-TYPE PROTON ATPASE 116 KDA SUBUNIT A 
ISOFORM 1 (PTHR11629:SF77) 
ATP synthase(PC00002); hydrolase(PC00121) 
NFASC Neurofascin NEUROFASCIN (PTHR10489:SF774) 
G-protein coupled receptor(PC00021); 
immunoglobulin receptor superfamily(PC00124); 
immunoglobulin superfamily cell adhesion 
molecule(PC00125); protein phosphatase(PC00195) 
UPP1 Uridine phosphorylase 1 URIDINE PHOSPHORYLASE 1 (PTHR43691:SF8) phosphorylase(PC00187) 
SLC25A10 Mitochondrial dicarboxylate carrier 
MITOCHONDRIAL DICARBOXYLATE CARRIER 
(PTHR24089:SF592) 
amino acid transporter(PC00046); 
calmodulin(PC00061); mitochondrial carrier 
protein(PC00158); ribosomal protein(PC00202); 
transfer/carrier protein(PC00219) 
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Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
LARP4B La-related protein 4B LA-RELATED PROTEIN 4B (PTHR22792:SF84) ribonucleoprotein(PC00201) 
NSA2 
Ribosome biogenesis protein NSA2 
homolog 
RIBOSOME BIOGENESIS PROTEIN NSA2 HOMOLOG 
(PTHR12642:SF1)  
BNIP3L 
BCL2/adenovirus E1B 19 kDa protein-
interacting protein 3-like 
BCL2/ADENOVIRUS E1B 19 KDA PROTEIN-
INTERACTING PROTEIN 3-LIKE (PTHR15186:SF9)  
SLTM SAFB-like transcription modulator 
SAFB-LIKE TRANSCRIPTION MODULATOR 
(PTHR15683:SF12)  
PFDN1 Prefoldin subunit 1 PREFOLDIN SUBUNIT 1 (PTHR20903:SF1) 
 
Gene 
Symbol 
Gene Name PANTHER Family/Subfamily PANTHER Protein Class 
TUSC3 Tumour suppressor candidate 3 
TUMOR SUPPRESSOR CANDIDATE 3 
(PTHR12692:SF6) 
glycosyltransferase(PC00111) 
SMG8 Protein SMG8 PROTEIN SMG8 (PTHR13091:SF1) 
 
PALM Paralemmin-1 PARALEMMIN-1 (PTHR10498:SF19) 
 
DHX57 
Putative ATP-dependent RNA helicase 
DHX57 
ATP-DEPENDENT RNA HELICASE DHX57-RELATED 
(PTHR18934:SF177) 
RNA helicase(PC00032) 
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6 Discussion 
Eukaryotic cells are remarkably complex biological units. Countless layers 
of redundancy and components with multiple functions fight to ensure at steep 
energetic cost, that the entropy levels remain low in such a complex system. Highly 
interconnected networks of proteins sometimes result in seemingly unrelated 
processes being mutually affected by certain perturbations in the system.  
In this work, we describe one of such situations, where a DNA repair 
glycosylase, the alkyladenine DNA glycosylase not only functions maintaining 
genome integrity but also mediating a very complex network of responses aimed to 
re-establish protein homeostasis in the cell, with the latter being a very distinct 
activity from its originally described function as a DNA glycosylase. 
AAG is responsible for repairing DNA base damage caused by a quite varied 
collection of sources that include chemotherapeutic drugs, environmental pollution, 
diet and endogenous metabolic by-products (Goldman & Shields, 2003; Nagy et al., 
2013; Sedgwick et al., 2007; West et al., 2006). Befitting such a varied range, AAG is 
well equipped to deal with a wide variety of substrates, being able to process 
methylated bases as 3-methyladenine, 3-methylguanine and 7-methylguanine, 
deaminated guanine and adenine, among others (C. I. Lee et al., 2009).  
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AAG is peculiar not only on its substrates, but also on the effects its 
presence has in specific experimental situations. Depending on factors as cell type, 
experimental model (in vitro vs. in vivo) and stress type, Aag can play the role of 
keeper of genomic integrity (Engelward et al., 1996; Maor-Shoshani et al., 2008; 
Meira et al., 2008, 2014) or its repair can initiate a cascade reaction that may 
culminate with alkylation-derived tissue degeneration and increased cancer risk (J. 
A. Calvo et al., 2013; Ebrahimkhani et al., 2014; Leitner-Dagan et al., 2012; Meira et 
al., 2009; M. L. Rinne et al., 2005). 
On Chapter 2 we analyse the response of wild-type ARPE-19, human retinal 
pigmented epithelium cell and two differentially-modulated (overexpressor and 
knockouts) AAG cell lines engineered based on ARPE-19. Firstly, we observed that 
cells overexpressing AAG were shown to be more sensitive to alkylation damage 
than its wild-type and AAG-/-counterparts using a survival (MTS) assay. This 
particular result agrees with was seen in the literature so far. Most of the studies 
overexpressing AAG seem to agree that the surplus repair activity, rather than 
conferring protection against alkylation, renders cells and sometimes tissues more 
susceptible to alkylation. Two of the earliest studies overexpressing Aag were 
performed in Chinese Hamster Ovary cells and it was seen that not only 
overexpression did not increase resistance to MMS and MNNG, but resulted in a 
sharp increase in chromosomal aberrations (Coquerelle et al., 1995; Ibeanu et al., 
1992). It seems that the overexpression effects are also quite dramatic in in vivo 
models, albeit limited to certain tissues: Aag overexpressing mice display an 
enhanced retinal degeneration (more specifically on the outer nuclear layer of cells) 
(Meira et al., 2009) and increased lethality when treated with MMS, although 
cytotoxic morphological effects can only be observed in some overexpressing 
tissues/cell types like, thymus, spleen, pancreatic β-cells and granular cerebellar 
cells (J. A. Calvo et al., 2013). 
Some authors have suggested that this effect may be caused by the repair 
of relatively innocuous and majoritarian lesions as 7MeG that generate toxic 
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intermediates (AP sites, 5’dRP, SSBs) that overburdens downstream BER enzymes, 
causing their accumulation and cytotoxicity (J. A. Calvo et al., 2013, 2014; Fu et al., 
2012; M. L. Rinne et al., 2005). This enhanced toxicity was proposed as a useful 
therapeutical strategy to enhance cell-killing in certain tumours (Fishel et al., 2007; 
Fishel, Seo, Smith, Dna, et al., 2003; Leguisamo et al., 2017; Mikael Rinne, Caldwell, 
& Kelley, 2004). 
Although our results with AAG overexpression are in agreement with the 
augmented toxicity found on the mouse models (J. A. Calvo et al., 2013; Meira et 
al., 2009) our AAG -/- do not replicate the findings in the in vivo models (i.e. AAG 
knock-out cells are not protected from alkylation-induced cell death). Our AAG-
deficient cells are, in fact, more sensitive to alkylation than the wild-type ARPE-19. A 
similar sensitization was found in Aag -/- embryonic cells and (Elder et al., 1998; 
Engelward et al., 1997a). HeLa cells also show a 5- to 10-fold increase in sensitivity 
towards alkylation when there are high levels of AAG silencing (Paik et al., 2005). 
Rather than invalidating our results the contrast of the phenotypes only reinforces 
the notion of how nuanced the biological response to alkylation can be. Even within 
the same organism, there are striking differences between the phenotypic response 
to alkylation in different tissues (J. A. Calvo et al., 2013; Meira et al., 2009). There 
may still be several unaccounted factors as replication status, metabolic demands, 
cellular microenvironment and BER enzymes expression levels that could dictate the 
contrasting results. 
It was precisely during the search to identify the factors dictating the 
differences in response to alkylation that we serendipitously observed, when 
analysing the transcriptional response of wild-type and Aag -/- mice to MMS 
treatment, that a subset of transcripts related to ER stress and the UPR were 
upregulated only in Aag wild-type animals. Although this still unpublished study 
examines the MMS-induced transcriptional response in a repair deficient 
mammalian model, they are mirrored by studies in wild type Saccharomyces 
cerevisiae finding that alkylation treatment leads to transcriptional induction of the 
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UPR (Jelinsky, Estep, Church, & Samson, 2000; Jelinsky & Samson, 1999). This led us 
to question whether this could somehow explain the different phenotypes observed 
in response to alkylation treatment. 
Thus, we started the investigation on the putative role of AAG in the ER 
stress response, described on Chapter 3. By using the human cell line ARPE-19, we 
could observe that, in fact, treatment with MMS leads to ER stress induction as 
measured using a luciferase reporter system containing ERSE repeats. That an 
alkylating agent induces ER stress is not unexpected. Although most of the studies 
investigating responses to alkylation tend focus on its genotoxic properties, MMS 
and other alkylating agents can alkylate proteins, preferentially attacking cysteines, 
histidines and N-terminal valines (Boffa et al., 1987; F. Zhang, Bartels, Pottenger, & 
Gollapudi, 2005). Thus, it is reasonable to infer that at least part of the MMS-
induced ER response is triggered by the misfolding of damaged proteins. 
Furthermore, several studies analysing the proteomic responses generated by MMS 
treatment in yeast (Mazumder, Pesudo, McRee, Bathe, & Samson, 2013; Rochette, 
Gagnon-Arsenault, Diss, & Landry, 2014) and HeLa cells point not only to 
enrichment of the expected DDR proteins, but also to ubiquitin-proteasomal and 
ubiquitin-independent proteasomal components (Aslanian, Yates, & Hunter, 2014; 
Mazumder et al., 2013; Rochette et al., 2014). Besides, being involved directly in the 
DNA repair process and protein turnover, these could also be targeting damaged 
proteins. 
Our investigation not only revealed MMS treatment could trigger the UPR, 
but also that AAG is important to elicit the full-scale response with both MMS and 
thapsigargin, as shown by the greatly attenuated response on AAG-/- clones. We 
propose two mechanisms by which AAG could be participating on the UPR. The first 
is that the induction of the ER stress response may be an aftereffect from the 
imbalance generated by AAG-initiated repair after alkylating treatment. As 
mentioned throughout this work, the repair initiated by AAG can be detrimental to 
cell survival, presumably by the accumulation of toxic repair intermediates. These 
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toxic intermediates might cause transcription stalling (Edenberg et al., 2014; 
Wurtmann & Wolin, 2009) and generate mRNAs that could, in turn, be translated as 
truncated or misfolded proteins, and the accumulation of those would trigger the 
ER stress response (Figure 50). 
On the repair-dependent hypothesis, when AAG is absent, no toxic repair 
intermediates would be formed. As mentioned in Chapter 3, the participation of 
AAG in the alkylation-induced tissue degeneration was documented in different 
Figure 50: Repair-dependent hypothesis for UPR activation. The repair initiated by AAG could 
culminate in the accumulation of toxic repair intermediates that might cause transcription stalling 
and/or generate mRNAs that could be translated as truncated or misfolding proteins, and the 
accumulation of those would trigger the ER stress response. 
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tissues, in vivo (J. A. Calvo et al., 2013; Meira et al., 2009). In this scenario, the 
activation of the UPR could be a consequence of erroneous mRNA transcription 
caused by the accumulation of AAG-initiated BER intermediates, and those 
truncated mRNAs could, in turn, cause transcription stalling (Edenberg et al., 2014) 
leading to an increase of truncated/misfolded proteins in the ER, triggering thus the 
UPR by the canonical pathway. It is also possible that the mitochondria plays a role 
in this response, as AAG also repairs alkylation damage in this organelle (van Loon & 
Samson, 2013). Mitochondria are known to stimulate the nuclear ER stress 
response directly by crosstalk with the nuclear UPR or by eliciting the integrated 
stress response that culminates on the phosphorylation of eIF2α (Schulz & Haynes, 
2015). The absence of AAG would spare the cell from this chain reaction, explaining 
the attenuation on the AAG-/- cells. 
Aag-mediated repair is also linked to Parp-1 activation (J. A. Calvo et al., 
2013) and there is evidence that the accumulation of Aag-derived repair 
intermediates triggers Parp-1hyperactivation, what causes NAD+ depletion 
(Alhumaydhi et al., 2017). This depletion in NAD+ levels slows ATP generation rates, 
and ATP imbalance further impairs NAD+ generation, a process that requires ATP 
(Houtkooper et al., 2010). ATP depletion also greatly interferes with proper protein 
folding inside the ER (M. Wang & Kaufman, 2014) and the accumulation of 
misfolded proteins can trigger the UPR (Figure 51). Therefore AAG-mediated repair 
of nuclear base damage could lead to an energetic impairment that could be further 
aggravated by mitochondrial dysfunction caused by mitochondrial AAG-initiated 
repair as suggested on the prior paragraph.  
This hypothesis, however would only partially explain the ER stress 
response attenuation, as it is also observed on the knockout cells treated with TG, 
that to the extent of our knowledge, does not cause any DNA damage (what is also 
supported by the lack of p21 induction on cells treated with TG). Thus, we propose 
that a second mechanism could explain the differences in ER stress response 
observed in the AAG-proficient and AAG-deficient genotypes. This latter mechanism 
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could be either solely responsible for the AAG-mediated ER response or 
complementary to the DNA repair-dependent UPR induction hypothesis formulated 
above. 
 
The second mechanism would be that AAG participates in signal 
transduction and the ER stress response either directly or through interaction with 
a partner, playing a novel repair-independent function in the process. AAG is known 
Figure 51: Repair and PARP-1 -dependent hypothesis for UPR activation. AAG-derived repair 
intermediates may trigger PARP-1 hyperactivation, what causes NAD and ATP depletion, which   
interferes with the proper protein folding inside the ER and the accumulation of misfolded proteins 
would trigger the UPR 
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to interact directly with human RAD23A and B, p53 and oestrogen receptor α 
[ERα/β] (C. Liang et al., 2013; Likhite, Cass, Anderson, Yates, & Nardulli, 2004; Miao 
et al., 2000). Of these interactors, one of great promise in unveiling the AAG role in 
the UPR is the oestrogen receptor. On their extranuclear pathways oestrogen 
receptor α and β have been linked to the triggering of UPR response to order to 
elicit  adaptive responses aimed either to prime the cells to an increased protein 
folding load or to trigger mitochondrial UPR (Andruska, Zheng, Yang, Helferich, & 
Shapiro, 2015; Papa & Germain, 2011; Rajapaksa, Thomas, & Gustafsson, 2016). 
AAG could be somehow involved in any of these responses further than effects 
reported on the work describing its interaction with ERα (Likhite et al., 2004). 
Furthermore, our search at the uniHI website (Kalathur et al., 2014) uncovered a 
total of 62 putative interactors and any of those might be a good candidate for 
further investigation on the participation of AAG on the ER stress response. 
To address the importance of the repair activity we propose complement 
our current AAG-/- models with AAG containing point-mutations that inactivate its 
catalytic activity, such as the E125Q mutant (Hendershot & O’Brien, 2014), kindly 
donated by Dr Leona Samson (MIT, USA). The interactors could also be interrogated 
by the co-immunoprecipitation of AAG and posterior mass spectrometry analysis. 
Despite being unable to achieve our original aim of quantifying changes on 
those interactors via proteomic analysis we were able to qualitatively portray a 
snapshot of the main gene ontologies that compose our sample. Not surprisingly, 
most of the GO-slim terms proportions were quite similar across genotypes. The 
AAG knockout was carried out on the same ARPE-19 background and none of the 
clones presented great changes in phenotype. It reassures that the CRISPR/Cas 9 
intervention was precise and did not have any major off target effects. 
Our high-stringency R script analysis, however, did found a total of 13 
proteins detected only in the wild-type replicates. No pattern or medium 
confidence connections were found among those (as given by STRING, data not 
shown) and they seem to perform a wide variety of functions. None of those 
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proteins are present in the list of interactors obtained from uniHI, but some of the 
proteins do seem to high-confidence (score of 0.9 or above) interactions with those 
from the list (Figure 52Erro). It would be highly desirable to directly confirm (by 
western blot) the absence of these proteins on the AAG-/- and to further investigate 
their biological relevance and relation to AAG. 
Although some of our questions still remain unanswered, with this work 
we were able to gain some insight in to a novel role of the alkyladenine glycosylase 
as a participant of the endoplasmic reticulum stress response. It adds to our 
understanding of the response to alkylating agents, a widespread class of reactive 
chemicals that originate from endogenous (e.g. inflammation, methyl donors) and 
exogenous sources (e.g. diet, cigarette smoke, pollution) and still has a great 
importance in the clinical setting as chemotherapeutic agents (Goldman & Shields, 
2003; Jones, 2015; Nagy et al., 2013; West et al., 2006). Not only this, but also 
integrates  with the complex unfolded protein response, whose deregulation is 
implicated in the pathology of diabetes, neurodegeneration, autoimmunity (Hetz & 
Mollereau, 2014; Schönthal, 2012; Todd et al., 2008). 
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Figure 52: High-confidence network of interactions between proteins found exclusively on wild-type 
cells and the list of putative AAG interactors. Small nodes correspond to proteins without known 3D 
structure and unconnected nodes were those which either no connection was found or connection 
evidence fell below the cut-off point (0.9 interaction score). Each coloured connector represents the 
type of evidence connecting each node (see legend). 
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 LIST OF CONTRIBUTIONS 
CHAPTER 2 
• Generated five isogenic cell lines: a GFP-expressing negative control, a 
whole-cell and a nuclear AAG overexpressor and two AAG knockdown cell 
lines; 
• Determined that AAG overexpression sensitizes cells to alkylation damage. 
CHAPTER 3 
• Generated two clones of an AAG-/- isogenic cell line; 
• Determined that, as with AAG overexpressor, AAG-/- cells are more sensitive 
to alkylation damage;  
CHAPTER 4 
• Generated a stably transfected AAG-complemented cell line (AAG++ A2C2); 
• Determined that MMS induces ER stress in a specific and dose-dependent 
manner in two distinct human cell lines; 
• Established that the absence of AAG attenuates ER stress induction and that 
levels are restored when AAG is reintroduced in the system; 
• Verified that ER stress induction is compose of at least two UPR branches: 
(ATF6 and IRE1α) are part of the ER stress induction;  
CHAPTER 5 
• Identified 5480 protein groups wild-type ARPE-19, 5377 in the AAG -/- A2C2 
and 5264 in AAG -/- B6C3; 
• Identified 44 overrepresented Biological Process GO-slim terms across all 
three cell lines; 
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• Identified 23 overrepresented (PANTHER) pathways across all three cell 
lines; 
• Identified a list of 13 proteins present only on wild type ARPE-19 proteomic 
data sets. 
 FUTURE WORK 
This work raises several questions as to the nature of AAG’s contributions 
to the unfolded protein response and therefore to fully dissect the mechanism of 
such a novel process some additional experiments would be desirable.  
First of all, complement AAG-/- cells with AAG catalytically dead mutants to 
define if attenuation of ER stress is repair related.  
To identify where in the cascade of the UPR AAG is acting upstream or 
downstream of PERK and IRE1α, it would be interesting to first repeat western-blot 
experiments to confirm AAG modulation on key UPR markers then and add 
phosphorylated and total PERK phosphorylated and total IRE1. 
Finally, to achieve our original objective of quantifying proteomic changes 
in AAG-proficient and AAG-deficient cell lines, it would be interesting to 
metabolically tag them with SILAC. Although the method requires some amount of 
optimization, it has a solid background in literature and the risk of applying this 
approach would be smaller than repeating the acquisition using WiSIM-DIA. 
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